{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "import requests\n",
    "import pandas as pd"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "# BASE_URL = \"https://clinicaltrials.gov/data-api/api/v1/studies\"\n",
    "# curl -X GET \"https://clinicaltrials.gov/api/v2/studies?query.id=BP28248\" \\\n",
    "#  -H \"accept: application/json\" \\\n",
    "\n",
    "BASE_URL = \"https://clinicaltrials.gov/api/v2/studies?format=json&query.id=\"\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [],
   "source": [
    "def fetch_study_info(study_id):\n",
    "    \"\"\"\n",
    "    Fetch study information from ClinicalTrials.gov API using a study ID.\n",
    "    \"\"\"\n",
    "    url = f\"{BASE_URL}/{study_id}\"\n",
    "    response = requests.get(url)\n",
    "\n",
    "    if response.status_code == 200:\n",
    "        return response.json()\n",
    "    else:\n",
    "        raise Exception(f\"Error fetching data: {response.status_code}, {response.text}\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "study_info = fetch_study_info(\"BP28248\")\n",
    "study_info"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [],
   "source": [
    "def format_study_info(study_data):\n",
    "    \"\"\"\n",
    "    Extract relevant fields and format as a DataFrame for tabular output.\n",
    "    \"\"\"\n",
    "    # Example: Extract key fields (adjust based on API response)\n",
    "    fields = {\n",
    "        \"NCT ID\": study_data.get(\"nctId\",\"\"),\n",
    "        \"Study ID\": study_data.get(\"studyId\", \"\"),\n",
    "        \"Title\": study_data.get(\"title\", \"\"),\n",
    "        \"Condition\": study_data.get(\"condition\", \"\"),\n",
    "        \"Status\": study_data.get(\"status\", \"\"),\n",
    "        \"Start Date\": study_data.get(\"startDate\", \"\"),\n",
    "        \"Completion Date\": study_data.get(\"completionDate\", \"\")\n",
    "    }\n",
    "    return pd.DataFrame([fields])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>NCT ID</th>\n",
       "      <th>Study ID</th>\n",
       "      <th>Title</th>\n",
       "      <th>Condition</th>\n",
       "      <th>Status</th>\n",
       "      <th>Start Date</th>\n",
       "      <th>Completion Date</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "  NCT ID Study ID Title Condition Status Start Date Completion Date\n",
       "0                                                                  "
      ]
     },
     "execution_count": 13,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "study_table = format_study_info(study_info)\n",
    "study_table"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "#curl -X GET \"https://clinicaltrials.gov/api/v2/studies?query.titles=high+blood+pressure\" \\\n",
    "#  -H \"accept: application/json\"\n",
    "\n",
    "BASE_URL1 = \"https://clinicaltrials.gov/api/v2/studies?format=json&query.titles=\"\n",
    "\n",
    "def fetch_trials_by_condition(condition):\n",
    "    \"\"\"\n",
    "    Fetch a list of trials from ClinicalTrials.gov API that match a given condition or disease.\n",
    "    \"\"\"\n",
    "\n",
    "    url = f\"{BASE_URL1}/{condition}\"\n",
    "    response = requests.get(url)\n",
    "\n",
    "    if response.status_code == 200:\n",
    "        data = response.json()\n",
    "        # Extract relevant details about each trial (e.g., NCT ID and title)\n",
    "        trials = [\n",
    "            {\"nct_id\": trial.get(\"id\"), \"title\": trial.get(\"brief_title\")}\n",
    "            for trial in data.get(\"studies\", [])\n",
    "        ]\n",
    "        return pd.DataFrame(trials)  # Convert to a DataFrame for easier analysis\n",
    "    else:\n",
    "        raise Exception(f\"Error fetching data: {response.status_code}, {response.text}\")\n",
    "\n",
    "\n",
    "\n",
    "condition_trials = fetch_trials_by_condition(\"diabetes\")\n",
    "print(\"Condition Trials:\")\n",
    "print(condition_trials)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Study Info: {'studies': [{'protocolSection': {'identificationModule': {'nctId': 'NCT01677754', 'orgStudyIdInfo': {'id': 'BP28248'}, 'secondaryIdInfos': [{'id': '2012-000943-29', 'type': 'EUDRACT_NUMBER'}], 'organization': {'fullName': 'Hoffmann-La Roche', 'class': 'INDUSTRY'}, 'briefTitle': 'A Study of RO4602522 in Participants With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy', 'officialTitle': \"A Phase II, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Investigate the Efficacy and Safety of RO4602522 Added to Background Alzheimer's Disease Therapy in Patients With Moderate Severity Alzheimer's Disease\", 'acronym': 'MAyflOwer RoAD'}, 'statusModule': {'statusVerifiedDate': '2017-05', 'overallStatus': 'COMPLETED', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2012-10-24', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2015-06-12', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2015-06-12', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2012-08-30', 'studyFirstSubmitQcDate': '2012-08-30', 'studyFirstPostDateStruct': {'date': '2012-09-03', 'type': 'ESTIMATED'}, 'dispFirstSubmitDate': '2016-07-20', 'dispFirstSubmitQcDate': '2016-07-20', 'dispFirstPostDateStruct': {'date': '2016-07-22', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2017-05-25', 'lastUpdatePostDateStruct': {'date': '2017-05-30', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Hoffmann-La Roche', 'class': 'INDUSTRY'}}, 'oversightModule': {'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': \"This Phase II, multicenter, randomized, double-blind, parallel-group, placebo-controlled study will evaluate the efficacy and safety of RO4602522 in participants with moderate severity Alzheimer's disease. Participants who are taking background therapy of acetylcholinesterase inhibitors (AChEI) alone or in combination with memantine for at least 4 months before screening will be randomized to receive either one of two doses of RO4602522 or placebo for 12 months.\"}, 'conditionsModule': {'conditions': [\"Alzheimer's Disease\"]}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'DOUBLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR']}}, 'enrollmentInfo': {'count': 542, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Placebo', 'type': 'PLACEBO_COMPARATOR', 'description': 'Participants will receive placebo as add-on to a background therapy of AChEI (donepezil, rivastigmine, or galantamine) alone or in combination with memantine.', 'interventionNames': ['Drug: Placebo', 'Drug: Donepezil', 'Drug: Memantine', 'Drug: Rivastigmine', 'Drug: Galantamine']}, {'label': 'RO4602522 1 milligram (mg)', 'type': 'EXPERIMENTAL', 'description': 'Participants will receive RO4602522 1 mg as add-on to a background therapy of AChEI (donepezil, rivastigmine, or galantamine) alone or in combination with memantine.', 'interventionNames': ['Drug: RO4602522', 'Drug: Donepezil', 'Drug: Memantine', 'Drug: Rivastigmine', 'Drug: Galantamine']}, {'label': 'RO4602522 5 mg', 'type': 'EXPERIMENTAL', 'description': 'Participants will receive RO4602522 5 mg as add-on to a background therapy of AChEI (donepezil, rivastigmine, or galantamine) alone or in combination with memantine.', 'interventionNames': ['Drug: RO4602522', 'Drug: Donepezil', 'Drug: Memantine', 'Drug: Rivastigmine', 'Drug: Galantamine']}], 'interventions': [{'type': 'DRUG', 'name': 'RO4602522', 'description': 'Participants will receive RO4602522 orally once daily for 12 months.', 'armGroupLabels': ['RO4602522 1 milligram (mg)', 'RO4602522 5 mg']}, {'type': 'DRUG', 'name': 'Placebo', 'description': 'Participants will receive placebo for RO4602522 orally once daily for 12 months.', 'armGroupLabels': ['Placebo']}, {'type': 'DRUG', 'name': 'Donepezil', 'description': 'Stable dose as background medication', 'armGroupLabels': ['Placebo', 'RO4602522 1 milligram (mg)', 'RO4602522 5 mg']}, {'type': 'DRUG', 'name': 'Memantine', 'description': 'Stable dose as background medication in combination with AChEIs', 'armGroupLabels': ['Placebo', 'RO4602522 1 milligram (mg)', 'RO4602522 5 mg']}, {'type': 'DRUG', 'name': 'Rivastigmine', 'description': 'Stable dose as background medication', 'armGroupLabels': ['Placebo', 'RO4602522 1 milligram (mg)', 'RO4602522 5 mg']}, {'type': 'DRUG', 'name': 'Galantamine', 'description': 'Stable dose as background medication', 'armGroupLabels': ['Placebo', 'RO4602522 1 milligram (mg)', 'RO4602522 5 mg']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': \"Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive Behavior Subscale (ADAS-Cog-11) Score at Month 12\", 'timeFrame': 'Baseline, Month 12'}], 'secondaryOutcomes': [{'measure': 'Percentage of Participants Achieving Response, Defined as an Increase From Baseline of Less Than or Equal to (<=) 4 Points in ADAS-Cog-11', 'timeFrame': 'Baseline, Month 12'}, {'measure': \"Change From Baseline in Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL) Scale Score at Month 12\", 'timeFrame': 'Baseline, Month 12'}, {'measure': \"Change From Baseline in Behavioral Pathology in Alzheimer's Disease Frequency-Weighted Severity Scale (BEHAVE-AD-FW) Score at Month 12\", 'timeFrame': 'Baseline, Month 12'}, {'measure': 'Percentage of Participants With Worsening in BEHAVE-AD-FW Score', 'timeFrame': 'Baseline to Month 12'}, {'measure': 'Change From Baseline in Apathy Evaluation Scale (AES) Score at 12 months', 'timeFrame': 'Baseline, Month 12'}, {'measure': \"Change From Baseline in Alzheimer's Disease Cooperative Study Clinician Global Impression of Change (ADCS-CGIC) Scale Score at 12 months\", 'timeFrame': 'Baseline, Month 12'}, {'measure': 'Percentage of Participants With Worsening in ADCS-CGIC Score', 'timeFrame': 'Baseline to Month 12'}, {'measure': 'Change From Baseline in Global Deterioration Scale (GDS) Score at 12 months', 'timeFrame': 'Baseline, Month 12'}, {'measure': 'Change From Baseline in Columbia Suicide Severity Rating Scale (C-SSRS) Score at 12 months', 'timeFrame': 'Baseline, Month 12'}, {'measure': 'Percentage of Participants with Adverse Events', 'timeFrame': 'Baseline up to 13 months'}, {'measure': 'Percentage of Participants with Change in Lens Opacity Grading', 'timeFrame': 'Baseline; Months 6, and 12'}, {'measure': 'Percentage of Participants with Abnormal Visual Acuity Test Results', 'timeFrame': 'Baseline, Months 6, and 12'}, {'measure': 'Change From Baseline in Michigan Neuropathy Screening Instrument Score', 'timeFrame': 'Baseline, Weeks 8, 18, 30, 44, 52, and at the last follow-up visit (12 weeks after last dose, up to 64 weeks)'}, {'measure': 'Percentage of Participants Receiving Concomitant Medications', 'timeFrame': 'Baseline to 13 Months'}, {'measure': 'Apparent Total Clearance of the Drug From Plasma After Administration of RO4602522', 'timeFrame': 'Day -1, pre-dose (0 hour) on Days 14, 28, 84, 168, 252, and 364; 1 to 2 hour post dose on Days 14, 84, 252; 2-4 and 5-6 hours post dose on Days 28, 168, and 364'}, {'measure': 'Apparent Volume of Distribution at Steady State after Administration of RO4602522', 'timeFrame': 'Day -1, pre-dose (0 hour) on Days 14, 28, 84, 168, 252, and 364; 1 to 2 hour post dose on Days 14, 84, 252; 2-4 and 5-6 hours post dose on Days 28, 168, and 364'}, {'measure': 'Area Under the Plasma Concentration-Time Curve of RO4602522', 'timeFrame': 'Day -1, pre-dose (0 hour) on Days 14, 28, 84, 168, 252, and 364; 1 to 2 hour post dose on Days 14, 84, 252; 2-4 and 5-6 hours post dose on Days 28, 168, and 364'}, {'measure': 'Maximum Plasma Concentration of RO4602522', 'timeFrame': 'Day -1, pre-dose (0 hour) on Days 14, 28, 84, 168, 252, and 364; 1 to 2 hour post dose on Days 14, 84, 252; 2-4 and 5-6 hours post dose on Days 28, 168, and 364'}]}, 'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\n\\n* Probable Alzheimer disease, based on the National Institute of Neurological and Communicative Disorders and Stroke (NINCDS)/Alzheimer's Disease and Related Disorders Association (ADRDA) and Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition (DSM-IV-TR) criteria\\n* Mini-Mental State Exam (MMSE) score at screening between 13 and 20, inclusive\\n* Body mass index (BMI) between 18 and 36 kilograms per square meter (kg/m\\\\^2) (inclusive) at screening\\n* Modified Hachinski Ischemia Score of less than or equal to (\\\\</=) 4\\n* Participants with Cornell Scale for Depression in Dementia (CSDD) scores \\\\</= 13 at screening\\n* Receiving treatment with donepezil, rivastigmine, galantamine or any AChEIs in combination with memantine for at least 4 months before screening, with their dose and formulation stabilized at least 3 months before screening. All formulation and dosages are allowed except donezepil 23 mg (alone or in combination)\\n* Females of childbearing potential must have a negative pregnancy test and must agree to use effective contraception\\n* Generally healthy and ambulatory or ambulatory-aided (i.e., walker or cane)\\n* Have a reliable caregiver or some other identified responsible person who has frequent contact with the participant\\n\\nExclusion Criteria:\\n\\n* Any neurological or psychiatric condition that may occur currently or during the course of the study that can impair cognition or functioning that is not associated with Alzheimer's disease\\n* Background of mental retardation\\n* Uncontrolled behavioral symptoms incompatible with compliance or evaluability\\n* Alcohol and/or substance abuse or dependence (DSM-IV-TR) in the past 2 years, except nicotine use which is allowed. However, smokers treated with nicotine replacement therapy or bupropion are excluded\\n* Unstable or poorly controlled hypertension as assessed by the investigator regardless of whether or not the participant is taking antihypertensive medications\\n* Unstable or clinically significant cardiovascular disease that could be expected to progress, recur, or change during study period to such an extent that it could bias the assessment of the clinical or mental status of the participant\\n* Inadequate hepatic, renal or thyroid function\\n* Positive for hepatitis B, hepatitis C or human immunodeficiency virus (HIV) infection\\n* Poorly controlled diabetes (glycosylated hemoglobin \\\\[HbA1c\\\\] greater than or equal to \\\\[\\\\>/=\\\\] 9 percent at screening)\\n* Requiring nursing home care. Participants living in assisted living facilities are allowed if a reliable caregiver is available (see inclusion criteria)\\n* Current treatment for Alzheimer's disease other than those listed in inclusion criteria\\n* Participation at any time in an active Alzheimer's disease vaccine study\\n* Participation in a passive Alzheimer's disease immunization study less than 1 year before screening except for a) participants where documented medical history indicate that they were randomized to the placebo group in these studies, b) participants treated with bapineuzumab where a 6-month exclusion period applies\\n* Recent (\\\\</= 12 weeks) or concomitant use of other Monoamine oxidase inhibitors (selective or not) including selegiline or rasagiline\\n* Antidepressant treatments are not allowed except for citalopram up to 20 mg daily, escitalopram up to 10 mg daily, paroxetine up to 30 mg daily, sertraline up to 100 mg daily and trazodone up to 100 mg daily. If treated with one of these antidepressants, the treatment should be present for at least 6 weeks at screening. All other antidepressants including other SSRIs, tricyclic antidepressants (TCAs), serotonin-norepinephrine reuptake inhibitors (SNRIs), St. John's wort and bupropion are excluded\\n* Anti-psychotic use within 4 weeks before screening is not permitted except risperidone up to 1.5 mg/day, quetiapine up to 100 milligrams per day (mg/day), olanzapine up to 5 mg/day, and aripiprazole up to 10 mg daily\\n* Anxiolytics/ hypnotics use is not permitted except for benzodiazepines of short or intermediate half-life for anxiety/sleeping disorders. Zolpidem (up to 5 mg/day), zopiclone (up to 7.5 mg/day), eszopiclone (up to 2 mg/day), trazodone (up to 50 mg/day, at bedtime) or zaleplon (up to 5 mg/day) is permitted for insomnia\\n* Anti-Parkinson's agents within 2 weeks before screening are not permitted\\n* Recent (less than 4 weeks prior to screening) or concomitant use of anticonvulsants\\n* Anticholinergics/ antihistaminics within 2 weeks before screening are not permitted, except i) if used episodically more than 3 days before the screening cognitive measurement, ii) non-sedating antihistaminic medications (without anticholinergic effects such as cetirizine) or peripheral anticholinergics without central anticholinergic effects (such as, trospium for the treatment of hyperactive bladder), which are permitted\\n* Recent (less than 1 week prior to screening) or concomitant use of opioid drugs (tramadol, methadone, propoxyphene, or meperidine), cyclobenzaprine and dextromethorphan\\n* Concomitant use of sympathomimetic drugs, including sympathomimetics in local anesthetics and ephedra supplements\", 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '50 Years', 'maximumAge': '90 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Clinical Trials', 'affiliation': 'Hoffmann-La Roche', 'role': 'STUDY_DIRECTOR'}], 'locations': [{'facility': 'Advanced Research Center, Inc.;In-Patient Unit', 'city': 'Anaheim', 'state': 'California', 'zip': '92801', 'country': 'United States', 'geoPoint': {'lat': 33.83529, 'lon': -117.9145}}, {'facility': 'Neurology Center of North Orange County', 'city': 'Fullerton', 'state': 'California', 'zip': '92835', 'country': 'United States', 'geoPoint': {'lat': 33.87029, 'lon': -117.92534}}, {'facility': 'Torrance Clinical Research', 'city': 'Lomita', 'state': 'California', 'zip': '90717', 'country': 'United States', 'geoPoint': {'lat': 33.79224, 'lon': -118.31507}}, {'facility': 'Artemis Institute for Clinical Research, LLC', 'city': 'San Diego', 'state': 'California', 'zip': '92103', 'country': 'United States', 'geoPoint': {'lat': 32.71533, 'lon': -117.15726}}, {'facility': 'Sharp Mesa Vista Hospital', 'city': 'San Diego', 'state': 'California', 'zip': '92123', 'country': 'United States', 'geoPoint': {'lat': 32.71533, 'lon': -117.15726}}, {'facility': 'San Francisco Clinical Research Center', 'city': 'San Francisco', 'state': 'California', 'zip': '94109', 'country': 'United States', 'geoPoint': {'lat': 37.77493, 'lon': -122.41942}}, {'facility': 'Neurological Research Inst', 'city': 'Santa Monica', 'state': 'California', 'zip': '90025', 'country': 'United States', 'geoPoint': {'lat': 34.01945, 'lon': -118.49119}}, {'facility': 'Yale University School Of Medicine', 'city': 'New Haven', 'state': 'Connecticut', 'zip': '06510', 'country': 'United States', 'geoPoint': {'lat': 41.30815, 'lon': -72.92816}}, {'facility': 'Research Center for Clinical Studies, Inc.', 'city': 'Norwalk', 'state': 'Connecticut', 'zip': '06851', 'country': 'United States', 'geoPoint': {'lat': 41.1176, 'lon': -73.4079}}, {'facility': \"Parkinson's Disease and Movement Disorders Center of Boca Raton\", 'city': 'Boca Raton', 'state': 'Florida', 'zip': '33486', 'country': 'United States', 'geoPoint': {'lat': 26.3669, 'lon': -80.13033}}, {'facility': 'Meridien Research', 'city': 'Brooksville', 'state': 'Florida', 'zip': '34601', 'country': 'United States', 'geoPoint': {'lat': 28.55554, 'lon': -82.38991}}, {'facility': 'Brain Matters Research, Inc.', 'city': 'Delray Beach', 'state': 'Florida', 'zip': '33445', 'country': 'United States', 'geoPoint': {'lat': 26.46146, 'lon': -80.07282}}, {'facility': 'Neurologic Consultants, P.A.', 'city': 'Fort Lauderdale', 'state': 'Florida', 'zip': '33308', 'country': 'United States', 'geoPoint': {'lat': 26.12231, 'lon': -80.14338}}, {'facility': 'Galiz Research, LLC', 'city': 'Hialeah', 'state': 'Florida', 'zip': '33016', 'country': 'United States', 'geoPoint': {'lat': 25.8576, 'lon': -80.27811}}, {'facility': 'Miami Jewish Health Systems', 'city': 'Miami', 'state': 'Florida', 'zip': '33137', 'country': 'United States', 'geoPoint': {'lat': 25.77427, 'lon': -80.19366}}, {'facility': 'Medical Research Group of Central Florida', 'city': 'Orange City', 'state': 'Florida', 'zip': '3273', 'country': 'United States', 'geoPoint': {'lat': 28.94888, 'lon': -81.29867}}, {'facility': 'Compass Research East, LLC', 'city': 'Orlando', 'state': 'Florida', 'zip': '32806', 'country': 'United States', 'geoPoint': {'lat': 28.53834, 'lon': -81.37924}}, {'facility': 'Comprehensive Clinical Development, Inc.- St. Petersburg, FL', 'city': 'Saint Petersburg', 'state': 'Florida', 'zip': '33716', 'country': 'United States', 'geoPoint': {'lat': 27.77086, 'lon': -82.67927}}, {'facility': 'Axiom Clinical Research of Florida', 'city': 'Tampa', 'state': 'Florida', 'zip': '33609', 'country': 'United States', 'geoPoint': {'lat': 27.94752, 'lon': -82.45843}}, {'facility': 'Premiere Research Institute', 'city': 'West Palm Beach', 'state': 'Florida', 'zip': '33407', 'country': 'United States', 'geoPoint': {'lat': 26.71534, 'lon': -80.05337}}, {'facility': 'iResearch Atlanta', 'city': 'Decatur', 'state': 'Georgia', 'zip': '30030', 'country': 'United States', 'geoPoint': {'lat': 33.77483, 'lon': -84.29631}}, {'facility': 'NeuroStudies.net, LLC', 'city': 'Decatur', 'state': 'Georgia', 'zip': '30033', 'country': 'United States', 'geoPoint': {'lat': 33.77483, 'lon': -84.29631}}, {'facility': 'Alexian Brothers Neurosci Inst', 'city': 'Elk Grove Village', 'state': 'Illinois', 'zip': '60007', 'country': 'United States', 'geoPoint': {'lat': 42.00392, 'lon': -87.97035}}, {'facility': 'Louisiana Research Associates', 'city': 'New Orleans', 'state': 'Louisiana', 'zip': '70114', 'country': 'United States', 'geoPoint': {'lat': 29.95465, 'lon': -90.07507}}, {'facility': 'Booker, J. Gary, MD, APMC', 'city': 'Shreveport', 'state': 'Louisiana', 'zip': '71104-2136', 'country': 'United States', 'geoPoint': {'lat': 32.52515, 'lon': -93.75018}}, {'facility': 'Northern Michigan Neurology', 'city': 'Traverse City', 'state': 'Michigan', 'zip': '49684', 'country': 'United States', 'geoPoint': {'lat': 44.76306, 'lon': -85.62063}}, {'facility': 'Hattiesburg Clinic', 'city': 'Hattiesburg', 'state': 'Mississippi', 'zip': '39401', 'country': 'United States', 'geoPoint': {'lat': 31.32712, 'lon': -89.29034}}, {'facility': 'Millennium Psychiatric Associates, LLC', 'city': 'Creve Coeur', 'state': 'Missouri', 'zip': '63141', 'country': 'United States', 'geoPoint': {'lat': 38.66089, 'lon': -90.42262}}, {'facility': 'Memory Enhancement Center of America, Inc.', 'city': 'Eatontown', 'state': 'New Jersey', 'zip': '07724', 'country': 'United States', 'geoPoint': {'lat': 40.29622, 'lon': -74.05097}}, {'facility': 'Albuquerque Neuroscience Inc.', 'city': 'Albuquerque', 'state': 'New Mexico', 'zip': '87109', 'country': 'United States', 'geoPoint': {'lat': 35.08449, 'lon': -106.65114}}, {'facility': 'New York University Medical Center;Child Study Center', 'city': 'New York', 'state': 'New York', 'zip': '10016', 'country': 'United States', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'facility': 'Richmond Behavioral Associates', 'city': 'Staten Island', 'state': 'New York', 'zip': '10312', 'country': 'United States', 'geoPoint': {'lat': 40.56233, 'lon': -74.13986}}, {'facility': 'Raleigh Neurology Associates', 'city': 'Raleigh', 'state': 'North Carolina', 'zip': '27607-6520', 'country': 'United States', 'geoPoint': {'lat': 35.7721, 'lon': -78.63861}}, {'facility': 'PMG Research of Winston-Salem, LLC', 'city': 'Winston-Salem', 'state': 'North Carolina', 'zip': '27103', 'country': 'United States', 'geoPoint': {'lat': 36.09986, 'lon': -80.24422}}, {'facility': 'Lynn Health Science Institute', 'city': 'Oklahoma City', 'state': 'Oklahoma', 'zip': '73112', 'country': 'United States', 'geoPoint': {'lat': 35.46756, 'lon': -97.51643}}, {'facility': 'Cutting Edge Research Group', 'city': 'Oklahoma City', 'state': 'Oklahoma', 'zip': '73116', 'country': 'United States', 'geoPoint': {'lat': 35.46756, 'lon': -97.51643}}, {'facility': 'The Clinical Trial Center, LLC', 'city': 'Jenkintown', 'state': 'Pennsylvania', 'zip': '19046', 'country': 'United States', 'geoPoint': {'lat': 40.09594, 'lon': -75.12517}}, {'facility': 'Radiant Research, Inc.', 'city': 'Wyomissing', 'state': 'Pennsylvania', 'zip': '19610', 'country': 'United States', 'geoPoint': {'lat': 40.32954, 'lon': -75.96521}}, {'facility': 'Rhode Island Mood & Memory Research Institute', 'city': 'East Providence', 'state': 'Rhode Island', 'zip': '02914', 'country': 'United States', 'geoPoint': {'lat': 41.81371, 'lon': -71.37005}}, {'facility': 'Rhode Island Hospital', 'city': 'Providence', 'state': 'Rhode Island', 'zip': '02903', 'country': 'United States', 'geoPoint': {'lat': 41.82399, 'lon': -71.41283}}, {'facility': \"Alzheimer's Research & Clinical Programs\", 'city': 'Charleston', 'state': 'South Carolina', 'zip': '29425', 'country': 'United States', 'geoPoint': {'lat': 32.77657, 'lon': -79.93092}}, {'facility': 'University of North Texas Health Science Center', 'city': 'Fort Worth', 'state': 'Texas', 'zip': '76107', 'country': 'United States', 'geoPoint': {'lat': 32.72541, 'lon': -97.32085}}, {'facility': \"St Vincent's Hospital Sydney\", 'city': 'Darlinghurst', 'state': 'New South Wales', 'zip': '2010', 'country': 'Australia', 'geoPoint': {'lat': -33.87939, 'lon': 151.21925}}, {'facility': 'Central Coast Neurosciences Research', 'city': 'Erina', 'state': 'New South Wales', 'zip': '2250', 'country': 'Australia', 'geoPoint': {'lat': -33.43218, 'lon': 151.38972}}, {'facility': 'Southern Neurology', 'city': 'Kogarah', 'state': 'New South Wales', 'zip': '2217', 'country': 'Australia', 'geoPoint': {'lat': -33.98333, 'lon': 151.11667}}, {'facility': 'Queen Elizabeth Hospital', 'city': 'Woodville', 'state': 'South Australia', 'zip': '5011', 'country': 'Australia', 'geoPoint': {'lat': -34.88333, 'lon': 138.55}}, {'facility': 'Box Hill Hospital; Eastern Clinical Research Unit', 'city': 'Box Hill', 'state': 'Victoria', 'zip': '3128', 'country': 'Australia', 'geoPoint': {'lat': -37.81887, 'lon': 145.12545}}, {'facility': 'A.G.Mander Pty Ltd', 'city': 'Geelong', 'state': 'Victoria', 'zip': '3220', 'country': 'Australia', 'geoPoint': {'lat': -38.14711, 'lon': 144.36069}}, {'facility': 'Heidelberg Repatriation Hospital', 'city': 'Heidelberg', 'state': 'Victoria', 'zip': '3084', 'country': 'Australia', 'geoPoint': {'lat': -37.75, 'lon': 145.06667}}, {'facility': 'Hollywood Specialist Centre', 'city': 'Nedlands', 'state': 'Western Australia', 'zip': '6009', 'country': 'Australia', 'geoPoint': {'lat': -31.98184, 'lon': 115.8073}}, {'facility': 'Neurodegenerative Disorders Research', 'city': 'Subiaco', 'state': 'Western Australia', 'zip': '6008', 'country': 'Australia', 'geoPoint': {'lat': -31.9485, 'lon': 115.8268}}, {'facility': 'The Medical Arts Health Research Group', 'city': 'Powell River', 'state': 'British Columbia', 'zip': 'V8A 3B6', 'country': 'Canada', 'geoPoint': {'lat': 49.83278, 'lon': -124.52368}}, {'facility': 'Vancouver Hospital - UBC Hospital Site', 'city': 'Vancouver', 'state': 'British Columbia', 'zip': 'V6T 2B5', 'country': 'Canada', 'geoPoint': {'lat': 49.24966, 'lon': -123.11934}}, {'facility': 'Vancouver Island Health Authority', 'city': 'Victoria', 'state': 'British Columbia', 'zip': 'V8R 1J8', 'country': 'Canada', 'geoPoint': {'lat': 48.43294, 'lon': -123.3693}}, {'facility': 'Capitol District Health Authority', 'city': 'Halilfax', 'state': 'Nova Scotia', 'zip': 'B3H 2E1', 'country': 'Canada', 'geoPoint': {'lat': 44.64533, 'lon': -63.57239}}, {'facility': 'True North Clinical Research Kentville', 'city': 'Kentville', 'state': 'Nova Scotia', 'zip': 'B4N 4K9', 'country': 'Canada', 'geoPoint': {'lat': 45.0771, 'lon': -64.49605}}, {'facility': 'Jbn Medical Diagnostic Services Inc.', 'city': 'Burlington', 'state': 'Ontario', 'zip': 'L7M 4Y1', 'country': 'Canada', 'geoPoint': {'lat': 43.38621, 'lon': -79.83713}}, {'facility': 'Bruyere Continuing Care', 'city': 'Ottawa', 'state': 'Ontario', 'zip': 'K1N 5C8', 'country': 'Canada', 'geoPoint': {'lat': 45.41117, 'lon': -75.69812}}, {'facility': 'Ingram, Jennifer MD', 'city': 'Peterborough', 'state': 'Ontario', 'zip': 'K9H 3S1', 'country': 'Canada', 'geoPoint': {'lat': 44.30012, 'lon': -78.31623}}, {'facility': 'Toronto Memory Program (Neurology Research Inc.)', 'city': 'Toronto', 'state': 'Ontario', 'zip': 'M3B 2S7', 'country': 'Canada', 'geoPoint': {'lat': 43.70011, 'lon': -79.4163}}, {'facility': 'The Centre for Memory and Aging', 'city': 'Toronto', 'state': 'Ontario', 'zip': 'M4G 3E8', 'country': 'Canada', 'geoPoint': {'lat': 43.70011, 'lon': -79.4163}}, {'facility': 'Toronto Sunnybrook Hospital', 'city': 'Toronto', 'state': 'Ontario', 'zip': 'M4N 3M5', 'country': 'Canada', 'geoPoint': {'lat': 43.70011, 'lon': -79.4163}}, {'facility': 'Recherches Neuro-Hippocame', 'city': 'Gatineau', 'state': 'Quebec', 'zip': 'J8T 8J1', 'country': 'Canada', 'geoPoint': {'lat': 45.47723, 'lon': -75.70164}}, {'facility': 'Clinique Neuro Rive-Sud', 'city': 'Greenfield Park', 'state': 'Quebec', 'zip': 'J4V 2J2', 'country': 'Canada', 'geoPoint': {'lat': 45.48649, 'lon': -73.46223}}, {'facility': 'Institut Universitaire de gériatrie de Sherbrooke; Service de gériatrie/pavillon Argyll', 'city': 'Sherbrooke', 'state': 'Quebec', 'zip': 'J1J 3H5', 'country': 'Canada', 'geoPoint': {'lat': 45.40008, 'lon': -71.89908}}, {'facility': 'McGill Univeristy; Douglas Mental Health University Institute; Neurological and Psychiatric', 'city': 'Verdun', 'state': 'Quebec', 'zip': 'H4H 1R3', 'country': 'Canada', 'geoPoint': {'lat': 44.0575, 'lon': -81.64667}}, {'facility': \"CHU de Quebec - Hôpital de l' Enfant Jésus\", 'city': 'Quebec', 'zip': 'G1J 1Z4', 'country': 'Canada', 'geoPoint': {'lat': 46.81228, 'lon': -71.21454}}, {'facility': 'NEUROHK s.r.o.', 'city': 'Chocen', 'zip': '565 01', 'country': 'Czechia', 'geoPoint': {'lat': 50.00161, 'lon': 16.22303}}, {'facility': 'P-P Klinika', 'city': 'Kladno', 'zip': '272 80', 'country': 'Czechia', 'geoPoint': {'lat': 50.14734, 'lon': 14.10285}}, {'facility': 'Supervize s.r.o.', 'city': 'Kutna Hora - Vnitrni Mesto', 'zip': '284 01', 'country': 'Czechia'}, {'facility': 'Nemocnice Na Bulovce', 'city': 'Prague', 'zip': '180 01', 'country': 'Czechia', 'geoPoint': {'lat': 50.08804, 'lon': 14.42076}}, {'facility': 'Clintrial,s.r.o.', 'city': 'Praha 10', 'zip': '100 00', 'country': 'Czechia', 'geoPoint': {'lat': 50.08804, 'lon': 14.42076}}, {'facility': 'AD71 s.r.o.', 'city': 'Praha 10', 'zip': '102 00', 'country': 'Czechia', 'geoPoint': {'lat': 50.08804, 'lon': 14.42076}}, {'facility': 'Thomayerova nemocnice', 'city': 'Praha 4 - Krc', 'zip': '140 59', 'country': 'Czechia', 'geoPoint': {'lat': 50.08804, 'lon': 14.42076}}, {'facility': 'Psychiatry Trial s.r.o.', 'city': 'Praha 5', 'zip': '158 00', 'country': 'Czechia', 'geoPoint': {'lat': 50.08804, 'lon': 14.42076}}, {'facility': 'Neurologicka ambulance', 'city': 'Praha 6', 'zip': '16000', 'country': 'Czechia', 'geoPoint': {'lat': 50.08804, 'lon': 14.42076}}, {'facility': 'FORBELI s.r.o.', 'city': 'Praha 6', 'zip': '165 00', 'country': 'Czechia', 'geoPoint': {'lat': 50.08804, 'lon': 14.42076}}, {'facility': 'Centre Hospitalier de la côte Basque', 'city': 'Bayonne', 'zip': '64109', 'country': 'France', 'geoPoint': {'lat': 43.48333, 'lon': -1.48333}}, {'facility': 'Hopital Neurologique Pierre Wertheimer', 'city': 'Bron', 'zip': '69500', 'country': 'France', 'geoPoint': {'lat': 45.73333, 'lon': 4.91667}}, {'facility': 'Hopital Nord Laënnec - CHU Nantes', 'city': 'Nantes', 'zip': '44093', 'country': 'France', 'geoPoint': {'lat': 47.21725, 'lon': -1.55336}}, {'facility': 'Hopital Cimiez; CMRR', 'city': 'Nice', 'zip': '06003', 'country': 'France', 'geoPoint': {'lat': 43.70313, 'lon': 7.26608}}, {'facility': 'Hôpital Lariboisière', 'city': 'Paris', 'zip': '75475', 'country': 'France', 'geoPoint': {'lat': 48.85341, 'lon': 2.3488}}, {'facility': 'Groupe Hospitalier Sud - Hôpital Xavier Arnozan', 'city': 'Pessac', 'zip': '33604', 'country': 'France', 'geoPoint': {'lat': 44.81011, 'lon': -0.64129}}, {'facility': 'Hôpital Maison Blanche', 'city': 'Reims', 'zip': '51092', 'country': 'France', 'geoPoint': {'lat': 49.25, 'lon': 4.03333}}, {'facility': 'CHU Rennes - Hopital Hôtel Dieu', 'city': 'Rennes', 'zip': '35064', 'country': 'France', 'geoPoint': {'lat': 48.11198, 'lon': -1.67429}}, {'facility': 'CHU Toulouse - La Grave', 'city': 'Toulouse', 'zip': '31059', 'country': 'France', 'geoPoint': {'lat': 43.60426, 'lon': 1.44367}}, {'facility': 'CHU Tours - Hôpital Bretonneau', 'city': 'Tours', 'zip': '37044', 'country': 'France', 'geoPoint': {'lat': 47.38333, 'lon': 0.68333}}, {'facility': 'Hôpital de Brabois Adultes', 'city': 'Vandoeuvre-les-nancy', 'zip': '54511', 'country': 'France', 'geoPoint': {'lat': 48.65, 'lon': 6.18333}}, {'facility': 'Hopital des Charpennes', 'city': 'Villeurbanne', 'zip': '69100', 'country': 'France', 'geoPoint': {'lat': 45.76667, 'lon': 4.88333}}, {'facility': 'Gemeinschaftspraxis', 'city': 'Ellwangen', 'zip': '73479', 'country': 'Germany', 'geoPoint': {'lat': 48.96164, 'lon': 10.13173}}, {'facility': 'Henriettenstiftung Hannover', 'city': 'Hannover', 'zip': '30559', 'country': 'Germany', 'geoPoint': {'lat': 52.37052, 'lon': 9.73322}}, {'facility': 'ISPG - Institut fuer Studien zur Psychischen Gesundheit', 'city': 'Mannheim', 'zip': '68165', 'country': 'Germany', 'geoPoint': {'lat': 49.4891, 'lon': 8.46694}}, {'facility': 'Klinikum rechts der Isar der Technischen Universität München', 'city': 'Munchen', 'zip': '81675', 'country': 'Germany', 'geoPoint': {'lat': 48.13743, 'lon': 11.57549}}, {'facility': 'Zentrum f. Neurologisch- Psychiatrische Studien und Begutachtung', 'city': 'Siegen', 'zip': '57072', 'country': 'Germany', 'geoPoint': {'lat': 50.87481, 'lon': 8.02431}}, {'facility': 'Nuovo Ospedale Civile S.Agostino - Estense', 'city': 'Modena', 'state': 'Emilia-Romagna', 'zip': '41126', 'country': 'Italy', 'geoPoint': {'lat': 44.64783, 'lon': 10.92539}}, {'facility': 'Policlinico Universitario Agostino Gemelli; Farmacia', 'city': 'Roma', 'state': 'Lazio', 'zip': '00168', 'country': 'Italy', 'geoPoint': {'lat': 41.89193, 'lon': 12.51133}}, {'facility': 'Fondazione Santa Lucia IRCCS', 'city': 'Roma', 'state': 'Lazio', 'zip': '00179', 'country': 'Italy', 'geoPoint': {'lat': 41.89193, 'lon': 12.51133}}, {'facility': 'Umberto I Policlinico di Roma-Università di Roma La Sapienza', 'city': 'Roma', 'state': 'Lazio', 'zip': '00185', 'country': 'Italy', 'geoPoint': {'lat': 41.89193, 'lon': 12.51133}}, {'facility': 'Ente Ospedaliero Ospedali Galliera', 'city': 'Genova', 'state': 'Liguria', 'zip': '16128', 'country': 'Italy', 'geoPoint': {'lat': 44.40478, 'lon': 8.94438}}, {'facility': 'Università degli Studi di Genova', 'city': 'Genova', 'state': 'Liguria', 'zip': '16132', 'country': 'Italy', 'geoPoint': {'lat': 44.40478, 'lon': 8.94438}}, {'facility': 'Azienda Ospedaliero Universitaria Pisana; Uff. Sperim. Clin. U.O. Farmaceutica', 'city': 'Pisa', 'state': 'Toscana', 'zip': '56126', 'country': 'Italy', 'geoPoint': {'lat': 43.70853, 'lon': 10.4036}}, {'facility': 'Università degli studi di Perugia', 'city': 'Perugia', 'state': 'Umbria', 'zip': '06126', 'country': 'Italy', 'geoPoint': {'lat': 43.1122, 'lon': 12.38878}}, {'facility': 'Dong-A University Hospital', 'city': 'Busan', 'zip': '49201', 'country': 'Korea, Republic of', 'geoPoint': {'lat': 35.10278, 'lon': 129.04028}}, {'facility': 'Seoul National University Bundang Hospital', 'city': 'Gyeonggi-do', 'zip': '13620', 'country': 'Korea, Republic of', 'geoPoint': {'lat': 37.58944, 'lon': 126.76917}}, {'facility': 'Ajou University Hospital', 'city': 'Gyeonggi-do', 'zip': '443-380', 'country': 'Korea, Republic of', 'geoPoint': {'lat': 37.58944, 'lon': 126.76917}}, {'facility': 'Inha University Hospital; Pulmonary Medicine', 'city': 'Incheon', 'zip': '400-711', 'country': 'Korea, Republic of', 'geoPoint': {'lat': 37.45646, 'lon': 126.70515}}, {'facility': 'Kyung Hee University Hospital', 'city': 'Seoul', 'zip': '02447', 'country': 'Korea, Republic of', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'facility': 'Korea University Anam Hospital', 'city': 'Seoul', 'zip': '02841', 'country': 'Korea, Republic of', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'facility': 'Severance Hospital, Yonsei University Health System', 'city': 'Seoul', 'zip': '03722', 'country': 'Korea, Republic of', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'facility': 'Konkuk University Medical Center', 'city': 'Seoul', 'zip': '05030', 'country': 'Korea, Republic of', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'facility': 'Samsung Medical Center', 'city': 'Seoul', 'zip': '06351', 'country': 'Korea, Republic of', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'facility': 'Podlaskie Centrum Psychogeriatrii', 'city': 'Bialystok', 'zip': '15-732', 'country': 'Poland', 'geoPoint': {'lat': 53.13333, 'lon': 23.16433}}, {'facility': 'Uniwersyteckie Centrum Kliniczne', 'city': 'Gdansk', 'zip': '80-214', 'country': 'Poland', 'geoPoint': {'lat': 54.35205, 'lon': 18.64637}}, {'facility': 'Specjal. Praktyka Lekarska; Prof. Grzegorz Opala', 'city': 'Katowice', 'zip': '40-588', 'country': 'Poland', 'geoPoint': {'lat': 50.25841, 'lon': 19.02754}}, {'facility': 'Centrum Medyczne Dendryt', 'city': 'Katowice', 'zip': '40-684', 'country': 'Poland', 'geoPoint': {'lat': 50.25841, 'lon': 19.02754}}, {'facility': 'NZOZ NEURO-KARD Ilkowski i Partnerzy Sp. Partn. Lek', 'city': 'Poznan', 'zip': '61-289', 'country': 'Poland', 'geoPoint': {'lat': 52.40692, 'lon': 16.92993}}, {'facility': 'NZOZ Syntonia', 'city': 'Pruszcz Gdanski', 'zip': '83-000', 'country': 'Poland', 'geoPoint': {'lat': 54.26217, 'lon': 18.63625}}, {'facility': 'NZOZ Pro-Cordis Sopockie Centrum Bad. Kardiolog', 'city': 'Sopot', 'zip': '81-717', 'country': 'Poland', 'geoPoint': {'lat': 54.4418, 'lon': 18.56003}}, {'facility': 'mMED Maciej Czarnecki', 'city': 'Warszawa', 'zip': '01-697', 'country': 'Poland', 'geoPoint': {'lat': 52.22977, 'lon': 21.01178}}, {'facility': 'Instytut Psychiatrii i Neurologii', 'city': 'Warszawa', 'zip': '02-957', 'country': 'Poland', 'geoPoint': {'lat': 52.22977, 'lon': 21.01178}}, {'facility': 'Hospital General Universitario de Elche; Servicio de Farmacia', 'city': 'Elche', 'state': 'Alicante', 'zip': '03203', 'country': 'Spain', 'geoPoint': {'lat': 38.26218, 'lon': -0.70107}}, {'facility': 'Fundació ACE', 'city': 'BArcelon', 'state': 'Barcelona', 'zip': '08034', 'country': 'Spain'}, {'facility': 'Hospital General De Catalunya; Servicio de Neurologia', 'city': 'Sant Cugat del Valles', 'state': 'Barcelona', 'zip': '8195', 'country': 'Spain', 'geoPoint': {'lat': 41.47063, 'lon': 2.08611}}, {'facility': 'Hospital Universitario Puerta de Hierro Majadahonda', 'city': 'Majadahonda', 'state': 'Madrid', 'zip': '28222', 'country': 'Spain', 'geoPoint': {'lat': 40.47353, 'lon': -3.87182}}, {'facility': 'Hospital Virgen del Puerto', 'city': 'Plasencia', 'state': 'Palencia', 'zip': '10600', 'country': 'Spain', 'geoPoint': {'lat': 40.03116, 'lon': -6.08845}}, {'facility': 'Hospital Universitario Virgen Macarena', 'city': 'Seville', 'state': 'Sevilla', 'zip': '41071', 'country': 'Spain', 'geoPoint': {'lat': 37.38283, 'lon': -5.97317}}, {'facility': 'CAE Oroitu', 'city': 'BaraKaldo', 'state': 'Vizcaya', 'zip': '48903', 'country': 'Spain', 'geoPoint': {'lat': 43.29639, 'lon': -2.98813}}, {'facility': 'Hospital Perpetuo Socorro, Servicio de Geriatria', 'city': 'Albacete', 'zip': '2006', 'country': 'Spain', 'geoPoint': {'lat': 38.99424, 'lon': -1.85643}}, {'facility': 'Hospital de la Santa Creu i Sant Pau', 'city': 'Barcelona', 'zip': '08041', 'country': 'Spain', 'geoPoint': {'lat': 41.38879, 'lon': 2.15899}}, {'facility': 'Hospital Universitario Ramón y Cajal', 'city': 'Madrid', 'zip': '28034', 'country': 'Spain', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'facility': 'Hospital Universitario Clínico San Carlos', 'city': 'Madrid', 'zip': '28040', 'country': 'Spain', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'facility': 'Hospital Universitari i Politecnic La Fe', 'city': 'Valencia', 'zip': '46026', 'country': 'Spain', 'geoPoint': {'lat': 39.46975, 'lon': -0.37739}}, {'facility': 'Skanes Universitetssjukhus, Malmo Skanes Universitetssjukhus, Malmo', 'city': 'Malmö', 'zip': '205 02', 'country': 'Sweden', 'geoPoint': {'lat': 55.60587, 'lon': 13.00073}}, {'facility': 'Karolinska Universitetssjukhuset Huddinge', 'city': 'Stockholm', 'zip': '171 64', 'country': 'Sweden', 'geoPoint': {'lat': 59.33258, 'lon': 18.0649}}, {'facility': 'Cognitive Treatment & Research Unit', 'city': 'Crowborough', 'zip': 'TN6 1HB', 'country': 'United Kingdom', 'geoPoint': {'lat': 51.06098, 'lon': 0.16342}}, {'facility': 'Ninewells Hospital', 'city': 'Dundee', 'zip': 'DD12 9SY', 'country': 'United Kingdom', 'geoPoint': {'lat': 56.46913, 'lon': -2.97489}}, {'facility': 'Glasgow Memory Clinic', 'city': 'Glasgow', 'zip': 'G20 0XA', 'country': 'United Kingdom', 'geoPoint': {'lat': 55.86515, 'lon': -4.25763}}, {'facility': 'West London Cognitive Disorders Treatment and Research Unit; Lakeside Metal Health Unit', 'city': 'Isleworth', 'zip': 'TW7 6FY', 'country': 'United Kingdom', 'geoPoint': {'lat': 51.47518, 'lon': -0.34246}}, {'facility': 'Institute of Psychiatry', 'city': 'London', 'zip': 'SE5 8AF', 'country': 'United Kingdom', 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}, {'facility': 'Norwich Medical School', 'city': 'Norwich', 'zip': 'NR4 7UY', 'country': 'United Kingdom', 'geoPoint': {'lat': 52.62783, 'lon': 1.29834}}, {'facility': 'Derriford Hospital', 'city': 'Plymouth', 'zip': 'PL6 8DH', 'country': 'United Kingdom', 'geoPoint': {'lat': 50.37153, 'lon': -4.14305}}, {'facility': 'Memory Service North', 'city': 'Sheffield', 'zip': 'S35 8QS', 'country': 'United Kingdom', 'geoPoint': {'lat': 53.38297, 'lon': -1.4659}}]}, 'referencesModule': {'references': [{'pmid': '28550255', 'type': 'DERIVED', 'citation': \"Nave S, Doody RS, Boada M, Grimmer T, Savola JM, Delmar P, Pauly-Evers M, Nikolcheva T, Czech C, Borroni E, Ricci B, Dukart J, Mannino M, Carey T, Moran E, Gilaberte I, Muelhardt NM, Gerlach I, Santarelli L, Ostrowitzki S, Fontoura P. Sembragiline in Moderate Alzheimer's Disease: Results of a Randomized, Double-Blind, Placebo-Controlled Phase II Trial (MAyflOwer RoAD). J Alzheimers Dis. 2017;58(4):1217-1228. doi: 10.3233/JAD-161309.\"}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2024-11-22', 'removedCountries': ['Czech Republic']}, 'conditionBrowseModule': {'meshes': [{'id': 'D000544', 'term': 'Alzheimer Disease'}], 'ancestors': [{'id': 'D003704', 'term': 'Dementia'}, {'id': 'D001927', 'term': 'Brain Diseases'}, {'id': 'D002493', 'term': 'Central Nervous System Diseases'}, {'id': 'D009422', 'term': 'Nervous System Diseases'}, {'id': 'D024801', 'term': 'Tauopathies'}, {'id': 'D019636', 'term': 'Neurodegenerative Diseases'}, {'id': 'D019965', 'term': 'Neurocognitive Disorders'}, {'id': 'D001523', 'term': 'Mental Disorders'}], 'browseLeaves': [{'id': 'M3885', 'name': 'Alzheimer Disease', 'asFound': \"Alzheimer's Disease\", 'relevance': 'HIGH'}, {'id': 'M6904', 'name': 'Dementia', 'relevance': 'LOW'}, {'id': 'M5204', 'name': 'Brain Diseases', 'relevance': 'LOW'}, {'id': 'M5742', 'name': 'Central Nervous System Diseases', 'relevance': 'LOW'}, {'id': 'M23002', 'name': 'Tauopathies', 'relevance': 'LOW'}, {'id': 'M21558', 'name': 'Neurodegenerative Diseases', 'relevance': 'LOW'}, {'id': 'M21836', 'name': 'Neurocognitive Disorders', 'relevance': 'LOW'}, {'id': 'M4815', 'name': 'Mental Disorders', 'relevance': 'LOW'}, {'id': 'M14473', 'name': 'Psychotic Disorders', 'relevance': 'LOW'}, {'id': 'T2192', 'name': 'Familial Alzheimer Disease', 'asFound': \"Alzheimer's Disease\", 'relevance': 'HIGH'}], 'browseBranches': [{'abbrev': 'BC10', 'name': 'Nervous System Diseases'}, {'abbrev': 'BXM', 'name': 'Behaviors and Mental Disorders'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'Rare', 'name': 'Rare Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D008559', 'term': 'Memantine'}, {'id': 'D000068836', 'term': 'Rivastigmine'}, {'id': 'D000077265', 'term': 'Donepezil'}, {'id': 'D005702', 'term': 'Galantamine'}], 'ancestors': [{'id': 'D002800', 'term': 'Cholinesterase Inhibitors'}, {'id': 'D004791', 'term': 'Enzyme Inhibitors'}, {'id': 'D045504', 'term': 'Molecular Mechanisms of Pharmacological Action'}, {'id': 'D018678', 'term': 'Cholinergic Agents'}, {'id': 'D018377', 'term': 'Neurotransmitter Agents'}, {'id': 'D045505', 'term': 'Physiological Effects of Drugs'}, {'id': 'D018697', 'term': 'Nootropic Agents'}, {'id': 'D000978', 'term': 'Antiparkinson Agents'}, {'id': 'D018726', 'term': 'Anti-Dyskinesia Agents'}, {'id': 'D015259', 'term': 'Dopamine Agents'}, {'id': 'D018691', 'term': 'Excitatory Amino Acid Antagonists'}, {'id': 'D018683', 'term': 'Excitatory Amino Acid Agents'}, {'id': 'D010277', 'term': 'Parasympathomimetics'}, {'id': 'D001337', 'term': 'Autonomic Agents'}, {'id': 'D018373', 'term': 'Peripheral Nervous System Agents'}, {'id': 'D018696', 'term': 'Neuroprotective Agents'}, {'id': 'D020011', 'term': 'Protective Agents'}], 'browseLeaves': [{'id': 'M1721', 'name': 'Donepezil', 'asFound': 'Endometrial', 'relevance': 'HIGH'}, {'id': 'M11542', 'name': 'Memantine', 'asFound': '0.05', 'relevance': 'HIGH'}, {'id': 'M317', 'name': 'Rivastigmine', 'asFound': 'PFU', 'relevance': 'HIGH'}, {'id': 'M8820', 'name': 'Galantamine', 'asFound': 'Amyotrophic Lateral Sclerosis', 'relevance': 'HIGH'}, {'id': 'M6040', 'name': 'Cholinesterase Inhibitors', 'relevance': 'LOW'}, {'id': 'M7951', 'name': 'Enzyme Inhibitors', 'relevance': 'LOW'}, {'id': 'M20758', 'name': 'Cholinergic Agents', 'relevance': 'LOW'}, {'id': 'M20504', 'name': 'Neurotransmitter Agents', 'relevance': 'LOW'}, {'id': 'M20774', 'name': 'Nootropic Agents', 'relevance': 'LOW'}, {'id': 'M4295', 'name': 'Antiparkinson Agents', 'relevance': 'LOW'}, {'id': 'M7473', 'name': 'Dopamine', 'relevance': 'LOW'}, {'id': 'M17962', 'name': 'Dopamine Agents', 'relevance': 'LOW'}, {'id': 'M20771', 'name': 'Excitatory Amino Acid Antagonists', 'relevance': 'LOW'}, {'id': 'M20773', 'name': 'Neuroprotective Agents', 'relevance': 'LOW'}, {'id': 'M21869', 'name': 'Protective Agents', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'NootAg', 'name': 'Nootropic Agents'}, {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}, {'abbrev': 'AnDyAg', 'name': 'Anti-Dyskinesia Agents'}, {'abbrev': 'NeuroAg', 'name': 'Neuroprotective Agents'}, {'abbrev': 'CaAg', 'name': 'Cardiotonic Agents'}]}}, 'hasResults': False}]}\n"
     ]
    }
   ],
   "source": [
    "import requests\n",
    "import pandas as pd\n",
    "\n",
    "BASE_URL = \"https://clinicaltrials.gov/api/v2/studies\"\n",
    "\n",
    "def fetch_study_info(study_id):\n",
    "    \"\"\"\n",
    "    Fetch study information from ClinicalTrials.gov API using a study ID.\n",
    "    \"\"\"\n",
    "    url = f\"{BASE_URL}?format=json&query.id={study_id}\"\n",
    "    response = requests.get(url)\n",
    "\n",
    "    if response.status_code == 200:\n",
    "        return response.json()\n",
    "    else:\n",
    "        raise Exception(f\"Error fetching data: {response.status_code}, {response.text}\")\n",
    "    \n",
    "study_info = fetch_study_info(\"BP28248\")\n",
    "print(\"Study Info:\", study_info)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "API Response: {'studies': [{'protocolSection': {'identificationModule': {'nctId': 'NCT00701831', 'orgStudyIdInfo': {'id': 'LANTU_L_03502'}, 'organization': {'fullName': 'Sanofi', 'class': 'INDUSTRY'}, 'briefTitle': 'Assessment of Insulin Glargine in Type 2 Patients for Good Glycemic Control', 'officialTitle': 'Assessment of Forced Titration to Reach the Effective Dose for Good Glycemic Control in Lantus Treated Type 2 Patients', 'acronym': 'LANTIT'}, 'statusModule': {'statusVerifiedDate': '2010-11', 'overallStatus': 'COMPLETED', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2008-05'}, 'primaryCompletionDateStruct': {'date': '2010-10', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2010-10', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2008-06-18', 'studyFirstSubmitQcDate': '2008-06-18', 'studyFirstPostDateStruct': {'date': '2008-06-19', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2010-11-03', 'lastUpdatePostDateStruct': {'date': '2010-11-04', 'type': 'ESTIMATED'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'oldNameTitle': 'Trial Transparency Team', 'oldOrganization': 'sanofi-aventis'}, 'leadSponsor': {'name': 'Sanofi', 'class': 'INDUSTRY'}}, 'descriptionModule': {'briefSummary': 'Primary objective:\\n\\n* To observe the efficacy of the forced titration to reach good glycemic control in Lantus treated patients\\n\\nSecondary objectives:\\n\\n* To assess the forced titration on physician and patient satisfaction\\n* To evaluate the impact of training tools by means of patient profile'}, 'conditionsModule': {'conditions': ['Diabetes Mellitus, Type 2']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE4'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 241, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': '1', 'type': 'EXPERIMENTAL', 'description': 'Insulin glargine', 'interventionNames': ['Drug: Insulin glargine']}], 'interventions': [{'type': 'DRUG', 'name': 'Insulin glargine', 'description': 'The dose is titrated according to patient needs', 'armGroupLabels': ['1']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'HbA1c, FBG', 'timeFrame': 'after treatment end (6 months)'}, {'measure': 'Final dose', 'timeFrame': 'after treatment end (6 months)'}, {'measure': 'Number of dose adjustment', 'timeFrame': 'after treatment end (6 months)'}, {'measure': 'Time to dose titration', 'timeFrame': 'after treatment end (6 months)'}], 'secondaryOutcomes': [{'measure': 'Hypoglycemia', 'timeFrame': 'after treatment end (6 months)'}, {'measure': 'Noctural hypoglycemia', 'timeFrame': 'after treatment end (6 months)'}, {'measure': 'DTSQ', 'timeFrame': 'after treatment end (6 months)'}, {'measure': 'Physician Satisfaction Questionnaire', 'timeFrame': 'after treatment end (6 months)'}]}, 'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\n\\n* T2 insulin naïve patients\\n* Patients whom their physician is considering initiation of Lantus treatment\\n* Poor glycemic control 7,5 %10 %\\n* T2 treatment with OADs more than 3 months\\n* BMI\\\\<40 kg/m2\\n\\nExclusion Criteria:\\n\\n* Impaired renal function (Cr\\\\>2mg/dl or current renal dialysis)\\n* Acute or chronic metabolic acidosis\\n* Active liver disease or serum ALT or AST \\\\>2,5 than normal\\n* History of hypoglycemia unawareness\\n* Diabetic retinopathy with surgery in the previous 3 months or planned within 3 months after study entry\\n* Pregnancy, breast feeding\\n\\nThe above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.\", 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Zeynep Cetin', 'affiliation': 'Sanofi', 'role': 'STUDY_DIRECTOR'}], 'locations': [{'facility': 'Sanofi-Aventis Administrative Office', 'city': 'Istanbul', 'country': 'Turkey', 'geoPoint': {'lat': 41.01384, 'lon': 28.94966}}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2024-11-22'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003924', 'term': 'Diabetes Mellitus, Type 2'}], 'ancestors': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}], 'browseLeaves': [{'id': 'M7119', 'name': 'Diabetes Mellitus, Type 2', 'asFound': 'Diabetes Mellitus, Type 2', 'relevance': 'HIGH'}, {'id': 'M7115', 'name': 'Diabetes Mellitus', 'relevance': 'LOW'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D000069036', 'term': 'Insulin Glargine'}], 'ancestors': [{'id': 'D007004', 'term': 'Hypoglycemic Agents'}, {'id': 'D045505', 'term': 'Physiological Effects of Drugs'}], 'browseLeaves': [{'id': 'M10365', 'name': 'Insulin', 'relevance': 'LOW'}, {'id': 'M347', 'name': 'Insulin Glargine', 'asFound': 'Memory', 'relevance': 'HIGH'}, {'id': 'M173166', 'name': 'Insulin, Globin Zinc', 'relevance': 'LOW'}, {'id': 'M10054', 'name': 'Hypoglycemic Agents', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'Hypo', 'name': 'Hypoglycemic Agents'}, {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT06081231', 'orgStudyIdInfo': {'id': 'MLei2'}, 'organization': {'fullName': 'Third Affiliated Hospital, Sun Yat-Sen University', 'class': 'OTHER'}, 'briefTitle': 'Open-Source Artificial Pancreas System Use Among People With Type 1 Diabetes Mellitus in China', 'officialTitle': 'The Safety and Efficacy of Open-Source Artificial Pancreas System Among People With Type 1 Diabetes Mellitus in China'}, 'statusModule': {'statusVerifiedDate': '2024-06', 'overallStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2019-01-01', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2026-01-01', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2026-06-01', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2023-09-26', 'studyFirstSubmitQcDate': '2023-10-05', 'studyFirstPostDateStruct': {'date': '2023-10-13', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2024-06-20', 'lastUpdatePostDateStruct': {'date': '2024-06-24', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorFullName': 'Jinhua Yan', 'investigatorTitle': 'Vice Professor,Principal Investigator,Department of Endocrinology and Metabolism', 'investigatorAffiliation': 'Third Affiliated Hospital, Sun Yat-Sen University'}, 'leadSponsor': {'name': 'Third Affiliated Hospital, Sun Yat-Sen University', 'class': 'OTHER'}}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False, 'isUsExport': False}, 'descriptionModule': {'briefSummary': 'This real-world observational study aims to reveal the current status of the open-source artificial pancreas system (APS) use among people with T1DM in China and assess the glycemic efficacy and potential related factors of the open-source APS.', 'detailedDescription': 'This is a real-world observational study analyzing data on open-source artificial pancreas systems(APS) in people with T1DM in China. Data will collected during clinical routine, questionnaires, standard-of-care laboratory tests, and CGM data among whom are willing to share. Baseline data from before the start (up to -3 months) of the open-source APS system and follow-up data at 3, 6, 9, 12, and the following period will be analyzed when available. There are no medical interventions, extra visits, or laboratory tests planned outside the normal clinical routine. Glycemic control and patient-reported outcomes during follow-up will be compared with glycemic control and patient-reported outcome data at baseline.'}, 'conditionsModule': {'conditions': ['Type 1 Diabetes Mellitus'], 'keywords': ['artificial pancreas system', 'automated insulin delivery', 'do-it-yourself', 'closed loop', 'open source']}, 'designModule': {'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'COHORT', 'timePerspective': 'OTHER'}, 'enrollmentInfo': {'count': 500, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'open-source APS', 'description': 'open-source APS consisted of an insulin pump, a CGM system, and a heuristic algorithm on an Android smartphone.', 'interventionNames': ['Device: open-source APS;']}], 'interventions': [{'type': 'DEVICE', 'name': 'open-source APS;', 'description': 'a continuous glucose monitoring system, an insulin pump, and an intelligent algorithm.', 'armGroupLabels': ['open-source APS']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'proportion of time spent in the target glucose range', 'description': 'time in range(TIR, 70-180mg/dL)', 'timeFrame': 'baseline(at least 2 weeks before the start of APS), and 3 months,6 months, 9 months, 12 months, and following period after the start of APS'}], 'secondaryOutcomes': [{'measure': 'proportion of time spent in the hypoglycemic range', 'description': 'time below range(TBR, \\\\<70mg/dL;\\\\<54mg/dL)', 'timeFrame': 'baseline(at least 2 weeks before the start of APS), and 3 months,6 months, 9 months, 12 months, and following period after the start of APS'}, {'measure': 'proportion of time spent in the hyperglycemic range', 'description': 'time above range(TAR, \\\\>180mg/dL;\\\\>250mg/dL)', 'timeFrame': 'baseline(at least 2 weeks before the start of APS), and 3 months,6 months, 9 months, 12 months, and following period after the start of APS'}, {'measure': 'concentration of HbA1c', 'description': 'glycated hemoglobin A1C', 'timeFrame': 'baseline(at least 2 weeks before the start of APS), and 3 months,6 months, 9 months, 12 months, and following period after the start of APS'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n1. diagnosed T1DM.\\n2. Currently use open-source APS for at least 3 months.\\n3. Willing and able to provide informed consent (or be a parent or other legally authorized representative) and to provide the data.\\n4. reside in China.\\n\\nExclusion Criteria:\\n\\nNone', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '3 Years', 'maximumAge': '75 Years', 'stdAges': ['CHILD', 'ADULT', 'OLDER_ADULT'], 'studyPopulation': 'people with T1DM regardless of age or pregnant state.', 'samplingMethod': 'PROBABILITY_SAMPLE'}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Jinhua Yan, PHD,MD', 'role': 'CONTACT', 'phone': '+8613929589959', 'email': 'yanjh79@163.com'}, {'name': 'Wen Xu, PHD,MD', 'role': 'CONTACT', 'phone': '02085253000', 'email': 'xwen@mail.sysu.edu.cn'}], 'overallOfficials': [{'name': 'Jinhua Yan, PHD,MD', 'affiliation': 'Third Affiliated Hospital, Sun Yat-Sen University', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'Jinhua Yan', 'status': 'RECRUITING', 'city': 'Guangzhou', 'state': 'Guangdong', 'zip': '510630', 'country': 'China', 'contacts': [{'name': 'Jinhua Yan', 'role': 'CONTACT', 'phone': '+8613929589959', 'email': 'yanjh79@163.com'}], 'geoPoint': {'lat': 23.11667, 'lon': 113.25}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2024-11-22'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D003922', 'term': 'Diabetes Mellitus, Type 1'}], 'ancestors': [{'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}, {'id': 'D001327', 'term': 'Autoimmune Diseases'}, {'id': 'D007154', 'term': 'Immune System Diseases'}], 'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'asFound': 'Diabetes Mellitus', 'relevance': 'HIGH'}, {'id': 'M7117', 'name': 'Diabetes Mellitus, Type 1', 'asFound': 'Type 1 Diabetes Mellitus', 'relevance': 'HIGH'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}, {'id': 'M4629', 'name': 'Autoimmune Diseases', 'relevance': 'LOW'}, {'id': 'M10200', 'name': 'Immune System Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC20', 'name': 'Immune System Diseases'}]}, 'interventionBrowseModule': {'browseLeaves': [{'id': 'M10365', 'name': 'Insulin', 'relevance': 'LOW'}, {'id': 'M173166', 'name': 'Insulin, Globin Zinc', 'relevance': 'LOW'}, {'id': 'M22554', 'name': 'Pancrelipase', 'relevance': 'LOW'}, {'id': 'M13114', 'name': 'Pancreatin', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'Hypo', 'name': 'Hypoglycemic Agents'}, {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}, {'abbrev': 'Gast', 'name': 'Gastrointestinal Agents'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT01835431', 'orgStudyIdInfo': {'id': 'NN5401-3816'}, 'secondaryIdInfos': [{'id': '2012-003566-41', 'type': 'EUDRACT_NUMBER'}, {'id': 'U1111-1133-0958', 'type': 'OTHER', 'domain': 'WHO'}, {'id': 'PIP no. be confirmed', 'type': 'OTHER', 'domain': 'EMA'}], 'organization': {'fullName': 'Novo Nordisk A/S', 'class': 'INDUSTRY'}, 'briefTitle': 'A Trial Investigating the Efficacy and Safety of Insulin Degludec/Insulin Aspart Once Daily Plus Insulin Aspart for the Remaining Meals Versus Insulin Detemir Once or Twice Daily Plus Meal Time Insulin Aspart in Children and Adolescents With Type 1 Diabetes Mellitus', 'officialTitle': 'A Trial Investigating the Efficacy and Safety of Insulin Degludec/Insulin Aspart Once Daily Plus Insulin Aspart for the Remaining Meals Versus Insulin Detemir Once or Twice Daily Plus Meal Time Insulin Aspart in Children and Adolescents With Type 1 Diabetes Mellitus'}, 'statusModule': {'statusVerifiedDate': '2019-06', 'overallStatus': 'COMPLETED', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2013-10-17', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2014-11-07', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2014-11-07', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2013-04-16', 'studyFirstSubmitQcDate': '2013-04-16', 'studyFirstPostDateStruct': {'date': '2013-04-19', 'type': 'ESTIMATED'}, 'resultsFirstSubmitDate': '2015-10-13', 'resultsFirstSubmitQcDate': '2015-10-13', 'resultsFirstPostDateStruct': {'date': '2015-11-17', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2019-06-03', 'lastUpdatePostDateStruct': {'date': '2019-06-11', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Novo Nordisk A/S', 'class': 'INDUSTRY'}}, 'oversightModule': {'oversightHasDmc': False}, 'descriptionModule': {'briefSummary': 'This trial is conducted in Asia, Europe and North and South America. The aim of the trial is to investigate the efficacy and safety of insulin degludec/insulin aspart once daily plus insulin aspart for the remaining meals in children and adolescents with type 1 diabetes mellitus.'}, 'conditionsModule': {'conditions': ['Diabetes', 'Diabetes Mellitus, Type 1']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE3'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 362, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Insulin degludec/insulin aspart', 'type': 'EXPERIMENTAL', 'interventionNames': ['Drug: insulin degludec/insulin aspart', 'Drug: insulin aspart']}, {'label': 'Insulin detemir', 'type': 'ACTIVE_COMPARATOR', 'interventionNames': ['Drug: insulin detemir', 'Drug: insulin aspart']}], 'interventions': [{'type': 'DRUG', 'name': 'insulin degludec/insulin aspart', 'description': 'Administered subcutaneously (s.c., under the skin) once daily with a main meal. Dose individually adjusted.', 'armGroupLabels': ['Insulin degludec/insulin aspart']}, {'type': 'DRUG', 'name': 'insulin aspart', 'description': 'Administered s.c. with the remaining meals. Dose individually adjusted.', 'armGroupLabels': ['Insulin degludec/insulin aspart']}, {'type': 'DRUG', 'name': 'insulin detemir', 'description': 'Administered s.c. once or twice daily. Dose individually adjusted. Subjects will continue with their pre-trial dosing scheme (once (OD) or twice daily (BID)) and will be allowed to switch from OD to BID dosing.', 'armGroupLabels': ['Insulin detemir']}, {'type': 'DRUG', 'name': 'insulin aspart', 'description': 'Administered s.c. at meal-times. Dose individually adjusted.', 'armGroupLabels': ['Insulin detemir']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Change From Baseline in HbA1c (Glycosylated Haemoglobin) (%)', 'description': 'Percentage point change in glycosylated haemoglobin A1c (HbA1c) from baseline (week 0) to 16 Weeks. Change from baseline summary statistics at week 16 contains only those who had both baseline and week 16 assesment.', 'timeFrame': 'Week 0 to week 16'}], 'secondaryOutcomes': [{'measure': 'Change From Baseline in Fasting Plasma Glucose', 'description': 'Change from baseline in FPG after 16 weeks of treatment. Change from baseline summary statistics at week 16 contains only those who had both baseline and week 16 assesment.', 'timeFrame': 'week 0, week 16'}, {'measure': 'Incidence of Treatment Emergent Adverse Events (TEAEs)', 'description': 'A Treatment Emergent Adverse Event (TEAE) was defined as an event with onset date on or after the first day of exposure to randomised treatment and no later than 7 days after the last day on randomised treatment.', 'timeFrame': 'After 16 weeks of treatment'}, {'measure': 'Number of Treatment Emergent Confirmed Hypoglycaemic Episodes (Plasma Glucose (PG) Below 3.1mmol/L (56mg/dL) or Severe Hypoglycaemia)', 'description': 'Treatment emergent hypoglycaemic episodes (PG \\\\< 3.1 mmol/L (56 mg/dL) or severe hypoglycaemia).\\n\\nConfirmed hypoglycaemic episodes were defined as episodes that were either:\\n\\n1. Severe (i.e. the child is having altered mental status and cannot assist in their care, is semiconscious or unconscious or in coma with or without convulsions and may require parenteral therapy (glucagon or i.v. glucose), or\\n2. An episode biochemically confirmed by PG value of \\\\<3.1 mmol/L (56 mg/dL), with or without symptoms consistent with hypoglycaemia.', 'timeFrame': 'After 16 weeks of treatment'}, {'measure': 'Number of Treatment Emergent Nocturnal Confirmed Hypoglycaemic Episodes', 'description': 'The confirmed hypoglycaemic episodes occurring between 23:00 and 07:00 were considered for this endpoint', 'timeFrame': 'After 16 weeks of treatment'}, {'measure': 'Number of Hyperglycaemic Episodes (PG Above 14.0 mmol/L (250 mg/dL) Where Subject Looks/Feels Ill', 'description': 'The episode of hyperglycaemia was noted when the glucose measurement was 14.0mmol/L or above and the subject looked /felt ill.', 'timeFrame': 'After 16 weeks of treatment'}, {'measure': 'Number of Hyperglycaemic Episodes (PG Above 14.0 mmol/L (250 mg/dL) Where Subject Looks/Feels Ill With Ketosis (Blood Ketones Above 1.5 mmol/L)', 'description': 'The episode of hyperglycaemia was noted when the glucose measurement was 14.0mmol/L or above and the subject looked /felt ill. The ketone meaurement involved an additional finger prick and ketosis was considered present if blood ketones were higher than 1.5mmol/L', 'timeFrame': 'After 16 weeks of treatment'}]}, 'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria: - Informed consent obtained before any trial related activities. Trial related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial - Subjects diagnosed with type 1 diabetes mellitus - HbA1c below or equal to 11.0% Exclusion Criteria: - Known hypoglycaemic unawareness or recurrent severe hypoglycaemic events as judged by the investigator - More than 1 episode of diabetic ketoacidosis requiring hospitalisation within the last 3 months prior to Visit 1 (Screening) - Any chronic disorder or significant concomitant disease, which in the investigator's opinion might jeopardise the subject's safety or compliance with the protocol\", 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '1 Year', 'maximumAge': '17 Years', 'stdAges': ['CHILD']}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Global Clinical Registry (GCR, 1452)', 'affiliation': 'Novo Nordisk A/S', 'role': 'STUDY_DIRECTOR'}], 'locations': [{'facility': 'Novo Nordisk Investigational Site', 'city': 'Phoenix', 'state': 'Arizona', 'zip': '85053', 'country': 'United States', 'geoPoint': {'lat': 33.44838, 'lon': -112.07404}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Tucson', 'state': 'Arizona', 'zip': '85724', 'country': 'United States', 'geoPoint': {'lat': 32.22174, 'lon': -110.92648}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Sacramento', 'state': 'California', 'zip': '95816', 'country': 'United States', 'geoPoint': {'lat': 38.58157, 'lon': -121.4944}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Aurora', 'state': 'Colorado', 'zip': '80045', 'country': 'United States', 'geoPoint': {'lat': 39.72943, 'lon': -104.83192}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Jacksonville', 'state': 'Florida', 'zip': '32207', 'country': 'United States', 'geoPoint': {'lat': 30.33218, 'lon': -81.65565}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Maitland', 'state': 'Florida', 'zip': '32751', 'country': 'United States', 'geoPoint': {'lat': 28.62778, 'lon': -81.36312}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Melbourne', 'state': 'Florida', 'zip': '32901', 'country': 'United States', 'geoPoint': {'lat': 28.08363, 'lon': -80.60811}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Tallahassee', 'state': 'Florida', 'zip': '32308', 'country': 'United States', 'geoPoint': {'lat': 30.43826, 'lon': -84.28073}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Tampa', 'state': 'Florida', 'zip': '33612', 'country': 'United States', 'geoPoint': {'lat': 27.94752, 'lon': -82.45843}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Atlanta', 'state': 'Georgia', 'zip': '30322', 'country': 'United States', 'geoPoint': {'lat': 33.749, 'lon': -84.38798}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Atlanta', 'state': 'Georgia', 'zip': '30339', 'country': 'United States', 'geoPoint': {'lat': 33.749, 'lon': -84.38798}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Idaho Falls', 'state': 'Idaho', 'zip': '83404-7596', 'country': 'United States', 'geoPoint': {'lat': 43.46658, 'lon': -112.03414}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Springfield', 'state': 'Illinois', 'zip': '62703', 'country': 'United States', 'geoPoint': {'lat': 39.80172, 'lon': -89.64371}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Indianapolis', 'state': 'Indiana', 'zip': '46202', 'country': 'United States', 'geoPoint': {'lat': 39.76838, 'lon': -86.15804}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Iowa City', 'state': 'Iowa', 'zip': '52242', 'country': 'United States', 'geoPoint': {'lat': 41.66113, 'lon': -91.53017}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Lexington', 'state': 'Kentucky', 'zip': '40503', 'country': 'United States', 'geoPoint': {'lat': 37.98869, 'lon': -84.47772}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Baltimore', 'state': 'Maryland', 'zip': '21229', 'country': 'United States', 'geoPoint': {'lat': 39.29038, 'lon': -76.61219}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Worcester', 'state': 'Massachusetts', 'zip': '01655', 'country': 'United States', 'geoPoint': {'lat': 42.26259, 'lon': -71.80229}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Kansas City', 'state': 'Missouri', 'zip': '64111', 'country': 'United States', 'geoPoint': {'lat': 39.09973, 'lon': -94.57857}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Buffalo', 'state': 'New York', 'zip': '14203', 'country': 'United States', 'geoPoint': {'lat': 42.88645, 'lon': -78.87837}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Tulsa', 'state': 'Oklahoma', 'zip': '74135', 'country': 'United States', 'geoPoint': {'lat': 36.15398, 'lon': -95.99277}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Philadelphia', 'state': 'Pennsylvania', 'zip': '19104', 'country': 'United States', 'geoPoint': {'lat': 39.95233, 'lon': -75.16379}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Philadelphia', 'state': 'Pennsylvania', 'zip': '19107', 'country': 'United States', 'geoPoint': {'lat': 39.95233, 'lon': -75.16379}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Dallas', 'state': 'Texas', 'zip': '75231', 'country': 'United States', 'geoPoint': {'lat': 32.78306, 'lon': -96.80667}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Brussels', 'zip': '1090', 'country': 'Belgium', 'geoPoint': {'lat': 50.85045, 'lon': 4.34878}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Brussels', 'zip': '1200', 'country': 'Belgium', 'geoPoint': {'lat': 50.85045, 'lon': 4.34878}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Leuven', 'zip': '3000', 'country': 'Belgium', 'geoPoint': {'lat': 50.87959, 'lon': 4.70093}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Curitiba', 'state': 'Parana', 'zip': '80810-040', 'country': 'Brazil', 'geoPoint': {'lat': -25.42778, 'lon': -49.27306}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Porto Alegre', 'state': 'Rio Grande Do Sul', 'zip': '91350-250', 'country': 'Brazil', 'geoPoint': {'lat': -30.03306, 'lon': -51.23}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'São Paulo', 'state': 'Sao Paulo', 'zip': '01228-200', 'country': 'Brazil', 'geoPoint': {'lat': -23.5475, 'lon': -46.63611}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Vancouver', 'state': 'British Columbia', 'zip': 'V6H 3V4', 'country': 'Canada', 'geoPoint': {'lat': 49.24966, 'lon': -123.11934}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'London', 'state': 'Ontario', 'zip': 'N6A 5W9', 'country': 'Canada', 'geoPoint': {'lat': 42.98339, 'lon': -81.23304}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Mississauga', 'state': 'Ontario', 'zip': 'L5B 1B8', 'country': 'Canada', 'geoPoint': {'lat': 43.5789, 'lon': -79.6583}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Montreal', 'state': 'Quebec', 'zip': 'H3T 1C5', 'country': 'Canada', 'geoPoint': {'lat': 45.50884, 'lon': -73.58781}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Montreal', 'state': 'Quebec', 'zip': 'HIT 2M4', 'country': 'Canada', 'geoPoint': {'lat': 45.50884, 'lon': -73.58781}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Zagreb', 'zip': '10 000', 'country': 'Croatia', 'geoPoint': {'lat': 45.81444, 'lon': 15.97798}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Zagreb', 'zip': '10000', 'country': 'Croatia', 'geoPoint': {'lat': 45.81444, 'lon': 15.97798}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Olomouc', 'zip': '779 00', 'country': 'Czechia', 'geoPoint': {'lat': 49.59552, 'lon': 17.25175}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Pardubice', 'zip': '53203', 'country': 'Czechia', 'geoPoint': {'lat': 50.04075, 'lon': 15.77659}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Prague 5', 'zip': '15018', 'country': 'Czechia', 'geoPoint': {'lat': 50.08804, 'lon': 14.42076}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Hyderabad', 'state': 'Andhra Pradesh', 'zip': '500034', 'country': 'India', 'geoPoint': {'lat': 17.38405, 'lon': 78.45636}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Bangalore', 'state': 'Karnataka', 'zip': '560034', 'country': 'India', 'geoPoint': {'lat': 12.97194, 'lon': 77.59369}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Mumbai', 'state': 'Maharashtra', 'zip': '400008', 'country': 'India', 'geoPoint': {'lat': 19.07283, 'lon': 72.88261}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Mumbai', 'state': 'Maharashtra', 'zip': '400012', 'country': 'India', 'geoPoint': {'lat': 19.07283, 'lon': 72.88261}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'New Dehli', 'state': 'New Delhi', 'zip': '110029', 'country': 'India'}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Chennai', 'state': 'Tamil Nadu', 'zip': '600086', 'country': 'India', 'geoPoint': {'lat': 13.08784, 'lon': 80.27847}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Beer Sheva', 'zip': '84101', 'country': 'Israel', 'geoPoint': {'lat': 31.25181, 'lon': 34.7913}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Haifa', 'zip': '31096', 'country': 'Israel', 'geoPoint': {'lat': 32.81841, 'lon': 34.9885}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Petah Tikva', 'zip': '49202', 'country': 'Israel', 'geoPoint': {'lat': 32.08707, 'lon': 34.88747}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Tel Aviv', 'country': 'Israel', 'geoPoint': {'lat': 32.08088, 'lon': 34.78057}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Tel Hashomer', 'zip': '52621', 'country': 'Israel', 'geoPoint': {'lat': 32.04195, 'lon': 34.85623}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Zerifin', 'zip': '70300', 'country': 'Israel', 'geoPoint': {'lat': 31.95857, 'lon': 4.83723}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Skopje', 'zip': '1000', 'country': 'North Macedonia', 'geoPoint': {'lat': 41.99646, 'lon': 21.43141}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Gdansk', 'zip': '80-952', 'country': 'Poland', 'geoPoint': {'lat': 54.35205, 'lon': 18.64637}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Warszawa', 'zip': '04-730', 'country': 'Poland', 'geoPoint': {'lat': 52.22977, 'lon': 21.01178}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Warszawa', 'zip': '04-736', 'country': 'Poland', 'geoPoint': {'lat': 52.22977, 'lon': 21.01178}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Moscow', 'zip': '125373', 'country': 'Russian Federation', 'geoPoint': {'lat': 55.75222, 'lon': 37.61556}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Novosibirsk', 'zip': '630048', 'country': 'Russian Federation', 'geoPoint': {'lat': 55.0415, 'lon': 82.9346}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Saint-Petersburg', 'zip': '191144', 'country': 'Russian Federation', 'geoPoint': {'lat': 59.93863, 'lon': 30.31413}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Tomsk', 'zip': '634050', 'country': 'Russian Federation', 'geoPoint': {'lat': 56.49771, 'lon': 84.97437}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Ufa', 'zip': '450106', 'country': 'Russian Federation', 'geoPoint': {'lat': 54.74306, 'lon': 55.96779}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Belgrade', 'zip': '11070', 'country': 'Serbia', 'geoPoint': {'lat': 44.80401, 'lon': 20.46513}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Nis', 'zip': '18 000', 'country': 'Serbia', 'geoPoint': {'lat': 43.32472, 'lon': 21.90333}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Novi Sad', 'zip': '21000', 'country': 'Serbia', 'geoPoint': {'lat': 45.25167, 'lon': 19.83694}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Ljubljana', 'zip': '1525', 'country': 'Slovenia', 'geoPoint': {'lat': 46.05108, 'lon': 14.50513}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Johannesburg', 'state': 'Gauteng', 'zip': '2193', 'country': 'South Africa', 'geoPoint': {'lat': -26.20227, 'lon': 28.04363}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Pretoria', 'state': 'Gauteng', 'zip': '0181', 'country': 'South Africa', 'geoPoint': {'lat': -25.74486, 'lon': 28.18783}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Mayville', 'state': 'KwaZulu-Natal', 'zip': '4058', 'country': 'South Africa', 'geoPoint': {'lat': -29.85, 'lon': 30.98333}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Barcelona', 'zip': '08035', 'country': 'Spain', 'geoPoint': {'lat': 41.38879, 'lon': 2.15899}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Esplugues Llobregat(Barcelona)', 'zip': '08950', 'country': 'Spain'}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Leganés', 'zip': '28911', 'country': 'Spain', 'geoPoint': {'lat': 40.32718, 'lon': -3.7635}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Madrid', 'zip': '28034', 'country': 'Spain', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'facility': 'Novo Nordisk Investigational Site', 'city': 'Madrid', 'zip': '28046', 'country': 'Spain', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}]}, 'referencesModule': {'references': [{'type': 'BACKGROUND', 'citation': 'Thalange N, Deeb L, Klingensmith G, Franco DR, Bardtrum L, Tutkunkardas D, Danne T. The rate of hyperglycemia and ketosis with insulin degludec-based treatment compared with insulin detemir in pediatric patients with type 1 diabetes: An analysis of data from two randomized trials. Pediatr Diabetes. 2019 May;20(3):314-320. doi: 10.1111/pedi.12821. Epub 2019 Feb 10. PMID:30666772'}, {'pmid': '30014589', 'type': 'RESULT', 'citation': 'Battelino T, Deeb LC, Ekelund M, Kinduryte O, Klingensmith GJ, Kocova M, Kovarenko M, Shehadeh N. Efficacy and safety of a fixed combination of insulin degludec/insulin aspart in children and adolescents with type 1 diabetes: A randomized trial. Pediatr Diabetes. 2018 Nov;19(7):1263-1270. doi: 10.1111/pedi.12724. Epub 2018 Aug 16.'}], 'seeAlsoLinks': [{'label': 'Clinical Trials at Novo Nordisk', 'url': 'http://novonordisk-trials.com'}]}}, 'resultsSection': {'participantFlowModule': {'recruitmentDetails': 'The trial was conducted at 63 sites in 14 countries as follows: Belgium: 3 sites; Brazil: 1 sites; Canada:\\n\\n3 sites; Czech Republic 3 sites; Croatia: 2 sites; Israel: 6 sites; Macedonia: 2 sites; Poland: 3 sites; Russia: 5 sites; Serbia: 4 sites; Slovenia: 1 sites; South Africa: 2 sites; Spain: 5 sites; and United States: 23 sites.', 'groups': [{'id': 'FG000', 'title': 'IDegAsp OD', 'description': 'Insulin degludec/insulin aspart (IDegAsp) once daily (OD) 2-4U was administered subcutaneously in the thigh, upper arm (deltoid area) or abdomen with the main meal and IAsp was given with the remaining meals 1-3 times daily for 16 weeks.'}, {'id': 'FG001', 'title': 'IDet OD/BID', 'description': 'Insulin detemir (IDet) OD/BID (once daily /twice daily) 2-4U was administered subcutaneously in the thigh, upper arm (deltoid area) or abdomen with the main meal and IAsp was given with the remaining meals 2-4 times daily for 16 weeks'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '182'}, {'groupId': 'FG001', 'numSubjects': '180'}]}, {'type': 'Exposed', 'achievements': [{'groupId': 'FG000', 'comment': 'One subject was withdrawn before exposure.', 'numSubjects': '181'}, {'groupId': 'FG001', 'comment': 'One subject was withdrawn before exposure', 'numSubjects': '179'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '174'}, {'groupId': 'FG001', 'numSubjects': '168'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '8'}, {'groupId': 'FG001', 'numSubjects': '12'}]}], 'dropWithdraws': [{'type': 'Adverse Event', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '0'}]}, {'type': 'other', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '2'}]}, {'type': 'Withdrawal by Subject', 'reasons': [{'groupId': 'FG000', 'numSubjects': '6'}, {'groupId': 'FG001', 'numSubjects': '10'}]}, {'type': 'Protocol Violation', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '0'}]}]}]}, 'baselineCharacteristicsModule': {'populationDescription': 'The Full Analysis set (FAS) included all randomised subjects.', 'groups': [{'id': 'BG000', 'title': 'IDegAsp OD', 'description': 'Insulin degludec/insulin aspart (IDegAsp) once daily (OD) 2-4U was administered subcutaneously in the thigh, upper arm (deltoid area) or abdomen with the main meal and IAsp was given with the remaining meals 1-3 times daily for 16 weeks.'}, {'id': 'BG001', 'title': 'IDet OD/BID', 'description': 'Insulin detemir (IDet) OD/BID (once daily /twice daily) 2-4U was administered subcutaneously in the thigh, upper arm (deltoid area) or abdomen with the main meal and IAsp was given with the remaining meals 2-4 times daily for 16 weeks'}, {'id': 'BG002', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'BG000', 'value': '182'}, {'groupId': 'BG001', 'value': '180'}, {'groupId': 'BG002', 'value': '362'}]}], 'measures': [{'title': 'Age, Continuous', 'paramType': 'MEAN', 'dispersionType': 'STANDARD_DEVIATION', 'unitOfMeasure': 'years', 'classes': [{'categories': [{'measurements': [{'groupId': 'BG000', 'value': '10.5', 'spread': '4.3'}, {'groupId': 'BG001', 'value': '10.8', 'spread': '4.6'}, {'groupId': 'BG002', 'value': '10.6', 'spread': '4.5'}]}]}]}, {'title': 'Sex: Female, Male', 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'groupId': 'BG000', 'value': '93'}, {'groupId': 'BG001', 'value': '94'}, {'groupId': 'BG002', 'value': '187'}]}, {'title': 'Male', 'measurements': [{'groupId': 'BG000', 'value': '89'}, {'groupId': 'BG001', 'value': '86'}, {'groupId': 'BG002', 'value': '175'}]}]}]}, {'title': 'HbA1c', 'paramType': 'MEAN', 'dispersionType': 'STANDARD_DEVIATION', 'unitOfMeasure': 'percentage (%)', 'classes': [{'categories': [{'measurements': [{'groupId': 'BG000', 'value': '8.1', 'spread': '1.2'}, {'groupId': 'BG001', 'value': '8.1', 'spread': '1.2'}, {'groupId': 'BG002', 'value': '8.1', 'spread': '1.2'}]}]}]}, {'title': 'Fasting plasma Glucose (FPG)', 'description': 'Capillary blood samples for fasting plasma glucose (FPG) were taken either at home or at the clinic in the morning on the day of visits 2, 14 and 18 by use of a home blood sampling kit. At baseline FPG assessment: IDegAsp OD: 172 subjects, IDet: 166 subjects. In total: 338 subjects', 'paramType': 'MEAN', 'dispersionType': 'STANDARD_DEVIATION', 'unitOfMeasure': 'mmol/L', 'classes': [{'categories': [{'measurements': [{'groupId': 'BG000', 'value': '8.6', 'spread': '4.4'}, {'groupId': 'BG001', 'value': '8.1', 'spread': '4.2'}, {'groupId': 'BG002', 'value': '8.4', 'spread': '4.3'}]}]}]}]}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Change From Baseline in HbA1c (Glycosylated Haemoglobin) (%)', 'description': 'Percentage point change in glycosylated haemoglobin A1c (HbA1c) from baseline (week 0) to 16 Weeks. Change from baseline summary statistics at week 16 contains only those who had both baseline and week 16 assesment.', 'populationDescription': 'The FAS included all randomised subjects. 20 subjects were withdrawn and only 4 subjects though completed the study did not have assesments.', 'reportingStatus': 'POSTED', 'paramType': 'MEAN', 'dispersionType': 'Standard Deviation', 'unitOfMeasure': 'percentage (%)', 'timeFrame': 'Week 0 to week 16', 'groups': [{'id': 'OG000', 'title': 'IDegAsp OD', 'description': 'Insulin degludec/insulin aspart (IDegAsp) once daily (OD) 2-4U was administered subcutaneously in the thigh, upper arm (deltoid area) or abdomen with the main meal and IAsp was given with the remaining meals 1-3 times daily for 16 weeks.'}, {'id': 'OG001', 'title': 'IDet OD/BID', 'description': 'Insulin detemir (IDet) OD/BID (once daily /twice daily) 2-4U was administered subcutaneously in the thigh, upper arm (deltoid area) or abdomen with the main meal and IAsp was given with the remaining meals 2-4 times daily for 16 weeks'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '173'}, {'groupId': 'OG001', 'value': '165'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-0.3', 'spread': '1.0'}, {'groupId': 'OG001', 'value': '-0.3', 'spread': '0.9'}]}]}]}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Fasting Plasma Glucose', 'description': 'Change from baseline in FPG after 16 weeks of treatment. Change from baseline summary statistics at week 16 contains only those who had both baseline and week 16 assesment.', 'populationDescription': 'The FAS included all randomised subjects. 338 subjects had assessment at baseline, 326 had assessment at week 16, 2 subjects were withdrawn before exposure and 22 subjects week 16 assessment was not done.', 'reportingStatus': 'POSTED', 'paramType': 'MEAN', 'dispersionType': 'Standard Deviation', 'unitOfMeasure': 'mmol/L', 'timeFrame': 'week 0, week 16', 'groups': [{'id': 'OG000', 'title': 'IDegAsp OD', 'description': 'Insulin degludec/insulin aspart (IDegAsp) once daily (OD) 2-4U was administered subcutaneously in the thigh, upper arm (deltoid area) or abdomen with the main meal and IAsp was given with the remaining meals 1-3 times daily for 16 weeks.'}, {'id': 'OG001', 'title': 'IDet OD/BID', 'description': 'Insulin detemir (IDet) OD/BID (once daily /twice daily) 2-4U was administered subcutaneously in the thigh, upper arm (deltoid area) or abdomen with the main meal and IAsp was given with the remaining meals 2-4 times daily for 16 weeks'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '162'}, {'groupId': 'OG001', 'value': '148'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-0.3', 'spread': '6.4'}, {'groupId': 'OG001', 'value': '-0.1', 'spread': '4.8'}]}]}]}, {'type': 'SECONDARY', 'title': 'Incidence of Treatment Emergent Adverse Events (TEAEs)', 'description': 'A Treatment Emergent Adverse Event (TEAE) was defined as an event with onset date on or after the first day of exposure to randomised treatment and no later than 7 days after the last day on randomised treatment.', 'populationDescription': 'The Safety analysis set (SAS) included all subjects receiving at least one dose of the trial product or its comparator', 'reportingStatus': 'POSTED', 'paramType': 'NUMBER', 'unitOfMeasure': 'number of events', 'timeFrame': 'After 16 weeks of treatment', 'groups': [{'id': 'OG000', 'title': 'IDegAsp OD', 'description': 'Insulin degludec/insulin aspart (IDegAsp) once daily (OD) 2-4U was administered subcutaneously in the thigh, upper arm (deltoid area) or abdomen with the main meal and IAsp was given with the remaining meals 1-3 times daily for 16 weeks.'}, {'id': 'OG001', 'title': 'IDet OD/BID', 'description': 'Insulin detemir (IDet) OD/BID (once daily /twice daily) 2-4U was administered subcutaneously in the thigh, upper arm (deltoid area) or abdomen with the main meal and IAsp was given with the remaining meals 2-4 times daily for 16 weeks'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '181'}, {'groupId': 'OG001', 'value': '179'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '501'}, {'groupId': 'OG001', 'value': '460'}]}]}]}, {'type': 'SECONDARY', 'title': 'Number of Treatment Emergent Confirmed Hypoglycaemic Episodes (Plasma Glucose (PG) Below 3.1mmol/L (56mg/dL) or Severe Hypoglycaemia)', 'description': 'Treatment emergent hypoglycaemic episodes (PG \\\\< 3.1 mmol/L (56 mg/dL) or severe hypoglycaemia).\\n\\nConfirmed hypoglycaemic episodes were defined as episodes that were either:\\n\\n1. Severe (i.e. the child is having altered mental status and cannot assist in their care, is semiconscious or unconscious or in coma with or without convulsions and may require parenteral therapy (glucagon or i.v. glucose), or\\n2. An episode biochemically confirmed by PG value of \\\\<3.1 mmol/L (56 mg/dL), with or without symptoms consistent with hypoglycaemia.', 'populationDescription': 'The SAS included all subjects receiving at least one dose of the trial product or its comparator', 'reportingStatus': 'POSTED', 'paramType': 'NUMBER', 'unitOfMeasure': 'episodes', 'timeFrame': 'After 16 weeks of treatment', 'groups': [{'id': 'OG000', 'title': 'IDegAsp OD', 'description': 'Insulin degludec/insulin aspart (IDegAsp) once daily (OD) 2-4U was administered subcutaneously in the thigh, upper arm (deltoid area) or abdomen with the main meal and IAsp was given with the remaining meals 1-3 times daily for 16 weeks.'}, {'id': 'OG001', 'title': 'IDet OD/BID', 'description': 'Insulin detemir (IDet) OD/BID (once daily /twice daily) 2-4U was administered subcutaneously in the thigh, upper arm (deltoid area) or abdomen with the main meal and IAsp was given with the remaining meals 2-4 times daily for 16 weeks'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '181'}, {'groupId': 'OG001', 'value': '179'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '2532'}, {'groupId': 'OG001', 'value': '2672'}]}]}]}, {'type': 'SECONDARY', 'title': 'Number of Treatment Emergent Nocturnal Confirmed Hypoglycaemic Episodes', 'description': 'The confirmed hypoglycaemic episodes occurring between 23:00 and 07:00 were considered for this endpoint', 'populationDescription': 'The SAS included all subjects receiving at least one dose of the trial product or its comparator', 'reportingStatus': 'POSTED', 'paramType': 'NUMBER', 'unitOfMeasure': 'episodes', 'timeFrame': 'After 16 weeks of treatment', 'groups': [{'id': 'OG000', 'title': 'IDegAsp OD', 'description': 'Insulin degludec/insulin aspart (IDegAsp) once daily (OD) 2-4U was administered subcutaneously in the thigh, upper arm (deltoid area) or abdomen with the main meal and IAsp was given with the remaining meals 1-3 times daily for 16 weeks.'}, {'id': 'OG001', 'title': 'IDet OD/BID', 'description': 'Insulin detemir (IDet) OD/BID (once daily /twice daily) 2-4U was administered subcutaneously in the thigh, upper arm (deltoid area) or abdomen with the main meal and IAsp was given with the remaining meals 2-4 times daily for 16 weeks'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '181'}, {'groupId': 'OG001', 'value': '179'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '316'}, {'groupId': 'OG001', 'value': '291'}]}]}]}, {'type': 'SECONDARY', 'title': 'Number of Hyperglycaemic Episodes (PG Above 14.0 mmol/L (250 mg/dL) Where Subject Looks/Feels Ill', 'description': 'The episode of hyperglycaemia was noted when the glucose measurement was 14.0mmol/L or above and the subject looked /felt ill.', 'populationDescription': 'The SAS included all subjects receiving at least one dose of the trial product or its comparator', 'reportingStatus': 'POSTED', 'paramType': 'NUMBER', 'unitOfMeasure': 'episodes', 'timeFrame': 'After 16 weeks of treatment', 'groups': [{'id': 'OG000', 'title': 'IDegAsp OD', 'description': 'Insulin degludec/insulin aspart (IDegAsp) once daily (OD) 2-4U was administered subcutaneously in the thigh, upper arm (deltoid area) or abdomen with the main meal and IAsp was given with the remaining meals 1-3 times daily for 16 weeks.'}, {'id': 'OG001', 'title': 'IDet OD/BID', 'description': 'Insulin detemir (IDet) OD/BID (once daily /twice daily) 2-4U was administered subcutaneously in the thigh, upper arm (deltoid area) or abdomen with the main meal and IAsp was given with the remaining meals 2-4 times daily for 16 weeks'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '181'}, {'groupId': 'OG001', 'value': '179'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '599'}, {'groupId': 'OG001', 'value': '449'}]}]}]}, {'type': 'SECONDARY', 'title': 'Number of Hyperglycaemic Episodes (PG Above 14.0 mmol/L (250 mg/dL) Where Subject Looks/Feels Ill With Ketosis (Blood Ketones Above 1.5 mmol/L)', 'description': 'The episode of hyperglycaemia was noted when the glucose measurement was 14.0mmol/L or above and the subject looked /felt ill. The ketone meaurement involved an additional finger prick and ketosis was considered present if blood ketones were higher than 1.5mmol/L', 'populationDescription': 'The SAS included all subjects receiving at least one dose of the trial product or its comparator', 'reportingStatus': 'POSTED', 'paramType': 'NUMBER', 'unitOfMeasure': 'episodes', 'timeFrame': 'After 16 weeks of treatment', 'groups': [{'id': 'OG000', 'title': 'IDegAsp OD', 'description': 'Insulin degludec/insulin aspart (IDegAsp) once daily (OD) 2-4U was administered subcutaneously in the thigh, upper arm (deltoid area) or abdomen with the main meal and IAsp was given with the remaining meals 1-3 times daily for 16 weeks.'}, {'id': 'OG001', 'title': 'IDet OD/BID', 'description': 'Insulin detemir (IDet) OD/BID (once daily /twice daily) 2-4U was administered subcutaneously in the thigh, upper arm (deltoid area) or abdomen with the main meal and IAsp was given with the remaining meals 2-4 times daily for 16 weeks'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '181'}, {'groupId': 'OG001', 'value': '179'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '6'}, {'groupId': 'OG001', 'value': '12'}]}]}]}]}, 'adverseEventsModule': {'frequencyThreshold': '5', 'timeFrame': 'Onset date on or after the first day of esxposure to randomised treatment and no later than 7 days after the last day on randomised treatment', 'description': 'The SAS included all subjects receiving at least one dose of the trial product or its comparator', 'eventGroups': [{'id': 'EG000', 'title': 'IDegAsp OD', 'description': 'Insulin degludec/insulin aspart (IDegAsp) once daily (OD) 2-4U was administered subcutaneously in the thigh, upper arm (deltoid area) or abdomen with the main meal and IAsp was given with the remaining meals 1-3 times daily for 16 weeks.', 'seriousNumAffected': 11, 'seriousNumAtRisk': 181, 'otherNumAffected': 96, 'otherNumAtRisk': 181}, {'id': 'EG001', 'title': 'IDet OD/BID', 'description': 'Insulin detemir (IDet) OD/BID (once daily /twice daily) 2-4U was administered subcutaneously in the thigh, upper arm (deltoid area) or abdomen with the main meal and IAsp was given with the remaining meals 2-4 times daily for 16 weeks', 'seriousNumAffected': 7, 'seriousNumAtRisk': 179, 'otherNumAffected': 97, 'otherNumAtRisk': 179}], 'seriousEvents': [{'term': 'Fall', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 17.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 181}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 179}]}, {'term': 'Fibula Fracture', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 17.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 181}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 179}]}, {'term': 'Tibia Fracture', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 17.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 181}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 179}]}, {'term': 'Diabetic Ketoacidosis', 'organSystem': 'Metabolism and nutrition disorders', 'sourceVocabulary': 'MedDRA 17.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 181}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 179}]}, {'term': 'Hyperglycaemia', 'organSystem': 'Metabolism and nutrition disorders', 'sourceVocabulary': 'MedDRA 17.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 181}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 179}]}, {'term': 'Hypoglycaemia', 'organSystem': 'Metabolism and nutrition disorders', 'sourceVocabulary': 'MedDRA 17.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 5, 'numAffected': 5, 'numAtRisk': 181}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 179}]}, {'term': 'Compartment syndrome', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 17.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 181}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 179}]}, {'term': 'Hypoglycaemic seizure', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 17.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 181}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 179}]}, {'term': 'Loss of consciousness', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 17.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 181}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 179}]}, {'term': 'Developmental glaucoma', 'organSystem': 'Congenital, familial and genetic disorders', 'sourceVocabulary': 'MedDRA 17.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 181}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 179}]}, {'term': 'Constipation', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 17.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 181}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 179}]}, {'term': 'Gastritis', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 17.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 181}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 179}]}, {'term': 'Laryngitis', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 17.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 181}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 179}]}, {'term': 'Viral infection', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 17.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 181}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 179}]}], 'otherEvents': [{'term': 'Abdominal pain', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 17.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 13, 'numAffected': 10, 'numAtRisk': 181}, {'groupId': 'EG001', 'numEvents': 13, 'numAffected': 7, 'numAtRisk': 179}]}, {'term': 'Abdominal pain upper', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 17.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 22, 'numAffected': 14, 'numAtRisk': 181}, {'groupId': 'EG001', 'numEvents': 26, 'numAffected': 17, 'numAtRisk': 179}]}, {'term': 'Vomiting', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 17.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 25, 'numAffected': 22, 'numAtRisk': 181}, {'groupId': 'EG001', 'numEvents': 13, 'numAffected': 12, 'numAtRisk': 179}]}, {'term': 'Influenza', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 17.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 10, 'numAffected': 9, 'numAtRisk': 181}, {'groupId': 'EG001', 'numEvents': 12, 'numAffected': 10, 'numAtRisk': 179}]}, {'term': 'Nasopharyngitis', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 17.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 43, 'numAffected': 36, 'numAtRisk': 181}, {'groupId': 'EG001', 'numEvents': 42, 'numAffected': 32, 'numAtRisk': 179}]}, {'term': 'Pharyngitis', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 17.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 181}, {'groupId': 'EG001', 'numEvents': 13, 'numAffected': 10, 'numAtRisk': 179}]}, {'term': 'Upper respiratory tract infection', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 17.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 12, 'numAffected': 11, 'numAtRisk': 181}, {'groupId': 'EG001', 'numEvents': 18, 'numAffected': 17, 'numAtRisk': 179}]}, {'term': 'Headache', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 17.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 47, 'numAffected': 23, 'numAtRisk': 181}, {'groupId': 'EG001', 'numEvents': 64, 'numAffected': 32, 'numAtRisk': 179}]}, {'term': 'Pyrexia', 'organSystem': 'General disorders', 'sourceVocabulary': 'MedDRA 17.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 26, 'numAffected': 17, 'numAtRisk': 181}, {'groupId': 'EG001', 'numEvents': 15, 'numAffected': 10, 'numAtRisk': 179}]}, {'term': 'cough', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'MedDRA 17.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 16, 'numAffected': 13, 'numAtRisk': 181}, {'groupId': 'EG001', 'numEvents': 9, 'numAffected': 9, 'numAtRisk': 179}]}, {'term': 'Oropharyngeal pain', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'MedDRA 17.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 13, 'numAffected': 9, 'numAtRisk': 181}, {'groupId': 'EG001', 'numEvents': 14, 'numAffected': 13, 'numAtRisk': 179}]}]}, 'moreInfoModule': {'certainAgreement': {'piSponsorEmployee': False, 'restrictionType': 'OTHER', 'restrictiveAgreement': True, 'otherDetails': 'Novo Nordisk maintains the right to be informed of plans by any investigator to publish and to review any scientific paper, presentation, communication or other information concerning the investigation described in this protocol. Any such communication must be submitted in writing to Novo Nordisk before submission for comments. Comments will be given within four weeks from receipt of the planned communication'}, 'pointOfContact': {'title': 'Public Access to Clinical Trials', 'organization': 'Novo Nordisk A/S', 'email': 'clinicaltrials@novonordisk.com'}}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2024-11-22', 'removedCountries': ['Czech Republic', 'Macedonia, The Former Yugoslav Republic of']}, 'conditionBrowseModule': {'meshes': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D003922', 'term': 'Diabetes Mellitus, Type 1'}], 'ancestors': [{'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}, {'id': 'D001327', 'term': 'Autoimmune Diseases'}, {'id': 'D007154', 'term': 'Immune System Diseases'}], 'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'asFound': 'Diabetes Mellitus', 'relevance': 'HIGH'}, {'id': 'M7117', 'name': 'Diabetes Mellitus, Type 1', 'asFound': 'Diabetes Mellitus, Type 1', 'relevance': 'HIGH'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}, {'id': 'M4629', 'name': 'Autoimmune Diseases', 'relevance': 'LOW'}, {'id': 'M10200', 'name': 'Immune System Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC20', 'name': 'Immune System Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D007328', 'term': 'Insulin'}, {'id': 'C557859', 'term': 'Insulin, Globin Zinc'}, {'id': 'D061267', 'term': 'Insulin Aspart'}, {'id': 'D049528', 'term': 'Insulin, Long-Acting'}, {'id': 'C578220', 'term': 'Insulin degludec, insulin aspart drug combination'}, {'id': 'D000069057', 'term': 'Insulin Detemir'}], 'ancestors': [{'id': 'D007004', 'term': 'Hypoglycemic Agents'}, {'id': 'D045505', 'term': 'Physiological Effects of Drugs'}], 'browseLeaves': [{'id': 'M10365', 'name': 'Insulin', 'asFound': 'Use', 'relevance': 'HIGH'}, {'id': 'M173166', 'name': 'Insulin, Globin Zinc', 'asFound': 'Use', 'relevance': 'HIGH'}, {'id': 'M29801', 'name': 'Insulin Aspart', 'asFound': 'Complications', 'relevance': 'HIGH'}, {'id': 'M349', 'name': 'Insulin Detemir', 'asFound': 'Generated', 'relevance': 'HIGH'}, {'id': 'M17768', 'name': 'Zinc', 'relevance': 'LOW'}, {'id': 'M26073', 'name': 'Insulin, Long-Acting', 'asFound': 'Complications', 'relevance': 'HIGH'}, {'id': 'M117006', 'name': 'Insulin degludec, insulin aspart drug combination', 'asFound': 'Complications', 'relevance': 'HIGH'}, {'id': 'M10054', 'name': 'Hypoglycemic Agents', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'Hypo', 'name': 'Hypoglycemic Agents'}, {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}, {'abbrev': 'Micro', 'name': 'Micronutrients'}]}}, 'hasResults': True}, {'protocolSection': {'identificationModule': {'nctId': 'NCT00272831', 'orgStudyIdInfo': {'id': 'PWH 2005-146-T'}, 'organization': {'fullName': 'Chinese University of Hong Kong', 'class': 'OTHER'}, 'briefTitle': 'The Use of Cilostazol in Patients With Diabetic Nephropathy', 'officialTitle': 'A Randomised, Double-Blind, Placebo-Controlled Study of Cilostazol 100 mg Twice Daily in the Treatment of Diabetic Nephropathy in Hong Kong Chinese'}, 'statusModule': {'statusVerifiedDate': '2009-05', 'overallStatus': 'COMPLETED', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2005-12'}, 'primaryCompletionDateStruct': {'date': '2007-12', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2007-12', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2006-01-05', 'studyFirstSubmitQcDate': '2006-01-05', 'studyFirstPostDateStruct': {'date': '2006-01-09', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2009-05-21', 'lastUpdatePostDateStruct': {'date': '2009-05-22', 'type': 'ESTIMATED'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'oldNameTitle': 'Dr Peter CY Tong', 'oldOrganization': 'Chinese University of Hong Kong'}, 'leadSponsor': {'name': 'Chinese University of Hong Kong', 'class': 'OTHER'}}, 'oversightModule': {'oversightHasDmc': False}, 'descriptionModule': {'briefSummary': 'Patients with type 2 diabetes have a long duration of disease for the development of complications. Among all complications, microangiopathic complications are major causes of mortality and morbidity in diabetic patients. In Asia, patients with type 2 diabetes are particularly susceptible to the development of kidney disease. Patients with diabetic kidney disease have more adverse metabolic profiles and increased risk of having other complications such as blindness, stroke, heart attack and nerve damage than those without. Despite receiving the best of care, the combined event rate of death, cardiovascular disease and end stage kidney disease in diabetic patients with renal impairment remained as high as 10% per year.\\n\\nCilostazol reduces platelet aggregation and prevents formation of blood clots. Furthermore, cilostazol treatment has been shown to reduce serum triglyceride concentrations and increase HDL-cholesterol levels. In this randomized placebo-controlled, double-blinded study, the investigators hypothesize that Cilostazol may reduce the rate of decline in renal function in Chinese patients with type 2 diabetes and mild to moderate renal impairment. Sixty patients will be randomised to receive either Cilostazol 100 mg twice daily or placebo for 12 months. The effect of Cilostazol on the progression of diabetic nephropathy, as defined by rates of decline in glomerular filtration rate, serum creatinine and urinary albumin excretion rate will be measured. The results will provide additional insight on the management of diabetic kidney disease which is prevalent among Chinese diabetic patients in Hong Kong.', 'detailedDescription': 'Hypothesis:\\n\\nCilostazol reduces the rate of decline in renal function in Chinese patients with type 2 diabetes and mild to moderate renal impairment secondary to diabetic nephropathy.\\n\\nObjectives:\\n\\nTo assess the suppressive effect of Cilostazol on the progression of diabetic nephropathy, as defined by rates of decline in glomerular filtration rate, serum creatinine and urinary albumin excretion rate.\\n\\nThe rising prevalence of diabetes in Asia imposes a heavy burden on the health care system. Given the increasingly early onset of disease, patients with type 2 diabetes have long duration of disease for the development of complications. Among all complications, microangiopathic complications are major causes of mortality and morbidity in diabetic patients. In Asia, patients with type 2 diabetes are particularly susceptible to the development of nephropathy. Among dialysis patients, the primary disease is diabetic nephropathy in about 40 to 50 % of patients. Despite the inhibition of the renin angiotensin system using either ACE inhibitor or AII receptor blocker (ARB) as well as introduction of tight glycaemic and blood pressure control, the prevalence of diabetic nephropathy remains high. More importantly, patients with nephropathy have more adverse metabolic profiles and increased risk of having other complications such as retinopathy, macrovascular diseases and neuropathy than those without. Indeed, according to the RENAAL Study, despite receiving the best of care, the combined event rate of death, cardiovascular disease and end stage renal disease in diabetic patients with renal impairment remained as high as 10% per year.\\n\\nCilostazol exerts antiplatelet, antithrombotic and vasodilating effects by inhibiting phosphodiesterase type 3 in platelets and vascular smooth muscle cells. Furthermore, cilostazol treatment has been shown to reduce serum triglyceride concentrations and increase HDL-cholesterol levels. In Japanese patients with type 2 diabetes, cilostazol therapy was associated with regression of carotid intimal media thickness and could prevent the onset of silent brain infarction. On the other hand, abnormal metabolism of prostaglandins in renal glomeruli has been postulated to modulate renal haemodynamics. Elevated levels of platelet-derived microparticles and soluble adhesion molecules may further contribute to the development of diabetic nephropathy. Cilostazol treatment had been shown to reduce serum levels of PMP, activated platelet subsets, soluble adhesion molecules and urinary excretion of thromboxane B2 in patients with type 2 diabetes. These changes were accompanied by a reduction in urinary albumin excretion and an increase in creatinine clearance.'}, 'conditionsModule': {'conditions': ['Diabetes Mellitus, Type 2', 'Diabetes Complications'], 'keywords': ['Diabetic nephropathy', 'Macroalbuminuria', 'Pletaal']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE4'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 62, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Cilostazol', 'type': 'ACTIVE_COMPARATOR', 'description': 'Cilostazol 100 mg twice daily', 'interventionNames': ['Drug: Cilostazol']}, {'label': 'Placebo', 'type': 'PLACEBO_COMPARATOR', 'interventionNames': ['Drug: Placebo']}], 'interventions': [{'type': 'DRUG', 'name': 'Cilostazol', 'description': 'Cilostazol 100 mg twice daily', 'armGroupLabels': ['Cilostazol'], 'otherNames': ['Pletaal']}, {'type': 'DRUG', 'name': 'Placebo', 'description': '1 tablet twice daily', 'armGroupLabels': ['Placebo']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Doubling of serum creatinine level', 'timeFrame': '1 year'}, {'measure': '50% reduction in GFR (estimated by MDRD equation)', 'timeFrame': '1 year'}, {'measure': 'GFR less than 15 ml/min/1.73m2', 'timeFrame': '1 year'}, {'measure': 'Need for dialysis', 'timeFrame': '1 year'}, {'measure': 'Death related to renal causes', 'timeFrame': '1 year'}, {'measure': 'Fatal or severe bleeding', 'timeFrame': '1 year'}], 'secondaryOutcomes': [{'measure': 'Composite cardiovascular endpoints (acute myocardial infarction, revascularisation procedures, heart failure or unstable angina or arrhythmia) requiring hospital admissions, lower extremity amputation)', 'timeFrame': '1 year'}, {'measure': 'Number of hospital admissions, total number of days of hospital stay and attendance at the Accident and Emergency Department', 'timeFrame': '1 year'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n1. Male or female patients aged between 20 and 70 years\\n2. Patients with Type 2 diabetic mellitus\\n3. A fasting urinary albumin/creatinine ratio greater than or equal to 30 mg/mmol or 24 hour urinary albumin excretion greater than or equal to 300 mg/day in two urine collections during the baseline period\\n4. Two consecutive serum creatinine levels during baseline period which meet the following requirements:\\n\\n   * Women: between 80 umol/l and 250 umol/l (inclusive)\\n   * Men: between 105 umol/l and 250 umol/l (inclusive)\\n5. Written informed consent\\n\\nExclusion Criteria:\\n\\n* Pregnancy\\n* Known allergy to cilostazol or aspirin\\n* Congestive heart failure (NYHA class III to IV)\\n* Severe liver impairment (greater than or equal to 3 times ULN of ALT)\\n* Serum potassium levels greater than or equal to 5.5 mmol/l on 2 consecutive specimens', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '20 Years', 'maximumAge': '70 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Peter C Tong, PhD, MBBS', 'affiliation': 'Chinese University of Hong Kong', 'role': 'PRINCIPAL_INVESTIGATOR'}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2024-11-22', 'removedCountries': ['Hong Kong']}, 'conditionBrowseModule': {'meshes': [{'id': 'D007674', 'term': 'Kidney Diseases'}, {'id': 'D003928', 'term': 'Diabetic Nephropathies'}, {'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D003924', 'term': 'Diabetes Mellitus, Type 2'}, {'id': 'D048909', 'term': 'Diabetes Complications'}], 'ancestors': [{'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}, {'id': 'D014570', 'term': 'Urologic Diseases'}, {'id': 'D052776', 'term': 'Female Urogenital Diseases'}, {'id': 'D005261', 'term': 'Female Urogenital Diseases and Pregnancy Complications'}, {'id': 'D000091642', 'term': 'Urogenital Diseases'}, {'id': 'D052801', 'term': 'Male Urogenital Diseases'}], 'browseLeaves': [{'id': 'M7119', 'name': 'Diabetes Mellitus, Type 2', 'asFound': 'Diabetes Mellitus, Type 2', 'relevance': 'HIGH'}, {'id': 'M10698', 'name': 'Kidney Diseases', 'asFound': 'Nephropathy', 'relevance': 'HIGH'}, {'id': 'M7115', 'name': 'Diabetes Mellitus', 'asFound': 'Diabetes', 'relevance': 'HIGH'}, {'id': 'M7123', 'name': 'Diabetic Nephropathies', 'asFound': 'Diabetic Nephropathy', 'relevance': 'HIGH'}, {'id': 'M26004', 'name': 'Diabetes Complications', 'asFound': 'Diabetes Complications', 'relevance': 'HIGH'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}, {'id': 'M17319', 'name': 'Urologic Diseases', 'relevance': 'LOW'}, {'id': 'M2875', 'name': 'Urogenital Diseases', 'relevance': 'LOW'}, {'id': 'M27093', 'name': 'Female Urogenital Diseases', 'relevance': 'LOW'}, {'id': 'M14127', 'name': 'Pregnancy Complications', 'relevance': 'LOW'}, {'id': 'M8399', 'name': 'Female Urogenital Diseases and Pregnancy Complications', 'relevance': 'LOW'}, {'id': 'M27095', 'name': 'Male Urogenital Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BXS', 'name': 'Urinary Tract, Sexual Organs, and Pregnancy Conditions'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D000077407', 'term': 'Cilostazol'}], 'ancestors': [{'id': 'D001993', 'term': 'Bronchodilator Agents'}, {'id': 'D001337', 'term': 'Autonomic Agents'}, {'id': 'D018373', 'term': 'Peripheral Nervous System Agents'}, {'id': 'D045505', 'term': 'Physiological Effects of Drugs'}, {'id': 'D018927', 'term': 'Anti-Asthmatic Agents'}, {'id': 'D019141', 'term': 'Respiratory System Agents'}, {'id': 'D005343', 'term': 'Fibrinolytic Agents'}, {'id': 'D050299', 'term': 'Fibrin Modulating Agents'}, {'id': 'D045504', 'term': 'Molecular Mechanisms of Pharmacological Action'}, {'id': 'D010975', 'term': 'Platelet Aggregation Inhibitors'}, {'id': 'D014665', 'term': 'Vasodilator Agents'}, {'id': 'D018696', 'term': 'Neuroprotective Agents'}, {'id': 'D020011', 'term': 'Protective Agents'}, {'id': 'D058987', 'term': 'Phosphodiesterase 3 Inhibitors'}, {'id': 'D010726', 'term': 'Phosphodiesterase Inhibitors'}, {'id': 'D004791', 'term': 'Enzyme Inhibitors'}], 'browseLeaves': [{'id': 'M1788', 'name': 'Cilostazol', 'asFound': 'Doxycycline', 'relevance': 'HIGH'}, {'id': 'M5269', 'name': 'Bronchodilator Agents', 'relevance': 'LOW'}, {'id': 'M20963', 'name': 'Anti-Asthmatic Agents', 'relevance': 'LOW'}, {'id': 'M21137', 'name': 'Respiratory System Agents', 'relevance': 'LOW'}, {'id': 'M8473', 'name': 'Fibrinolytic Agents', 'relevance': 'LOW'}, {'id': 'M13865', 'name': 'Platelet Aggregation Inhibitors', 'relevance': 'LOW'}, {'id': 'M17412', 'name': 'Vasodilator Agents', 'relevance': 'LOW'}, {'id': 'M20773', 'name': 'Neuroprotective Agents', 'relevance': 'LOW'}, {'id': 'M21869', 'name': 'Protective Agents', 'relevance': 'LOW'}, {'id': 'M29333', 'name': 'Phosphodiesterase 3 Inhibitors', 'relevance': 'LOW'}, {'id': 'M13629', 'name': 'Phosphodiesterase Inhibitors', 'relevance': 'LOW'}, {'id': 'M7951', 'name': 'Enzyme Inhibitors', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'FiAg', 'name': 'Fibrinolytic Agents'}, {'abbrev': 'VaDiAg', 'name': 'Vasodilator Agents'}, {'abbrev': 'NeuroAg', 'name': 'Neuroprotective Agents'}, {'abbrev': 'PlAggInh', 'name': 'Platelet Aggregation Inhibitors'}, {'abbrev': 'Resp', 'name': 'Respiratory System Agents'}, {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT01871831', 'orgStudyIdInfo': {'id': 'IDT-1326-IU'}, 'organization': {'fullName': 'Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm', 'class': 'OTHER'}, 'briefTitle': 'Assessment of Blood Glucose Monitoring Systems - Evaluation of Oxygen Dependency', 'officialTitle': 'Prüfung Von Blutzuckermesssystemen - Bewertung Der Sauerstoffabhängigkeit', 'acronym': 'IDT-1326-IU'}, 'statusModule': {'statusVerifiedDate': '2013-10', 'overallStatus': 'COMPLETED', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2013-06'}, 'primaryCompletionDateStruct': {'date': '2013-10', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2013-10', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2013-05-29', 'studyFirstSubmitQcDate': '2013-06-04', 'studyFirstPostDateStruct': {'date': '2013-06-07', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2015-01-13', 'lastUpdatePostDateStruct': {'date': '2015-01-14', 'type': 'ESTIMATED'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm', 'class': 'OTHER'}, 'collaborators': [{'name': 'Roche Diagnostics GmbH', 'class': 'INDUSTRY'}]}, 'descriptionModule': {'briefSummary': 'Systems for blood glucose monitoring with glucose oxidase enzyme reaction on test strips can be affected by the partial pressure of oxygen of the blood sample. In this study, we investigate the influence of different partial pressure of oxygen in blood samples on measurement results. Systems with labelled oxygen-dependency as well as systems without labelled oxygen-dependency are evaluated.'}, 'conditionsModule': {'conditions': ['Diabetes']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'enrollmentInfo': {'count': 20, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'interventions': [{'type': 'DEVICE', 'name': '6 blood glucose monitoring systems for self-testing'}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': \"Influence of the blood sample's partial pressure on blood glucose measurement results\", 'timeFrame': 'For each sample, preparation and measurment procedure have an expected duration of about 2 hours'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* 18 years of age or older\\n* male or female subjects with type 1 or type 2 diabetes or healthy subjects\\n* signed informed consent form\\n\\nExclusion Criteria:\\n\\n* pregnancy or lactation period\\n* severe acute illness that, in the opinion of the investigator, might pose additional risk to the subject\\n* severe chronic illness that, in the opinion of the investigator, might pose additional risk to the subject', 'healthyVolunteers': True, 'sex': 'ALL', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Cornelia Haug, MD', 'affiliation': 'Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft an der Universität Ulm', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft an der Universität Ulm', 'city': 'Ulm', 'zip': '89081', 'country': 'Germany', 'geoPoint': {'lat': 48.39841, 'lon': 9.99155}}]}, 'referencesModule': {'references': [{'pmid': '24351177', 'type': 'RESULT', 'citation': 'Baumstark A, Schmid C, Pleus S, Haug C, Freckmann G. Influence of partial pressure of oxygen in blood samples on measurement performance in glucose-oxidase-based systems for self-monitoring of blood glucose. J Diabetes Sci Technol. 2013 Nov 1;7(6):1513-21. doi: 10.1177/193229681300700611.'}], 'seeAlsoLinks': [{'label': 'Related Info', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24351177'}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2024-11-22'}, 'conditionBrowseModule': {'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT01643031', 'orgStudyIdInfo': {'id': '6793'}, 'organization': {'fullName': 'Rabin Medical Center', 'class': 'OTHER'}, 'briefTitle': 'Effect of Modifying Anti-platelet Treatment to Ticagrelor in Patients With Diabetes and Low Response to Clopidogrel', 'officialTitle': 'Effect of Modifying Anti-platelet Treatment to Ticagrelor in Patients With Diabetes and Low Response to Clopidogrel', 'acronym': 'MATTIS-D'}, 'statusModule': {'statusVerifiedDate': '2013-06', 'overallStatus': 'UNKNOWN', 'lastKnownStatus': 'NOT_YET_RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2012-08'}, 'primaryCompletionDateStruct': {'date': '2014-09', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2014-10', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2012-07-15', 'studyFirstSubmitQcDate': '2012-07-15', 'studyFirstPostDateStruct': {'date': '2012-07-17', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2013-06-14', 'lastUpdatePostDateStruct': {'date': '2013-06-17', 'type': 'ESTIMATED'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorFullName': 'eli lev', 'investigatorTitle': 'Prof. Eli Lev, Director, Cardiac catheterization laboratory, Hasharon Hospital, Rabin Medical Center, Israel', 'investigatorAffiliation': 'Rabin Medical Center'}, 'leadSponsor': {'name': 'Rabin Medical Center', 'class': 'OTHER'}, 'collaborators': [{'name': 'Tel Aviv Medical Center', 'class': 'OTHER'}, {'name': 'Sheba Medical Center', 'class': 'OTHER_GOV'}, {'name': 'Meir Medical Center', 'class': 'OTHER'}, {'name': 'Rambam Health Care Campus', 'class': 'OTHER'}]}, 'oversightModule': {'oversightHasDmc': True}, 'descriptionModule': {'briefSummary': 'In recent years numerous studies have shown that the response of patients to the anti-platelet drug clopidogrel is widely variable. Furthermore, patients who do not respond well to the drug (\"resistant\") have been shown to be at increased risk to develop cardiac events, including myocardial infarction and mortality. It thus seems reasonable to test the efficacy of the drug (by platelet function tests) and modify treatment accordingly. However, a large study that examined a strategy of routine testing of clopidogrel response in thousands of patients (GRAVITAS study) did not show any clinical benefit. This study was limited, however, by a very low event rate (2.3%), and by the strategy employed to treat patients with low response (increasing the clopidogrel dose), which is currently known to be ineffective in many patients with low response. To overcome these limitations the investigators plan to examine a high risk population - patients with diabetes planned to undergo coronary angiography - and to treat clopidogrel low responders by switching their treatment to the potent anti-platelet drug ticagrelor, which has been shown to overcome clopidogrel low response.\\n\\nThe investigators hypothesize that patients with diabetes and low response to clopidogrel will benefit clinically from switching therapy to ticagrelor. The main endpoint of the study will be the risk of myocardial enzyme elevation following percutaneous coronary intervention (PCI); a marker which has been strongly associated with poor clinical outcome.\\n\\nThe aim of the study is, therefore, to assess whether a strategy of monitoring platelet function during clopidogrel treatment in patients with diabetes undergoing PCI, and modifying treatment to ticagrelor in patients with low response, will be associated with reduced risk of myocardial enzyme release.\\n\\nThe investigators plan to enroll patients with treated diabetes, planned to undergo coronary angiography. Patients with acute or recent myocardial infarction will be excluded. They will be tested for response to clopidogrel by the VerifyNow P2Y12 assay (either on chronic clopidogrel treatment or 12-24 hours after receiving 300 mg clopidogrel). Patients with low response to clopidogrel (≥ 208 PRU) will be randomized to either continued treatment with clopidogrel (75 mg/day), or switching of treatment to ticagrelor (90 mg twice a day) for 30 days (followed by continued clopidogrel therapy). The primary endpoint will be the rate of troponin of CK-MB (cardiac enzymes) measured 20-24 hours after the PCI. Secondary endpoints will be the occurrence of adverse clinical endpoints - myocardial infarction, need for urgent revascularization or mortality at 30 days. The investigators aim to enroll 100 patients in each study group (ticagrelor vs. continued clopidogrel). Assuming a clopidogrel low response rate of 40% among patients with diabetes, about 500 patients would have to be screened to identify 200 patients with low response.', 'detailedDescription': \"BACKGOUND The concept of monitoring platelet reactivity in patients treated with clopidogrel and tailoring treatment according to the results has been under intense debate in recent years. There is clear and consistent evidence that there is wide variability in the anti-platelet response to clopidogrel, and that patients with low response (more accurately termed - high on treatment platelet reactivity) are at increased risk of adverse cardiac events - mainly stent thrombosis and myocardial infarction. However, the only large randomized trial that examined a strategy of routing monitoring of platelet reactivity and response to clopidogrel and tailoring treatment accordingly (by increasing the clopidogrel maintenance dose) - the GRAVITAS study - was negative. Thus, although from a physiological perspective it seems reasonable to monitor the effects of a drug with such wide variability (and poor prognosis associated with low response), clinical evidence in support of routine monitoring is lacking. When analyzing the negative results of the GRAVITAS study, two main factors should be discussed: a very low clinical adverse event rate (2.3% in each of study the groups) probably reflecting a low risk patient population, and the strategy chosen to overcome high on treatment platelet reactivity (HTPR) - increasing the maintenance clopidogrel dose from 75 mg daily to 150 mg daily, which is currently known to be ineffective in overcoming clopidogrel HTPR in many of the patients.\\n\\nIn light of these potential limitations of the GRAVITAS study the investigators propose a study based on the following aspects:\\n\\n1. A potent strategy to overcome clopidogrel HTPR - treatment with ticagrelor, which has been clearly shown to overcome low response to clopidogrel.\\n2. Higher risk population - only patients with treated diabetes (shown in the BARI-2D study to have a 10-12% rate of major cardiovascular events at 1 year).\\n3. Rather than a composite clinical endpoint, the primary endpoint will be the rate of CK-MB or troponin elevation following percutaneous coronary intervention (PCI), which has been consistently associated with a higher risk of cardiovascular adverse events, and occurs at a rate of about 35% in patients with low response to clopidogrel.\\n\\nThe aim of the study is to assess whether a strategy of monitoring platelet reactivity during clopidogrel treatment in patients with diabetes undergoing PCI, and modifying the treatment to ticagrelor in patients with HTPR, is associated with a lower rate of myocardial enzyme elevation following PCI.\\n\\nMETHODS\\n\\nSee inclusion and exclusion criteria in the following sections.\\n\\nPatients treated chronically with clopidogrel 75 mg per day will undergo platelet function testing under this treatment regimen. Patients who are clopidogrel naïve will be given 300 mg loading of clopidogrel and be tested about 12-24 hours after this loading dose. For all patients, platelet function testing will be performed before the coronary angiography.\\n\\nPlatelet function testing will be performed with the VerifyNow P2Y12 assay (Accumetrics Inc.), using a cutoff value of ≥ 208 reaction units to define HTPR.\\n\\nPatients with HTPR will be randomized 1:1 to receive either ticagrelor or additional clopidogrel.\\n\\nTicagrelor regimen: 180 mg given 1-2 hours before the coronary angiography, followed by 90 mg twice a day for 30 days in case PCI was performed. After 30 days the patient will be invited to a special research clinic in the hospital and his treatment will be switched to clopidogrel (with 300 mg loading, and 75 mg a day thereafter for 11 additional months - for a total period of 1 year). The 30 day ticagrelor period was chosen because prior studies have shown that platelet hyper-reactivity and low response to clopidogrel are prominent in the first days after PCI, and subside significantly within 30 days after the procedure. In addition, most cases of stent thrombosis occur in the first month following PCI.\\n\\nClopidogrel regimen: 300 mg given 1-2 hours before coronary angiography (in addition to the previous 300 mg load or chronic clopidogrel therapy the patient received), followed by 75 mg a day for 1 year case PCI was performed.\\n\\nThe investigators aim to enroll a total of 200 patients with HTPR who will undergo PCI - 100 patients in each group (ticagrelor vs. continued clopidogrel). Patients who will not undergo PCI will be withdrawn from the study.\\n\\nChoice of stent during PCI will be left to the operator's discretion, but given the diabetes status of all patients, use of drug eluting stents will be encouraged. PCI will be performed according to standard practice and operator preferences (regarding to access, pre- and post dilatation etc.). Use of glycoprotein IIb/IIIa inhibitors will be discouraged, unless in bailout situations. Patients who will receive glycoprotein IIb/IIIa inhibitors will be excluded from the analysis.\\n\\nAn additional VerifyNow P2Y12 test will be performed in the 200 patients with initial HTPR, 20-24 hours following the PCI; at this time point troponin and CK-MB levels will also be evaluated.\\n\\nPrimary endpoint: rate of elevation of troponin or CK-MB (above the upper limit of normal, and above 3 times the upper limit of normal) measured 20-24 hours after the PCI.\\n\\nSecondary endpoint: rate of major adverse cardiovascular endpoints including death, myocardial infarction or urgent target vessel revascularization at 30 days.\\n\\nSample size calculation: assuming a rate of CK-MB or troponin elevation post-PCI of 35% among patients with low response to clopidogrel, 100 patients in each group would allow detection of a 50% difference in the primary endpoint between the groups (50% reduction in myocardial enzyme elevation rate with ticagrelor), with an alpha of 0.05 and power of 0.80. Assuming a HTPR rate of 40% using the 208 VerifyNow cutoff value, 500 patients would have to be screened in order to identify 200 patients with HTPR (not taking into consideration the patients that would not require PCI and be withdrawn from the study).\"}, 'conditionsModule': {'conditions': ['Diabetes Mellitus', 'Coronary Disease'], 'keywords': ['Diabetes', 'Platelets aggregation inhibitors', 'Platelet function tests']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE4'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 500, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Ticagrelor', 'type': 'EXPERIMENTAL', 'description': 'Patients randomized to the ticagrelor group will receive ticagrelor at a dose of 180 mg given 1-2 hours before the coronary angiography, followed by 90 mg twice a day for 30 days after the PCI. After 30 days the patient will be invited to a special research clinic in the hospital and his treatment will be switched back to clopidogrel (to complete 1 year of treatment).', 'interventionNames': ['Drug: Ticagrelor']}, {'label': 'Continued Clopidogrel', 'type': 'ACTIVE_COMPARATOR', 'description': 'Patients randomized to continued clopidogrel treatment will be given an additional 300 mg of clopidogrel loading 1-2 hours before coronary angiography (in addition to the previous 300 mg load or chronic clopidogrel therapy the patient received), followed by 75 mg a day for 1 year after the PCI', 'interventionNames': ['Drug: Continued clopidogrel']}], 'interventions': [{'type': 'DRUG', 'name': 'Ticagrelor', 'description': \"Ticagrelor will be given (to patients with low response to clopidogrel randomized to the Ticagrelor group) at a dose of 180 mg given 1-2 hours before the coronary angiography, followed by 90 mg twice a day for 30 days after the PCI. After 30 days the patient's treatment will be switched back to clopidogrel (to complete 1 year of treatment).\", 'armGroupLabels': ['Ticagrelor'], 'otherNames': ['Brilinta']}, {'type': 'DRUG', 'name': 'Continued clopidogrel', 'description': 'Patients with low response to clopidogrel randomized to continued clopidogrel treatment will be given an additional 300 mg of clopidogrel loading 1-2 hours before coronary angiography (in addition to the previous 300 mg load or chronic clopidogrel therapy the patient received), followed by 75 mg a day for 1 year after the PCI', 'armGroupLabels': ['Continued Clopidogrel'], 'otherNames': ['Plavix']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Rate of elevation of troponin or CK-MB (above the upper limit of normal, and above 3 times the upper limit of normal) measured 20-24 hours after the PCI.', 'description': 'Rate of elevation of troponin or CK-MB (above the upper limit of normal, and above 3 times the upper limit of normal) measured 20-24 hours after the PCI.', 'timeFrame': '20-24 hours after the PCI'}], 'secondaryOutcomes': [{'measure': 'Rate of major adverse cardiovascular endpoints including death, myocardial infarction or urgent target vessel revascularization at 30 days', 'description': 'Rate of major adverse cardiovascular endpoints including death, myocardial infarction or urgent target vessel revascularization at 30 days', 'timeFrame': '30 days'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n1. Patients with diabetes treated with oral hypoglycemic medications and/or insulin.\\n2. Aged 30-80 years.\\n3. Patients with stable angina and a positive non-invasive test, or patients with unstable angina, all planned to undergo coronary angiography.\\n4. Treated with aspirin 75-100 mg per day.\\n\\n   -\\n\\nExclusion Criteria:\\n\\n1. Any myocardial infarction (STEMI or non-STEMI) as the indication for the cardiac catheterization. Thus, only troponin-negative and CK-MB negative patients will be included.\\n2. Any contraindications to ticagrelor or clopidogrel.\\n3. Anemia (Hg\\\\<10 g/dL) or thrombocytopenia (\\\\<100,000 / mm3)\\n4. Chronic renal failure (Cr ≥ 2.5 mg/dL)\\n\\n   -', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '30 Years', 'maximumAge': '80 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Hagar Medan', 'role': 'CONTACT', 'phone': '972-3-9376442', 'email': 'hagarme@clalit.org.il'}, {'name': 'Ofira Yehoshua', 'role': 'CONTACT', 'phone': '972-3-9376441', 'email': 'ofiray@clalit.org.il'}], 'overallOfficials': [{'name': 'Eli I Lev, MD', 'affiliation': 'Rabin Medical Center', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'Rabin Medical Center', 'city': 'Petah-Tikva', 'zip': '49100', 'country': 'Israel', 'contacts': [{'name': 'Hagar Medan', 'role': 'CONTACT'}, {'name': 'Eli I Lev, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 32.08707, 'lon': 34.88747}}]}, 'referencesModule': {'references': [{'pmid': '20828644', 'type': 'BACKGROUND', 'citation': 'Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo DJ, Becker R, Bhatt DL, Cattaneo M, Collet JP, Cuisset T, Gachet C, Montalescot G, Jennings LK, Kereiakes D, Sibbing D, Trenk D, Van Werkum JW, Paganelli F, Price MJ, Waksman R, Gurbel PA; Working Group on High On-Treatment Platelet Reactivity. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol. 2010 Sep 14;56(12):919-33. doi: 10.1016/j.jacc.2010.04.047.'}, {'type': 'BACKGROUND', 'citation': '2. Price MJ, Berger PB, Teirstein PS, Tanguay JF, Angiolillo DJ, Spriggs D, Puri S, Robbins M, Garratt KN, Bertrand OF, Stillabower ME, Aragon JR, Kandzari DE, Stinis CT, Lee MS, Manoukian SV, Cannon CP, Schork NJ, Topol EJ; GRAVITAS Investigators. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA. 2011 ;305(11):1097-105'}, {'type': 'BACKGROUND', 'citation': '3. Oestreich JH, Holt J, Dunn SP, Smyth SS, Campbell CL, Charnigo R, Akers WS, Steinhubl SR. Considerable variability in platelet activity among patients with coronary artery disease in response to an increased maintenance dose of clopidogrel.Coron Artery Dis. 2009 ;20(3):207-13.'}, {'type': 'BACKGROUND', 'citation': '4. Gladding P, Webster M, Zeng I, Farrell H, Stewart J, Ruygrok P, Ormiston J, El-Jack S, Armstrong G, Kay P, Scott D, Gunes A, Dahl ML. The antiplatelet effect of higher loading and maintenance dose regimens of clopidogrel: the PRINC (Plavix Response in Coronary Intervention) trial. JACC Cardiovasc Interv. ;1(6):612-9'}, {'type': 'BACKGROUND', 'citation': '5. Gurbel PA, Bliden KP, Butler K, Antonino MJ, Wei C, Teng R, Rasmussen L, Storey RF, Nielsen T, Eikelboom JW, Sabe-Affaki G, Husted S, Kereiakes DJ, Henderson D, Patel DV, Tantry US. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation. 2010 ;121(10):1188-99'}, {'type': 'BACKGROUND', 'citation': '6. BARI 2D Study Group, Frye RL, August P, Brooks MM, Hardison RM, Kelsey SF, MacGregor JM, Orchard TJ, Chaitman BR, Genuth SM, Goldberg SH, Hlatky MA, Jones TL, Molitch ME, Nesto RW, Sako EY, Sobel BE. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009 ;360(24):2503-15'}, {'pmid': '21574239', 'type': 'BACKGROUND', 'citation': 'Feldman DN, Kim L, Rene AG, Minutello RM, Bergman G, Wong SC. Prognostic value of cardiac troponin-I or troponin-T elevation following nonemergent percutaneous coronary intervention: a meta-analysis. Catheter Cardiovasc Interv. 2011 Jun 1;77(7):1020-30. doi: 10.1002/ccd.22962. Epub 2011 May 13.'}, {'type': 'BACKGROUND', 'citation': '8. Nienhuis MB, Ottervanger JP, Bilo HJ, Dikkeschei BD, Zijlstra F. Prognostic value of troponin after elective percutaneous coronary intervention: A meta-analysis. Catheter Cardiovasc Interv. 2008 ;71(3):318-24'}, {'pmid': '16386660', 'type': 'BACKGROUND', 'citation': 'Lev EI, Patel RT, Maresh KJ, Guthikonda S, Granada J, DeLao T, Bray PF, Kleiman NS. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. J Am Coll Cardiol. 2006 Jan 3;47(1):27-33. doi: 10.1016/j.jacc.2005.08.058. Epub 2005 Dec 9.'}, {'type': 'BACKGROUND', 'citation': '10. Price MJ, Angiolillo DJ, Teirstein PS, Lillie E, Manoukian SV, Berger PB, Tanguay JF, Cannon CP, Topol EJ. Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial. Circulation. 2011 ;124(10):1132-7'}, {'type': 'BACKGROUND', 'citation': '11. Campo G, Parrinello G, Ferraresi P, Lunghi B, Tebaldi M, Miccoli M, Marchesini J, Bernardi F, Ferrari R, Valgimigli M. Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. J Am Coll Cardiol. 2011 ;57(25):2474-83'}, {'pmid': '12796140', 'type': 'BACKGROUND', 'citation': \"Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation. 2003 Jun 17;107(23):2908-13. doi: 10.1161/01.CIR.0000072771.11429.83. Epub 2003 Jun 9.\"}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2024-11-22'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003327', 'term': 'Coronary Disease'}, {'id': 'D003920', 'term': 'Diabetes Mellitus'}], 'ancestors': [{'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}, {'id': 'D017202', 'term': 'Myocardial Ischemia'}, {'id': 'D006331', 'term': 'Heart Diseases'}, {'id': 'D002318', 'term': 'Cardiovascular Diseases'}, {'id': 'D014652', 'term': 'Vascular Diseases'}], 'browseLeaves': [{'id': 'M6549', 'name': 'Coronary Disease', 'asFound': 'Coronary Disease', 'relevance': 'HIGH'}, {'id': 'M6546', 'name': 'Coronary Artery Disease', 'relevance': 'LOW'}, {'id': 'M7115', 'name': 'Diabetes Mellitus', 'asFound': 'Diabetes', 'relevance': 'HIGH'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}, {'id': 'M10543', 'name': 'Ischemia', 'relevance': 'LOW'}, {'id': 'M19506', 'name': 'Myocardial Ischemia', 'relevance': 'LOW'}, {'id': 'M9419', 'name': 'Heart Diseases', 'relevance': 'LOW'}, {'id': 'M17400', 'name': 'Vascular Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC14', 'name': 'Heart and Blood Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D000077144', 'term': 'Clopidogrel'}, {'id': 'D000077486', 'term': 'Ticagrelor'}], 'ancestors': [{'id': 'D010975', 'term': 'Platelet Aggregation Inhibitors'}, {'id': 'D058921', 'term': 'Purinergic P2Y Receptor Antagonists'}, {'id': 'D058919', 'term': 'Purinergic P2 Receptor Antagonists'}, {'id': 'D058914', 'term': 'Purinergic Antagonists'}, {'id': 'D058905', 'term': 'Purinergic Agents'}, {'id': 'D018377', 'term': 'Neurotransmitter Agents'}, {'id': 'D045504', 'term': 'Molecular Mechanisms of Pharmacological Action'}, {'id': 'D045505', 'term': 'Physiological Effects of Drugs'}], 'browseLeaves': [{'id': 'M1669', 'name': 'Clopidogrel', 'asFound': 'Back', 'relevance': 'HIGH'}, {'id': 'M1812', 'name': 'Ticagrelor', 'asFound': 'Due', 'relevance': 'HIGH'}, {'id': 'M13865', 'name': 'Platelet Aggregation Inhibitors', 'relevance': 'LOW'}, {'id': 'M29294', 'name': 'Purinergic P2Y Receptor Antagonists', 'relevance': 'LOW'}, {'id': 'M20504', 'name': 'Neurotransmitter Agents', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'PlAggInh', 'name': 'Platelet Aggregation Inhibitors'}, {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT05631431', 'orgStudyIdInfo': {'id': 'Cura-01'}, 'organization': {'fullName': 'CuraLife', 'class': 'INDUSTRY'}, 'briefTitle': 'Evaluation of Efficacy and Safety of Curalin As Add-On Therapy in Adults With Type 2 Diabetes Mellitus', 'officialTitle': 'A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Curalin As Add-On Therapy in Adults With Type 2 Diabetes Mellitus'}, 'statusModule': {'statusVerifiedDate': '2022-11', 'overallStatus': 'UNKNOWN', 'lastKnownStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2021-10-15', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2023-05-15', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2023-06-30', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2021-06-08', 'studyFirstSubmitQcDate': '2022-11-20', 'studyFirstPostDateStruct': {'date': '2022-11-30', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2022-11-20', 'lastUpdatePostDateStruct': {'date': '2022-11-30', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'CuraLife', 'class': 'INDUSTRY'}}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False, 'isUsExport': True}, 'descriptionModule': {'briefSummary': 'Evaluation of Efficacy and Safety of Curalin As Add-On Therapy in Adults with Type 2 Diabetes Mellitus', 'detailedDescription': 'A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Curalin As Add-On Therapy in Adults with Type 2 Diabetes Mellitus'}, 'conditionsModule': {'conditions': ['Type2 Diabetes'], 'keywords': ['Diabetes', 'Type 2 Diabetes', 'placebo', 'Curalin', 'CuraLife', 'Momordica Charantia', 'Gymnema Sylvestre', 'Trigonella Foenum Graecum', 'Curcuma Longa', 'Emblica Officinalis', 'Swertia Chirata', 'Picrorhiza Kurroa', 'Syzygium Cumini/ Eugenia Jambolana', 'Cinnamomum Zeylanicum']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'interventionModelDescription': 'Double-blind for 3 months, after 3 months - open-label', 'primaryPurpose': 'SUPPORTIVE_CARE', 'maskingInfo': {'masking': 'TRIPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR']}}, 'enrollmentInfo': {'count': 120, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Placebo', 'type': 'PLACEBO_COMPARATOR', 'interventionNames': ['Dietary Supplement: Curalin']}, {'label': 'Treatment', 'type': 'ACTIVE_COMPARATOR', 'interventionNames': ['Dietary Supplement: Curalin']}], 'interventions': [{'type': 'DIETARY_SUPPLEMENT', 'name': 'Curalin', 'description': 'Curalin capsules, 2 capsules, 3 times a day after meals Placebo: matching placebo capsules, 2 capsules, 3 times a day after meals', 'armGroupLabels': ['Placebo', 'Treatment']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'primary objective', 'description': 'The primary objective of this study is to evaluate the effect of treatment with Curalin on the change in plasma HbA1c.', 'timeFrame': '3-6 months'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Diagnosis and Criteria for Inclusion:\\n\\nPatients may be included in the study if they meet all of the following criteria:\\n\\n* Written informed consent is obtained.\\n* Adult patients (18-85 years of age) with Type II diabetes mellitus\\n* HbA1c at screening is 7.5% - 10%\\n* Body mass index (BMI)\\\\>25\\n* Stable body weight (±10%) within the 3 months preceding study entry\\n\\n  • Patients were steadily treated with anti-diabetic medications, such as: GLP-1, Glucophage, DPP-4 inhibitor, or SGLT-2 inhibitor for at least 3 months or more prior to study entry\\n* The patient must be willing and able to comply with study restrictions and to remain at the clinic for the required duration during the study period, and willing to return to the clinic for the follow-up evaluation as specified in this protocol.\\n\\nCriteria for Exclusion: Patients will be excluded from participating in this study if they meet 1 or more of the following criteria:\\n\\n* Patients who have been using Curalin At least once in the past 3 months\\n* Persons with known sensitivity to any of the components of the Curalin product.\\n* The patient has any clinically significant uncontrolled medical condition (treated or untreated).\\n* Patients with renal insufficiency (glomerular filtration rate \\\\[GFR\\\\]≤30 mL/min/1.73m2)\\n* Pregnant or lactating women. Women of childbearing potential will be administered a urine pregnancy test at study entry. All study participants will confirm their willingness to use birth control throughout the study.\\n* Patients deemed by the Investigator as unable to complete study participation.\\n* Patients currently treated with insulin or those that have been treated with insulin for more than 10 days in the 3 months prior to study entry.\\n\\n  • Use of medications known to modify glucose metabolism or to decrease the ability to recover from hypoglycemia such as oral, parenteral, local, dermal and inhaled steroids, and immunosuppressive or immunomodulating agents for more than a month prior to study entry, or during the study\\n* The patient participated in a clinical study (investigational study drug or study device) within 30 days of the study entry\\n* Life expectancy less than 1 year\\n* History of stroke, transient ischemic attack, or myocardial infarction within six months prior to screening\\n\\n  * Patients with uncontrolled hypertension defined as a systolic blood pressure ≥180 mmHg or a diastolic blood pressure ≥100mmHg.\\n  * Patients who have thyroid-stimulating hormone (TSH) levels \\\\>1.5 times the upper limit of normal.\\n  * Patients with significant liver disease or liver function impairment defined as any of the following; cirrhosis, hepatitis, biliary obstruction with hyperbilirubinemia (total bilirubin \\\\>2 times the upper limit of normal) and aspartate aminotransferase (AST) or alanine aminotransferase levels (ALT) \\\\>3 times the upper limit of normal.\\n  * Patients with creatine kinase concentrations \\\\> 10 times the upper limit of normal or creatine kinase elevation due to known muscle disease at visit 1 (screening 1)\\n* Laboratory abnormalities at screening including:\\n* Potassium \\\\> 5.5 mEq/L\\n* Sodium under 130 mEq/L\\n* Hemoglobin under 10 g/dl for Women or Under 11 g/dl for man', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'maximumAge': '85 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Ofer Yigdal, Msc/ CPO', 'role': 'CONTACT', 'phone': '+972522582179', 'email': 'Ofer@curalife.com'}, {'name': 'Liron Hason, Bsc/ CRA', 'role': 'CONTACT', 'phone': '+972543838100', 'email': 'Liron@curalife.com'}], 'locations': [{'facility': 'Soroka Medical Center', 'status': 'RECRUITING', 'city': \"Be'er Sheva\", 'country': 'Israel', 'contacts': [{'name': 'Bar Bourenbloum, B.sc', 'role': 'CONTACT', 'phone': '54-2529452', 'phoneExt': '+972', 'email': 'barborn@clalit.org.il'}, {'name': 'Idit Liberty, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 31.25181, 'lon': 34.7913}}, {'facility': 'Lin Medical Center', 'status': 'RECRUITING', 'city': 'Haifa', 'country': 'Israel', 'contacts': [{'name': 'Elinor Man, B.sc', 'role': 'CONTACT', 'phone': '54-8380118', 'phoneExt': '+972', 'email': 'ElinorMa23@clalit.org.il'}, {'name': 'Michal Gershinsky, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 32.81841, 'lon': 34.9885}}, {'facility': 'Herzelia Diebetes Center', 'status': 'RECRUITING', 'city': 'Herzliya', 'country': 'Israel', 'contacts': [{'name': 'Lilach Dolgikh, B.sc', 'role': 'CONTACT', 'phone': '52-5292240', 'phoneExt': '+972', 'email': 'Lilachdo1@clalit.org.il'}, {'name': 'Eitan Roitman, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 32.16627, 'lon': 34.82536}}, {'facility': 'Ichilov Medical Center', 'status': 'RECRUITING', 'city': 'Tel Aviv', 'country': 'Israel', 'contacts': [{'name': 'Asaf Buch, Phd', 'role': 'CONTACT', 'phone': '54-9931033', 'phoneExt': '+972', 'email': 'asafbu@tlvmc.gov.il'}, {'name': 'Roy Eldor, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 32.08088, 'lon': 34.78057}}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2024-11-22'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D003924', 'term': 'Diabetes Mellitus, Type 2'}], 'ancestors': [{'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}], 'browseLeaves': [{'id': 'M7119', 'name': 'Diabetes Mellitus, Type 2', 'asFound': 'Type 2 Diabetes', 'relevance': 'HIGH'}, {'id': 'M7115', 'name': 'Diabetes Mellitus', 'asFound': 'Diabetes', 'relevance': 'HIGH'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}]}, 'interventionBrowseModule': {'browseLeaves': [{'id': 'M342247', 'name': 'Turmeric extract', 'relevance': 'LOW'}, {'id': 'T319', 'name': 'Turmeric', 'relevance': 'LOW'}, {'id': 'T112', 'name': 'Chirata', 'relevance': 'LOW'}, {'id': 'T115', 'name': 'Cinnamon', 'relevance': 'LOW'}, {'id': 'T180', 'name': 'Gymnema Sylvestre', 'relevance': 'LOW'}, {'id': 'T154', 'name': 'Fenugreek', 'relevance': 'LOW'}, {'id': 'T69', 'name': 'Bitter Melon', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'All', 'name': 'All Drugs and Chemicals'}, {'abbrev': 'HB', 'name': 'Herbal and Botanical'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT05427682', 'orgStudyIdInfo': {'id': 'DJT1116PG-DM-105'}, 'organization': {'fullName': 'Sunshine Lake Pharma Co., Ltd.', 'class': 'INDUSTRY'}, 'briefTitle': 'A Clinical Trial to Evaluate the Pharmacokinetics and Safety of Pyroglutamate Rongliflozin Capsules in Subjects With Mild and Moderate Liver Damage', 'officialTitle': 'A Single-center, Non-randomized, Open, Single-dose Clinical Trial to Evaluate the Pharmacokinetics and Safety of Pyroglutamate Rongliflozin Capsules in Subjects With Mild and Moderate Liver Damage'}, 'statusModule': {'statusVerifiedDate': '2022-06', 'overallStatus': 'UNKNOWN', 'lastKnownStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2022-04-19', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2023-03-04', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2023-06-02', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2022-06-17', 'studyFirstSubmitQcDate': '2022-06-17', 'studyFirstPostDateStruct': {'date': '2022-06-22', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2022-06-17', 'lastUpdatePostDateStruct': {'date': '2022-06-22', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Sunshine Lake Pharma Co., Ltd.', 'class': 'INDUSTRY'}}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'To evaluate the pharmacokinetic characteristics of pyroglutamate rongliflozin capsules in subjects with mild and moderate liver damage and healthy subjects'}, 'conditionsModule': {'conditions': ['Diabetes Mellitus, Type 2']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE1'], 'designInfo': {'allocation': 'NON_RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 32, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Group A (normal liver function)', 'type': 'EXPERIMENTAL', 'description': 'Each subject will receive a single dose of rongliflozin on Day 1', 'interventionNames': ['Drug: pyroglutamate rongliflozin capsules']}, {'label': 'Group B (mild liver damage)', 'type': 'EXPERIMENTAL', 'description': 'Each subject will receive a single dose of rongliflozin on Day 1', 'interventionNames': ['Drug: pyroglutamate rongliflozin capsules']}, {'label': 'Group C (normal liver function)', 'type': 'EXPERIMENTAL', 'description': 'Each subject will receive a single dose of rongliflozin on Day 1', 'interventionNames': ['Drug: pyroglutamate rongliflozin capsules']}, {'label': 'Group D (moderate liver damage)', 'type': 'EXPERIMENTAL', 'description': 'Each subject will receive a single dose of rongliflozin on Day 1', 'interventionNames': ['Drug: pyroglutamate rongliflozin capsules']}], 'interventions': [{'type': 'DRUG', 'name': 'pyroglutamate rongliflozin capsules', 'description': 'Subjects will receive one 50mg capsule on Day 1', 'armGroupLabels': ['Group A (normal liver function)', 'Group B (mild liver damage)', 'Group C (normal liver function)', 'Group D (moderate liver damage)']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Plasma concentrations of rongliflozin', 'description': 'Plasma concentrations of rongliflizin following the administration of a single dose of rongliflozin, the pharmacokinetic parameters for rongliflozin will be measured in varying degrees of liver function.', 'timeFrame': '0 hour（pre-dose） to 96 hours after administration'}], 'secondaryOutcomes': [{'measure': 'Incidence of Adverse Events [safety]', 'description': 'To evaluate the safety of pyroglutamate rongliflozin capsules in subjects with mild to moderate liver damage and healthy subjects', 'timeFrame': 'Day -1 (Baseline) to Day 5'}]}, 'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\n\\n* Sign the informed consent form before the experiment, understand and abide by the research process, and participate voluntarily;\\n* Adult subjects between the ages of 18 and 70 (including boundary values), both male and female;\\n* Female subjects or male subjects with potential fertility must agree to use effective contraceptive methods (see Appendix 2 for specific contraceptive methods) from signing informed consent to taking the trial drug within 4 weeks to avoid pregnancy or make their partners pregnant.\\n* The following selection criteria are only applicable to healthy subjects with normal liver function (groups A and C): the gender and age (+ or - 5 years) of subjects in groups A and C are matched with subjects in groups B and D respectively;\\n* The following selection criteria are only applicable to healthy subjects with normal liver function (groups A and C): body mass index (BMI): 18-30kg/m2 (including cut-off value) \\\\[BMI=weight (kg)/height 2 (m2) )\\\\] (BMI matching between groups A and C and groups B and D is + or - 15%);\\n* The following selection criteria are only applicable to healthy subjects with normal liver function (groups A and C): medical history, physical examination, vital signs monitoring, electrocardiogram, laboratory tests (blood routine, urine routine, blood biochemistry, coagulation) Function), alpha-fetoprotein (AFP), abdominal B-ultrasound (liver, spleen, gallbladder, pancreas, kidneys), and chest radiographs have normal or abnormal results, but the investigator judges them to be of no clinical significance.\\n* The following selection criteria are only applicable to subjects with liver dysfunction (groups B and D): for subjects with liver dysfunction without ascites, subclinical ascites, clinically mild and moderate ascites detected only by ultrasound or other imaging , Allow the body mass index (BMI) to be between 18-30 kg/m2 (including the critical value) \\\\[BMI= weight (kg) / height 2 (m2)\\\\];\\n* The following selection criteria are only applicable to subjects with liver dysfunction (groups B and D): according to the Child-Pugh classification (see Appendix 3) at the time of screening to evaluate the severity of patients with liver dysfunction in accordance with: (Grade A/Mild: Child -Pugh score 5 or 6 points; B grade/moderate: Child Pugh score 7-9 points);\\n* The following selection criteria are only applicable to subjects with liver dysfunction (groups B and D): combined with previous medical history, physical examination results, serological indicators (such as albumin, ALT, AST, bilirubin, prothrombin time, INR, etc.) ) And one of the following tests performed with standard diagnostic and treatment methods that meets the diagnostic basis for chronic liver disease: liver biopsy, computed tomography, magnetic resonance imaging, ultrasound, radioactive liver/spleen scan, laparoscopy;\\n* The following selection criteria are only applicable to subjects with liver damage (groups B and D): within 1 month before taking the test drug or 5 half-lives of the concomitant drug (whichever is longer) to the end of the study Those who have stable medication regimens for the treatment of liver dysfunction, liver disease complications and other concomitant diseases without adjustment (including the type of medication, dosage, or frequency of medication) or those who have not taken medication before enrollment; however, the study doctor's judgment does not affect Except for the adjustment of subject safety and pharmacokinetic endpoints;\\n* The following selection criteria are only applicable to subjects with liver dysfunction (groups B and D): the investigator judges that the liver function status of the subjects is stable and will not deteriorate significantly during the period from 1 month before taking the test drug to the end of the study By.\\n\\nExclusion Criteria:\\n\\n* The subject has a history of severe allergies or allergies to the test drug and any of its components or related excipients;\\n* People with history of gastrointestinal or kidney disease or surgery (except for uncomplicated appendicitis resection and hernia repair) that may potentially affect the absorption, distribution, metabolism, and excretion of the test drug in the 6 months prior to screening, or the presence can make compliance People with reduced disease;\\n* The researcher judged that he currently has bleeding disorders, such as gastric and duodenal ulcers;\\n* People with a history of liver cancer or other malignant tumors before signing the informed consent form \\\\[exceptions: specific cancers (basal cell carcinoma of the skin, squamous cell carcinoma, or cervical carcinoma in situ, etc.) that are surgically removed and completely cured can be selected\\\\] or are currently assessed for existence People with potential malignant tumors;\\n* Patients with a history of repeated urinary tract infections or/and genital infections within 6 months before screening (recurrent urinary tract infection is defined as: repeated urinary tract infections \\\\> or = 2 times within 6 months, or repeated urinary tract infections in the past 12 months Infection \\\\> or =3 times);\\n* People with a history of recurring severe unconscious hypoglycemia (repeated severe hypoglycemia is defined as: 2 severe neurological symptoms in 4 weeks, hypoglycemia requiring the assistance of others to treat, or 2 blood glucose in 4 weeks\\\\< 3.0 mmol/L, or blood glucose \\\\< or = 3.9 mmol/L \\\\> or =3 times detected within 1 week);\\n* People with a history of alcoholism (alcoholism is defined as: drinking 14 units of alcohol per week: 1 unit = 285 mL of beer, or 25 mL of spirits, or 100 mL of wine) or those who have a positive alcohol breath test during the screening period;\\n* Those who have a history of drug abuse or have used drugs within 2 years before screening or those who have a positive urine drug screening during the screening period;\\n* Those who smoked more than 5 cigarettes a day in the 3 months before screening or who could not give up smoking from signing informed consent to leaving the group;\\n* Treponema pallidum antibody and/or human immunodeficiency virus (HIV) antibody test results are positive;\\n* Have taken food or drinks that affect CYP3A4 metabolic enzymes, such as grapefruit or drinks containing grapefruit within 7 days before the first medication;\\n* Consume chocolate, any food or drink that contains caffeine or is rich in xanthine within 72 hours before the first medication;\\n* Have taken any alcohol-containing products within 48 hours before the first medication;\\n* Those who donated blood \\\\> or = 400 mL or a large amount of blood loss within 3 months before screening, or who have a history of blood transfusion within 1 month before screening, or who plan to donate blood within 1 month after the end of the test;\\n* Have taken similar SGLT-2 inhibitor drugs within 14 days before screening or participated in other clinical trials within 3 months before screening (if the subject withdrew from the study before treatment, that is, not randomized or received treatment, they can be included in the group Research);\\n* The subject is breastfeeding or the result of serum pregnancy is positive;\\n* Take the prohibited concomitant medications within 1 month before taking the trial drug or within the 5 half-life period of the concomitant medication (whichever is the longer) to the end of the study (see Chapter 5.5.1 for details);\\n* The investigator believes that there are other subjects who are not suitable for participating in this trial (such as inability to tolerate oral drugs, poor peripheral venous access conditions, or significant risks to the subjects, etc.).\\n* The following exclusion criteria are only applicable to healthy subjects with normal liver function (groups A and C): hepatitis B surface antigen (HBsAg) and hepatitis C virus (HCV) antibody test results are positive;\\n* The following exclusion criteria are only applicable to healthy subjects with normal liver function (groups A and C): the subjects have the following clinically significant diseases before screening, including but not limited to gastrointestinal tract, kidney, liver, nerve, blood , Endocrine, tumor, lung, immune, mental or cardiovascular and cerebrovascular diseases;\\n* The following exclusion criteria are only applicable to healthy subjects with normal liver function (groups A and C): any prescription drugs, non-prescription drugs, any vitamin products or Chinese herbal medicines have been taken within 2 weeks before the first medication.\\n* The following exclusion criteria are only applicable to subjects with liver dysfunction (groups B and D): the laboratory test results at the time of screening meet any of the following: a) ALT\\\\>10×ULN; b) absolute value of neutrophils \\\\<0.75 ×109/L; c) platelets \\\\<50×109/L (except for cases in a stable state as judged by the investigator); d) hemoglobin \\\\<60 g/L; e) AFP\\\\>100 ng/mL; if 20 ng/ mL=AFP=100 ng/mL, liver ultrasonography or other imaging examinations (CT, MRI, etc.) are required to exclude subjects suspected of hepatocellular carcinoma; f) Estimated using the modified dietary test for kidney disease (MDRD) formula Glomerular filtration rate (eGFR) \\\\<60 mL/min/1.73m2 (for eGFR estimation formula, please refer to Appendix 4).\\n* The following exclusion criteria are only applicable to subjects with liver dysfunction (groups B and D): those with cardiovascular and cerebrovascular events within 6 months before screening, including stroke (except for lacunar infarction), acute myocardial infarction, cardiac Dysfunction (New York College of Cardiology \\\\[NYHA\\\\] Grade III or IV, see Appendix 6), transient ischemic attack, coronary intervention (including stent thrombosis), peripheral vascular intervention, unstable angina, etc.;\\n* The following exclusion criteria are only applicable to subjects with liver dysfunction (groups B and D): subjects who have severe esophageal and gastric varices or have undergone portal venous shunt, including transjugular intrahepatic portosystemic shunt Surgery (TIPS);\\n* The following exclusion criteria are only applicable to subjects with liver dysfunction (groups B and D): subjects suffering from biliary obstruction and other diseases that affect bile excretion or drug-induced liver injury;\\n* The following exclusion criteria are only applicable to subjects with liver damage (groups B and D): subjects suffering from liver failure or severe complications of liver cirrhosis (such as spontaneous bacterial peritonitis, bleeding from esophageal and gastric fundus veins, liver and kidney Syndrome, etc.);\\n* The following exclusion criteria are only applicable to subjects with liver damage (groups B and D): a history of liver transplantation;\\n* The following exclusion criteria are only applicable to subjects with liver damage (groups B and D): any prescription drugs, over-the-counter drugs, and any vitamins other than those used to treat liver damage or their comorbidities have been used within 2 weeks before the first medication Products or Chinese herbal medicine;\\n* The following exclusion criteria are only applicable to subjects with liver dysfunction (groups B and D): the investigator is based on the subject's medical history, physical examination, vital signs, laboratory tests (blood routine, urine routine, blood biochemistry, coagulation function) , AFP, 12-lead electrocardiogram, EEG, and judge that the subject has other clinically significant abnormalities (except for abnormal indexes related to liver function, HBsAg and HCV antibody positive), such as uncontrolled heart, breathing, gastrointestinal Tract, blood, nerve, or other diseases that may interfere with the subject's treatment, evaluation, or compliance with the research protocol, and those who are not suitable for inclusion in this study will also be excluded.\", 'healthyVolunteers': True, 'sex': 'ALL', 'minimumAge': '18 Years', 'maximumAge': '70 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Jia Miao, Doctor', 'role': 'CONTACT', 'phone': '18980601806', 'email': 'miaosiyi1971@163.com'}, {'name': 'Hong Tang, Doctor', 'role': 'CONTACT', 'phone': '18980601313', 'email': 'Htang6198@hotmail.com'}], 'locations': [{'facility': 'West China Hospital of Sichuan University', 'status': 'RECRUITING', 'city': 'Chengdu', 'state': 'Sichuan', 'country': 'China', 'contacts': [{'name': 'Jia Miao, Doctor', 'role': 'CONTACT', 'phone': '18980601806', 'email': 'miaosiyi1971@163.com'}, {'name': 'Hong Tang, Doctor', 'role': 'CONTACT', 'phone': '18980601313', 'email': 'Htang6198@hotmail.com'}], 'geoPoint': {'lat': 30.66667, 'lon': 104.06667}}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2024-11-22'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003924', 'term': 'Diabetes Mellitus, Type 2'}], 'ancestors': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}], 'browseLeaves': [{'id': 'M7119', 'name': 'Diabetes Mellitus, Type 2', 'asFound': 'Diabetes Mellitus, Type 2', 'relevance': 'HIGH'}, {'id': 'M7115', 'name': 'Diabetes Mellitus', 'relevance': 'LOW'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}]}, 'interventionBrowseModule': {'browseLeaves': [{'id': 'M11110', 'name': 'Liver Extracts', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'Hemat', 'name': 'Hematinics'}, {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT01648582', 'orgStudyIdInfo': {'id': '13439'}, 'secondaryIdInfos': [{'id': 'H9X-CR-GBDK', 'type': 'OTHER', 'domain': 'Eli Lilly and Company'}], 'organization': {'fullName': 'Eli Lilly and Company', 'class': 'INDUSTRY'}, 'briefTitle': 'A Study Comparing the Effects and Safety of Dulaglutide With Insulin Glargine in Type 2 Diabetes Mellitus', 'officialTitle': 'The Efficacy and Safety of Once-Weekly, Subcutaneous Dulaglutide Compared to Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Mellitus on Metformin and/or a Sulfonylurea', 'acronym': 'AWARD-CHN2'}, 'statusModule': {'statusVerifiedDate': '2019-09', 'overallStatus': 'COMPLETED', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2012-07'}, 'primaryCompletionDateStruct': {'date': '2014-08', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2014-12', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2012-07-16', 'studyFirstSubmitQcDate': '2012-07-19', 'studyFirstPostDateStruct': {'date': '2012-07-24', 'type': 'ESTIMATED'}, 'resultsFirstSubmitDate': '2015-05-08', 'resultsFirstSubmitQcDate': '2015-06-29', 'resultsFirstPostDateStruct': {'date': '2015-07-24', 'type': 'ESTIMATED'}, 'dispFirstSubmitDate': '2014-09-29', 'dispFirstSubmitQcDate': '2014-09-29', 'dispFirstPostDateStruct': {'date': '2014-10-08', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2019-09-05', 'lastUpdatePostDateStruct': {'date': '2019-09-18', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Eli Lilly and Company', 'class': 'INDUSTRY'}}, 'oversightModule': {'oversightHasDmc': True}, 'descriptionModule': {'briefSummary': 'The purpose of this study is to examine if once-weekly dulaglutide is efficient and safe compared to once-daily insulin glargine in participants with type 2 diabetes mellitus who have inadequate glycemic control with 1 or 2 oral antihyperglycemic medications (OAM) (metformin and/or a sulfonylurea), in addition to any healthy lifestyle changes recommended by their healthcare providers.'}, 'conditionsModule': {'conditions': ['Type 2 Diabetes Mellitus']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE3'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 774, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': '1.5 mg Dulaglutide', 'type': 'EXPERIMENTAL', 'description': \"1.5 milligrams (mg) dulaglutide administered as one subcutaneous (SC) injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea for up to 52 weeks. Participants are blinded to the dulaglutide dose.\", 'interventionNames': ['Drug: Dulaglutide', 'Drug: Metformin', 'Drug: Sulfonylureas']}, {'label': '0.75 mg Dulaglutide', 'type': 'EXPERIMENTAL', 'description': \"0.75 mg Dulaglutide administered as one SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea for up to 52 weeks. Participants are blinded to the dulaglutide dose.\", 'interventionNames': ['Drug: Dulaglutide', 'Drug: Metformin', 'Drug: Sulfonylureas']}, {'label': 'Insulin Glargine', 'type': 'ACTIVE_COMPARATOR', 'description': \"Insulin glargine administered based on fasting blood glucose concentrations per the dosing titration schedule as once daily SC injection at bedtime added to participant's pre-study prescribed dose of metformin and /or a sulfonylurea for up to 52 weeks.\", 'interventionNames': ['Drug: Insulin glargine', 'Drug: Metformin', 'Drug: Sulfonylureas']}], 'interventions': [{'type': 'DRUG', 'name': 'Dulaglutide', 'description': 'Administered SC', 'armGroupLabels': ['0.75 mg Dulaglutide', '1.5 mg Dulaglutide'], 'otherNames': ['LY2189265']}, {'type': 'DRUG', 'name': 'Insulin glargine', 'description': 'Administered SC per dosing titration schedule', 'armGroupLabels': ['Insulin Glargine']}, {'type': 'DRUG', 'name': 'Metformin', 'description': 'Administered orally at pre-study prescribed dose, and is not being provided as part of the trial.', 'armGroupLabels': ['0.75 mg Dulaglutide', '1.5 mg Dulaglutide', 'Insulin Glargine']}, {'type': 'DRUG', 'name': 'Sulfonylureas', 'description': 'Administered orally at pre-study prescribed dose, and is not being provided as part of the trial.', 'armGroupLabels': ['0.75 mg Dulaglutide', '1.5 mg Dulaglutide', 'Insulin Glargine']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 26 Weeks', 'description': 'HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. Least square (LS) means of change from baseline in HbA1c were calculated using a mixed-effects model for repeated measures (MMRM) with the change in HbA1c as the dependent variable and treatment, baseline HbA1c, country, oral antihyperglycemic medication (OAM) , visit, and treatment-by-visit interaction as fixed effects, and participant was the random effect.', 'timeFrame': 'Baseline, 26 Weeks'}], 'secondaryOutcomes': [{'measure': 'Change From Baseline in HbA1c at 52 Weeks', 'description': 'HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. LS means of change from baseline in HbA1c were calculated using a MMRM with the change in HbA1c as the dependent variable and treatment, baseline HbA1c, country, OAM, visit, and treatment-by-visit interaction as fixed effects, and participant was as the random effect.', 'timeFrame': 'Baseline, 52 Weeks'}, {'measure': 'Percentage of Participants Attaining HbA1c of <7% or ≤6.5% at 26 Weeks and 52 Weeks', 'description': 'The percentage of participants was calculated by dividing the number of participants reaching target HbA1c by the total number of participants analyzed, multiplied by 100.', 'timeFrame': 'Up to 26 and 52 weeks'}, {'measure': 'Change From Baseline in Fasting Blood Glucose (FBG) at 26 Weeks and 52 Weeks', 'description': 'LS means of change from baseline were calculated using MMRM with the change in FBG as the dependent variable and treatment, baseline value, country, OAM, visit, and treatment-by-visit interaction as fixed effects, and participant was the random effect.', 'timeFrame': 'Baseline, 26 Weeks, 52 Weeks'}, {'measure': 'Change From Baseline in 7-point Self-monitored Blood Glucose (SMBG) Profiles at 26 Weeks and 52 Weeks', 'description': 'Participants were required to perform 7-point SMBG profiles on 2 separate, nonconsecutive days during the 2 weeks before randomization and Weeks 8, 14, 20, 26, 39, and 52 (or the Early Discontinuation Visit). SMBG measurements were taken using a plasma-equivalent blood glucose (BG) meter at 7 time points: morning pre-meal, morning 2 hours post-meal, mid-day pre-meal, mid-day 2 hours post-meal, evening pre-meal, evening 2 hours post-meal, and at bedtime. Mean and Week 26 and Week 52 was assessed in all treatment groups. LS means of change from baseline were calculated using MMRM with the change in 7-point SMBG as the dependent variable and treatment, baseline value, country, OAM, visit, and treatment-by-visit interaction as fixed effects, and participant was the random effect.', 'timeFrame': 'Baseline, 26 Weeks, 52 Weeks'}, {'measure': 'Change From Baseline in Homeostasis Model Assessment 2 Steady-state Beta (β)- Cell Function (HOMA2-%B) at 26 Weeks and 52 Weeks', 'description': 'The updated Homeostasis Model Assessment (HOMA2) was used to quantify steady state beta-cell function (%B). HOMA2-%B is a computer model that uses fasting plasma insulin and glucose concentrations to estimate %B as a percentage of a normal reference population. LS means were calculated using a homeostasis model assessment with change from baseline in HOMA-%B as a covariate and country, baseline measurement, OAM, and treatment as fixed effects.', 'timeFrame': 'Baseline, 26 weeks, 52 weeks'}, {'measure': 'Change From Baseline in Homeostasis Model Assessment 2 Insulin Sensitivity - Cell Function (HOMA2-%S) at 26 Weeks and 52 Weeks', 'description': 'The HOMA2 was used to estimate the steady-state insulin sensitivity (%S). HOMA2-S is a computer model that uses fasting plasma insulin and glucose concentrations to estimate insulin sensitivity (%S) as a percentage of the normal reference population. LS means were calculated using an homeostasis model assessment with change from baseline in HOMA-%S as a covariate and country, baseline measurement, OAM, and treatment as fixed effects.', 'timeFrame': 'Baseline, 26 Weeks, 52 Weeks'}, {'measure': 'Rate of Hypoglycemic Events', 'description': 'Hypoglycemic events (HE) were classified as documented symptomatic hypoglycemia, asymptomatic hypoglycemia, severe hypoglycemia, and probable symptomatic hypoglycemia. The 1-year adjusted rate of HEs was summarized cumulatively at 26 weeks and 52 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.', 'timeFrame': 'Baseline through 26 weeks and 52 weeks'}, {'measure': 'Number of Self-reported Hypoglycemic Events', 'description': 'Hypoglycemic events (HE) were classified as severe (defined as episodes requiring the assistance of another person to actively administer resuscitative actions), documented symptomatic (defined as any time a participant felt that he/she was experiencing symptoms and/or signs associated with hypoglycemia, and had a plasma glucose level of less than or equal to 3.9 millimoles/liter \\\\[mmol/L\\\\]), asymptomatic (defined as events not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose of less than or equal to 3.9 mmol/L), nocturnal (defined as any hypoglycemic event that occurred between bedtime and waking), or probable symptomatic (defined as events during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination). The number of self-reported hypoglycemic events was summarized cumulatively at 52 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.', 'timeFrame': 'Baseline through 26 Weeks and 52 Weeks'}, {'measure': 'Change From Baseline to 26 Weeks and 52 Weeks on Blood Pressure (BP)', 'description': 'Seated systolic blood pressure (SBP) and seated diastolic blood pressure (DBP) were measured. LS means of change from baseline were calculated using a MMRM with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.', 'timeFrame': 'Baseline, 26 Weeks, 52 Weeks'}, {'measure': 'Change From Baseline at 26 Weeks and 52 Weeks on Pulse Rate', 'description': 'Seated pulse rate was measured. LS means of change from baseline were calculated using a MMRM with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.', 'timeFrame': 'Baseline, 26 Weeks, 52 Weeks'}, {'measure': 'Change From Baseline in Electrocardiogram Parameters, Fridericia Corrected QT (QTcF) Interval and PR Interval', 'description': \"The QT interval is a measure of the time between the start of the Q wave and the end of the T wave and was calculated from electrocardiogram (ECG) data using Fridericia's formula: QTc = QT/RR\\\\^0.33. Corrected QT (QTc) is the QT interval corrected for heart rate and RR, which is the interval between two R waves. PR is the interval between the P wave and the QRS complex.\", 'timeFrame': 'Baseline, 26 Weeks, 52 Weeks'}, {'measure': 'Change From Baseline in Electrocardiogram Parameters, Heart Rate (HR)', 'timeFrame': 'Baseline, 26 Weeks, 52 Weeks'}, {'measure': 'Change From Baseline in Pancreatic Enzymes', 'description': 'Amylase (total and pancreas-derived) and lipase concentrations were measured', 'timeFrame': 'Baseline, 26 Weeks, 52 Weeks'}, {'measure': 'Change From Baseline in Serum Calcitonin', 'timeFrame': 'Baseline, 26 Weeks, 52 Weeks'}, {'measure': 'Number of Participants With Adjudicated Cardiovascular (CV) Events', 'description': 'Deaths and nonfatal cardiovascular adverse events were adjudicated by a committee of physicians with cardiology expertise external to the Sponsor. The nonfatal cardiovascular events subjected to adjudication included myocardial infarction, hospitalization for unstable angina, hospitalization for heart failure, coronary interventions (such as coronary artery bypass graft or percutaneous coronary intervention), and cerebrovascular events including cerebrovascular accident (stroke) and transient ischemic attack. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.', 'timeFrame': 'Baseline through 52 weeks'}, {'measure': 'Number of Participants With Adjudicated Pancreatitis', 'description': 'The number of participants with pancreatitis confirmed by adjudication is summarized. Events of pancreatitis (including suspected pancreatitis and severe or serious abdominal pain) were adjudicated by a committee of expert physicians external to the Sponsor. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.', 'timeFrame': 'Baseline through 52 Weeks'}, {'measure': 'Change From Baseline in Body Weight', 'timeFrame': 'Baseline, 26 Weeks, 52 Weeks'}, {'measure': 'Change in Body Mass Index', 'description': 'Body mass index is an estimate of body fat based on body weight divided by height squared.', 'timeFrame': 'Baseline, 26 Weeks, 52 Weeks'}, {'measure': 'Percentages of Participants Developing Treatment-Emergent Dulaglutide Anti-drug Antibody (ADA)', 'description': 'Number of participants with treatment emergent (TE) dulaglutide anti-drug antibodies from postbaseline to follow up were summarized. A participant was considered to have TE dulaglutide ADA if the participant had at least one titer that was treatment-emergent relative to baseline, defined as a 4-fold or greater increase in titer from baseline measurement.', 'timeFrame': 'Baseline through 52 Weeks'}, {'measure': 'EQ-5D Health State Score Responses', 'description': 'The EQ-5D questionnaire is a widely used, generic questionnaire that assesses health-related quality of life. It consists of 2 parts. The first part assesses 5 dimensions associated with quality of life (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). Each dimension has 3 possible levels of response: no problem, some problem, and extreme problem. Additional categories of response include ambiguous and missing. The number of participants per each of the 3 response categories is summarized for each of the 5 dimensions.', 'timeFrame': 'Baseline, 26 Weeks, 52 Weeks'}, {'measure': 'Change From Baseline in EQ-5D Visual Analog Scale Score', 'description': 'The EQ-5D is a generic, multidimensional, health-related, quality-of-life instrument. Overall health state score was self-reported using a visual analogue scale (VAS) marked on a scale of 0 to 100 with 0 representing worst imaginable health state and 100 representing best imaginable health state. LS means of change from baseline were calculated using ANCOVA and adjusted by treatment, country, and baseline.', 'timeFrame': 'Baseline, 26 weeks, 52 weeks'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* Have type 2 diabetes mellitus for at least 6 months\\n* Have been taking metformin and/or a sulfonylurea for at least 3 months before screening and have been on a stable therapeutic dose for at least 8 weeks\\n* Glycosylated hemoglobin (HbA1c) value of ≥7.0% to ≤11.0%\\n* Adult men or adult non-pregnant, non-breastfeeding women\\n* Body Mass Index (BMI) of ≥19.0 to ≤35.0 kilograms/square meter (kg/m\\\\^2)\\n* Stable weight (±5%) ≥3 months prior to screening\\n\\nExclusion Criteria:\\n\\n* Have type 1 diabetes mellitus\\n* Have previous treatment with a glucagon-like peptide-1 (GLP-1) receptor agonist, GLP-1 analog, or any other incretin mimetic\\n* Have treatment with dipeptidyl peptidase-IV (DPP-IV) inhibitor, an alpha-glucosidase inhibitor (AGI), thiazolidinedione (TZD), or glinide\\n* Have gastric emptying abnormality\\n* Have cardiac disorder defined as unstable angina, myocardial infarction, coronary artery bypass graft surgery, percutaneous coronary intervention, heart failure, arrhythmia, transient ischemic attack, or stroke\\n* Have poorly controlled hypertension (systolic blood pressure above 160 millimeter of mercury\\\\[mmHg\\\\] or diastolic blood pressure above 95 mmHg)\\n* Have impaired liver function\\n* Have impaired kidney function\\n* Have history of chronic pancreatitis or acute pancreatitis\\n* Have a serum calcitonin ≥20 picograms per milliliter (pg/mL)\\n* Have a personal or family history of medullary C-cell hyperplasia, focal hyperplasia, carcinoma, or multiple endocrine neoplasia type 2 (MEN 2)', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)', 'affiliation': 'Eli Lilly and Company', 'role': 'STUDY_DIRECTOR'}], 'locations': [{'facility': 'For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.', 'city': 'Beijing', 'zip': '100730', 'country': 'China', 'geoPoint': {'lat': 39.9075, 'lon': 116.39723}}, {'facility': 'For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.', 'city': 'Changsha', 'zip': '410011', 'country': 'China', 'geoPoint': {'lat': 28.19874, 'lon': 112.97087}}, {'facility': 'For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.', 'city': 'Chengdu', 'zip': '610041', 'country': 'China', 'geoPoint': {'lat': 30.66667, 'lon': 104.06667}}, {'facility': 'For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.', 'city': 'Chongqing', 'zip': '400030', 'country': 'China', 'geoPoint': {'lat': 29.56278, 'lon': 106.55278}}, {'facility': 'For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.', 'city': 'Dalian', 'zip': '116011', 'country': 'China', 'geoPoint': {'lat': 38.91222, 'lon': 121.60222}}, {'facility': 'For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.', 'city': 'Guang Zhou', 'zip': '510120', 'country': 'China'}, {'facility': 'For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.', 'city': 'Guiyang', 'zip': '550004', 'country': 'China', 'geoPoint': {'lat': 26.58333, 'lon': 106.71667}}, {'facility': 'For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.', 'city': 'Hangzhou', 'zip': '310009', 'country': 'China', 'geoPoint': {'lat': 30.29365, 'lon': 120.16142}}, {'facility': 'For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.', 'city': 'Harbin', 'zip': '150001', 'country': 'China', 'geoPoint': {'lat': 45.75, 'lon': 126.65}}, {'facility': 'For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.', 'city': 'Hefei', 'zip': '230022', 'country': 'China', 'geoPoint': {'lat': 31.86389, 'lon': 117.28083}}, {'facility': 'For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.', 'city': 'Nanchang', 'zip': '330006', 'country': 'China', 'geoPoint': {'lat': 28.68396, 'lon': 115.85306}}, {'facility': 'For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.', 'city': 'Nanjing', 'zip': '210006', 'country': 'China', 'geoPoint': {'lat': 32.06167, 'lon': 118.77778}}, {'facility': 'For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.', 'city': 'Nanning', 'zip': '530021', 'country': 'China', 'geoPoint': {'lat': 22.81667, 'lon': 108.31667}}, {'facility': 'For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.', 'city': 'Shanghai', 'zip': '200080', 'country': 'China', 'geoPoint': {'lat': 31.22222, 'lon': 121.45806}}, {'facility': 'For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.', 'city': 'Shenyang', 'zip': '110004', 'country': 'China', 'geoPoint': {'lat': 41.79222, 'lon': 123.43278}}, {'facility': 'For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.', 'city': 'Shijiazhuang', 'zip': '050051', 'country': 'China', 'geoPoint': {'lat': 38.04139, 'lon': 114.47861}}, {'facility': 'For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.', 'city': 'Wu Han', 'zip': '430022', 'country': 'China'}, {'facility': 'For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.', 'city': \"Xi'An\", 'zip': '710032', 'country': 'China', 'geoPoint': {'lat': 34.25833, 'lon': 108.92861}}, {'facility': 'For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.', 'city': 'Yangzhou', 'zip': '225001', 'country': 'China', 'geoPoint': {'lat': 32.39722, 'lon': 119.43583}}, {'facility': 'For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.', 'city': 'Zhenjiang', 'zip': '212000', 'country': 'China', 'geoPoint': {'lat': 32.21086, 'lon': 119.45508}}, {'facility': 'For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.', 'city': 'Bucheon,', 'zip': '420-717', 'country': 'Korea, Republic of', 'geoPoint': {'lat': 37.49889, 'lon': 126.78306}}, {'facility': 'For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.', 'city': 'Kyunggi-Do', 'zip': '425-020', 'country': 'Korea, Republic of'}, {'facility': 'For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.', 'city': 'Seoul', 'zip': '137-701', 'country': 'Korea, Republic of', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'facility': 'For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.', 'city': 'Wonju-Si', 'zip': '220-701', 'country': 'Korea, Republic of'}, {'facility': 'For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.', 'city': 'Chihuahua', 'zip': '31238', 'country': 'Mexico', 'geoPoint': {'lat': 28.63528, 'lon': -106.08889}}, {'facility': 'For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.', 'city': 'Monterrey', 'zip': '64460', 'country': 'Mexico', 'geoPoint': {'lat': 25.67507, 'lon': -100.31847}}, {'facility': 'For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.', 'city': 'Chelyabinsk', 'zip': '454047', 'country': 'Russian Federation', 'geoPoint': {'lat': 55.15402, 'lon': 61.42915}}, {'facility': 'For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.', 'city': 'Moscow', 'zip': '127018', 'country': 'Russian Federation', 'geoPoint': {'lat': 55.75222, 'lon': 37.61556}}, {'facility': 'For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.', 'city': 'Saint Petersburg', 'zip': '192012', 'country': 'Russian Federation', 'geoPoint': {'lat': 59.93863, 'lon': 30.31413}}, {'facility': 'For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.', 'city': 'Sankt-Petersburg', 'zip': '190000', 'country': 'Russian Federation', 'geoPoint': {'lat': 59.93863, 'lon': 30.31413}}]}, 'referencesModule': {'references': [{'pmid': '34580638', 'type': 'DERIVED', 'citation': 'Cai TT, Li HQ, Jiang LL, Wang HY, Luo MH, Su XF, Ma JH. Effects of GLP-1 Receptor Agonists on Bone Mineral Density in Patients with Type 2 Diabetes Mellitus: A 52-Week Clinical Study. Biomed Res Int. 2021 Sep 17;2021:3361309. doi: 10.1155/2021/3361309. eCollection 2021.'}, {'pmid': '34453682', 'type': 'DERIVED', 'citation': 'Zhou Y, Zhu J, Wu H, Deng Y, Ji Q. Pancreatic Safety of Once-Weekly Dulaglutide in Chinese Patients with Type 2 Diabetes Mellitus: Subgroup Analysis by Potential Influencing Factors. Diabetes Ther. 2021 Oct;12(10):2677-2690. doi: 10.1007/s13300-021-01139-2. Epub 2021 Aug 28.'}, {'pmid': '33161492', 'type': 'DERIVED', 'citation': 'Ma J, Zhang B, Hou J, Peng Y. Efficacy and Safety of Once Weekly Dulaglutide in East Asian Patients with Type 2 Diabetes: Subgroup Analysis by Potential Influential Factors. Diabetes Ther. 2021 Jan;12(1):211-222. doi: 10.1007/s13300-020-00955-2. Epub 2020 Nov 8.'}, {'pmid': '32857293', 'type': 'DERIVED', 'citation': 'Kuang J, Zhu J, Liu S, Li Q. Efficacy and Safety of Once-Weekly Dulaglutide in Elderly Chinese Patients with Type 2 Diabetes: A Post Hoc Analysis of AWARD-CHN Studies. Diabetes Ther. 2020 Oct;11(10):2329-2339. doi: 10.1007/s13300-020-00910-1. Epub 2020 Aug 28.'}, {'pmid': '32621083', 'type': 'DERIVED', 'citation': 'Guo L, Zhang B, Hou J, Zhou Z. Evaluation of Characteristics of Gastrointestinal Adverse Events with Once-Weekly Dulaglutide Treatment in Chinese Patients with Type 2 Diabetes: A Post Hoc Pooled Analysis of Two Randomized Trials. Diabetes Ther. 2020 Aug;11(8):1821-1833. doi: 10.1007/s13300-020-00869-z. Epub 2020 Jul 4.'}, {'pmid': '32277401', 'type': 'DERIVED', 'citation': 'Yu M, Yuan GY, Zhang B, Wu HY, Lv XF. Efficacy and Safety of Dulaglutide by Baseline HbA1c in Chinese Patients with Type 2 Diabetes: A Post Hoc Analysis. Diabetes Ther. 2020 May;11(5):1147-1159. doi: 10.1007/s13300-020-00804-2. Epub 2020 Apr 10.'}, {'pmid': '31950036', 'type': 'DERIVED', 'citation': 'Wang J, Li HQ, Xu XH, Kong XC, Sun R, Jing T, Ye L, Su XF, Ma JH. The Effects of Once-Weekly Dulaglutide and Insulin Glargine on Glucose Fluctuation in Poorly Oral-Antidiabetic Controlled Patients with Type 2 Diabetes Mellitus. Biomed Res Int. 2019 Dec 24;2019:2682657. doi: 10.1155/2019/2682657. eCollection 2019.'}, {'pmid': '31228090', 'type': 'DERIVED', 'citation': 'Li Y, Li L, De Peng Y, Song GY, Ye SD, Du LY, Hou JN, Ji QH. Efficacy and Safety of Dulaglutide Versus Insulin Glargine in Chinese T2DM Patients: A Subgroup Analysis of a Randomized Trial (AWARD-CHN2). Diabetes Ther. 2019 Aug;10(4):1435-1452. doi: 10.1007/s13300-019-0646-y. Epub 2019 Jun 21.'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'YES', 'description': 'Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.', 'infoTypes': ['STUDY_PROTOCOL', 'SAP', 'CSR'], 'timeFrame': 'Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.', 'accessCriteria': 'A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.', 'url': 'https://vivli.org/'}}, 'resultsSection': {'participantFlowModule': {'preAssignmentDetails': 'This was a parallel-arm, non-inferiority study. Study treatment continued for up to 52 weeks and participants were randomized in a 1:1:1 ratio to one of the 3 treatment arms: 1.5 milligrams (mg) dulaglutide once-weekly , 0.75 mg dulaglutide once-weekly, or insulin glargine once-daily.', 'groups': [{'id': 'FG000', 'title': '1.5 mg Dulaglutide', 'description': \"1.5 mg dulaglutide administered as 1 subcutaneous (SC) injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.\"}, {'id': 'FG001', 'title': '0.75 mg Dulaglutide', 'description': \"0.75 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.\"}, {'id': 'FG002', 'title': 'Insulin Glargine', 'description': \"Insulin glargine administered per dosing titration schedule as once daily SC injection at bedtime added to participant's pre-study prescribed dose of metformin and /or a sulfonylurea.\"}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '258'}, {'groupId': 'FG001', 'numSubjects': '257'}, {'groupId': 'FG002', 'numSubjects': '259'}]}, {'type': 'Received at Least One Dose of Study Drug', 'achievements': [{'groupId': 'FG000', 'numSubjects': '258'}, {'groupId': 'FG001', 'numSubjects': '257'}, {'groupId': 'FG002', 'numSubjects': '259'}]}, {'type': 'Modified Intent-to-Treat Population', 'achievements': [{'groupId': 'FG000', 'numSubjects': '253'}, {'groupId': 'FG001', 'numSubjects': '252'}, {'groupId': 'FG002', 'numSubjects': '250'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '226'}, {'groupId': 'FG001', 'numSubjects': '219'}, {'groupId': 'FG002', 'numSubjects': '227'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '32'}, {'groupId': 'FG001', 'numSubjects': '38'}, {'groupId': 'FG002', 'numSubjects': '32'}]}], 'dropWithdraws': [{'type': 'Adverse Event', 'reasons': [{'groupId': 'FG000', 'numSubjects': '6'}, {'groupId': 'FG001', 'numSubjects': '11'}, {'groupId': 'FG002', 'numSubjects': '2'}]}, {'type': 'Lost to Follow-up', 'reasons': [{'groupId': 'FG000', 'numSubjects': '9'}, {'groupId': 'FG001', 'numSubjects': '6'}, {'groupId': 'FG002', 'numSubjects': '8'}]}, {'type': 'Protocol Violation', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '2'}, {'groupId': 'FG002', 'numSubjects': '1'}]}, {'type': 'Withdrawal by Subject', 'reasons': [{'groupId': 'FG000', 'numSubjects': '15'}, {'groupId': 'FG001', 'numSubjects': '17'}, {'groupId': 'FG002', 'numSubjects': '17'}]}, {'type': 'Physician Decision', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '1'}, {'groupId': 'FG002', 'numSubjects': '3'}]}, {'type': 'Death', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}]}, {'type': 'Sponsor Decision', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '1'}, {'groupId': 'FG002', 'numSubjects': '1'}]}]}]}, 'baselineCharacteristicsModule': {'populationDescription': 'Baseline characteristics are reported for the modified intent-to-treat (mITT) population, who are all randomized participants with a baseline glycosylated hemoglobin (HbA1c) measurement, at least 1 post-baseline HbA1c measurement, and received at least 1 dose of study drug.', 'groups': [{'id': 'BG000', 'title': '1.5 mg Dulaglutide', 'description': \"1.5 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.\"}, {'id': 'BG001', 'title': '0.75 mg Dulaglutide', 'description': \"0.75 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.\"}, {'id': 'BG002', 'title': 'Insulin Glargine', 'description': \"Insulin glargine administered per dosing titration schedule as once daily SC injection at bedtime added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.\"}, {'id': 'BG003', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'BG000', 'value': '253'}, {'groupId': 'BG001', 'value': '252'}, {'groupId': 'BG002', 'value': '250'}, {'groupId': 'BG003', 'value': '755'}]}], 'measures': [{'title': 'Age, Continuous', 'paramType': 'MEAN', 'dispersionType': 'STANDARD_DEVIATION', 'unitOfMeasure': 'years', 'classes': [{'categories': [{'measurements': [{'groupId': 'BG000', 'value': '55.03', 'spread': '9.572'}, {'groupId': 'BG001', 'value': '54.54', 'spread': '10.006'}, {'groupId': 'BG002', 'value': '55.44', 'spread': '9.197'}, {'groupId': 'BG003', 'value': '55.00', 'spread': '9.593'}]}]}]}, {'title': 'Sex: Female, Male', 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'groupId': 'BG000', 'value': '118'}, {'groupId': 'BG001', 'value': '109'}, {'groupId': 'BG002', 'value': '111'}, {'groupId': 'BG003', 'value': '338'}]}, {'title': 'Male', 'measurements': [{'groupId': 'BG000', 'value': '135'}, {'groupId': 'BG001', 'value': '143'}, {'groupId': 'BG002', 'value': '139'}, {'groupId': 'BG003', 'value': '417'}]}]}]}, {'title': 'Race (NIH/OMB)', 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'classes': [{'categories': [{'title': 'American Indian or Alaska Native', 'measurements': [{'groupId': 'BG000', 'value': '14'}, {'groupId': 'BG001', 'value': '14'}, {'groupId': 'BG002', 'value': '13'}, {'groupId': 'BG003', 'value': '41'}]}, {'title': 'Asian', 'measurements': [{'groupId': 'BG000', 'value': '213'}, {'groupId': 'BG001', 'value': '209'}, {'groupId': 'BG002', 'value': '209'}, {'groupId': 'BG003', 'value': '631'}]}, {'title': 'Native Hawaiian or Other Pacific Islander', 'measurements': [{'groupId': 'BG000', 'value': '0'}, {'groupId': 'BG001', 'value': '0'}, {'groupId': 'BG002', 'value': '0'}, {'groupId': 'BG003', 'value': '0'}]}, {'title': 'Black or African American', 'measurements': [{'groupId': 'BG000', 'value': '0'}, {'groupId': 'BG001', 'value': '0'}, {'groupId': 'BG002', 'value': '0'}, {'groupId': 'BG003', 'value': '0'}]}, {'title': 'White', 'measurements': [{'groupId': 'BG000', 'value': '26'}, {'groupId': 'BG001', 'value': '29'}, {'groupId': 'BG002', 'value': '28'}, {'groupId': 'BG003', 'value': '83'}]}, {'title': 'More than one race', 'measurements': [{'groupId': 'BG000', 'value': '0'}, {'groupId': 'BG001', 'value': '0'}, {'groupId': 'BG002', 'value': '0'}, {'groupId': 'BG003', 'value': '0'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'groupId': 'BG000', 'value': '0'}, {'groupId': 'BG001', 'value': '0'}, {'groupId': 'BG002', 'value': '0'}, {'groupId': 'BG003', 'value': '0'}]}]}]}, {'title': 'Region of Enrollment', 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'classes': [{'title': 'China', 'categories': [{'measurements': [{'groupId': 'BG000', 'value': '200'}, {'groupId': 'BG001', 'value': '196'}, {'groupId': 'BG002', 'value': '195'}, {'groupId': 'BG003', 'value': '591'}]}]}, {'title': 'Korea, Republic of', 'categories': [{'measurements': [{'groupId': 'BG000', 'value': '13'}, {'groupId': 'BG001', 'value': '13'}, {'groupId': 'BG002', 'value': '14'}, {'groupId': 'BG003', 'value': '40'}]}]}, {'title': 'Mexico', 'categories': [{'measurements': [{'groupId': 'BG000', 'value': '22'}, {'groupId': 'BG001', 'value': '24'}, {'groupId': 'BG002', 'value': '24'}, {'groupId': 'BG003', 'value': '70'}]}]}, {'title': 'Russian Federation', 'categories': [{'measurements': [{'groupId': 'BG000', 'value': '18'}, {'groupId': 'BG001', 'value': '19'}, {'groupId': 'BG002', 'value': '17'}, {'groupId': 'BG003', 'value': '54'}]}]}]}]}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 26 Weeks', 'description': 'HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. Least square (LS) means of change from baseline in HbA1c were calculated using a mixed-effects model for repeated measures (MMRM) with the change in HbA1c as the dependent variable and treatment, baseline HbA1c, country, oral antihyperglycemic medication (OAM) , visit, and treatment-by-visit interaction as fixed effects, and participant was the random effect.', 'populationDescription': 'Participants who were randomized, received at least one dose of study drug, and had evaluable HbA1c data at both baseline and post-baseline.', 'reportingStatus': 'POSTED', 'paramType': 'LEAST_SQUARES_MEAN', 'dispersionType': 'Standard Error', 'unitOfMeasure': 'percentage of HbA1c', 'timeFrame': 'Baseline, 26 Weeks', 'groups': [{'id': 'OG000', 'title': '1.5 mg Dulaglutide', 'description': \"1.5 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.\"}, {'id': 'OG001', 'title': '0.75 mg Dulaglutide', 'description': \"0.75 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.\"}, {'id': 'OG002', 'title': 'Insulin Glargine', 'description': \"Insulin glargine administered per dosing titration schedule as once daily SC injection at bedtime added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.\"}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '253'}, {'groupId': 'OG001', 'value': '252'}, {'groupId': 'OG002', 'value': '250'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-1.73', 'spread': '0.067'}, {'groupId': 'OG001', 'value': '-1.33', 'spread': '0.067'}, {'groupId': 'OG002', 'value': '-1.16', 'spread': '0.067'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG002'], 'nonInferiorityType': 'NON_INFERIORITY_OR_EQUIVALENCE_LEGACY', 'nonInferiorityComment': 'Analyses were based on a pre-defined non-inferiority margin of 0.4%.', 'paramType': 'Mean Difference (Net)', 'paramValue': '-0.57', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-0.74', 'ciUpperLimit': '-0.40'}, {'groupIds': ['OG001', 'OG002'], 'nonInferiorityType': 'NON_INFERIORITY_OR_EQUIVALENCE_LEGACY', 'nonInferiorityComment': 'Analyses were based on a pre-defined non-inferiority margin of 0.4%.', 'paramType': 'Mean Difference (Net)', 'paramValue': '-0.18', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-0.35', 'ciUpperLimit': '-0.01'}]}, {'type': 'SECONDARY', 'title': 'Change From Baseline in HbA1c at 52 Weeks', 'description': 'HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. LS means of change from baseline in HbA1c were calculated using a MMRM with the change in HbA1c as the dependent variable and treatment, baseline HbA1c, country, OAM, visit, and treatment-by-visit interaction as fixed effects, and participant was as the random effect.', 'populationDescription': 'Participants who were randomized, received at least one dose of study drug, and had evaluable HbA1c data at both baseline and post-baseline.', 'reportingStatus': 'POSTED', 'paramType': 'LEAST_SQUARES_MEAN', 'dispersionType': 'Standard Error', 'unitOfMeasure': 'percentage of HbA1c', 'timeFrame': 'Baseline, 52 Weeks', 'groups': [{'id': 'OG000', 'title': '1.5 mg Dulaglutide', 'description': \"1.5 mg dulaglutide administered as one SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.\"}, {'id': 'OG001', 'title': '0.75 mg Dulaglutide', 'description': \"0.75 mg dulaglutide administered as one SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.\"}, {'id': 'OG002', 'title': 'Insulin Glargine', 'description': \"Insulin glargine administered per dosing titration schedule as once daily SC injection at bedtime added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.\"}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '253'}, {'groupId': 'OG001', 'value': '252'}, {'groupId': 'OG002', 'value': '250'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-1.47', 'spread': '0.076'}, {'groupId': 'OG001', 'value': '-1.03', 'spread': '0.076'}, {'groupId': 'OG002', 'value': '-0.89', 'spread': '0.075'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG002'], 'nonInferiorityType': 'NON_INFERIORITY_OR_EQUIVALENCE_LEGACY', 'nonInferiorityComment': 'Analyses were based on a pre-defined non-inferiority margin of 0.4%.', 'paramType': 'Mean Difference (Net)', 'paramValue': '-0.57', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-0.77', 'ciUpperLimit': '-0.38'}, {'groupIds': ['OG001', 'OG002'], 'nonInferiorityType': 'NON_INFERIORITY_OR_EQUIVALENCE_LEGACY', 'nonInferiorityComment': 'Analyses were based on a pre-defined non-inferiority margin of 0.4%.', 'paramType': 'Mean Difference (Net)', 'paramValue': '-0.13', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-0.33', 'ciUpperLimit': '-0.06'}]}, {'type': 'SECONDARY', 'title': 'Percentage of Participants Attaining HbA1c of <7% or ≤6.5% at 26 Weeks and 52 Weeks', 'description': 'The percentage of participants was calculated by dividing the number of participants reaching target HbA1c by the total number of participants analyzed, multiplied by 100.', 'populationDescription': 'Participants who were randomized, received at least one dose of study drug, and had evaluable HbA1c data at both baseline and post-baseline. Missing endpoints were imputed with the last observation carried forward (LOCF) method.', 'reportingStatus': 'POSTED', 'paramType': 'NUMBER', 'unitOfMeasure': 'percentage of participants', 'timeFrame': 'Up to 26 and 52 weeks', 'groups': [{'id': 'OG000', 'title': '1.5 mg Dulaglutide', 'description': \"1.5 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.\"}, {'id': 'OG001', 'title': '0.75 mg Dulaglutide', 'description': \"0.75 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.\"}, {'id': 'OG002', 'title': 'Insulin Glargine', 'description': \"Insulin glargine administered per dosing titration schedule as once daily SC injection at bedtime added to participant's pre-study prescribed dose of metformin and /or a sulfonylurea.\"}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '253'}, {'groupId': 'OG001', 'value': '252'}, {'groupId': 'OG002', 'value': '250'}]}], 'classes': [{'title': 'HbA1c <7%, Week 26', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '64.8'}, {'groupId': 'OG001', 'value': '52.8'}, {'groupId': 'OG002', 'value': '40.0'}]}]}, {'title': 'HbA1c ≤6.5%, Week 26', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '51.4'}, {'groupId': 'OG001', 'value': '38.9'}, {'groupId': 'OG002', 'value': '21.6'}]}]}, {'title': 'HbA1c <7%, Week 52', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '51.8'}, {'groupId': 'OG001', 'value': '45.6'}, {'groupId': 'OG002', 'value': '32.0'}]}]}, {'title': 'HbA1c ≤6.5%, Week 52', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '37.2'}, {'groupId': 'OG001', 'value': '31.3'}, {'groupId': 'OG002', 'value': '17.2'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG002'], 'groupDescription': '\\\\<7.0% Week 26', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'pValue': '<0.001', 'statisticalMethod': 'Fisher Exact', 'ciNumSides': 'TWO_SIDED'}, {'groupIds': ['OG001', 'OG002'], 'groupDescription': '\\\\<7.0 Week 26', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'pValue': '0.004', 'statisticalMethod': 'Fisher Exact'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': '\\\\<=6.5% Week 26', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'pValue': '<0.001', 'statisticalMethod': 'Fisher Exact'}, {'groupIds': ['OG001', 'OG002'], 'groupDescription': '\\\\<=6.5% Week 26', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'pValue': '<0.001', 'statisticalMethod': 'Fisher Exact'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': '\\\\<7.0% Week 52', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'pValue': '<0.001', 'statisticalMethod': 'Fisher Exact'}, {'groupIds': ['OG001', 'OG002'], 'groupDescription': '\\\\<7.0% Week 52', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'pValue': '0.002', 'statisticalMethod': 'Fisher Exact'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': '\\\\<=6.5% Week 52', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'pValue': '<0.001', 'statisticalMethod': 'Fisher Exact'}, {'groupIds': ['OG001', 'OG002'], 'groupDescription': '\\\\<=6.5% Week 52', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'pValue': '<0.001', 'statisticalMethod': 'Fisher Exact'}]}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Fasting Blood Glucose (FBG) at 26 Weeks and 52 Weeks', 'description': 'LS means of change from baseline were calculated using MMRM with the change in FBG as the dependent variable and treatment, baseline value, country, OAM, visit, and treatment-by-visit interaction as fixed effects, and participant was the random effect.', 'populationDescription': 'Participants who were randomized, received at least one dose of study drug, and had evaluable HbA1c data at both baseline and post-baseline.', 'reportingStatus': 'POSTED', 'paramType': 'LEAST_SQUARES_MEAN', 'dispersionType': 'Standard Error', 'unitOfMeasure': 'millimoles per liter (mmol/L)', 'timeFrame': 'Baseline, 26 Weeks, 52 Weeks', 'groups': [{'id': 'OG000', 'title': '1.5 mg Dulaglutide', 'description': \"1.5 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.\"}, {'id': 'OG001', 'title': '0.75 mg Dulaglutide', 'description': \"0.75 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.\"}, {'id': 'OG002', 'title': 'Insulin Glargine', 'description': \"Insulin glargine administered per dosing titration schedule as once daily SC injection at bedtime added to participant's pre-study prescribed dose of metformin and /or a sulfonylurea.\"}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '253'}, {'groupId': 'OG001', 'value': '252'}, {'groupId': 'OG002', 'value': '250'}]}], 'classes': [{'title': 'Change from baseline in FBG, 26 Weeks', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-2.35', 'spread': '0.162'}, {'groupId': 'OG001', 'value': '-1.71', 'spread': '0.161'}, {'groupId': 'OG002', 'value': '-2.59', 'spread': '0.161'}]}]}, {'title': 'Change from baseline in FBG, 52 Weeks', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-2.23', 'spread': '0.166'}, {'groupId': 'OG001', 'value': '-1.53', 'spread': '0.165'}, {'groupId': 'OG002', 'value': '-2.35', 'spread': '0.164'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 26', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'pValue': '0.177', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Net)', 'paramValue': '0.24', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-0.11', 'ciUpperLimit': '0.59'}, {'groupIds': ['OG001', 'OG002'], 'groupDescription': 'Week 26', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'pValue': '<0.001', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Net)', 'paramValue': '0.88', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '0.53', 'ciUpperLimit': '1.23'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 52', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'pValue': '0.518', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Net)', 'paramValue': '0.12', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-0.25', 'ciUpperLimit': '0.50'}, {'groupIds': ['OG001', 'OG002'], 'groupDescription': 'Week 52', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'pValue': '<0.001', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Net)', 'paramValue': '0.82', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '0.45', 'ciUpperLimit': '1.20'}]}, {'type': 'SECONDARY', 'title': 'Change From Baseline in 7-point Self-monitored Blood Glucose (SMBG) Profiles at 26 Weeks and 52 Weeks', 'description': 'Participants were required to perform 7-point SMBG profiles on 2 separate, nonconsecutive days during the 2 weeks before randomization and Weeks 8, 14, 20, 26, 39, and 52 (or the Early Discontinuation Visit). SMBG measurements were taken using a plasma-equivalent blood glucose (BG) meter at 7 time points: morning pre-meal, morning 2 hours post-meal, mid-day pre-meal, mid-day 2 hours post-meal, evening pre-meal, evening 2 hours post-meal, and at bedtime. Mean and Week 26 and Week 52 was assessed in all treatment groups. LS means of change from baseline were calculated using MMRM with the change in 7-point SMBG as the dependent variable and treatment, baseline value, country, OAM, visit, and treatment-by-visit interaction as fixed effects, and participant was the random effect.', 'populationDescription': 'Participants who were randomized, received at least one dose of study drug, and had evaluable HbA1c data at both baseline and post-baseline.', 'reportingStatus': 'POSTED', 'paramType': 'LEAST_SQUARES_MEAN', 'dispersionType': 'Standard Error', 'unitOfMeasure': 'mmol/L', 'timeFrame': 'Baseline, 26 Weeks, 52 Weeks', 'groups': [{'id': 'OG000', 'title': '1.5 mg Dulaglutide', 'description': \"1.5 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.\"}, {'id': 'OG001', 'title': '0.75 mg Dulaglutide', 'description': \"0.75 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.\"}, {'id': 'OG002', 'title': 'Insulin Glargine', 'description': \"Insulin glargine administered per dosing titration schedule as once daily SC injection at bedtime added to participant's pre-study prescribed dose of metformin and /or a sulfonylurea.\"}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '258'}, {'groupId': 'OG001', 'value': '257'}, {'groupId': 'OG002', 'value': '253'}]}], 'classes': [{'title': 'Morning pre-meal, Week 26', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-2.18', 'spread': '0.104'}, {'groupId': 'OG001', 'value': '-1.89', 'spread': '0.103'}, {'groupId': 'OG002', 'value': '-2.83', 'spread': '0.103'}]}]}, {'title': 'Morning 2 hours post-meal, Week 26', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-3.81', 'spread': '0.190'}, {'groupId': 'OG001', 'value': '-3.43', 'spread': '0.188'}, {'groupId': 'OG002', 'value': '-3.32', 'spread': '0.188'}]}]}, {'title': 'Mid-day pre-meal, Week 26', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-2.45', 'spread': '0.159'}, {'groupId': 'OG001', 'value': '-2.07', 'spread': '0.157'}, {'groupId': 'OG002', 'value': '-2.10', 'spread': '0.157'}]}]}, {'title': 'Mid-day 2 hours post-meal, Week 26', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-3.16', 'spread': '0.182'}, {'groupId': 'OG001', 'value': '-2.71', 'spread': '0.179'}, {'groupId': 'OG002', 'value': '-2.11', 'spread': '0.179'}]}]}, {'title': 'Evening pre-meal, Week 26', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-2.25', 'spread': '0.150'}, {'groupId': 'OG001', 'value': '-1.74', 'spread': '0.147'}, {'groupId': 'OG002', 'value': '-1.62', 'spread': '0.148'}]}]}, {'title': 'Evening 2 hours post-meal, Week 26', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-3.00', 'spread': '0.180'}, {'groupId': 'OG001', 'value': '-2.58', 'spread': '0.178'}, {'groupId': 'OG002', 'value': '-2.11', 'spread': '0.178'}]}]}, {'title': 'Bed time, Week 26', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-2.95', 'spread': '0.170'}, {'groupId': 'OG001', 'value': '-2.51', 'spread': '0.167'}, {'groupId': 'OG002', 'value': '-2.16', 'spread': '0.167'}]}]}, {'title': 'Morning pre-meal, Week 52', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-2.06', 'spread': '0.108'}, {'groupId': 'OG001', 'value': '-1.76', 'spread': '0.108'}, {'groupId': 'OG002', 'value': '-2.83', 'spread': '0.107'}]}]}, {'title': 'Morning 2 hours post-meal, Week 52', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-3.58', 'spread': '0.201'}, {'groupId': 'OG001', 'value': '-3.25', 'spread': '0.200'}, {'groupId': 'OG002', 'value': '-3.05', 'spread': '0.197'}]}]}, {'title': 'Mid-day pre-meal, Week 52', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-2.37', 'spread': '0.162'}, {'groupId': 'OG001', 'value': '-1.89', 'spread': '0.162'}, {'groupId': 'OG002', 'value': '-1.94', 'spread': '0.160'}]}]}, {'title': 'Mid-day 2 hours post-meal, Week 52', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-2.75', 'spread': '0.187'}, {'groupId': 'OG001', 'value': '-2.61', 'spread': '0.186'}, {'groupId': 'OG002', 'value': '-2.12', 'spread': '0.184'}]}]}, {'title': 'Evening pre-meal, Week 52', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-2.15', 'spread': '0.159'}, {'groupId': 'OG001', 'value': '-1.61', 'spread': '0.158'}, {'groupId': 'OG002', 'value': '-1.51', 'spread': '0.156'}]}]}, {'title': 'Evening 2 hours post-meal, Week 52', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-2.93', 'spread': '0.183'}, {'groupId': 'OG001', 'value': '-2.54', 'spread': '0.182'}, {'groupId': 'OG002', 'value': '-2.10', 'spread': '0.180'}]}]}, {'title': 'Bed time, Week 52', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-2.90', 'spread': '0.172'}, {'groupId': 'OG001', 'value': '-2.50', 'spread': '0.171'}, {'groupId': 'OG002', 'value': '-1.91', 'spread': '0.168'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Morning pre-meal, Week 26', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'pValue': '<0.001', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Net)', 'paramValue': '0.65', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '0.42', 'ciUpperLimit': '0.88'}, {'groupIds': ['OG001', 'OG002'], 'groupDescription': 'Morning pre-meal, Week 26', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'pValue': '<0.001', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Net)', 'paramValue': '0.94', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '0.71', 'ciUpperLimit': '1.17'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Morning 2-hours post-meal, Week 26', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'pValue': '0.024', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Net)', 'paramValue': '-0.49', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-0.92', 'ciUpperLimit': '-0.07'}, {'groupIds': ['OG001', 'OG002'], 'groupDescription': 'Morning 2-hours post-meal, Week 26', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'pValue': '0.617', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Net)', 'paramValue': '-0.11', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-0.53', 'ciUpperLimit': '0.32'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Mid-day pre-meal, Week 26', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'pValue': '0.055', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Net)', 'paramValue': '-0.35', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-0.70', 'ciUpperLimit': '0.01'}, {'groupIds': ['OG001', 'OG002'], 'groupDescription': 'Mid-day pre-meal, Week 26', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'pValue': '0.855', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Net)', 'paramValue': '0.03', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-0.32', 'ciUpperLimit': '0.39'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Mid-day 2-hours post-meal, Week 26', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'pValue': '<0.001', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Net)', 'paramValue': '-1.05', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-1.46', 'ciUpperLimit': '-0.64'}, {'groupIds': ['OG001', 'OG002'], 'groupDescription': 'Mid-day 2-hours post-meal, Week 26', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'pValue': '0.004', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Net)', 'paramValue': '-0.60', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-1.01', 'ciUpperLimit': '-0.19'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Evening pre-meal, Week 26', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'pValue': '<0.001', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Net)', 'paramValue': '-0.63', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-0.97', 'ciUpperLimit': '-0.29'}, {'groupIds': ['OG001', 'OG002'], 'groupDescription': 'Evening pre-meal, Week 26', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'pValue': '0.489', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Net)', 'paramValue': '-0.12', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-0.45', 'ciUpperLimit': '0.22'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Evening 2-hours post-meal, Week 26', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'pValue': '<0.001', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Net)', 'paramValue': '-0.89', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-1.30', 'ciUpperLimit': '-0.48'}, {'groupIds': ['OG001', 'OG002'], 'groupDescription': 'Evening 2-hours post-meal, Week 26', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'pValue': '0.024', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Net)', 'paramValue': '-0.47', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-0.88', 'ciUpperLimit': '-0.06'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Bedtime, Week 26', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'pValue': '<0.001', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Net)', 'paramValue': '-0.79', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-1.17', 'ciUpperLimit': '-0.41'}, {'groupIds': ['OG001', 'OG002'], 'groupDescription': 'Bedtime, Week 26', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'pValue': '0.067', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Net)', 'paramValue': '-0.35', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-0.73', 'ciUpperLimit': '-0.03'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Morning pre-meal, Week 52', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'pValue': '<0.001', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Net)', 'paramValue': '0.77', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '0.52', 'ciUpperLimit': '1.01'}, {'groupIds': ['OG001', 'OG002'], 'groupDescription': 'Morning pre-meal, Week 52', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'pValue': '<0.001', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Net)', 'paramValue': '1.06', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '0.82', 'ciUpperLimit': '1.31'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Morning 2-hours post-meal, Week 52', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'pValue': '0.025', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Net)', 'paramValue': '-0.53', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-1.00', 'ciUpperLimit': '-0.07'}, {'groupIds': ['OG001', 'OG002'], 'groupDescription': 'Morning 2-hours post-meal, Week 52', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'pValue': '0.384', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Net)', 'paramValue': '-0.21', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-0.67', 'ciUpperLimit': '0.26'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Mid-day pre-meal, Week 52', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'pValue': '0.024', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Net)', 'paramValue': '-0.43', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-0.80', 'ciUpperLimit': '-0.06'}, {'groupIds': ['OG001', 'OG002'], 'groupDescription': 'Mid-day pre-meal, Week 52', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'pValue': '0.783', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Net)', 'paramValue': '-0.05', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-0.32', 'ciUpperLimit': '0.42'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Mid-day 2-hours post-meal, Week 52', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'pValue': '0.004', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Net)', 'paramValue': '-0.63', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-1.07', 'ciUpperLimit': '-0.20'}, {'groupIds': ['OG001', 'OG002'], 'groupDescription': 'Mid-day 2-hours post-meal, Week 52', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'pValue': '0.029', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Net)', 'paramValue': '-0.48', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-0.92', 'ciUpperLimit': '-0.05'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Evening pre-meal, Week 52', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'pValue': '<0.001', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Net)', 'paramValue': '-0.64', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-1.01', 'ciUpperLimit': '-0.27'}, {'groupIds': ['OG001', 'OG002'], 'groupDescription': 'Evening pre-meal, Week 52', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'pValue': '0.603', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Net)', 'paramValue': '-0.10', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-0.47', 'ciUpperLimit': '0.27'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Evening 2-hours post-meal, Week 52', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'pValue': '<0.001', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Net)', 'paramValue': '-0.83', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-1.26', 'ciUpperLimit': '-0.41'}, {'groupIds': ['OG001', 'OG002'], 'groupDescription': 'Evening 2-hours post-meal, Week 52', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'pValue': '0.039', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Net)', 'paramValue': '-0.45', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-0.87', 'ciUpperLimit': '-0.02'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Bedtime, Week 52', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'pValue': '<0.001', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Net)', 'paramValue': '-0.99', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-1.39', 'ciUpperLimit': '-0.60'}, {'groupIds': ['OG001', 'OG002'], 'groupDescription': 'Bedtime, Week 52', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'pValue': '0.003', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Net)', 'paramValue': '-0.59', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-0.98', 'ciUpperLimit': '-0.20'}]}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Homeostasis Model Assessment 2 Steady-state Beta (β)- Cell Function (HOMA2-%B) at 26 Weeks and 52 Weeks', 'description': 'The updated Homeostasis Model Assessment (HOMA2) was used to quantify steady state beta-cell function (%B). HOMA2-%B is a computer model that uses fasting plasma insulin and glucose concentrations to estimate %B as a percentage of a normal reference population. LS means were calculated using a homeostasis model assessment with change from baseline in HOMA-%B as a covariate and country, baseline measurement, OAM, and treatment as fixed effects.', 'populationDescription': 'Participants who were randomized, received at least one dose of study drug, and had evaluable HbA1c data at both baseline and post-baseline. Missing endpoints were imputed with the LOCF method. HOMA2 was not evaluated for insulin glargine, as the use of this model has not been validated in participants treated with insulin.', 'reportingStatus': 'POSTED', 'paramType': 'LEAST_SQUARES_MEAN', 'dispersionType': 'Standard Error', 'unitOfMeasure': 'percentage of HOMA2-%B', 'timeFrame': 'Baseline, 26 weeks, 52 weeks', 'groups': [{'id': 'OG000', 'title': '1.5 mg Dulaglutide', 'description': \"1.5 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.\"}, {'id': 'OG001', 'title': '0.75 mg Dulaglutide', 'description': \"0.75 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.\"}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '253'}, {'groupId': 'OG001', 'value': '252'}]}], 'classes': [{'title': 'Insulin-Based HOMA2-%B, 26 Weeks', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '34.41', 'spread': '3.831'}, {'groupId': 'OG001', 'value': '31.17', 'spread': '3.761'}]}]}, {'title': 'Insulin-Based HOMA2-%B, 52 Weeks', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '45.12', 'spread': '4.147'}, {'groupId': 'OG001', 'value': '36.64', 'spread': '4.061'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'groupDescription': 'HOMA2-%B, Dula 1.5 mg, Week 26', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'pValue': '0.352', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Net)', 'paramValue': '34.41', 'ciNumSides': 'TWO_SIDED', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.831'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'HOMA2-%B, Dula 0.75 mg, Week 26', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'pValue': '0.352', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Net)', 'paramValue': '31.17', 'ciNumSides': 'TWO_SIDED', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.761'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'HOMA2-%B, Dula 1.5, Week 52', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'pValue': '0.025', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Net)', 'paramValue': '45.12', 'ciNumSides': 'TWO_SIDED', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.147'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'HOMA2-%B, Dula 0.75 mg, Week 52', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'pValue': '0.025', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Net)', 'paramValue': '36.64', 'ciNumSides': 'TWO_SIDED', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.061'}]}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Homeostasis Model Assessment 2 Insulin Sensitivity - Cell Function (HOMA2-%S) at 26 Weeks and 52 Weeks', 'description': 'The HOMA2 was used to estimate the steady-state insulin sensitivity (%S). HOMA2-S is a computer model that uses fasting plasma insulin and glucose concentrations to estimate insulin sensitivity (%S) as a percentage of the normal reference population. LS means were calculated using an homeostasis model assessment with change from baseline in HOMA-%S as a covariate and country, baseline measurement, OAM, and treatment as fixed effects.', 'populationDescription': 'Participants who were randomized, received at least one dose of study drug, and had evaluable HbA1c data at both baseline and post-baseline. Missing endpoints were imputed with the LOCF method. HOMA2 was not evaluated for insulin glargine, as the use of this model has not been validated in participants treated with insulin.', 'reportingStatus': 'POSTED', 'paramType': 'LEAST_SQUARES_MEAN', 'dispersionType': 'Standard Error', 'unitOfMeasure': 'percentage of HOMA2-%S', 'timeFrame': 'Baseline, 26 Weeks, 52 Weeks', 'groups': [{'id': 'OG000', 'title': '1.5 mg Dulaglutide', 'description': \"1.5 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.\"}, {'id': 'OG001', 'title': '0.75 mg Dulaglutide', 'description': \"0.75 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.\"}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '253'}, {'groupId': 'OG001', 'value': '252'}]}], 'classes': [{'title': 'Insulin-Based HOMA2-%S, Week 26', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-6.86', 'spread': '3.649'}, {'groupId': 'OG001', 'value': '-10.03', 'spread': '3.591'}]}]}, {'title': 'Insulin-Based HOMA2-%S, Week 52', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-10.19', 'spread': '3.677'}, {'groupId': 'OG001', 'value': '-12.32', 'spread': '3.609'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'groupDescription': 'HOMA2-%S, Dula 1.5 mg, Week 26', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'pValue': '0.025', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Net)', 'paramValue': '36.57', 'ciNumSides': 'TWO_SIDED', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.977'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'HOMA2-%S, Dula 0.75 mg, Week 26', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'pValue': '0.025', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Net)', 'paramValue': '30.42', 'ciNumSides': 'TWO_SIDED', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.940'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'HOMA2-%S, Dula 1.5 mg, Week 52', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'pValue': '0.029', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Net)', 'paramValue': '41.02', 'ciNumSides': 'TWO_SIDED', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.900'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'HOMA2-%S, Dula 0.75 mg, Week 52', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'pValue': '0.029', 'statisticalMethod': 'Mixed Models Analysis', 'paramType': 'Mean Difference (Net)', 'paramValue': '35.19', 'ciNumSides': 'TWO_SIDED', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.864'}]}, {'type': 'SECONDARY', 'title': 'Rate of Hypoglycemic Events', 'description': 'Hypoglycemic events (HE) were classified as documented symptomatic hypoglycemia, asymptomatic hypoglycemia, severe hypoglycemia, and probable symptomatic hypoglycemia. The 1-year adjusted rate of HEs was summarized cumulatively at 26 weeks and 52 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.', 'populationDescription': 'Participants in the safety population who were randomized and received at least one dose of study drug.', 'reportingStatus': 'POSTED', 'paramType': 'MEAN', 'dispersionType': 'Standard Deviation', 'unitOfMeasure': 'events per participant per year', 'timeFrame': 'Baseline through 26 weeks and 52 weeks', 'groups': [{'id': 'OG000', 'title': '1.5 mg Dulaglutide', 'description': \"1.5 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.\"}, {'id': 'OG001', 'title': '0.75 mg Dulaglutide', 'description': \"0.75 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.\"}, {'id': 'OG002', 'title': 'Insulin Glargine', 'description': \"Insulin glargine administered per dosing titration schedule as once daily SC injection at bedtime added to participant's pre-study prescribed dose of metformin and /or a sulfonylurea.\"}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '258'}, {'groupId': 'OG001', 'value': '257'}, {'groupId': 'OG002', 'value': '253'}]}], 'classes': [{'title': '1-year Rate of HE, Week 26', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '1.27', 'spread': '4.485'}, {'groupId': 'OG001', 'value': '0.98', 'spread': '4.202'}, {'groupId': 'OG002', 'value': '2.13', 'spread': '6.724'}]}]}, {'title': 'Severe HE Week 26', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': 'NA', 'spread': 'NA', 'comment': 'Data not available because no severe hypoglycemic episodes occurred.'}, {'groupId': 'OG001', 'value': 'NA', 'spread': 'NA', 'comment': 'Data not available because no severe hypoglycemic episodes occurred.'}, {'groupId': 'OG002', 'value': 'NA', 'spread': 'NA', 'comment': 'Data not available because no severe hypoglycemic episodes occurred.'}]}]}, {'title': 'Nocturnal HE Week 26', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '0.19', 'spread': '0.904'}, {'groupId': 'OG001', 'value': '0.13', 'spread': '0.762'}, {'groupId': 'OG002', 'value': '0.38', 'spread': '1.444'}]}]}, {'title': '1-year Rate of HE, Week 52', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '0.89', 'spread': '3.777'}, {'groupId': 'OG001', 'value': '0.80', 'spread': '3.914'}, {'groupId': 'OG002', 'value': '1.92', 'spread': '6.983'}]}]}, {'title': 'Severe HE Week 52', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': 'NA', 'spread': 'NA', 'comment': 'Data not available because no severe hypoglycemic episodes occurred.'}, {'groupId': 'OG001', 'value': 'NA', 'spread': 'NA', 'comment': 'Data not available because no severe hypoglycemic episodes occurred.'}, {'groupId': 'OG002', 'value': 'NA', 'spread': 'NA', 'comment': 'Data not available because no severe hypoglycemic episodes occurred.'}]}]}, {'title': 'Nocturnal HE Week 52', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '0.11', 'spread': '0.488'}, {'groupId': 'OG001', 'value': '0.10', 'spread': '0.551'}, {'groupId': 'OG002', 'value': '0.31', 'spread': '1.261'}]}]}]}, {'type': 'SECONDARY', 'title': 'Number of Self-reported Hypoglycemic Events', 'description': 'Hypoglycemic events (HE) were classified as severe (defined as episodes requiring the assistance of another person to actively administer resuscitative actions), documented symptomatic (defined as any time a participant felt that he/she was experiencing symptoms and/or signs associated with hypoglycemia, and had a plasma glucose level of less than or equal to 3.9 millimoles/liter \\\\[mmol/L\\\\]), asymptomatic (defined as events not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose of less than or equal to 3.9 mmol/L), nocturnal (defined as any hypoglycemic event that occurred between bedtime and waking), or probable symptomatic (defined as events during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination). The number of self-reported hypoglycemic events was summarized cumulatively at 52 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.', 'populationDescription': 'Participants in the safety population who were randomized and received at least one dose of study drug.', 'reportingStatus': 'POSTED', 'paramType': 'NUMBER', 'unitOfMeasure': 'percentage of participants', 'timeFrame': 'Baseline through 26 Weeks and 52 Weeks', 'groups': [{'id': 'OG000', 'title': '1.5 mg Dulaglutide', 'description': \"1.5 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.\"}, {'id': 'OG001', 'title': '0.75 mg Dulaglutide', 'description': \"0.75 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.\"}, {'id': 'OG002', 'title': 'Insulin Glargine', 'description': \"Insulin glargine administered per dosing titration schedule as once daily SC injection at bedtime added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.\"}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '258'}, {'groupId': 'OG001', 'value': '257'}, {'groupId': 'OG002', 'value': '253'}]}], 'classes': [{'title': 'Total HE Week 26', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '19.4'}, {'groupId': 'OG001', 'value': '16.7'}, {'groupId': 'OG002', 'value': '29.6'}]}]}, {'title': 'Severe HE Week 26', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '0.0'}, {'groupId': 'OG001', 'value': '0.0'}, {'groupId': 'OG002', 'value': '0.0'}]}]}, {'title': 'Nocturnal HE Week 26', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '6.2'}, {'groupId': 'OG001', 'value': '3.9'}, {'groupId': 'OG002', 'value': '11.1'}]}]}, {'title': 'Documented Symptomatic Week 26', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '11.2'}, {'groupId': 'OG001', 'value': '7.8'}, {'groupId': 'OG002', 'value': '17.0'}]}]}, {'title': 'Asymptomatic HE Week 26', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '10.1'}, {'groupId': 'OG001', 'value': '8.2'}, {'groupId': 'OG002', 'value': '14.2'}]}]}, {'title': 'Probable HE Week 26', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '4.3'}, {'groupId': 'OG001', 'value': '5.1'}, {'groupId': 'OG002', 'value': '7.5'}]}]}, {'title': 'Total HE Week 52', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '22.5'}, {'groupId': 'OG001', 'value': '19.8'}, {'groupId': 'OG002', 'value': '34.8'}]}]}, {'title': 'Severe HE Week 52', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '0.0'}, {'groupId': 'OG001', 'value': '0.0'}, {'groupId': 'OG002', 'value': '0.0'}]}]}, {'title': 'Nocturnal HE Week 52', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '7.0'}, {'groupId': 'OG001', 'value': '4.3'}, {'groupId': 'OG002', 'value': '13.8'}]}]}, {'title': 'Documented Symptomatic HE Week 52', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '12.4'}, {'groupId': 'OG001', 'value': '9.7'}, {'groupId': 'OG002', 'value': '20.6'}]}]}, {'title': 'Asymptomatic HE Week 52', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '12.0'}, {'groupId': 'OG001', 'value': '10.1'}, {'groupId': 'OG002', 'value': '19.4'}]}]}, {'title': 'Probable HE Week 52', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '4.7'}, {'groupId': 'OG001', 'value': '5.4'}, {'groupId': 'OG002', 'value': '8.3'}]}]}]}, {'type': 'SECONDARY', 'title': 'Change From Baseline to 26 Weeks and 52 Weeks on Blood Pressure (BP)', 'description': 'Seated systolic blood pressure (SBP) and seated diastolic blood pressure (DBP) were measured. LS means of change from baseline were calculated using a MMRM with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.', 'populationDescription': 'Participants in the safety population who were randomized and received at least one dose of study drug.', 'reportingStatus': 'POSTED', 'paramType': 'LEAST_SQUARES_MEAN', 'dispersionType': 'Standard Error', 'unitOfMeasure': 'millimeters of mercury (mmHg)]', 'timeFrame': 'Baseline, 26 Weeks, 52 Weeks', 'groups': [{'id': 'OG000', 'title': '1.5 mg Dulaglutide', 'description': \"1.5 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.\"}, {'id': 'OG001', 'title': '0.75 mg Dulaglutide', 'description': \"0.75 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.\"}, {'id': 'OG002', 'title': 'Insulin Glargine', 'description': \"Insulin glargine administered per dosing titration schedule as once daily SC injection at bedtime added to participant's pre-study prescribed dose of metformin and /or a sulfonylurea.\"}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '258'}, {'groupId': 'OG001', 'value': '257'}, {'groupId': 'OG002', 'value': '253'}]}], 'classes': [{'title': 'SBP 26 Weeks', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-5.53', 'spread': '12.037'}, {'groupId': 'OG001', 'value': '-2.77', 'spread': '11.920'}, {'groupId': 'OG002', 'value': '-2.22', 'spread': '12.743'}]}]}, {'title': 'DBP 26 Weeks', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-1.58', 'spread': '7.842'}, {'groupId': 'OG001', 'value': '-0.92', 'spread': '7.898'}, {'groupId': 'OG002', 'value': '-1.61', 'spread': '8.417'}]}]}, {'title': 'SBP 52 Weeks', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-2.18', 'spread': '11.134'}, {'groupId': 'OG001', 'value': '-0.61', 'spread': '12.081'}, {'groupId': 'OG002', 'value': '-0.25', 'spread': '11.717'}]}]}, {'title': 'DBP 52 Weeks', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-0.19', 'spread': '7.542'}, {'groupId': 'OG001', 'value': '0.44', 'spread': '7.582'}, {'groupId': 'OG002', 'value': '-1.13', 'spread': '8.810'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001', 'OG002'], 'groupDescription': 'Week 26 SBP', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'pValue': '0.008', 'pValueComment': 'Overall p-value', 'statisticalMethod': 'Mixed Models Analysis'}, {'groupIds': ['OG000', 'OG001', 'OG002'], 'groupDescription': 'Week 26 DBP', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'pValue': '0.584', 'pValueComment': 'Overall p-value', 'statisticalMethod': 'Mixed Models Analysis'}, {'groupIds': ['OG000', 'OG001', 'OG002'], 'groupDescription': 'Week 52 SBP', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'pValue': '0.169', 'pValueComment': 'Overall p-value', 'statisticalMethod': 'Mixed Models Analysis'}, {'groupIds': ['OG000', 'OG001', 'OG002'], 'groupDescription': 'Week 52 DBP', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'pValue': '0.110', 'pValueComment': 'Overall p-value', 'statisticalMethod': 'Mixed Models Analysis'}]}, {'type': 'SECONDARY', 'title': 'Change From Baseline at 26 Weeks and 52 Weeks on Pulse Rate', 'description': 'Seated pulse rate was measured. LS means of change from baseline were calculated using a MMRM with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.', 'populationDescription': 'Participants in the safety population who were randomized and received at least one dose of study drug.', 'reportingStatus': 'POSTED', 'paramType': 'LEAST_SQUARES_MEAN', 'dispersionType': 'Standard Error', 'unitOfMeasure': 'beats per minute (bpm)', 'timeFrame': 'Baseline, 26 Weeks, 52 Weeks', 'groups': [{'id': 'OG000', 'title': '1.5 mg Dulaglutide', 'description': \"1.5 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.\"}, {'id': 'OG001', 'title': '0.75 mg Dulaglutide', 'description': \"0.75 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.\"}, {'id': 'OG002', 'title': 'Insulin Glargine', 'description': \"Insulin glargine administered per dosing titration schedule as once daily SC injection at bedtime added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.\"}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '258'}, {'groupId': 'OG001', 'value': '257'}, {'groupId': 'OG002', 'value': '253'}]}], 'classes': [{'title': 'Change From Baseline on Pulse rate at Week 26', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '4.63', 'spread': '8.681'}, {'groupId': 'OG001', 'value': '0.65', 'spread': '8.631'}, {'groupId': 'OG002', 'value': '-0.86', 'spread': '9.546'}]}]}, {'title': 'Change From Baseline on Pulse rate at Week 52', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '4.18', 'spread': '8.336'}, {'groupId': 'OG001', 'value': '3.18', 'spread': '8.917'}, {'groupId': 'OG002', 'value': '0.07', 'spread': '8.205'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001', 'OG002'], 'groupDescription': 'Week 26', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'pValue': '<0.001', 'pValueComment': 'Overall p-value', 'statisticalMethod': 'Mixed Models Analysis'}, {'groupIds': ['OG000', 'OG001', 'OG002'], 'groupDescription': 'Week 52', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'pValue': '<0.001', 'pValueComment': 'Overall p-value', 'statisticalMethod': 'Mixed Models Analysis'}]}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Electrocardiogram Parameters, Fridericia Corrected QT (QTcF) Interval and PR Interval', 'description': \"The QT interval is a measure of the time between the start of the Q wave and the end of the T wave and was calculated from electrocardiogram (ECG) data using Fridericia's formula: QTc = QT/RR\\\\^0.33. Corrected QT (QTc) is the QT interval corrected for heart rate and RR, which is the interval between two R waves. PR is the interval between the P wave and the QRS complex.\", 'populationDescription': 'Participants in the safety population who were randomized and received at least one dose of study drug.', 'reportingStatus': 'POSTED', 'paramType': 'MEAN', 'dispersionType': 'Standard Deviation', 'unitOfMeasure': 'millisecond (msec)', 'timeFrame': 'Baseline, 26 Weeks, 52 Weeks', 'groups': [{'id': 'OG000', 'title': '1.5 mg Dulaglutide', 'description': \"1.5 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.\"}, {'id': 'OG001', 'title': '0.75 mg Dulaglutide', 'description': \"0.75 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.\"}, {'id': 'OG002', 'title': 'Insulin Glargine', 'description': \"Insulin glargine administered per dosing titration schedule as once daily SC injection at bedtime added to participant's pre-study prescribed dose of metformin and /or a sulfonylurea.\"}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '258'}, {'groupId': 'OG001', 'value': '257'}, {'groupId': 'OG002', 'value': '253'}]}], 'classes': [{'title': 'QTcF Interval 26 Weeks', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-1.65', 'spread': '13.157'}, {'groupId': 'OG001', 'value': '0.76', 'spread': '11.643'}, {'groupId': 'OG002', 'value': '2.56', 'spread': '11.911'}]}]}, {'title': 'PR Interval 26 Weeks', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '3.09', 'spread': '1.700'}, {'groupId': 'OG001', 'value': '2.88', 'spread': '10.801'}, {'groupId': 'OG002', 'value': '-0.86', 'spread': '10.272'}]}]}, {'title': 'QTcF Interval 52 Weeks', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '0.55', 'spread': '11.209'}, {'groupId': 'OG001', 'value': '1.19', 'spread': '12.165'}, {'groupId': 'OG002', 'value': '4.03', 'spread': '11.446'}]}]}, {'title': 'PR Interval 52 Weeks', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '3.60', 'spread': '12.425'}, {'groupId': 'OG001', 'value': '3.55', 'spread': '11.526'}, {'groupId': 'OG002', 'value': '0.63', 'spread': '11.861'}]}]}]}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Electrocardiogram Parameters, Heart Rate (HR)', 'populationDescription': 'Participants in the safety population who were randomized and received at least one dose of study drug.', 'reportingStatus': 'POSTED', 'paramType': 'MEAN', 'dispersionType': 'Standard Deviation', 'unitOfMeasure': 'beats per minute (bpm)', 'timeFrame': 'Baseline, 26 Weeks, 52 Weeks', 'groups': [{'id': 'OG000', 'title': '1.5 mg Dulaglutide', 'description': \"1.5 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.\"}, {'id': 'OG001', 'title': '0.75 mg Dulaglutide', 'description': \"0.75 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.\"}, {'id': 'OG002', 'title': 'Insulin Glargine', 'description': \"Insulin glargine administered per dosing titration schedule as once daily SC injection at bedtime added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.\"}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '258'}, {'groupId': 'OG001', 'value': '257'}, {'groupId': 'OG002', 'value': '253'}]}], 'classes': [{'title': 'Week 26', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '6.13', 'spread': '8.924'}, {'groupId': 'OG001', 'value': '3.77', 'spread': '9.002'}, {'groupId': 'OG002', 'value': '-0.46', 'spread': '9.329'}]}]}, {'title': 'Week 52', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '5.04', 'spread': '8.223'}, {'groupId': 'OG001', 'value': '3.40', 'spread': '7.986'}, {'groupId': 'OG002', 'value': '0.43', 'spread': '8.060'}]}]}]}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Pancreatic Enzymes', 'description': 'Amylase (total and pancreas-derived) and lipase concentrations were measured', 'populationDescription': 'Participants in the safety population who were randomized and received at least one dose of study drug. Last observation carried forward (LOCF) was used to impute missing postbaseline values. If there were no data after the date of randomization, the endpoint was considered missing.', 'reportingStatus': 'POSTED', 'paramType': 'MEAN', 'dispersionType': 'Standard Deviation', 'unitOfMeasure': 'Units/Liter (U/L)', 'timeFrame': 'Baseline, 26 Weeks, 52 Weeks', 'groups': [{'id': 'OG000', 'title': '1.5 mg Dulaglutide', 'description': \"1.5 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.\"}, {'id': 'OG001', 'title': '0.75 mg Dulaglutide', 'description': \"0.75 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.\"}, {'id': 'OG002', 'title': 'Insulin Glargine', 'description': \"Insulin glargine administered per dosing titration schedule as once daily SC injection at bedtime added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.\"}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '258'}, {'groupId': 'OG001', 'value': '257'}, {'groupId': 'OG002', 'value': '253'}]}], 'classes': [{'title': 'Amylase, Total 26 Weeks', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '7.50', 'spread': '18.755'}, {'groupId': 'OG001', 'value': '7.54', 'spread': '22.388'}, {'groupId': 'OG002', 'value': '-0.37', 'spread': '18.196'}]}]}, {'title': 'Amylase, pancreas derived 26 Weeks', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '5.83', 'spread': '14.607'}, {'groupId': 'OG001', 'value': '5.14', 'spread': '19.360'}, {'groupId': 'OG002', 'value': '-0.21', 'spread': '11.287'}]}]}, {'title': 'Lipase 26 Weeks', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '11.00', 'spread': '34.134'}, {'groupId': 'OG001', 'value': '10.67', 'spread': '39.989'}, {'groupId': 'OG002', 'value': '-2.74', 'spread': '21.818'}]}]}, {'title': 'Amylase, Total 52 Weeks', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '7.82', 'spread': '16.250'}, {'groupId': 'OG001', 'value': '6.42', 'spread': '20.675'}, {'groupId': 'OG002', 'value': '0.64', 'spread': '18.696'}]}]}, {'title': 'Amylase, pancreas derived 52 Weeks', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '5.48', 'spread': '12.449'}, {'groupId': 'OG001', 'value': '4.05', 'spread': '15.490'}, {'groupId': 'OG002', 'value': '-0.49', 'spread': '12.576'}]}]}, {'title': 'Lipase 52 Weeks', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '10.76', 'spread': '27.360'}, {'groupId': 'OG001', 'value': '9.64', 'spread': '33.715'}, {'groupId': 'OG002', 'value': '-3.66', 'spread': '20.484'}]}]}]}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Serum Calcitonin', 'populationDescription': 'Participants in the safety population who were randomized and received at least one dose of study drug. Only pre-rescue measurements were used. LOCF was used to impute missing postbaseline values. If there were no data after the date of randomization, the endpoint was considered missing.', 'reportingStatus': 'POSTED', 'paramType': 'MEAN', 'dispersionType': 'Standard Deviation', 'unitOfMeasure': 'picomole/liter', 'timeFrame': 'Baseline, 26 Weeks, 52 Weeks', 'groups': [{'id': 'OG000', 'title': '1.5 mg Dulaglutide', 'description': \"1.5 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.\"}, {'id': 'OG001', 'title': '0.75 mg Dulaglutide', 'description': \"0.75 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.\"}, {'id': 'OG002', 'title': 'Insulin Glargine', 'description': \"Insulin glargine administered per dosing titration schedule as once daily SC injection at bedtime added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.\"}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '258'}, {'groupId': 'OG001', 'value': '257'}, {'groupId': 'OG002', 'value': '253'}]}], 'classes': [{'title': 'Week 26', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '0.01', 'spread': '0.240'}, {'groupId': 'OG001', 'value': '-0.07', 'spread': '0.289'}, {'groupId': 'OG002', 'value': '0.02', 'spread': '0.256'}]}]}, {'title': 'Week 52', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-0.03', 'spread': '0.279'}, {'groupId': 'OG001', 'value': '-0.08', 'spread': '0.325'}, {'groupId': 'OG002', 'value': '-0.05', 'spread': '0.306'}]}]}]}, {'type': 'SECONDARY', 'title': 'Number of Participants With Adjudicated Cardiovascular (CV) Events', 'description': 'Deaths and nonfatal cardiovascular adverse events were adjudicated by a committee of physicians with cardiology expertise external to the Sponsor. The nonfatal cardiovascular events subjected to adjudication included myocardial infarction, hospitalization for unstable angina, hospitalization for heart failure, coronary interventions (such as coronary artery bypass graft or percutaneous coronary intervention), and cerebrovascular events including cerebrovascular accident (stroke) and transient ischemic attack. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.', 'populationDescription': 'Participants in the safety population who were randomized and received at least one dose of study drug.', 'reportingStatus': 'POSTED', 'paramType': 'NUMBER', 'unitOfMeasure': 'participants with adjudicated CV events', 'timeFrame': 'Baseline through 52 weeks', 'groups': [{'id': 'OG000', 'title': '1.5 mg Dulaglutide', 'description': \"1.5 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.\"}, {'id': 'OG001', 'title': '0.75 mg Dulaglutide', 'description': \"0.75 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.\"}, {'id': 'OG002', 'title': 'Insulin Glargine', 'description': \"Insulin glargine administered per dosing titration schedule as once daily SC injection at bedtime added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.\"}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '258'}, {'groupId': 'OG001', 'value': '257'}, {'groupId': 'OG002', 'value': '253'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '6'}, {'groupId': 'OG001', 'value': '2'}, {'groupId': 'OG002', 'value': '2'}]}]}]}, {'type': 'SECONDARY', 'title': 'Number of Participants With Adjudicated Pancreatitis', 'description': 'The number of participants with pancreatitis confirmed by adjudication is summarized. Events of pancreatitis (including suspected pancreatitis and severe or serious abdominal pain) were adjudicated by a committee of expert physicians external to the Sponsor. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.', 'populationDescription': 'Participants in the safety population who were randomized and received at least one dose of study drug.', 'reportingStatus': 'POSTED', 'paramType': 'NUMBER', 'unitOfMeasure': 'participants', 'timeFrame': 'Baseline through 52 Weeks', 'groups': [{'id': 'OG000', 'title': '1.5 mg Dulaglutide', 'description': \"1.5 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.\"}, {'id': 'OG001', 'title': '0.75 mg Dulaglutide', 'description': \"0.75 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.\"}, {'id': 'OG002', 'title': 'Insulin Glargine', 'description': \"Insulin glargine administered per dosing titration schedule as once daily SC injection at bedtime added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.\"}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '258'}, {'groupId': 'OG001', 'value': '257'}, {'groupId': 'OG002', 'value': '253'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '0'}, {'groupId': 'OG001', 'value': '0'}, {'groupId': 'OG002', 'value': '0'}]}]}]}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Body Weight', 'populationDescription': 'Participants in the safety population who were randomized and received at least one dose of study drug.', 'reportingStatus': 'POSTED', 'paramType': 'LEAST_SQUARES_MEAN', 'dispersionType': 'Standard Error', 'unitOfMeasure': 'kilogram (kg)', 'timeFrame': 'Baseline, 26 Weeks, 52 Weeks', 'groups': [{'id': 'OG000', 'title': '1.5 mg Dulaglutide', 'description': \"1.5 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.\"}, {'id': 'OG001', 'title': '0.75 mg Dulaglutide', 'description': \"0.75 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.\"}, {'id': 'OG002', 'title': 'Insulin Glargine', 'description': \"Insulin glargine administered per dosing titration schedule as once daily SC injection at bedtime added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.\"}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '258'}, {'groupId': 'OG001', 'value': '257'}, {'groupId': 'OG002', 'value': '253'}]}], 'classes': [{'title': 'Week 26', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-1.47', 'spread': '0.197'}, {'groupId': 'OG001', 'value': '-0.88', 'spread': '0.197'}, {'groupId': 'OG002', 'value': '0.97', 'spread': '0.198'}]}]}, {'title': 'Week 52', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-1.08', 'spread': '0.201'}, {'groupId': 'OG001', 'value': '-0.76', 'spread': '0.202'}, {'groupId': 'OG002', 'value': '1.35', 'spread': '0.201'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001', 'OG002'], 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'pValue': '<0.001', 'pValueComment': 'Week 26', 'statisticalMethod': 'Mixed Models Analysis', 'ciNumSides': 'TWO_SIDED'}, {'groupIds': ['OG000', 'OG001', 'OG002'], 'groupDescription': 'Week 52', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'pValue': '<0.001', 'statisticalMethod': 'Mixed Models Analysis', 'ciNumSides': 'TWO_SIDED'}]}, {'type': 'SECONDARY', 'title': 'Change in Body Mass Index', 'description': 'Body mass index is an estimate of body fat based on body weight divided by height squared.', 'populationDescription': 'Participants in the safety population who were randomized and received at least one dose of study drug.', 'reportingStatus': 'POSTED', 'paramType': 'LEAST_SQUARES_MEAN', 'dispersionType': 'Standard Error', 'unitOfMeasure': 'kilogram/square meter (kg/m2)', 'timeFrame': 'Baseline, 26 Weeks, 52 Weeks', 'groups': [{'id': 'OG000', 'title': '1.5 mg Dulaglutide', 'description': \"1.5 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.\"}, {'id': 'OG001', 'title': '0.75 mg Dulaglutide', 'description': \"0.75 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.\"}, {'id': 'OG002', 'title': 'Insulin Glargine', 'description': \"Insulin glargine administered per dosing titration schedule as once daily SC injection at bedtime added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.\"}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '258'}, {'groupId': 'OG001', 'value': '257'}, {'groupId': 'OG002', 'value': '253'}]}], 'classes': [{'title': 'Week 26', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-0.53', 'spread': '0.071'}, {'groupId': 'OG001', 'value': '-0.32', 'spread': '0.071'}, {'groupId': 'OG002', 'value': '0.37', 'spread': '0.071'}]}]}, {'title': 'Week 52', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-0.40', 'spread': '0.072'}, {'groupId': 'OG001', 'value': '-0.27', 'spread': '0.072'}, {'groupId': 'OG002', 'value': '0.52', 'spread': '0.072'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 26', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'pValue': '<0.001', 'statisticalMethod': 'Mixed Models Analysis', 'ciNumSides': 'TWO_SIDED'}, {'groupIds': ['OG000', 'OG001', 'OG002'], 'groupDescription': 'Week 52', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER_LEGACY', 'pValue': '<0.001', 'statisticalMethod': 'Mixed Models Analysis', 'ciNumSides': 'TWO_SIDED'}]}, {'type': 'SECONDARY', 'title': 'Percentages of Participants Developing Treatment-Emergent Dulaglutide Anti-drug Antibody (ADA)', 'description': 'Number of participants with treatment emergent (TE) dulaglutide anti-drug antibodies from postbaseline to follow up were summarized. A participant was considered to have TE dulaglutide ADA if the participant had at least one titer that was treatment-emergent relative to baseline, defined as a 4-fold or greater increase in titer from baseline measurement.', 'populationDescription': 'Participants in the safety population who were randomized and received at least one dose of study drug.', 'reportingStatus': 'POSTED', 'paramType': 'NUMBER', 'unitOfMeasure': 'Percentage of participants', 'timeFrame': 'Baseline through 52 Weeks', 'groups': [{'id': 'OG000', 'title': '1.5 mg Dulaglutide', 'description': \"1.5 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.\"}, {'id': 'OG001', 'title': '0.75 mg Dulaglutide', 'description': \"0.75 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.\"}, {'id': 'OG002', 'title': 'Insulin Glargine', 'description': \"Insulin glargine administered per dosing titration schedule as once daily SC injection at bedtime added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.\"}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '258'}, {'groupId': 'OG001', 'value': '257'}, {'groupId': 'OG002', 'value': '253'}]}], 'classes': [{'title': 'Participants with >=1 TE Dula ADA', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '3.9'}, {'groupId': 'OG001', 'value': '4.3'}, {'groupId': 'OG002', 'value': '1.6'}]}]}, {'title': 'Participants with TE Dula ADA and Neutralizing', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '0.8'}, {'groupId': 'OG001', 'value': '1.6'}, {'groupId': 'OG002', 'value': '0.0'}]}]}]}, {'type': 'SECONDARY', 'title': 'EQ-5D Health State Score Responses', 'description': 'The EQ-5D questionnaire is a widely used, generic questionnaire that assesses health-related quality of life. It consists of 2 parts. The first part assesses 5 dimensions associated with quality of life (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). Each dimension has 3 possible levels of response: no problem, some problem, and extreme problem. Additional categories of response include ambiguous and missing. The number of participants per each of the 3 response categories is summarized for each of the 5 dimensions.', 'populationDescription': 'Participants who were randomized, received at least one dose of study drug, and had evaluable HbA1c data at both baseline and post-baseline.', 'reportingStatus': 'POSTED', 'paramType': 'NUMBER', 'unitOfMeasure': 'participants', 'timeFrame': 'Baseline, 26 Weeks, 52 Weeks', 'groups': [{'id': 'OG000', 'title': '1.5 mg Dulaglutide', 'description': \"1.5 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.\"}, {'id': 'OG001', 'title': '0.75 mg Dulaglutide', 'description': \"0.75 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.\"}, {'id': 'OG002', 'title': 'Insulin Glargine', 'description': \"Insulin glargine administered per dosing titration schedule as once daily SC injection at bedtime added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.\"}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '258'}, {'groupId': 'OG001', 'value': '257'}, {'groupId': 'OG002', 'value': '253'}]}], 'classes': [{'title': 'Mobility - no problem Week 26', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '219'}, {'groupId': 'OG001', 'value': '215'}, {'groupId': 'OG002', 'value': '210'}]}]}, {'title': 'Mobility - some problem Week 26', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '7'}, {'groupId': 'OG001', 'value': '16'}, {'groupId': 'OG002', 'value': '20'}]}]}, {'title': 'Mobility - extreme problem Week 26', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '0'}, {'groupId': 'OG001', 'value': '0'}, {'groupId': 'OG002', 'value': '0'}]}]}, {'title': 'Mobility - missing Week 26', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '4'}, {'groupId': 'OG001', 'value': '1'}, {'groupId': 'OG002', 'value': '4'}]}]}, {'title': 'Self-care - no problem Week 26', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '223'}, {'groupId': 'OG001', 'value': '227'}, {'groupId': 'OG002', 'value': '224'}]}]}, {'title': 'Self-care - some problem Week 26', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '0'}, {'groupId': 'OG001', 'value': '0'}, {'groupId': 'OG002', 'value': '0'}]}]}, {'title': 'Self-care - extreme problem Week 26', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '0'}, {'groupId': 'OG001', 'value': '0'}, {'groupId': 'OG002', 'value': '0'}]}]}, {'title': 'Self-care - missing Week 26', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '4'}, {'groupId': 'OG001', 'value': '1'}, {'groupId': 'OG002', 'value': '4'}]}]}, {'title': 'Usual activities - no problems Week 26', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '219'}, {'groupId': 'OG001', 'value': '220'}, {'groupId': 'OG002', 'value': '218'}]}]}, {'title': 'Usual activities - some problems Week 26', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '7'}, {'groupId': 'OG001', 'value': '11'}, {'groupId': 'OG002', 'value': '11'}]}]}, {'title': 'Usual activities - extreme problems Week 26', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '0'}, {'groupId': 'OG001', 'value': '0'}, {'groupId': 'OG002', 'value': '0'}]}]}, {'title': 'Usual activities - missing Week 26', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '4'}, {'groupId': 'OG001', 'value': '1'}, {'groupId': 'OG002', 'value': '4'}]}]}, {'title': 'Pain/Discomfort - no problems Week 26', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '193'}, {'groupId': 'OG001', 'value': '201'}, {'groupId': 'OG002', 'value': '188'}]}]}, {'title': 'Pain/Discomfort - some problems Week 26', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '32'}, {'groupId': 'OG001', 'value': '30'}, {'groupId': 'OG002', 'value': '37'}]}]}, {'title': 'Pain/Discomfort - ambiguous', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '0'}, {'groupId': 'OG001', 'value': '0'}, {'groupId': 'OG002', 'value': '0'}]}]}, {'title': 'Pain/Discomfort - missing Week 26', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '4'}, {'groupId': 'OG001', 'value': '1'}, {'groupId': 'OG002', 'value': '4'}]}]}, {'title': 'Anxiety/Depression - no problems Week 26', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '208'}, {'groupId': 'OG001', 'value': '204'}, {'groupId': 'OG002', 'value': '203'}]}]}, {'title': 'Anxiety/Depression - some problems Week 26', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '19'}, {'groupId': 'OG001', 'value': '27'}, {'groupId': 'OG002', 'value': '26'}]}]}, {'title': 'Anxiety/Depression - extreme problems Week 26', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '0'}, {'groupId': 'OG001', 'value': '0'}, {'groupId': 'OG002', 'value': '1'}]}]}, {'title': 'Anxiety/Depression - missing Week 26', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '4'}, {'groupId': 'OG001', 'value': '1'}, {'groupId': 'OG002', 'value': '4'}]}]}, {'title': 'Mobility - no problems Week 52', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '218'}, {'groupId': 'OG001', 'value': '207'}, {'groupId': 'OG002', 'value': '214'}]}]}, {'title': 'Mobility - some problems Week 52', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '8'}, {'groupId': 'OG001', 'value': '14'}, {'groupId': 'OG002', 'value': '16'}]}]}, {'title': 'Mobility - extreme problems Week 52', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '0'}, {'groupId': 'OG001', 'value': '1'}, {'groupId': 'OG002', 'value': '0'}]}]}, {'title': 'Mobility - missing Week 52', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '0'}, {'groupId': 'OG001', 'value': '0'}, {'groupId': 'OG002', 'value': '1'}]}]}, {'title': 'Self-care - no problems Week 52', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '224'}, {'groupId': 'OG001', 'value': '215'}, {'groupId': 'OG002', 'value': '223'}]}]}, {'title': 'Self-care - some problems Week 52', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '2'}, {'groupId': 'OG001', 'value': '7'}, {'groupId': 'OG002', 'value': '7'}]}]}, {'title': 'Self-care - extreme problems Week 52', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '0'}, {'groupId': 'OG001', 'value': '0'}, {'groupId': 'OG002', 'value': '0'}]}]}, {'title': 'Self-care - missing Week 52', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '0'}, {'groupId': 'OG001', 'value': '0'}, {'groupId': 'OG002', 'value': '1'}]}]}, {'title': 'Usual Activities - no problems Week 52', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '219'}, {'groupId': 'OG001', 'value': '211'}, {'groupId': 'OG002', 'value': '219'}]}]}, {'title': 'Usual Activities - some problems Week 52', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '6'}, {'groupId': 'OG001', 'value': '10'}, {'groupId': 'OG002', 'value': '11'}]}]}, {'title': 'Usual Activities - extreme problems Week 52', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '1'}, {'groupId': 'OG001', 'value': '1'}, {'groupId': 'OG002', 'value': '0'}]}]}, {'title': 'Usual Activities - missing Week 52', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '0'}, {'groupId': 'OG001', 'value': '0'}, {'groupId': 'OG002', 'value': '1'}]}]}, {'title': 'Pain/Discomfort - no problems Week 52', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '191'}, {'groupId': 'OG001', 'value': '188'}, {'groupId': 'OG002', 'value': '185'}]}]}, {'title': 'Pain/Discomfort - some problems Week 52', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '34'}, {'groupId': 'OG001', 'value': '33'}, {'groupId': 'OG002', 'value': '43'}]}]}, {'title': 'Pain/Discomfort - extreme problems Week 52', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '1'}, {'groupId': 'OG001', 'value': '1'}, {'groupId': 'OG002', 'value': '1'}]}]}, {'title': 'Pain/Discomfort - missing Week 52', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '0'}, {'groupId': 'OG001', 'value': '0'}, {'groupId': 'OG002', 'value': '1'}]}]}, {'title': 'Anxiety/Depression - no problems Week 52', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '205'}, {'groupId': 'OG001', 'value': '207'}, {'groupId': 'OG002', 'value': '201'}]}]}, {'title': 'Anxiety/Depression - some problems Week 52', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '21'}, {'groupId': 'OG001', 'value': '15'}, {'groupId': 'OG002', 'value': '29'}]}]}, {'title': 'Anxiety/Depression - extreme problems Week 52', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '0'}, {'groupId': 'OG001', 'value': '0'}, {'groupId': 'OG002', 'value': '0'}]}]}, {'title': 'Anxiety/Depression - missing Week 52', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '0'}, {'groupId': 'OG001', 'value': '0'}, {'groupId': 'OG002', 'value': '1'}]}]}]}, {'type': 'SECONDARY', 'title': 'Change From Baseline in EQ-5D Visual Analog Scale Score', 'description': 'The EQ-5D is a generic, multidimensional, health-related, quality-of-life instrument. Overall health state score was self-reported using a visual analogue scale (VAS) marked on a scale of 0 to 100 with 0 representing worst imaginable health state and 100 representing best imaginable health state. LS means of change from baseline were calculated using ANCOVA and adjusted by treatment, country, and baseline.', 'populationDescription': 'Participants who were randomized, received at least one dose of study drug, and had evaluable HbA1c data at both baseline and post-baseline.', 'reportingStatus': 'POSTED', 'paramType': 'MEAN', 'dispersionType': 'Standard Deviation', 'unitOfMeasure': 'units on a scale', 'timeFrame': 'Baseline, 26 weeks, 52 weeks', 'groups': [{'id': 'OG000', 'title': '1.5 mg Dulaglutide', 'description': \"1.5 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.\"}, {'id': 'OG001', 'title': '0.75 mg Dulaglutide', 'description': \"0.75 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.\"}, {'id': 'OG002', 'title': 'Insulin Glargine', 'description': \"Insulin glargine administered per dosing titration schedule as once daily SC injection at bedtime added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.\"}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '258'}, {'groupId': 'OG001', 'value': '257'}, {'groupId': 'OG002', 'value': '253'}]}], 'classes': [{'title': 'Week 26', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '1.08', 'spread': '12.644'}, {'groupId': 'OG001', 'value': '1.67', 'spread': '13.456'}, {'groupId': 'OG002', 'value': '1.41', 'spread': '10.885'}]}]}, {'title': 'Week 52', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '2.65', 'spread': '12.029'}, {'groupId': 'OG001', 'value': '2.34', 'spread': '14.003'}, {'groupId': 'OG002', 'value': '2.55', 'spread': '12.257'}]}]}]}]}, 'adverseEventsModule': {'frequencyThreshold': '0', 'eventGroups': [{'id': 'EG000', 'title': '1.5 mg Dulaglutide', 'description': \"1.5 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.\", 'seriousNumAffected': 24, 'seriousNumAtRisk': 258, 'otherNumAffected': 184, 'otherNumAtRisk': 258}, {'id': 'EG001', 'title': '0.75 mg Dulaglutide', 'description': \"0.75 mg dulaglutide administered as 1 SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea.\", 'seriousNumAffected': 15, 'seriousNumAtRisk': 257, 'otherNumAffected': 188, 'otherNumAtRisk': 257}, {'id': 'EG002', 'title': 'Insulin Glargine', 'description': \"Insulin glargine administered per dosing titration schedule as once daily SC injection at bedtime added to participant's pre-study prescribed dose of metformin and /or a sulfonylurea.\", 'seriousNumAffected': 9, 'seriousNumAtRisk': 253, 'otherNumAffected': 157, 'otherNumAtRisk': 253}], 'seriousEvents': [{'term': 'Angina unstable', 'organSystem': 'Cardiac disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Arteriosclerosis coronary artery', 'organSystem': 'Cardiac disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Cardiac failure chronic', 'organSystem': 'Cardiac disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Coronary artery disease', 'organSystem': 'Cardiac disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Extrasystoles', 'organSystem': 'Cardiac disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Myocardial ischaemia', 'organSystem': 'Cardiac disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Sinus node dysfunction', 'organSystem': 'Cardiac disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Deafness neurosensory', 'organSystem': 'Ear and labyrinth disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Vision blurred', 'organSystem': 'Eye disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Abdominal pain upper', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Chronic gastritis', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Gastrooesophageal reflux disease', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Intestinal polyp', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Pancreatitis', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Chest pain', 'organSystem': 'General disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Cyst', 'organSystem': 'General disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Cholecystitis acute', 'organSystem': 'Hepatobiliary disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Cholelithiasis', 'organSystem': 'Hepatobiliary disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Bronchitis', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Cystitis', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Gallbladder empyema', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Gastroenteritis', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Gastroenteritis salmonella', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Herpes zoster', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Pneumonia', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Pulmonary tuberculoma', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Sinusitis', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Accident', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Comminuted fracture', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Gun shot wound', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Tendon rupture', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Hyperglycaemia', 'organSystem': 'Metabolism and nutrition disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Hyperlipidaemia', 'organSystem': 'Metabolism and nutrition disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Type 2 diabetes mellitus', 'organSystem': 'Metabolism and nutrition disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Intervertebral disc protrusion', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Periarthritis', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Spinal osteoarthritis', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Benign ovarian tumour', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 119}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 113}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 112}]}, {'term': 'Bladder papilloma', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Invasive breast carcinoma', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Papillary thyroid cancer', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Renal cancer', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Thyroid adenoma', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Cerebral infarction', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Cerebral ischaemia', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Cerebrovascular stenosis', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Haemorrhagic cerebral infarction', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Ischaemic cerebral infarction', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Transient ischaemic attack', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Vertebrobasilar insufficiency', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Nephrolithiasis', 'organSystem': 'Renal and urinary disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Perinephritis', 'organSystem': 'Renal and urinary disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Rash', 'organSystem': 'Skin and subcutaneous tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Hypertension', 'organSystem': 'Vascular disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Hypertensive crisis', 'organSystem': 'Vascular disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}], 'otherEvents': [{'term': 'Eosinophilia', 'organSystem': 'Blood and lymphatic system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Iron deficiency anaemia', 'organSystem': 'Blood and lymphatic system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Leukopenia', 'organSystem': 'Blood and lymphatic system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Lymphadenitis', 'organSystem': 'Blood and lymphatic system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Microcytosis', 'organSystem': 'Blood and lymphatic system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Angina pectoris', 'organSystem': 'Cardiac disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Arrhythmia', 'organSystem': 'Cardiac disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Arteriosclerosis coronary artery', 'organSystem': 'Cardiac disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Atrioventricular block first degree', 'organSystem': 'Cardiac disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Bundle branch block left', 'organSystem': 'Cardiac disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Bundle branch block right', 'organSystem': 'Cardiac disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Coronary artery disease', 'organSystem': 'Cardiac disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 253}]}, {'term': 'Extrasystoles', 'organSystem': 'Cardiac disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Left ventricular hypertrophy', 'organSystem': 'Cardiac disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Myocardial infarction', 'organSystem': 'Cardiac disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Myocardial ischaemia', 'organSystem': 'Cardiac disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Palpitations', 'organSystem': 'Cardiac disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Sinus arrhythmia', 'organSystem': 'Cardiac disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Sinus bradycardia', 'organSystem': 'Cardiac disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Sinus tachycardia', 'organSystem': 'Cardiac disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 2, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Tachycardia', 'organSystem': 'Cardiac disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Ventricular extrasystoles', 'organSystem': 'Cardiac disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Tinnitus', 'organSystem': 'Ear and labyrinth disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Hyperthyroidism', 'organSystem': 'Endocrine disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Hypothyroidism', 'organSystem': 'Endocrine disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Thyroid mass', 'organSystem': 'Endocrine disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Cataract', 'organSystem': 'Eye disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Conjunctival hyperaemia', 'organSystem': 'Eye disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Diabetic retinopathy', 'organSystem': 'Eye disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Dry eye', 'organSystem': 'Eye disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Eye inflammation', 'organSystem': 'Eye disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Eye pain', 'organSystem': 'Eye disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Eyelid oedema', 'organSystem': 'Eye disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Keratitis', 'organSystem': 'Eye disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Retinal haemorrhage', 'organSystem': 'Eye disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Retinopathy', 'organSystem': 'Eye disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 253}]}, {'term': 'Vision blurred', 'organSystem': 'Eye disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 4, 'numAffected': 4, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Abdominal discomfort', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 6, 'numAffected': 5, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 4, 'numAffected': 3, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Abdominal distension', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 29, 'numAffected': 18, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 16, 'numAffected': 13, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Abdominal pain', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 6, 'numAffected': 2, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 4, 'numAffected': 3, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Abdominal pain upper', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 7, 'numAffected': 6, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 5, 'numAffected': 3, 'numAtRisk': 253}]}, {'term': 'Chronic gastritis', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Constipation', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 11, 'numAffected': 9, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 8, 'numAffected': 8, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Diarrhoea', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 92, 'numAffected': 43, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 51, 'numAffected': 28, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 7, 'numAffected': 7, 'numAtRisk': 253}]}, {'term': 'Dry mouth', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Dyspepsia', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 6, 'numAffected': 5, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 11, 'numAffected': 8, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 253}]}, {'term': 'Enteritis', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Epigastric discomfort', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Eructation', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 6, 'numAffected': 4, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Faeces hard', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Flatulence', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 5, 'numAffected': 4, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Food poisoning', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Frequent bowel movements', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Gastric dilatation', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 2, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Gastric disorder', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Gastric ulcer', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Gastritis', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 3, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 4, 'numAffected': 4, 'numAtRisk': 253}]}, {'term': 'Gastrointestinal inflammation', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Gastrointestinal obstruction', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Gastrooesophageal reflux disease', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 7, 'numAffected': 4, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 2, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Haemorrhoids', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Impaired gastric emptying', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Intestinal polyp', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Mouth ulceration', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Nausea', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 47, 'numAffected': 27, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 21, 'numAffected': 14, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 253}]}, {'term': 'Oesophagitis', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Pancreatitis', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Pancreatitis chronic', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Rectal polyp', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Regurgitation', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Tooth impacted', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Toothache', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 253}]}, {'term': 'Vomiting', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 23, 'numAffected': 16, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 6, 'numAffected': 6, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 253}]}, {'term': 'Asthenia', 'organSystem': 'General disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Chest discomfort', 'organSystem': 'General disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Chest pain', 'organSystem': 'General disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 5, 'numAffected': 5, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Chills', 'organSystem': 'General disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Discomfort', 'organSystem': 'General disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Fatigue', 'organSystem': 'General disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Hunger', 'organSystem': 'General disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Hyperthermia', 'organSystem': 'General disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Induration', 'organSystem': 'General disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Injection site erythema', 'organSystem': 'General disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Injection site induration', 'organSystem': 'General disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 19, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Injection site pain', 'organSystem': 'General disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Injection site pruritus', 'organSystem': 'General disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Injection site swelling', 'organSystem': 'General disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Malaise', 'organSystem': 'General disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 253}]}, {'term': 'Nodule', 'organSystem': 'General disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Oedema', 'organSystem': 'General disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Oedema peripheral', 'organSystem': 'General disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 5, 'numAffected': 3, 'numAtRisk': 253}]}, {'term': 'Pain', 'organSystem': 'General disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Peripheral swelling', 'organSystem': 'General disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Pyrexia', 'organSystem': 'General disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 4, 'numAffected': 4, 'numAtRisk': 253}]}, {'term': 'Temperature intolerance', 'organSystem': 'General disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Cholecystitis', 'organSystem': 'Hepatobiliary disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Cholecystitis chronic', 'organSystem': 'Hepatobiliary disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Cholelithiasis', 'organSystem': 'Hepatobiliary disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Hepatic cyst', 'organSystem': 'Hepatobiliary disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Hepatic fibrosis', 'organSystem': 'Hepatobiliary disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Hepatic function abnormal', 'organSystem': 'Hepatobiliary disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 4, 'numAffected': 4, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 253}]}, {'term': 'Hepatic steatosis', 'organSystem': 'Hepatobiliary disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Liver disorder', 'organSystem': 'Hepatobiliary disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Liver injury', 'organSystem': 'Hepatobiliary disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 4, 'numAffected': 4, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Non-alcoholic fatty liver', 'organSystem': 'Hepatobiliary disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 7, 'numAffected': 7, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 253}]}, {'term': 'Non-alcoholic steatohepatitis', 'organSystem': 'Hepatobiliary disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Post cholecystectomy syndrome', 'organSystem': 'Hepatobiliary disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Anaphylactic reaction', 'organSystem': 'Immune system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Drug hypersensitivity', 'organSystem': 'Immune system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 253}]}, {'term': 'Immunodeficiency', 'organSystem': 'Immune system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Seasonal allergy', 'organSystem': 'Immune system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Asymptomatic bacteriuria', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Bacterial infection', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Bronchitis', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Cat scratch disease', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Chronic sinusitis', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Conjunctivitis', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Conjunctivitis bacterial', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Cystitis', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Ear infection', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Erysipelas', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Fungal infection', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Gastroenteritis', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 5, 'numAffected': 4, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Gingivitis', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 253}]}, {'term': 'Herpes zoster', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Influenza', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 4, 'numAffected': 3, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 253}]}, {'term': 'Laryngitis', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Localised infection', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Mastitis', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Nasopharyngitis', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 22, 'numAffected': 18, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 23, 'numAffected': 17, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 29, 'numAffected': 22, 'numAtRisk': 253}]}, {'term': 'Onychomycosis', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Pharyngitis', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 5, 'numAffected': 5, 'numAtRisk': 253}]}, {'term': 'Pharyngitis bacterial', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 4, 'numAffected': 4, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Pneumonia', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Pyelonephritis acute', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Pyelonephritis chronic', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Respiratory tract infection', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Rhinitis', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Skin infection', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Tonsillitis', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Tracheobronchitis', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Upper respiratory tract infection', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 9, 'numAffected': 7, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 11, 'numAffected': 10, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 15, 'numAffected': 13, 'numAtRisk': 253}]}, {'term': 'Urinary tract infection', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 15, 'numAffected': 13, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 14, 'numAffected': 14, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 11, 'numAffected': 11, 'numAtRisk': 253}]}, {'term': 'Vaginal infection', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 2, 'numAtRisk': 119}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 113}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 112}]}, {'term': 'Vestibular neuronitis', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Animal bite', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Arthropod bite', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Clavicle fracture', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Exposure via father', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Fall', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Fracture', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Hand fracture', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Heat stroke', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Ligament sprain', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Limb injury', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Patella fracture', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Radius fracture', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Rib fracture', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Scratch', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Spinal fracture', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Alanine aminotransferase increased', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Albumin urine present', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 253}]}, {'term': 'Amylase abnormal', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 3, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Amylase increased', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 10, 'numAffected': 7, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 13, 'numAffected': 5, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Bacterial test positive', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Blood cholesterol increased', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 6, 'numAffected': 6, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 6, 'numAffected': 6, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Blood creatine phosphokinase increased', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Blood creatinine increased', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Blood potassium abnormal', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Blood pressure increased', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 3, 'numAffected': 2, 'numAtRisk': 253}]}, {'term': 'Blood triglycerides', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Blood triglycerides increased', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 4, 'numAffected': 4, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 6, 'numAffected': 6, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 4, 'numAffected': 3, 'numAtRisk': 253}]}, {'term': 'Blood uric acid increased', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 253}]}, {'term': 'Blood urine', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Blood urine present', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 253}]}, {'term': 'Body temperature increased', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Calcium ionised increased', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Carbohydrate antigen 19-9 increased', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Creatinine renal clearance decreased', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Creatinine renal clearance increased', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Crystal urine present', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 2, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Electrocardiogram abnormal', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Electrocardiogram low voltage', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Electrocardiogram t wave abnormal', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Gamma-glutamyltransferase increased', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 4, 'numAffected': 4, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Glucose urine', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Glucose urine present', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Heart rate increased', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'High density lipoprotein decreased', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Lipase abnormal', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 3, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Lipase increased', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 35, 'numAffected': 27, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 23, 'numAffected': 18, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 253}]}, {'term': 'Low density lipoprotein increased', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Pancreatic enzymes increased', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Platelet count decreased', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Protein urine', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Protein urine present', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 253}]}, {'term': 'Urine albumin/creatinine ratio increased', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 4, 'numAffected': 4, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 4, 'numAffected': 4, 'numAtRisk': 253}]}, {'term': 'Weight decreased', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'White blood cell count increased', 'organSystem': 'Investigations', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Decreased appetite', 'organSystem': 'Metabolism and nutrition disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 22, 'numAffected': 19, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 19, 'numAffected': 14, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Diabetes mellitus', 'organSystem': 'Metabolism and nutrition disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Dyslipidaemia', 'organSystem': 'Metabolism and nutrition disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 10, 'numAffected': 9, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 6, 'numAffected': 6, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 10, 'numAffected': 9, 'numAtRisk': 253}]}, {'term': 'Gout', 'organSystem': 'Metabolism and nutrition disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Hyperamylasaemia', 'organSystem': 'Metabolism and nutrition disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Hypercholesterolaemia', 'organSystem': 'Metabolism and nutrition disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 253}]}, {'term': 'Hyperlipidaemia', 'organSystem': 'Metabolism and nutrition disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 49, 'numAffected': 46, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 54, 'numAffected': 50, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 48, 'numAffected': 47, 'numAtRisk': 253}]}, {'term': 'Hypertriglyceridaemia', 'organSystem': 'Metabolism and nutrition disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 5, 'numAffected': 5, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Hyperuricaemia', 'organSystem': 'Metabolism and nutrition disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 6, 'numAffected': 6, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 7, 'numAffected': 7, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 4, 'numAffected': 4, 'numAtRisk': 253}]}, {'term': 'Hypoalbuminaemia', 'organSystem': 'Metabolism and nutrition disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Hypokalaemia', 'organSystem': 'Metabolism and nutrition disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Hypolipidaemia', 'organSystem': 'Metabolism and nutrition disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Arthralgia', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 6, 'numAffected': 5, 'numAtRisk': 253}]}, {'term': 'Back pain', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 253}]}, {'term': 'Bone pain', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Bursitis', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Fasciitis', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Intervertebral disc protrusion', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 253}]}, {'term': 'Joint swelling', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Lumbar spinal stenosis', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Muscle spasms', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Muscular weakness', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 253}]}, {'term': 'Musculoskeletal pain', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Myalgia', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Osteoarthritis', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 253}]}, {'term': 'Osteoporosis', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Pain in extremity', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 4, 'numAffected': 3, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 8, 'numAffected': 5, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 2, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Periarthritis', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Rotator cuff syndrome', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 253}]}, {'term': 'Scoliosis', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Spinal osteoarthritis', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Synovitis', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Tenosynovitis', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Fibroma', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Parathyroid tumour benign', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Uterine leiomyoma', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 119}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 113}, {'groupId': 'EG002', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 112}]}, {'term': 'Carotid artery stenosis', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Cerebral arteriosclerosis', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Cerebral artery stenosis', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Cerebrovascular disorder', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Diabetic autonomic neuropathy', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Diabetic neuropathy', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 253}]}, {'term': 'Dizziness', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 6, 'numAffected': 5, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 253}]}, {'term': 'Encephalopathy', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Facial paralysis', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Headache', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 9, 'numAffected': 8, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 8, 'numAffected': 8, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 253}]}, {'term': 'Hypoaesthesia', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 4, 'numAffected': 3, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 6, 'numAffected': 5, 'numAtRisk': 253}]}, {'term': 'Lacunar infarction', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Neuropathy peripheral', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Paraesthesia', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Poor quality sleep', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Sciatica', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Tension headache', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Transient ischaemic attack', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Vocal cord paralysis', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Anxiety', 'organSystem': 'Psychiatric disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Depression', 'organSystem': 'Psychiatric disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Insomnia', 'organSystem': 'Psychiatric disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Albuminuria', 'organSystem': 'Renal and urinary disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 253}]}, {'term': 'Chronic kidney disease', 'organSystem': 'Renal and urinary disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Diabetic nephropathy', 'organSystem': 'Renal and urinary disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 5, 'numAffected': 5, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 5, 'numAffected': 5, 'numAtRisk': 253}]}, {'term': 'Dysuria', 'organSystem': 'Renal and urinary disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Haematuria', 'organSystem': 'Renal and urinary disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 253}]}, {'term': 'Hypertensive nephropathy', 'organSystem': 'Renal and urinary disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Hyperuricosuria', 'organSystem': 'Renal and urinary disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Microalbuminuria', 'organSystem': 'Renal and urinary disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 253}]}, {'term': 'Nephrolithiasis', 'organSystem': 'Renal and urinary disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Nephroptosis', 'organSystem': 'Renal and urinary disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Pollakiuria', 'organSystem': 'Renal and urinary disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Proteinuria', 'organSystem': 'Renal and urinary disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Renal cyst', 'organSystem': 'Renal and urinary disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Renal impairment', 'organSystem': 'Renal and urinary disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Ureterolithiasis', 'organSystem': 'Renal and urinary disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Benign prostatic hyperplasia', 'organSystem': 'Reproductive system and breast disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 139}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 144}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 141}]}, {'term': 'Endometrial thickening', 'organSystem': 'Reproductive system and breast disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 119}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 113}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 112}]}, {'term': 'Menstrual disorder', 'organSystem': 'Reproductive system and breast disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 119}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 113}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 112}]}, {'term': 'Polycystic ovaries', 'organSystem': 'Reproductive system and breast disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 119}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 113}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 112}]}, {'term': 'Prostatitis', 'organSystem': 'Reproductive system and breast disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 139}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 144}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 141}]}, {'term': 'Bronchitis chronic', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Catarrh', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Choking sensation', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Cough', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 7, 'numAffected': 7, 'numAtRisk': 253}]}, {'term': 'Dyspnoea', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Hiccups', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 4, 'numAffected': 2, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Nasal congestion', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Oropharyngeal pain', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 3, 'numAffected': 2, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 3, 'numAffected': 3, 'numAtRisk': 253}]}, {'term': 'Respiratory disorder', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Rhinitis allergic', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Rhinorrhoea', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Sneezing', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Dermatitis allergic', 'organSystem': 'Skin and subcutaneous tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Erythema', 'organSystem': 'Skin and subcutaneous tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Hyperhidrosis', 'organSystem': 'Skin and subcutaneous tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 4, 'numAffected': 3, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Pruritus', 'organSystem': 'Skin and subcutaneous tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Pruritus generalised', 'organSystem': 'Skin and subcutaneous tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Rash', 'organSystem': 'Skin and subcutaneous tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 2, 'numAffected': 2, 'numAtRisk': 253}]}, {'term': 'Rash maculo-papular', 'organSystem': 'Skin and subcutaneous tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Rash papular', 'organSystem': 'Skin and subcutaneous tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Skin mass', 'organSystem': 'Skin and subcutaneous tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Solar dermatitis', 'organSystem': 'Skin and subcutaneous tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Urticaria', 'organSystem': 'Skin and subcutaneous tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Urticaria contact', 'organSystem': 'Skin and subcutaneous tissue disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Intestinal polypectomy', 'organSystem': 'Surgical and medical procedures', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Lung lobectomy', 'organSystem': 'Surgical and medical procedures', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Modified radical mastectomy', 'organSystem': 'Surgical and medical procedures', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Percutaneous coronary intervention', 'organSystem': 'Surgical and medical procedures', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Retinal laser coagulation', 'organSystem': 'Surgical and medical procedures', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Skin neoplasm excision', 'organSystem': 'Surgical and medical procedures', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Aneurysm', 'organSystem': 'Vascular disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Diabetic vascular disorder', 'organSystem': 'Vascular disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Essential hypertension', 'organSystem': 'Vascular disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Hypertension', 'organSystem': 'Vascular disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 20, 'numAffected': 20, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 28, 'numAffected': 28, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 19, 'numAffected': 19, 'numAtRisk': 253}]}, {'term': 'Peripheral arterial occlusive disease', 'organSystem': 'Vascular disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 253}]}, {'term': 'Thrombophlebitis', 'organSystem': 'Vascular disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}, {'term': 'Varicose vein', 'organSystem': 'Vascular disorders', 'sourceVocabulary': 'MedDRA 19.1', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG001', 'numEvents': 0, 'numAffected': 0, 'numAtRisk': 257}, {'groupId': 'EG002', 'numEvents': 1, 'numAffected': 1, 'numAtRisk': 253}]}]}, 'moreInfoModule': {'certainAgreement': {'piSponsorEmployee': False, 'restrictionType': 'GT60', 'restrictiveAgreement': True}, 'pointOfContact': {'title': 'Chief Medical Officer', 'organization': 'Eli Lilly and Company', 'phone': '800-545-5979'}}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2024-11-22', 'removedCountries': ['India']}, 'conditionBrowseModule': {'meshes': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D003924', 'term': 'Diabetes Mellitus, Type 2'}], 'ancestors': [{'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}], 'browseLeaves': [{'id': 'M7119', 'name': 'Diabetes Mellitus, Type 2', 'asFound': 'Type 2 Diabetes Mellitus', 'relevance': 'HIGH'}, {'id': 'M7115', 'name': 'Diabetes Mellitus', 'asFound': 'Diabetes Mellitus', 'relevance': 'HIGH'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D008687', 'term': 'Metformin'}, {'id': 'D000069036', 'term': 'Insulin Glargine'}, {'id': 'C555680', 'term': 'Dulaglutide'}], 'ancestors': [{'id': 'D007004', 'term': 'Hypoglycemic Agents'}, {'id': 'D045505', 'term': 'Physiological Effects of Drugs'}, {'id': 'D000097789', 'term': 'Glucagon-Like Peptide-1 Receptor Agonists'}], 'browseLeaves': [{'id': 'M10365', 'name': 'Insulin', 'relevance': 'LOW'}, {'id': 'M11667', 'name': 'Metformin', 'asFound': 'Control group', 'relevance': 'HIGH'}, {'id': 'M347', 'name': 'Insulin Glargine', 'asFound': 'Memory', 'relevance': 'HIGH'}, {'id': 'M173166', 'name': 'Insulin, Globin Zinc', 'relevance': 'LOW'}, {'id': 'M258626', 'name': 'Dulaglutide', 'asFound': 'Adult immunoblastic large cell lymphoma', 'relevance': 'HIGH'}, {'id': 'M10054', 'name': 'Hypoglycemic Agents', 'relevance': 'LOW'}, {'id': 'M9043', 'name': 'Glucagon', 'relevance': 'LOW'}, {'id': 'M26997', 'name': 'Glucagon-Like Peptide 1', 'relevance': 'LOW'}, {'id': 'M3401', 'name': 'Glucagon-Like Peptide-1 Receptor Agonists', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'Hypo', 'name': 'Hypoglycemic Agents'}, {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}, {'abbrev': 'Gast', 'name': 'Gastrointestinal Agents'}]}}, 'hasResults': True}, {'protocolSection': {'identificationModule': {'nctId': 'NCT05449782', 'orgStudyIdInfo': {'id': 'OCTA2'}, 'organization': {'fullName': 'University of Surrey', 'class': 'OTHER'}, 'briefTitle': 'Macro- and Microvascular Response to Cocoa Flavanols in Healthy and Type 2 Diabetes', 'officialTitle': 'Proof-of-concept Study to Investigate Hand and Foot Microvascular Response to Cocoa Flavanols in Healthy and Type 2 Diabetes Participant'}, 'statusModule': {'statusVerifiedDate': '2022-05', 'overallStatus': 'COMPLETED', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2021-05-17', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2021-06-01', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2022-05-17', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2021-05-18', 'studyFirstSubmitQcDate': '2022-07-04', 'studyFirstPostDateStruct': {'date': '2022-07-08', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2022-07-04', 'lastUpdatePostDateStruct': {'date': '2022-07-08', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'University of Surrey', 'class': 'OTHER'}}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'The greatest challenge in our ageing society are cardiovascular diseases such as stroke, heart attack, peripheral artery disease of the legs with non-healing wounds (ulcers), or diabetes. Specific diets with high polyphenol content are associated with lower incidence of cardiovascular disease and can improve macrovascular function when consumed acutely and chronically. Which role the smallest blood vessels (microcirculation) play in this and if the microcirculation responds to therapies is not well understood. One reason for this is that no generally available medical instrument has the resolution to study the microcirculation. The recently developed optical coherence tomography angiography (OCTA), currently mainly used by eye doctors, is able to visualise the microcirculation.\\n\\nThe current randomised controlled cross-over proof-of-concept study will test the acute effect of a cocoa flavanol intervention on cutaneous microvascular structure and function of hands and feet together with macrovascular function of upper and lower extremities in healthy and type 2 diabetes participants. It is the hypothesis that cocoa flavanol intervention as compared to placebo can acutely increase microvascular vasodilation and macrovascular endothelial function in arms and legs together with arterial stiffness in both healthy and type 2 diabetes participants.'}, 'conditionsModule': {'conditions': ['Microangiopathy, Diabetic', 'Polyphenol', 'Optical Tomography', 'Vascular Endothelium', 'Arterial Stiffness', 'Healthy Participants']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'CROSSOVER', 'interventionModelDescription': '2 group (healthy and type 2 diabetes) randomised controlled cross-over (2-period, 2-sequence) study', 'primaryPurpose': 'BASIC_SCIENCE', 'maskingInfo': {'masking': 'TRIPLE', 'maskingDescription': 'Placebo and cocoa flavanols will be delivered in same number of identical appearing capsules', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 22, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Healthy participants: Cocoa flavanol - Placebo', 'type': 'OTHER', 'description': 'Healthy participants receiving cocoa flavanols on first study day and placebo on second study day', 'interventionNames': ['Dietary Supplement: Cocoa flavanol', 'Other: Placebo']}, {'label': 'Healthy participant: Placebo - Cocoa flavanol', 'type': 'OTHER', 'description': 'Healthy participants receiving placebo on first study day and cocoa flavanols on second study day', 'interventionNames': ['Dietary Supplement: Cocoa flavanol', 'Other: Placebo']}, {'label': 'Type 2 diabetes participants: Cocoa flavanol - Placebo', 'type': 'OTHER', 'description': 'Participants with type 2 diabetes receiving cocoa flavanols on first study day and placebo on second study day', 'interventionNames': ['Dietary Supplement: Cocoa flavanol', 'Other: Placebo']}, {'label': 'Type 2 diabetes participants: Placebo - Cocoa flavanol', 'type': 'OTHER', 'description': 'Participants with type 2 diabetes receiving placebo on first study day and cocoa flavanols on second study day', 'interventionNames': ['Dietary Supplement: Cocoa flavanol', 'Other: Placebo']}], 'interventions': [{'type': 'DIETARY_SUPPLEMENT', 'name': 'Cocoa flavanol', 'description': 'Commercially available Cocoa Via Brand capsules containing 1350 mg cocoa flavanols (6 capsules)', 'armGroupLabels': ['Healthy participant: Placebo - Cocoa flavanol', 'Healthy participants: Cocoa flavanol - Placebo', 'Type 2 diabetes participants: Cocoa flavanol - Placebo', 'Type 2 diabetes participants: Placebo - Cocoa flavanol']}, {'type': 'OTHER', 'name': 'Placebo', 'description': 'Capsules identical to ccocoa flavanol capsules filled with calorically matched brown sugar (6 capsules)', 'armGroupLabels': ['Healthy participant: Placebo - Cocoa flavanol', 'Healthy participants: Cocoa flavanol - Placebo', 'Type 2 diabetes participants: Cocoa flavanol - Placebo', 'Type 2 diabetes participants: Placebo - Cocoa flavanol']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Microvascular dilation', 'description': 'Microvascular diameter increase in response to 5 min limb occlusion on hands and feet', 'timeFrame': 'Change at 2 hours as compared to baseline after ingestion of cocoa flavanol vs placebo'}, {'measure': 'Macrovascular endothelial function', 'description': 'Flow-mediated dilation determined with ultrasound in brachial and common femoral artery', 'timeFrame': 'Change at 2 hours as compared to baseline after ingestion of cocoa flavanol vs placebo'}], 'secondaryOutcomes': [{'measure': 'Arterial stiffness', 'description': 'Pulse wave velocity (Arteriograph)', 'timeFrame': 'Change at 2 hours as compared to baseline after ingestion of cocoa flavanol vs placebo'}, {'measure': 'Blood pressure', 'description': 'Upper arm blood pressure measured with Arteriograph', 'timeFrame': 'Change at 2 hours as compared to baseline after ingestion of cocoa flavanol vs placebo'}, {'measure': 'Leg perfusion pressure', 'description': 'Doppler based perfusion pressure of leg', 'timeFrame': 'Change at 2 hours as compared to baseline after ingestion of cocoa flavanol vs placebo'}], 'otherOutcomes': [{'measure': 'Photoplethysmography (PPG) based pulse wave velocity (PWV)', 'description': 'PWV velocity calculated based on PPG sensor at hand and foot', 'timeFrame': 'Change at 2 hours as compared to baseline after ingestion of cocoa flavanol vs placebo'}, {'measure': 'Photoplethysmography (PPG) blood flow', 'description': 'Based on PPG signals on hand and foot', 'timeFrame': 'Change at 2 hours as compared to baseline after ingestion of cocoa flavanol vs placebo'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Healthy:\\n\\nInclusion Criteria:\\n\\n* Healthy, 20-70 years\\n* BMI 20-30 kg/m\\\\^2\\n\\nExclusion Criteria:\\n\\n* Diabetes mellitus\\n* Symptoms of acute infection\\n* Cardiac rhythm other than sinus\\n* Active malignancy\\n* Clinical signs or symptoms of cardiovascular disease (coronary artery disease, lower extremity artery disease, cerebrovascular disease): angina pectoris, dyspnea, palpitation, syncope, claudication\\n* Active vasoactive medication.\\n\\nType 2 Diabetes:\\n\\nInclusion Criteria:\\n\\n* Type 2 diabetes mellitus\\n* 20-70 years\\n* BMI 20-30 kg/m\\\\^2\\n\\nExclusion Criteria:\\n\\n* Symptoms of acute infection\\n* Cardiac rhythm other than sinus\\n* Active malignancy\\n* Clinical signs or symptoms of cardiovascular disease (coronary artery disease, lower extremity artery disease, cerebrovascular disease): angina pectoris, dyspnea, palpitation, syncope, claudication\\n* Active vasoactive medication.', 'healthyVolunteers': True, 'sex': 'ALL', 'minimumAge': '20 Years', 'maximumAge': '70 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Christian Heiss, Prof.', 'affiliation': 'University of Surrey, Department of Clinical and Experimental Medicine', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'University of Surrey', 'city': 'Guildford', 'zip': 'GU2 7XH', 'country': 'United Kingdom', 'geoPoint': {'lat': 51.23536, 'lon': -0.57427}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO', 'description': 'Will be decided on an individual basis and after study completion.'}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2024-11-22'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003925', 'term': 'Diabetic Angiopathies'}], 'ancestors': [{'id': 'D014652', 'term': 'Vascular Diseases'}, {'id': 'D002318', 'term': 'Cardiovascular Diseases'}, {'id': 'D048909', 'term': 'Diabetes Complications'}, {'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}], 'browseLeaves': [{'id': 'M7119', 'name': 'Diabetes Mellitus, Type 2', 'relevance': 'LOW'}, {'id': 'M7115', 'name': 'Diabetes Mellitus', 'relevance': 'LOW'}, {'id': 'M7120', 'name': 'Diabetic Angiopathies', 'asFound': 'Microangiopathy, Diabetic', 'relevance': 'HIGH'}, {'id': 'M17400', 'name': 'Vascular Diseases', 'relevance': 'LOW'}, {'id': 'M26004', 'name': 'Diabetes Complications', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC14', 'name': 'Heart and Blood Diseases'}]}}, 'hasResults': False}], 'nextPageToken': 'NF0g5JKPmvQ'}\n",
      "Condition Trials:\n",
      "        nct_id                                              title\n",
      "0  NCT00701831  Assessment of Forced Titration to Reach the Ef...\n",
      "1  NCT06081231  The Safety and Efficacy of Open-Source Artific...\n",
      "2  NCT01835431  A Trial Investigating the Efficacy and Safety ...\n",
      "3  NCT00272831  A Randomised, Double-Blind, Placebo-Controlled...\n",
      "4  NCT01871831  Prüfung Von Blutzuckermesssystemen - Bewertung...\n",
      "5  NCT01643031  Effect of Modifying Anti-platelet Treatment to...\n",
      "6  NCT05631431  A Randomized, Double-Blind, Placebo-Controlled...\n",
      "7  NCT05427682  A Single-center, Non-randomized, Open, Single-...\n",
      "8  NCT01648582  The Efficacy and Safety of Once-Weekly, Subcut...\n",
      "9  NCT05449782  Proof-of-concept Study to Investigate Hand and...\n"
     ]
    }
   ],
   "source": [
    "BASE_URL = \"https://clinicaltrials.gov/api/v2/studies\"\n",
    "\n",
    "def fetch_trials_by_condition(condition):\n",
    "    \"\"\"\n",
    "    Fetch a list of trials from ClinicalTrials.gov API that match a given condition or disease.\n",
    "    \"\"\"\n",
    "    url = f\"{BASE_URL}?format=json&query.cond={condition}\"\n",
    "    response = requests.get(url)\n",
    "\n",
    "    if response.status_code == 200:\n",
    "        data = response.json()\n",
    "\n",
    "        # Debugging: Print the raw JSON response to understand its structure\n",
    "        print(\"API Response:\", data)\n",
    "\n",
    "        # Extract the studies list and handle cases where it's missing or empty\n",
    "        studies = data.get(\"studies\", [])\n",
    "        if not studies:\n",
    "            print(\"No studies found for the given condition.\")\n",
    "            return pd.DataFrame(columns=[\"nct_id\", \"title\"])  # Return an empty DataFrame\n",
    "\n",
    "        # Extract relevant details from the nested structure\n",
    "        trials = []\n",
    "        for trial in studies:\n",
    "            try:\n",
    "                nct_id = trial[\"protocolSection\"][\"identificationModule\"][\"nctId\"]\n",
    "                title = trial[\"protocolSection\"][\"identificationModule\"].get(\"officialTitle\", \"Title Not Available\")\n",
    "                trials.append({\"nct_id\": nct_id, \"title\": title})\n",
    "            except KeyError as e:\n",
    "                print(f\"Missing expected key in trial: {e}\")\n",
    "        \n",
    "        return pd.DataFrame(trials)  # Convert to a DataFrame for easier analysis\n",
    "    else:\n",
    "        raise Exception(f\"Error fetching data: {response.status_code}, {response.text}\")\n",
    "\n",
    "# Example usage\n",
    "condition_trials = fetch_trials_by_condition(\"diabetes\")\n",
    "print(\"Condition Trials:\")\n",
    "print(condition_trials)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "import requests\n",
    "import pandas as pd\n",
    "\n",
    "BASE_URL = \"https://clinicaltrials.gov/api/v2/studies\"\n",
    "\n",
    "def fetch_trials(**query_params):\n",
    "    \"\"\"\n",
    "    Fetch a list of trials from ClinicalTrials.gov API based on dynamic query parameters.\n",
    "    \n",
    "    Args:\n",
    "        **query_params: Arbitrary keyword arguments representing API query parameters.\n",
    "            Examples: \n",
    "                query_params={'query.cond': 'diabetes', 'query.id': 'BP28248', 'query.titles': 'high blood pressure'}\n",
    "    \n",
    "    Returns:\n",
    "        DataFrame containing NCT IDs and titles of matching trials.\n",
    "    \"\"\"\n",
    "    # Construct query string from query_params\n",
    "    query_string = \"&\".join(f\"{key}={value}\" for key, value in query_params.items())\n",
    "    url = f\"{BASE_URL}?format=json&{query_string}\"\n",
    "\n",
    "    response = requests.get(url)\n",
    "\n",
    "    if response.status_code == 200:\n",
    "        data = response.json()\n",
    "\n",
    "        # Debugging: Print the raw JSON response to understand its structure\n",
    "        print(\"API Response:\", data)\n",
    "\n",
    "        # Extract the studies list and handle cases where it's missing or empty\n",
    "        studies = data.get(\"studies\", [])\n",
    "        if not studies:\n",
    "            print(\"No studies found for the given query.\")\n",
    "            return pd.DataFrame(columns=[\"nct_id\", \"title\"])  # Return an empty DataFrame\n",
    "\n",
    "        # Extract relevant details from the nested structure\n",
    "        trials = []\n",
    "        for trial in studies:\n",
    "            try:\n",
    "                nct_id = trial[\"protocolSection\"][\"identificationModule\"][\"nctId\"]\n",
    "                title = trial[\"protocolSection\"][\"identificationModule\"].get(\"officialTitle\", \"Title Not Available\")\n",
    "                trials.append({\"nct_id\": nct_id, \"title\": title})\n",
    "            except KeyError as e:\n",
    "                print(f\"Missing expected key in trial: {e}\")\n",
    "\n",
    "        return pd.DataFrame(trials)  # Convert to a DataFrame for easier analysis\n",
    "    else:\n",
    "        raise Exception(f\"Error fetching data: {response.status_code}, {response.text}\")\n",
    "\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "API Response: {'studies': [{'protocolSection': {'identificationModule': {'nctId': 'NCT03532620', 'orgStudyIdInfo': {'id': 'BZ-1702'}, 'organization': {'fullName': 'First Affiliated Hospital, Sun Yat-Sen University', 'class': 'OTHER'}, 'briefTitle': 'China Protection Trial of Glucose Metabolism by Pitavastatin in Patients With Prediabetes and Hypertension', 'officialTitle': 'A Multi-center, Open-label, Randomized, 12-month, Parallel-group, Non-inferiority Study to Compare the Hemoglobin A1C Metabolism of Pitavastatin Therapy Versus Atorvastatin in Chinese Patients With Prediabetes and Hypertension', 'acronym': 'CAMPUS'}, 'statusModule': {'statusVerifiedDate': '2019-05', 'overallStatus': 'UNKNOWN', 'lastKnownStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2018-08-09', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2019-09', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2020-09', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2018-04-27', 'studyFirstSubmitQcDate': '2018-05-10', 'studyFirstPostDateStruct': {'date': '2018-05-22', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2019-05-31', 'lastUpdatePostDateStruct': {'date': '2019-06-03', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR_INVESTIGATOR', 'investigatorFullName': 'Jun Tao', 'investigatorTitle': 'Director, Head of the Department of Hypertension and Cardiovascular Disease, Principal Investigator, Clinical Professor', 'investigatorAffiliation': 'First Affiliated Hospital, Sun Yat-Sen University'}, 'leadSponsor': {'name': 'Jun Tao', 'class': 'OTHER'}, 'collaborators': [{'name': 'Sun Yat-sen University', 'class': 'OTHER'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False, 'isUsExport': True}, 'descriptionModule': {'briefSummary': 'The primary purpose of this trial is to test the hypothesis that Pitavastatin treatment compared to Atorvastatin, in patients with dyslipidemia, prediabetes and hypertension, will have less adverse effect on Hemoglobin A1C (HbA1C), which represents long-term glucose metabolism.', 'detailedDescription': 'Within the 12 months of the study procedure, the 3rd month is what we called the \"check point\". At this point, participants\\' plasma LDL-C will be measured whether it reached individual standard or not. If the results didn\\'t meet the particular LDL-C standard, the participants would be adjusted the drug dosage (pitavastatin 4mg/day, atorvastatin 40mg/day).'}, 'conditionsModule': {'conditions': ['Prediabetic State', 'Hypertension', 'Dyslipidemias'], 'keywords': ['Pitavastatin', 'Prediabetic State', 'Hypertension', 'Dyslipidemias', 'Cardiovascular Disease']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE4'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 396, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'pitavastatin', 'type': 'EXPERIMENTAL', 'description': 'Pitavastatin Calcium + lifestyle modification', 'interventionNames': ['Drug: Pitavastatin Calcium']}, {'label': 'atorvastatin', 'type': 'ACTIVE_COMPARATOR', 'description': 'Atorvastatin Calcium + lifestyle modification', 'interventionNames': ['Drug: Atorvastatin Calcium']}], 'interventions': [{'type': 'DRUG', 'name': 'Pitavastatin Calcium', 'description': 'In Pitavastatin treatment group, Pitavastatin calcium tablet 2mg/day was given for 12 months in combination with lifestyle modification. But month 3 is the \"check point\". If LDL-C target was achieved at Month 3, doses remained the same. If LDL-C target was not achieved at Month 3, doses were doubled.', 'armGroupLabels': ['pitavastatin']}, {'type': 'DRUG', 'name': 'Atorvastatin Calcium', 'description': 'In Atorvastatin treatment group, Atorvastatin calcium tablet 20mg/day was given for 12 months in combination with lifestyle modification. But month 3 is the \"check point\". If LDL-C target was achieved at Month 3, doses remained the same. If LDL-C target was not achieved at Month 3, doses were doubled.', 'armGroupLabels': ['atorvastatin'], 'otherNames': ['Lipitor®']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Change from baseline in hemoglobin A1c levels', 'description': 'Change of HbA1C values at study initiation and study completion', 'timeFrame': 'Month 12'}], 'secondaryOutcomes': [{'measure': 'Changes from baseline in FPG levels', 'description': 'Change of fasting plasma glucose (FPG) values at study initiation and study completion', 'timeFrame': 'Month 12'}, {'measure': 'Changes from baseline in OGTT-2h PG levels', 'description': 'Change of oral glucose tolerance test (OGTT)-2h plasma glucose (PG) values at study initiation and study completion', 'timeFrame': 'Month 12'}, {'measure': 'Proportion of subjects in LDL-C normalization state', 'description': 'Proportion of subjects in each group who achieved low-density lipoprotein cholesterol (LDL-C) target', 'timeFrame': 'Month 3 and 12'}, {'measure': 'Changes from baseline in high-density lipoprotein cholesterol (HDL-C) levels', 'description': 'Change of HDL-C values at study initiation and study completion', 'timeFrame': 'Month 12'}, {'measure': 'Changes from baseline in total cholesterol (TC) levels', 'description': 'Change of TC values at study initiation and study completion', 'timeFrame': 'Month 12'}, {'measure': 'Changes from baseline in triglycerides (TG) levels', 'description': 'Change of TG values at study initiation and study completion', 'timeFrame': 'Month 12'}, {'measure': 'Changes from baseline in inflammatory parameters', 'description': 'Change of C-reactive protein (CRP) values at study initiation and study completion', 'timeFrame': 'Month 12'}, {'measure': 'Incidence of cardiovascular disease (CVD) events', 'description': 'Incidence of cardiovascular disease (CVD) events, including acute coronary syndrome, stable coronary artery disease, ischemic cardiomyopathy etc.', 'timeFrame': 'Month 12'}, {'measure': 'Change from baseline in blood pressure levels', 'description': 'Change from baseline in systolic and diastolic blood pressure levels', 'timeFrame': 'Month 12'}, {'measure': 'Changes from baseline in vascular endothelial function', 'description': 'Change of brachial-ankle pulse wave velocity (baPWV) values at study initiation and study completion', 'timeFrame': 'Month 12'}, {'measure': 'Changes from baseline in left ventricular mass index', 'description': 'Change of left ventricular mass index (LVMI) values at study initiation and study completion', 'timeFrame': 'Month 12'}, {'measure': 'Changes from baseline in carotid intima-media thickness', 'description': 'Change of carotid intima-media thickness (CIMT) values at study initiation and study completion', 'timeFrame': 'Month 12'}], 'otherOutcomes': [{'measure': 'Incidence of adverse events (AEs)', 'description': 'Incidence of adverse events (AEs) after treatment initiation', 'timeFrame': 'Month 12'}]}, 'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\n\\n1. Age 18-80 years old;\\n2. IFG: 5.6mmol/L (100mg/dl)≤FPG\\\\<7.0mmol/L (126mg/dl), or IGT: 7.8mmol/L (140mg/dl)≤OGTT 2-h PG\\\\<11.1mmol/L (200mg/dl), or HbA1C 5.7-6.4% (39-47mmol/mol);\\n3. 2.6mmol/L (100mg/dl)≤LDL-C≤5.2mmol/L (200mg/dl), and TG\\\\<5.7mmol/L (500mg/dl);\\n4. 130mmHg≤SBP\\\\<180mmHg, or 80mmHg≤DBP\\\\<110mmHg or ongoing anti-hypertensive therapy;\\n5. Patients volunteered for the study and signed informed consent.\\n\\nExclusion Criteria:\\n\\n1. Past history of hypersensitivity to the study drug;\\n2. Diagnosed diabetes;\\n3. Severe liver disease (including ALT or AST≥2.5-fold the normal upper limit), biliary obstruction;\\n4. Ongoing treatment with cyclosporine within 2 weeks;\\n5. Renal dysfunction, including endogenous creatinine clearance male\\\\<120ml/min, female\\\\<105ml/min, serum creatinine≥2mg/dl (186umol/L), Renal function progressive decline, GFR\\\\<30ml•min-1•1.73m-2;\\n6. Diagnosed or past history of ASCVD (including ACS, SCAD, revascularization, ICM, ischemic stroke, TIA, PASD, etc.\\n7. SBP≥180mmHg, or DBP≥110mmHg;\\n8. Ongoing treatment with Beta blockers, Diuretic;\\n9. Secondary hypertension, including SAS, PA, RAS, pheochromocytoma, Cushing's syndrome, aorta diseases, drug induced hypertension;\\n10. Ongoing treatment with statins, fibrates, and/or cation exchange resins within 2 weeks;\\n11. Pancreatic disease;\\n12. History of gastrectomy, short bowel syndrome;\\n13. Ongoing hormone replacement therapy;\\n14. Diagnosed or suspected malignant tumor;\\n15. Familial hypercholesterolemia;\\n16. Any diseases may limit the efficacy or safety of the study;\\n17. Pregnant or possibly pregnant woman, or breastfeeding woman, or woman who wishes to become pregnant during study participation;\\n18. Patient who was not judged as eligible by the investigator/coinvestigator.\\n\\n    * IFG impaired fast glucose, FPG fasting plasma glucose, IGT impaired glucose tolerance, OGTT oral glucose tolerance test, PG plasma glucose, HbA1C hemoglobin A1C, LDL-C low-density lipoprotein cholesterol, TG triglycerides, SBP systolic blood pressure, DBP diastolic blood pressure, ALT alanine aminotransferase, AST aspartate aminotransferase, GFR glomerular filtration rate, ASCVD arteriosclerotic cardiovascular disease, ACS acute coronary syndrome, SCAD stable coronary artery disease, ICM ischemic cardiomyopathy, TIA transient ischemic attack, PASD peripheral atherosclerotic disease, SAS sleep apnea syndrome, PA primary aldosteronism, RAS renal arterial stenosis\", 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'maximumAge': '80 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Jun Tao, MD,PhD', 'role': 'CONTACT', 'phone': '+8613922191609', 'email': 'taojungz123@163.com'}, {'name': 'Jianning Zhang', 'role': 'CONTACT', 'phone': '+8615521264372', 'email': 'ningjenny@yeah.net'}], 'overallOfficials': [{'name': 'Jun Tao, MD,PhD', 'affiliation': 'First Affiliated Hospital, Sun Yat-Sen University', 'role': 'STUDY_CHAIR'}], 'locations': [{'facility': \"Fourth People's Hospital of Chongqing\", 'status': 'RECRUITING', 'city': 'Chongqing', 'state': 'Chongqing', 'zip': '400014', 'country': 'China', 'contacts': [{'name': 'Ruihua Yue, MD', 'role': 'CONTACT'}, {'name': 'Ruihua Yue, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 29.56278, 'lon': 106.55278}}, {'facility': 'First Affiliated Hospital,Sun Yat-sen University', 'status': 'RECRUITING', 'city': 'Guangzhou', 'state': 'Guangdong', 'zip': '510000', 'country': 'China', 'contacts': [{'name': 'Jun Tao, MD,PhD', 'role': 'CONTACT', 'phone': '+8613922191609', 'email': 'taojungz123@163.com'}, {'name': 'Jianning Zhang', 'role': 'CONTACT', 'phone': '+8615521264372', 'email': 'ningjenny@yeah.net'}, {'name': 'Jun Tao, MD,PhD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 23.11667, 'lon': 113.25}}, {'facility': 'Second Affiliated Hospital of Guangzhou Medical University', 'status': 'RECRUITING', 'city': 'Guangzhou', 'state': 'Guangdong', 'zip': '510260', 'country': 'China', 'contacts': [{'name': 'Wenchao Qu, MD', 'role': 'CONTACT'}, {'name': 'Wenchao Qu, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 23.11667, 'lon': 113.25}}, {'facility': 'First Affiliated Hospital of Jinan University', 'status': 'RECRUITING', 'city': 'Guangzhou', 'state': 'Guangdong', 'zip': '510630', 'country': 'China', 'contacts': [{'name': 'Jun Guo, MD', 'role': 'CONTACT'}, {'name': 'Jun Guo, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 23.11667, 'lon': 113.25}}, {'facility': \"Shenzhen People's Hospital\", 'status': 'NOT_YET_RECRUITING', 'city': 'Shenzhen', 'state': 'Guangdong', 'zip': '518020', 'country': 'China', 'contacts': [{'name': 'Xin Jiang, MD', 'role': 'CONTACT'}, {'name': 'Xin Jiang, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 22.54554, 'lon': 114.0683}}, {'facility': \"People's Hospital of Zhongshan City\", 'status': 'RECRUITING', 'city': 'Zhongshan', 'state': 'Guangdong', 'zip': '528403', 'country': 'China', 'contacts': [{'name': 'Li Feng, MD', 'role': 'CONTACT'}, {'name': 'Li Feng, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 21.31992, 'lon': 110.5723}}, {'facility': 'First Affiliated Hospital of Zhengzhou University', 'status': 'RECRUITING', 'city': 'Zhengzhou', 'state': 'Henan', 'zip': '450052', 'country': 'China', 'contacts': [{'name': 'Heping Gu, MD', 'role': 'CONTACT'}, {'name': 'Heping Gu, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 34.75778, 'lon': 113.64861}}, {'facility': 'Yichang Central Hospital', 'status': 'RECRUITING', 'city': 'Yichang', 'state': 'Hubei', 'zip': '443003', 'country': 'China', 'contacts': [{'name': 'Jiawang Ding, MD', 'role': 'CONTACT'}, {'name': 'Jiawang Ding, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 30.71444, 'lon': 111.28472}}, {'facility': 'Taizhou Hospital of TCM', 'status': 'RECRUITING', 'city': 'Taizhou', 'state': 'Jiangsu', 'zip': '214504', 'country': 'China', 'contacts': [{'name': 'Yongguang Zhang, MD', 'role': 'CONTACT'}, {'name': 'Yongguang Zhang, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 32.49069, 'lon': 119.90812}}, {'facility': \"Wuxi People's Hospital\", 'status': 'RECRUITING', 'city': 'Wuxi', 'state': 'Jiangsu', 'zip': '214023', 'country': 'China', 'contacts': [{'name': 'Ruxing Wang, MD', 'role': 'CONTACT'}, {'name': 'Ruxing Wang, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 31.56887, 'lon': 120.28857}}, {'facility': \"Subei People's Hospital of Jiangsu province\", 'status': 'NOT_YET_RECRUITING', 'city': 'Yangzhou', 'state': 'Jiangsu', 'zip': '225001', 'country': 'China', 'contacts': [{'name': 'Shenghu He, MD', 'role': 'CONTACT'}, {'name': 'Shenghu He, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 32.39722, 'lon': 119.43583}}, {'facility': 'Lanzhou University Second Hospital', 'status': 'RECRUITING', 'city': 'Lanzhou', 'state': 'Qinghai', 'zip': '730030', 'country': 'China', 'contacts': [{'name': 'Feng Bai, MD', 'role': 'CONTACT'}, {'name': 'Feng Bai, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 36.05701, 'lon': 103.83987}}, {'facility': 'Yantaishan Hospital, Yantai', 'status': 'NOT_YET_RECRUITING', 'city': 'Yantai', 'state': 'Shandong', 'zip': '264001', 'country': 'China', 'contacts': [{'name': 'Lan Zhao, MD', 'role': 'CONTACT'}, {'name': 'Lan Zhao, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 37.47649, 'lon': 121.44081}}]}, 'referencesModule': {'references': [{'pmid': '24793439', 'type': 'BACKGROUND', 'citation': 'Maki KC, Ridker PM, Brown WV, Grundy SM, Sattar N, The Diabetes Subpanel of the National Lipid Association Expert Panel. An assessment by the Statin Diabetes Safety Task Force: 2014 update. J Clin Lipidol. 2014 May-Jun;8(3 Suppl):S17-29. doi: 10.1016/j.jacl.2014.02.012.'}, {'pmid': '27039945', 'type': 'BACKGROUND', 'citation': 'Yusuf S, Lonn E, Pais P, Bosch J, Lopez-Jaramillo P, Zhu J, Xavier D, Avezum A, Leiter LA, Piegas LS, Parkhomenko A, Keltai M, Keltai K, Sliwa K, Chazova I, Peters RJ, Held C, Yusoff K, Lewis BS, Jansky P, Khunti K, Toff WD, Reid CM, Varigos J, Accini JL, McKelvie R, Pogue J, Jung H, Liu L, Diaz R, Dans A, Dagenais G; HOPE-3 Investigators. Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease. N Engl J Med. 2016 May 26;374(21):2032-43. doi: 10.1056/NEJMoa1600177. Epub 2016 Apr 2. Erratum In: N Engl J Med. 2018 Oct 11;379(15):1486.'}, {'pmid': '26432671', 'type': 'BACKGROUND', 'citation': 'Baudrand R, Pojoga LH, Vaidya A, Garza AE, Vohringer PA, Jeunemaitre X, Hopkins PN, Yao TM, Williams J, Adler GK, Williams GH. Statin Use and Adrenal Aldosterone Production in Hypertensive and Diabetic Subjects. Circulation. 2015 Nov 10;132(19):1825-33. doi: 10.1161/CIRCULATIONAHA.115.016759. Epub 2015 Oct 2.'}, {'pmid': '22878405', 'type': 'BACKGROUND', 'citation': \"Warita S, Kawasaki M, Tanaka R, Ono K, Kojima T, Hirose T, Iwama M, Watanabe T, Nishigaki K, Takemura G, Noda T, Watanabe S, Minatoguchi S. Effects of pitavastatin on cardiac structure and function and on prevention of atrial fibrillation in elderly hypertensive patients: a prospective study of 2-years' follow-up. Circ J. 2012;76(12):2755-62. doi: 10.1253/circj.cj-12-0722. Epub 2012 Aug 8.\"}, {'pmid': '21028996', 'type': 'BACKGROUND', 'citation': 'Yoshika M, Komiyama Y, Masuda M, Yokoi T, Masaki H, Ohkura H, Takahashi H. Pitavastatin further decreases serum high-sensitive C-reactive protein levels in hypertensive patients with hypercholesterolemia treated with angiotensin II, type-1 receptor antagonists. Clin Exp Hypertens. 2010;32(6):341-6. doi: 10.3109/10641961003628460.'}, {'pmid': '12551878', 'type': 'BACKGROUND', 'citation': 'Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC Jr, Taubert K, Tracy RP, Vinicor F; Centers for Disease Control and Prevention; American Heart Association. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003 Jan 28;107(3):499-511. doi: 10.1161/01.cir.0000052939.59093.45. No abstract available.'}, {'pmid': '19104004', 'type': 'BACKGROUND', 'citation': 'Kushiro T, Mizuno K, Nakaya N, Ohashi Y, Tajima N, Teramoto T, Uchiyama S, Nakamura H; Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese Study Group. Pravastatin for cardiovascular event primary prevention in patients with mild-to-moderate hypertension in the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study. Hypertension. 2009 Feb;53(2):135-41. doi: 10.1161/HYPERTENSIONAHA.108.120584. Epub 2008 Dec 22.'}, {'pmid': '18997196', 'type': 'BACKGROUND', 'citation': 'Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008 Nov 20;359(21):2195-207. doi: 10.1056/NEJMoa0807646. Epub 2008 Nov 9.'}, {'pmid': '20736443', 'type': 'BACKGROUND', 'citation': 'Ridker PM, Macfadyen JG, Nordestgaard BG, Koenig W, Kastelein JJ, Genest J, Glynn RJ. Rosuvastatin for primary prevention among individuals with elevated high-sensitivity c-reactive protein and 5% to 10% and 10% to 20% 10-year risk. Implications of the Justification for Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial for \"intermediate risk\". Circ Cardiovasc Qual Outcomes. 2010 Sep;3(5):447-52. doi: 10.1161/CIRCOUTCOMES.110.938118. Epub 2010 Aug 24.'}, {'pmid': '30187345', 'type': 'DERIVED', 'citation': 'Zhang J, Shao Y, Liu Y, Tao J. A Multi-Center, Open-Label, Two-Arm Parallel Group Non-inferiority Randomized Controlled Trial Evaluating the Effect of Pitavastatin, Compared to Atorvastatin, on Glucose Metabolism in Prediabetics with Hypertension and Dyslipidemia: Rationale and Design for the China Hemoglobin A1c Metabolism Protection Union Study (CAMPUS). Cardiovasc Drugs Ther. 2018 Dec;32(6):581-589. doi: 10.1007/s10557-018-6826-6.'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'YES', 'description': 'Study protocol, Statistical Analysis Plan, Clinical Study Report are planned to be available to other researchers. The information will be published on scientific journal and is anticipated to be available in public no more than a year after the study completion.', 'infoTypes': ['STUDY_PROTOCOL', 'SAP', 'CSR'], 'timeFrame': 'Study protocol will be published on scientific journal and is anticipated to be available online by the end of 2018. Statistical Analysis Plan will be finished before the trial ends. Clinical Study Report will be published in public no more than a year after the study completion.', 'accessCriteria': 'All researchers will be available to get the individual participant data (IPD) as long as the information is published.'}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2024-11-22'}, 'conditionBrowseModule': {'meshes': [{'id': 'D006973', 'term': 'Hypertension'}, {'id': 'D050171', 'term': 'Dyslipidemias'}, {'id': 'D011236', 'term': 'Prediabetic State'}], 'ancestors': [{'id': 'D014652', 'term': 'Vascular Diseases'}, {'id': 'D002318', 'term': 'Cardiovascular Diseases'}, {'id': 'D052439', 'term': 'Lipid Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}], 'browseLeaves': [{'id': 'M10024', 'name': 'Hypertension', 'asFound': 'Hypertension', 'relevance': 'HIGH'}, {'id': 'M26181', 'name': 'Dyslipidemias', 'asFound': 'Dyslipidemia', 'relevance': 'HIGH'}, {'id': 'M14117', 'name': 'Prediabetic State', 'asFound': 'Prediabetic State', 'relevance': 'HIGH'}, {'id': 'M20295', 'name': 'Glucose Intolerance', 'relevance': 'LOW'}, {'id': 'M17400', 'name': 'Vascular Diseases', 'relevance': 'LOW'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M27029', 'name': 'Lipid Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7115', 'name': 'Diabetes Mellitus', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC14', 'name': 'Heart and Blood Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D002136', 'term': 'Calcium, Dietary'}, {'id': 'D000069059', 'term': 'Atorvastatin'}, {'id': 'C108475', 'term': 'Pitavastatin'}, {'id': 'D002118', 'term': 'Calcium'}], 'ancestors': [{'id': 'D000077264', 'term': 'Calcium-Regulating Hormones and Agents'}, {'id': 'D045505', 'term': 'Physiological Effects of Drugs'}, {'id': 'D050071', 'term': 'Bone Density Conservation Agents'}, {'id': 'D000924', 'term': 'Anticholesteremic Agents'}, {'id': 'D000960', 'term': 'Hypolipidemic Agents'}, {'id': 'D000963', 'term': 'Antimetabolites'}, {'id': 'D045504', 'term': 'Molecular Mechanisms of Pharmacological Action'}, {'id': 'D057847', 'term': 'Lipid Regulating Agents'}, {'id': 'D019161', 'term': 'Hydroxymethylglutaryl-CoA Reductase Inhibitors'}, {'id': 'D004791', 'term': 'Enzyme Inhibitors'}], 'browseLeaves': [{'id': 'M351', 'name': 'Atorvastatin', 'asFound': 'Harvest', 'relevance': 'HIGH'}, {'id': 'M5398', 'name': 'Calcium, Dietary', 'asFound': 'Protocol', 'relevance': 'HIGH'}, {'id': 'M5381', 'name': 'Calcium', 'asFound': 'Protocol', 'relevance': 'HIGH'}, {'id': 'M207501', 'name': 'Chrysarobin', 'relevance': 'LOW'}, {'id': 'M349896', 'name': 'Pitavastatin', 'asFound': 'Spine Surgery', 'relevance': 'HIGH'}, {'id': 'M9789', 'name': 'Hormones', 'relevance': 'LOW'}, {'id': 'M4243', 'name': 'Anticholesteremic Agents', 'relevance': 'LOW'}, {'id': 'M4278', 'name': 'Hypolipidemic Agents', 'relevance': 'LOW'}, {'id': 'M4281', 'name': 'Antimetabolites', 'relevance': 'LOW'}, {'id': 'M28883', 'name': 'Lipid Regulating Agents', 'relevance': 'LOW'}, {'id': 'M21155', 'name': 'Hydroxymethylglutaryl-CoA Reductase Inhibitors', 'relevance': 'LOW'}, {'id': 'M7951', 'name': 'Enzyme Inhibitors', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'Lipd', 'name': 'Lipid Regulating Agents'}, {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}, {'abbrev': 'BDCA', 'name': 'Bone Density Conservation Agents'}, {'abbrev': 'Infl', 'name': 'Anti-Inflammatory Agents'}, {'abbrev': 'ARhu', 'name': 'Antirheumatic Agents'}, {'abbrev': 'Analg', 'name': 'Analgesics'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT00328965', 'orgStudyIdInfo': {'id': 'LAC103842'}, 'secondaryIdInfos': [{'id': 'VAXAR FEV'}], 'organization': {'fullName': 'GlaxoSmithKline', 'class': 'INDUSTRY'}, 'briefTitle': 'Lacidipine In Mild To Moderate Essential Hypertension Patients With Type 2 Diabetes In Korea', 'officialTitle': 'An Open Label, Multi-centre, Single Arm Phase IV Study to Evaluate the Antihypertensive Effect of Lacidipine in Mild to Moderate Essential Hypertension Patients With Type 2 Diabetes in Korea'}, 'statusModule': {'statusVerifiedDate': '2010-08', 'overallStatus': 'COMPLETED', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2004-11'}, 'primaryCompletionDateStruct': {'date': '2006-05', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2006-05', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2006-05-22', 'studyFirstSubmitQcDate': '2006-05-22', 'studyFirstPostDateStruct': {'date': '2006-05-24', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2010-08-12', 'lastUpdatePostDateStruct': {'date': '2010-08-16', 'type': 'ESTIMATED'}}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'GlaxoSmithKline', 'class': 'INDUSTRY'}}, 'oversightModule': {'oversightHasDmc': False}, 'descriptionModule': {'briefSummary': 'This study was designed to evaluate the anti-hypertensive efficacy of lacidipine in hypertensives with Type 2 diabetes and effectiveness on endothelial cell function in Korean population.'}, 'conditionsModule': {'conditions': ['Diabetes Mellitus, Type 2', 'Essential Hypertension'], 'keywords': ['Korean patients', 'Type 2 diabetes', 'Endothelial function', 'lacidipine', 'Essential hypertension']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE4'], 'designInfo': {'allocation': 'NON_RANDOMIZED', 'interventionModel': 'SINGLE_GROUP', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Lacidipine', 'type': 'OTHER', 'description': 'All subjects who meet eligiblity criteria receive 2mg for the first 4 weeks in an open manner. If target systolic blood pressure is not ahcieved, subject can increase the dose to 4mg and then 6mg consequently.', 'interventionNames': ['Drug: Lacidipine']}], 'interventions': [{'type': 'DRUG', 'name': 'Lacidipine', 'description': 'Lacidipine 2, 4, 6mg', 'armGroupLabels': ['Lacidipine']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'To investigate the clinical effectiveness of lacidipine on elevated systolic blood pressure (SBP) in Korean patients aged 35 to 75 years.', 'timeFrame': '12 weeks from baseline'}], 'secondaryOutcomes': [{'measure': 'To investigate the clinical effectiveness of lacidipine on elevated diastolic blood pressure and endothelial function by flow-medicated vasodilation and measurement of markers of inflammation in Korean patients aged 35 to 75 years with type 2 diabetes.', 'timeFrame': '12 weeks from baseline'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion criteria:\\n\\n* Newly diagnosed as essential hypertension or not treated in the past 2 weeks(If the subject took medication in the past 2 weeks, a wash-out period of at least 2 weeks will be completed prior to performing screening (week -2) assessments)\\n* Mean seated SBP at screen visit = 130mmHg (as measured by a mercury sphygmomanometer)\\n* Type 2 diabetes (American Diabetes Association criteria 2004) and HbA1C \\\\<11%\\n* Agree to practice acceptable contraceptive measures during the study, and for 30 days after the last dose of study medication is taken if the subject a female of child-bearing potential\\n* Provide written informed consent\\n\\nExclusion criteria:\\n\\n* Mean seated SBP of \\\\> 180 mmHg\\n* Known or suspected secondary hypertension\\n* Anemia defined by haemoglobin concentration \\\\< 10.0 g/dL\\n* Hemoglobinopathy or peripheral vascular disease\\n* Clinically significant renal or hepatic disease (i.e., subjects with serum creatinine = 2.0 mg/dL; Alanine aminotransferase, Aspartate aminotransferase, total bilirubin, or alkaline phosphatase \\\\> 2.5 times the upper limit of the normal reference range)\\n* Unstable or severe angina, coronary insufficiency, or any congestive heart failure requiring pharmacologic treatment\\n* Chronic disease requiring intermittent or chronic treatment with oral, intravenous, or intra-articular corticosteroids (i.e. only use of topical, inhaled or nasal corticosteroids is permissible)\\n* Female who is lactating, pregnant, or planning to become pregnant\\n* clinically significant abnormality identified at screening which in the judgement of the investigator makes the subject unsuitable for inclusion in the study (e.g. physical examination, laboratory tests, or electrocardiogram etc.)\\n* Acute or chronic metabolic acidosis or a history of diabetic ketoacidosis', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '35 Years', 'maximumAge': '75 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'GSK Clinical Trials, M.D., PH.D.', 'affiliation': 'GlaxoSmithKline', 'role': 'STUDY_DIRECTOR'}]}}, 'annotationSection': {'annotationModule': {'unpostedAnnotation': {'unpostedResponsibleParty': 'GlaxoSmithKline', 'unpostedEvents': [{'type': 'RELEASE', 'date': '2017-11-01'}, {'type': 'UNRELEASE', 'date': '2018-08-15'}]}}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2024-11-22', 'removedCountries': ['Korea, Republic of'], 'submissionTracking': {'estimatedResultsFirstSubmitDate': '2017-11-01', 'submissionInfos': [{'releaseDate': '2017-11-01', 'unreleaseDate': '2018-08-15'}]}}, 'conditionBrowseModule': {'meshes': [{'id': 'D006973', 'term': 'Hypertension'}, {'id': 'D000075222', 'term': 'Essential Hypertension'}, {'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D003924', 'term': 'Diabetes Mellitus, Type 2'}], 'ancestors': [{'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}, {'id': 'D014652', 'term': 'Vascular Diseases'}, {'id': 'D002318', 'term': 'Cardiovascular Diseases'}], 'browseLeaves': [{'id': 'M7119', 'name': 'Diabetes Mellitus, Type 2', 'asFound': 'Diabetes Mellitus, Type 2', 'relevance': 'HIGH'}, {'id': 'M7115', 'name': 'Diabetes Mellitus', 'asFound': 'Diabetes', 'relevance': 'HIGH'}, {'id': 'M10024', 'name': 'Hypertension', 'asFound': 'Hypertension', 'relevance': 'HIGH'}, {'id': 'M1470', 'name': 'Essential Hypertension', 'asFound': 'Essential Hypertension', 'relevance': 'HIGH'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}, {'id': 'M17400', 'name': 'Vascular Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC14', 'name': 'Heart and Blood Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C060285', 'term': 'Lacidipine'}], 'ancestors': [{'id': 'D000959', 'term': 'Antihypertensive Agents'}, {'id': 'D002121', 'term': 'Calcium Channel Blockers'}, {'id': 'D049990', 'term': 'Membrane Transport Modulators'}, {'id': 'D045504', 'term': 'Molecular Mechanisms of Pharmacological Action'}, {'id': 'D000077264', 'term': 'Calcium-Regulating Hormones and Agents'}, {'id': 'D045505', 'term': 'Physiological Effects of Drugs'}], 'browseLeaves': [{'id': 'M4277', 'name': 'Antihypertensive Agents', 'relevance': 'LOW'}, {'id': 'M252101', 'name': 'Lacidipine', 'asFound': 'Vigilance', 'relevance': 'HIGH'}, {'id': 'M5398', 'name': 'Calcium, Dietary', 'relevance': 'LOW'}, {'id': 'M5381', 'name': 'Calcium', 'relevance': 'LOW'}, {'id': 'M5384', 'name': 'Calcium Channel Blockers', 'relevance': 'LOW'}, {'id': 'M9789', 'name': 'Hormones', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'AnAg', 'name': 'Antihypertensive Agents'}, {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}, {'abbrev': 'ChanBlk', 'name': 'Channel Blockers'}, {'abbrev': 'BDCA', 'name': 'Bone Density Conservation Agents'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT00004266', 'orgStudyIdInfo': {'id': '199/11643'}, 'secondaryIdInfos': [{'id': 'UMN-1967', 'type': 'OTHER', 'domain': 'Hennepin County Medical Center, Minneapolis'}, {'id': 'R01DK047112', 'type': 'NIH', 'link': 'https://reporter.nih.gov/quickSearch/R01DK047112'}], 'organization': {'fullName': 'National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)', 'class': 'NIH'}, 'briefTitle': 'Drugs for High Blood Pressure and High Cholesterol in American Indians With Type 2 Diabetes', 'officialTitle': 'Randomized Study of Antihypertensives and Antilipemics in American Indians With Non-Insulin-Dependent Diabetes Mellitus at High Risk of Developing Nephropathy and Cardiovascular Disease'}, 'statusModule': {'statusVerifiedDate': '2018-03', 'overallStatus': 'COMPLETED', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '1993-08', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '1999-07', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '1999-07', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '1999-10-18', 'studyFirstSubmitQcDate': '1999-10-18', 'studyFirstPostDateStruct': {'date': '1999-10-19', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2018-03-05', 'lastUpdatePostDateStruct': {'date': '2018-03-07', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)', 'class': 'NIH'}, 'collaborators': [{'name': 'Hennepin County Medical Center, Minneapolis', 'class': 'OTHER'}]}, 'oversightModule': {'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'OBJECTIVES:\\n\\nI. Establish a long-term working relationship between clinical investigators and the Minnesota American Indian community.\\n\\nII. Compare the effectiveness of lisinopril (an angiotensin-converting enzyme inhibitor) and nifedipine (a calcium channel blocker) in preventing nephropathy and vascular disease in Minnesota American Indians with non-insulin-dependent diabetes mellitus and microalbuminuria.\\n\\nIII. Compare the effectiveness of simvastatin (a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor) with lipid-lowering strategies recommended by the National Cholesterol Education Program in preventing nephropathy and vascular diseases in these patients.', 'detailedDescription': 'PROTOCOL OUTLINE:\\n\\nPatients are randomly assigned to 1 of 4 treatment groups; therapy continues for 3 years. All patients receive instruction on diet, exercise, and smoking cessation.\\n\\nThe first group receives daily nifedipine at a dose adjusted for high blood pressure. Cholestyramine or gemfibrozil is administered per National Cholesterol Education Program guidelines. Diuretics and doxazosin may be given concurrently.\\n\\nThe second group receives daily lisinopril at a dose adjusted for high blood pressure. Cholestyramine or gemfibrozil is administered per National Cholesterol Education Program guidelines. Diuretics and doxazosin may be given concurrently.\\n\\nThe third group receives daily nifedipine at a dose adjusted for high blood pressure, and simvastatin at a dose adjusted for high low-density lipoproteins. Supplemental cholestyramine may be given as needed. If cholestyramine is not tolerated or if triglycerides are high, gemfibrozil is substituted for cholestyramine.\\n\\nThe fourth group receives lisinopril at a dose adjusted for high blood pressure and simvastatin at a dose adjusted for high low-density lipoproteins.'}, 'conditionsModule': {'conditions': ['Diabetic Nephropathy'], 'keywords': ['diabetic nephropathy', 'rare disease', 'renal and genitourinary disorders']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE3'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'PREVENTION', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 160, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Nifedipine', 'type': 'EXPERIMENTAL', 'description': 'Daily nifedipine at a dose adjusted for high blood pressure. Cholestyramine or gemfibrozil is administered per National Cholesterol Education Program guidelines. Diuretics and doxazosin may be given concurrently.', 'interventionNames': ['Drug: Nifedipine']}, {'label': 'Lisinopril', 'type': 'EXPERIMENTAL', 'description': 'Daily lisinopril at a dose adjusted for high blood pressure. Cholestyramine or gemfibrozil is administered per National Cholesterol Education Program guidelines. Diuretics and doxazosin may be given concurrently.', 'interventionNames': ['Drug: Lisinopril']}, {'label': 'Nifedipine and simvastatin', 'type': 'EXPERIMENTAL', 'description': 'Daily nifedipine at a dose adjusted for high blood pressure, and simvastatin at a dose adjusted for high low-density lipoproteins. Supplemental cholestyramine may be given as needed. If cholestyramine is not tolerated or if triglycerides are high, gemfibrozil is substituted for cholestyramine.', 'interventionNames': ['Drug: Nifedipine', 'Drug: Simvastatin']}, {'label': 'Lisinopril and simvastatin', 'type': 'EXPERIMENTAL', 'description': 'Lisinopril at a dose adjusted for high blood pressure and simvastatin at a dose adjusted for high low-density lipoproteins.', 'interventionNames': ['Drug: Lisinopril', 'Drug: Simvastatin']}], 'interventions': [{'type': 'DRUG', 'name': 'Lisinopril', 'armGroupLabels': ['Lisinopril', 'Lisinopril and simvastatin']}, {'type': 'DRUG', 'name': 'Nifedipine', 'armGroupLabels': ['Nifedipine', 'Nifedipine and simvastatin']}, {'type': 'DRUG', 'name': 'Simvastatin', 'armGroupLabels': ['Lisinopril and simvastatin', 'Nifedipine and simvastatin']}]}, 'eligibilityModule': {'eligibilityCriteria': 'PROTOCOL ENTRY CRITERIA:\\n\\n--Disease Characteristics-- Non-insulin-dependent diabetes mellitus with documented fasting hyperglycemia Microalbuminuria OR clinically detectable albuminuria; Urine albumin excretion rate at least 30 mg/24 hours Low-density lipoproteins (fasting) at least 80 mg/dL Recruitment from American Indian population at Red Lake and Leech Lake reservations\\n\\n--Prior/Concurrent Therapy-- At least 5 days since antihypertensives or antilipemics\\n\\n--Patient Characteristics-- Renal: Urine albumin-to-creatinine ratio at least 30 mg/g; Creatinine clearance or estimated creatinine clearance at least 30 mL/min; No active urine sediment suggestive of glomerulonephritis, i.e.: No RBCs greater than 10/high-power field; No WBCs greater than 15/high-power field; No RBC casts\\n\\nCardiovascular: No symptomatic orthostatic hypotension; No poorly-compensated congestive heart failure; No requirement for angiotensin-converting enzyme inhibitors; No angina pectoris requiring nifedipine; No unstable angina; No episodes of angina occurring more than once a month; No chest pain of undetermined cause within 1 month; No severe hypertension requiring multiple antihypertensives; No myocardial infarction within 1 year; No stroke or transient ischemic attack within 1 year\\n\\nOther: No known allergy to nifedipine, lisinopril, or simvastatin; No untreated proliferative retinopathy; Documented retinal exam within 1 year prior to entry; No alcohol or drug abuse affecting compliance; No other debilitating or acute illness; No pregnant or nursing women; Effective contraception required of fertile women', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Bertram L. Kasiske', 'affiliation': 'Hennepin County Medical Center, Minneapolis', 'role': 'STUDY_CHAIR'}], 'locations': [{'facility': 'Hennepin County Medical Center', 'city': 'Minneapolis', 'state': 'Minnesota', 'zip': '55415', 'country': 'United States', 'geoPoint': {'lat': 44.97997, 'lon': -93.26384}}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2024-11-22'}, 'conditionBrowseModule': {'meshes': [{'id': 'D007674', 'term': 'Kidney Diseases'}, {'id': 'D003928', 'term': 'Diabetic Nephropathies'}], 'ancestors': [{'id': 'D014570', 'term': 'Urologic Diseases'}, {'id': 'D052776', 'term': 'Female Urogenital Diseases'}, {'id': 'D005261', 'term': 'Female Urogenital Diseases and Pregnancy Complications'}, {'id': 'D000091642', 'term': 'Urogenital Diseases'}, {'id': 'D052801', 'term': 'Male Urogenital Diseases'}, {'id': 'D048909', 'term': 'Diabetes Complications'}, {'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}], 'browseLeaves': [{'id': 'M7119', 'name': 'Diabetes Mellitus, Type 2', 'relevance': 'LOW'}, {'id': 'M10698', 'name': 'Kidney Diseases', 'asFound': 'Nephropathy', 'relevance': 'HIGH'}, {'id': 'M7115', 'name': 'Diabetes Mellitus', 'relevance': 'LOW'}, {'id': 'M9988', 'name': 'Hypercholesterolemia', 'relevance': 'LOW'}, {'id': 'M10024', 'name': 'Hypertension', 'relevance': 'LOW'}, {'id': 'M7123', 'name': 'Diabetic Nephropathies', 'asFound': 'Diabetic Nephropathy', 'relevance': 'HIGH'}, {'id': 'M2875', 'name': 'Urogenital Diseases', 'relevance': 'LOW'}, {'id': 'M24518', 'name': 'Rare Diseases', 'relevance': 'LOW'}, {'id': 'M17319', 'name': 'Urologic Diseases', 'relevance': 'LOW'}, {'id': 'M27093', 'name': 'Female Urogenital Diseases', 'relevance': 'LOW'}, {'id': 'M14127', 'name': 'Pregnancy Complications', 'relevance': 'LOW'}, {'id': 'M8399', 'name': 'Female Urogenital Diseases and Pregnancy Complications', 'relevance': 'LOW'}, {'id': 'M27095', 'name': 'Male Urogenital Diseases', 'relevance': 'LOW'}, {'id': 'M26004', 'name': 'Diabetes Complications', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BXS', 'name': 'Urinary Tract, Sexual Organs, and Pregnancy Conditions'}, {'abbrev': 'BC14', 'name': 'Heart and Blood Diseases'}, {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D017706', 'term': 'Lisinopril'}, {'id': 'D009543', 'term': 'Nifedipine'}, {'id': 'D019821', 'term': 'Simvastatin'}], 'ancestors': [{'id': 'D000924', 'term': 'Anticholesteremic Agents'}, {'id': 'D000960', 'term': 'Hypolipidemic Agents'}, {'id': 'D000963', 'term': 'Antimetabolites'}, {'id': 'D045504', 'term': 'Molecular Mechanisms of Pharmacological Action'}, {'id': 'D057847', 'term': 'Lipid Regulating Agents'}, {'id': 'D019161', 'term': 'Hydroxymethylglutaryl-CoA Reductase Inhibitors'}, {'id': 'D004791', 'term': 'Enzyme Inhibitors'}, {'id': 'D002121', 'term': 'Calcium Channel Blockers'}, {'id': 'D049990', 'term': 'Membrane Transport Modulators'}, {'id': 'D000077264', 'term': 'Calcium-Regulating Hormones and Agents'}, {'id': 'D045505', 'term': 'Physiological Effects of Drugs'}, {'id': 'D014665', 'term': 'Vasodilator Agents'}, {'id': 'D015149', 'term': 'Tocolytic Agents'}, {'id': 'D012102', 'term': 'Reproductive Control Agents'}, {'id': 'D000806', 'term': 'Angiotensin-Converting Enzyme Inhibitors'}, {'id': 'D011480', 'term': 'Protease Inhibitors'}, {'id': 'D000959', 'term': 'Antihypertensive Agents'}, {'id': 'D002316', 'term': 'Cardiotonic Agents'}, {'id': 'D020011', 'term': 'Protective Agents'}], 'browseLeaves': [{'id': 'M21713', 'name': 'Simvastatin', 'asFound': 'Gene', 'relevance': 'HIGH'}, {'id': 'M4277', 'name': 'Antihypertensive Agents', 'relevance': 'LOW'}, {'id': 'M7411', 'name': 'Diuretics', 'relevance': 'LOW'}, {'id': 'M6032', 'name': 'Cholestyramine Resin', 'relevance': 'LOW'}, {'id': 'M17952', 'name': 'Gemfibrozil', 'relevance': 'LOW'}, {'id': 'M12483', 'name': 'Nifedipine', 'asFound': 'Conjugate Vaccine', 'relevance': 'HIGH'}, {'id': 'M19924', 'name': 'Lisinopril', 'asFound': 'Heel', 'relevance': 'HIGH'}, {'id': 'M19586', 'name': 'Doxazosin', 'relevance': 'LOW'}, {'id': 'M4278', 'name': 'Hypolipidemic Agents', 'relevance': 'LOW'}, {'id': 'M4243', 'name': 'Anticholesteremic Agents', 'relevance': 'LOW'}, {'id': 'M4281', 'name': 'Antimetabolites', 'relevance': 'LOW'}, {'id': 'M28883', 'name': 'Lipid Regulating Agents', 'relevance': 'LOW'}, {'id': 'M21155', 'name': 'Hydroxymethylglutaryl-CoA Reductase Inhibitors', 'relevance': 'LOW'}, {'id': 'M7951', 'name': 'Enzyme Inhibitors', 'relevance': 'LOW'}, {'id': 'M5398', 'name': 'Calcium, Dietary', 'relevance': 'LOW'}, {'id': 'M5381', 'name': 'Calcium', 'relevance': 'LOW'}, {'id': 'M5384', 'name': 'Calcium Channel Blockers', 'relevance': 'LOW'}, {'id': 'M9789', 'name': 'Hormones', 'relevance': 'LOW'}, {'id': 'M17412', 'name': 'Vasodilator Agents', 'relevance': 'LOW'}, {'id': 'M17869', 'name': 'Tocolytic Agents', 'relevance': 'LOW'}, {'id': 'M4134', 'name': 'Angiotensin-Converting Enzyme Inhibitors', 'relevance': 'LOW'}, {'id': 'M19609', 'name': 'HIV Protease Inhibitors', 'relevance': 'LOW'}, {'id': 'M14343', 'name': 'Protease Inhibitors', 'relevance': 'LOW'}, {'id': 'M5572', 'name': 'Cardiotonic Agents', 'relevance': 'LOW'}, {'id': 'M21869', 'name': 'Protective Agents', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'Lipd', 'name': 'Lipid Regulating Agents'}, {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}, {'abbrev': 'AnAg', 'name': 'Antihypertensive Agents'}, {'abbrev': 'ChanBlk', 'name': 'Channel Blockers'}, {'abbrev': 'VaDiAg', 'name': 'Vasodilator Agents'}, {'abbrev': 'Repr', 'name': 'Reproductive Control Agents'}, {'abbrev': 'CaAg', 'name': 'Cardiotonic Agents'}, {'abbrev': 'BDCA', 'name': 'Bone Density Conservation Agents'}, {'abbrev': 'Infe', 'name': 'Anti-Infective Agents'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT02517866', 'orgStudyIdInfo': {'id': 'AZI-P4-002'}, 'secondaryIdInfos': [{'id': 'U1111-1156-8501', 'type': 'REGISTRY', 'domain': 'WHO'}], 'organization': {'fullName': 'Takeda', 'class': 'INDUSTRY'}, 'briefTitle': 'Azilsartan Medoxomil in the Treatment of Essential Hypertension and Type 2 Diabetes in Asia', 'officialTitle': 'A Prospective Study of Azilsartan Medoxomil in the Treatment of Patients With Essential Hypertension and Type 2 Diabetes in Asia'}, 'statusModule': {'statusVerifiedDate': '2018-10', 'overallStatus': 'COMPLETED', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2015-07-13', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2016-11-15', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2016-11-25', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2015-06-24', 'studyFirstSubmitQcDate': '2015-08-06', 'studyFirstPostDateStruct': {'date': '2015-08-07', 'type': 'ESTIMATED'}, 'resultsFirstSubmitDate': '2017-10-04', 'resultsFirstSubmitQcDate': '2018-10-29', 'resultsFirstPostDateStruct': {'date': '2019-03-01', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2018-10-29', 'lastUpdatePostDateStruct': {'date': '2019-03-01', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Takeda', 'class': 'INDUSTRY'}}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'The purpose of this study is to evaluate the efficacy and safety of azilsartan medoxomil (AZM) in Asian adult participants with both essential hypertension and type 2 diabetes.', 'detailedDescription': \"The drug being tested in this study is called azilsartan medoxomil. Azilsartan medoxomil is being tested to treat people who have essential hypertension and type 2 diabetes mellitus (T2DM). This study will look at the blood pressure of people who take azilsartan medoxomil in addition to standard care for T2DM.\\n\\nThe study will enroll approximately 380 patients. All participants will receive azilsartan medoxomil 40 mg tablets to be administered orally, once a day, for 12 weeks. If a participant's blood pressure (BP) has not reached BP goal of \\\\<140/85 mmHg at week 6, azilsartan medoxomil dose will be up-titrated to 80 mg daily.\\n\\nAll participants will be asked to take one tablet at the same time each day throughout the study.\\n\\nThis multi-center trial will be conducted in Asia. The overall time to participate in this study is 14 weeks. Participants will make multiple visits to the clinic, and will be contacted by 14 days after last dose of study drug for a follow-up assessment.\"}, 'conditionsModule': {'conditions': ['Essential Hypertension', 'Type 2 Diabetes Mellitus'], 'keywords': ['Drug therapy']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE4'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 380, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Azilsartan medoxomil', 'type': 'EXPERIMENTAL', 'description': 'Azilsartan medoxomil 40 mg, tablets, orally, once, daily, for 12 weeks. Azilsartan medoxomil dose may be increased to 80 mg once daily if blood pressure has not reach BP goal of \\\\<140/85 mmHg at Week 6.', 'interventionNames': ['Drug: Azilsartan Medoxomil']}], 'interventions': [{'type': 'DRUG', 'name': 'Azilsartan Medoxomil', 'description': 'Azilsartan medoxomil tablets', 'armGroupLabels': ['Azilsartan medoxomil'], 'otherNames': ['Edarbi®']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Percentage of Participants With Blood Pressure (BP) <140/85 mmHg (Systolic BP <140 mmHg and Diastolic BP <85 mmHg) by Clinic-Measured Sitting BP at Week 12', 'description': 'Three serial BP measurements were determined while the participant was seated, with a sphygmomanometer.', 'timeFrame': 'Week 12'}], 'secondaryOutcomes': [{'measure': 'Percentage of \"Treatment-Naïve\" Participants Reaching BP <140/85 mmHg', 'description': 'Treatment-naïve participants are defined as participants who have not received anti-hypertensive treatment for at least four weeks prior to screening. At each visit 3 serial BP measurements were determined while the participant was seated, with a sphygmomanometer.', 'timeFrame': 'Up to Week 12'}, {'measure': 'Percentage of Participants Treated With Calcium Channel Blocker (CCB) Before Baseline Reaching BP<140/85 mmHg', 'description': 'At each visit three serial BP measurements were determined while the participant was seated, with a sphygmomanometer.', 'timeFrame': 'Weeks 6 and 12'}, {'measure': 'Percentage of Participants Treated With Angiotensin Converting Enzyme (ACE) Inhibitors or Other Angiotensin Receptor Blockers (ARBs) Before Baseline Reaching BP <140/85 mmHg', 'description': 'At each visit 3 serial BP measurements were determined while the participant was seated, with a sphygmomanometer.', 'timeFrame': 'Weeks 6 and 12'}, {'measure': 'Percentage of Participants Treated With Thiazides Before Baseline Reaching BP <140/85 mmHg', 'description': 'At each visit three serial BP measurements were determined while the participant was seated, with a sphygmomanometer.', 'timeFrame': 'Weeks 6 and 12'}, {'measure': 'Percentage of \"Treatment-Naïve\" Participants Reaching BP <130/80 mmHg', 'description': 'Treatment-naïve participants are defined as participants who have not received anti-hypertensive treatment for at least four weeks prior to screening. At each visit 3 serial BP measurements were determined while the participant was seated, with a sphygmomanometer.', 'timeFrame': 'Up to Week 12'}, {'measure': 'Percentage of Participants Treated With CCB Before Baseline Reaching BP <130/80 mmHg', 'description': 'At each visit 3 serial BP measurements were determined while the participant was seated, with a sphygmomanometer.', 'timeFrame': 'Weeks 6 and 12'}, {'measure': 'Percentage of Participants Treated With ACE Inhibitors or Other ARBs Before Baseline Reaching BP <130/80 mmHg', 'description': 'At each visit 3 serial BP measurements were determined while the participant was seated, with a sphygmomanometer.', 'timeFrame': 'Weeks 6 and 12'}, {'measure': 'Percentage of Participants Treated With Thiazides Before Baseline Reaching BP <130/80 mmHg', 'description': 'At each visit 3 serial BP measurements were determined while the participant was seated, with a sphygmomanometer.', 'timeFrame': 'Weeks 6 and 12'}, {'measure': 'Percentage of Participants With Systolic Blood Pressure (SBP) <140 mmHg at Week 12', 'description': 'Three serial BP measurements were determined while the participant was seated, with a sphygmomanometer.', 'timeFrame': 'Week 12'}, {'measure': 'Percentage of Participants With Diastolic Blood Pressure (DBP) <85 mmHg at Week 12', 'description': 'Three serial BP measurements were determined while the participant was seated, with a sphygmomanometer.', 'timeFrame': 'Week 12'}, {'measure': 'Percentage of Participants With DBP <90 mmHg at Week 12', 'description': 'Three serial BP measurements were determined while the participant was seated, with a sphygmomanometer.', 'timeFrame': 'Week 12'}, {'measure': 'Percentage of Participants With BP <130/80 mmHg at Week 12', 'description': 'Three serial BP measurements were determined while the participant was seated, with a sphygmomanometer.', 'timeFrame': 'Week 12'}, {'measure': 'Percentage of Participants With SBP <130 mmHg at Week 12', 'description': 'Three serial BP measurements were determined while the participant was seated, with a sphygmomanometer.', 'timeFrame': 'Week 12'}, {'measure': 'Percentage of Participants With DBP <80 mmHg at Week 12', 'description': 'Three serial BP measurements were determined while the participant was seated, with a sphygmomanometer.', 'timeFrame': 'Week 12'}, {'measure': 'Percentage of Participants With BP <140/90 mmHg at Week 12', 'description': 'Three serial BP measurements were determined while the participant was seated, with a sphygmomanometer.', 'timeFrame': 'Week 12'}, {'measure': 'Change From Baseline in Trough Sitting SBP at Week 12', 'description': 'At each visit 3 serial BP measurements were determined while the participant was seated, with a sphygmomanometer. Change from Baseline was estimated using an ANCOVA model with fixed effects, country, baseline hypertension therapy (BHT) and baseline SBP (or DBP) included as a covariate. A negative change from baseline indicates improvement.', 'timeFrame': 'Baseline and Week 12'}, {'measure': 'Change From Baseline in Trough Sitting SBP at Week 12 in \"Treatment-Naïve\" Participants', 'description': 'At each visit 3 serial BP measurements were determined while the participant was seated, with a sphygmomanometer. Change from Baseline was estimated using an ANCOVA model with fixed effects, country, baseline hypertension therapy (BHT) and baseline SBP (or DBP) included as a covariate. A negative change from baseline indicates improvement.', 'timeFrame': 'Baseline and Week 12'}, {'measure': 'Change From Baseline in DBP at Week 12', 'description': 'At each visit 3 serial BP measurements were determined while the participant was seated, with a sphygmomanometer. Change from Baseline was estimated using an ANCOVA model with fixed effects, country, BHT and baseline SBP (or DBP) included as a covariate. A negative change from baseline indicates improvement.', 'timeFrame': 'Baseline and Week 12'}, {'measure': 'Change From Baseline in DBP at Week 12 in \"Treatment-Naïve\" Participants', 'description': 'At each visit 3 serial BP measurements were determined while the participant was seated, with a sphygmomanometer. Change from Baseline was estimated using an ANCOVA model with fixed effects, country, BHT and baseline SBP (or DBP) included as a covariate. A negative change from baseline indicates improvement.', 'timeFrame': 'Baseline and Week 12'}]}, 'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\n\\n1. In the opinion of the investigator, the participant is capable of understanding and complying with protocol requirements.\\n2. The participant or, when applicable, the participant's legally acceptable representative signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures.\\n3. Has type 2 diabetes mellitus (T2DM) with essential hypertension.\\n4. T2DM participants are either treated by stable life style intervention or by oral antidiabetic drugs (OADs) that are stable, including no dose adjustment within 12 weeks before baseline.\\n5. Is male or female and aged 18 to 75 years, inclusive.\\n6. Uncontrolled hypertension (systolic blood pressure ≥140 mmHg to \\\\<180 mmHg, or diastolic blood pressure ≥85 mmHg and \\\\<110 mmHg at screening and baseline.\\n7. Has screening glycosylated hemoglobin (HbA1C) \\\\<9.5%.\\n8. Female participants must be either of non-childbearing potential, ie, surgically sterilized (defined as having undergone hysterectomy and/or bilateral oophorectomy and/or bilateral salpingectomy; tubal ligation alone is not considered sufficient) or one year after the last menstrual period; or, if of childbearing potential and participant is sexually active with a nonsterilized male partner, must agree to use routinely adequate contraception from signing of informed consent throughout the duration of study.\\n\\nExclusion Criteria:\\n\\n1. Has systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg despite concurrent treatment with three antihypertensive medications from different classes at adequate doses including a diuretic.\\n2. Has type 1 or poorly controlled type 2 diabetes mellitus, defined as HbA1c ≥9.5% at screening.\\n3. Is treated with OADs has not been on stable treatment including no dose change of their OADs for at least 12 weeks prior to baseline.\\n4. Has been previously treated with azilsartan medoxomil (AZM) or azilsartan.\\n5. Has secondary hypertension of any etiology (eg, renovascular disease, pheochromocytoma, Cushing's syndrome).\\n6. Has congestive heart failure (New York Heart Association class III or IV), clinically relevant cardiac arrhythmias (as determined by the investigator's clinical judgment on a participant-by-participant basis), severe obstructive coronary artery disease.\\n7. Has participated in a clinical trial including interventional and observational studies, or received any investigational compound currently or 30 days prior to screening.\\n8. Has severe renal impairment (based on estimated glomerular filtration rate \\\\[GFR\\\\] \\\\<30 mL/min/1.73m\\\\^2) at Screening.\\n9. Has hyperkalemia defined as serum potassium \\\\>5.0 mEq/L.\\n10. Has an alanine aminotransferase (ALT) level of greater than 2.5 times the upper limit of normal, active liver disease, or jaundice at screening.\\n11. Has any clinically relevant disease (eg malignancy, neurological, hepatic abnormalities) and/or significant abnormal laboratory findings (past or present), which, in the opinion of the investigator, may put the participant at risk because of participation in the study.\\n12. Is taking prohibited medications including lithium and aliskiren (refer to Edarbi® product insert).\\n13. Has known hypersensitivity to any excipients or angiotensin converting enzyme inhibitor (ACEIs)/ angiotensin receptor blockers (ARBs).\\n14. Has prior angioedema due to an ACE inhibitor or ARB.\\n15. Breast feeding or pregnant women or women who are intending to become pregnant before, during or within 1 month after participating in the study; or intending to donate ova during such time period, or refusal to submit to a urine test to rule out pregnancy prior to enrolment and at end of study.\\n16. Have a history of alcohol abuse, drug abuse or illegal drug addiction within the 6 months prior to signing the informed consent.\\n17. Is an immediate family member, study site employee, or is in a dependent relationship with a study site employee who is involved in conduct of this study (eg, spouse, parent, child, sibling) or may consent under duress.\", 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'maximumAge': '75 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Medical Director Clinical Science', 'affiliation': 'Takeda', 'role': 'STUDY_DIRECTOR'}], 'locations': [{'city': 'Hong Kong', 'state': 'Hong Kong', 'country': 'China', 'geoPoint': {'lat': 22.39407, 'lon': 114.13737}}, {'city': 'Changhua County', 'country': 'Taiwan'}, {'city': 'Kaohsiung City', 'country': 'Taiwan', 'geoPoint': {'lat': 22.61626, 'lon': 120.31333}}, {'city': 'Kaohsiung', 'country': 'Taiwan', 'geoPoint': {'lat': 22.61626, 'lon': 120.31333}}, {'city': 'Taichung', 'country': 'Taiwan', 'geoPoint': {'lat': 24.1469, 'lon': 120.6839}}, {'city': 'Tainan City', 'country': 'Taiwan', 'geoPoint': {'lat': 22.99083, 'lon': 120.21333}}, {'city': 'Taipei', 'country': 'Taiwan', 'geoPoint': {'lat': 25.04776, 'lon': 121.53185}}, {'city': 'Taoyuan County', 'country': 'Taiwan'}, {'city': 'Bangkok', 'country': 'Thailand', 'geoPoint': {'lat': 13.75398, 'lon': 100.50144}}, {'city': 'Chiang Mai', 'country': 'Thailand', 'geoPoint': {'lat': 18.79038, 'lon': 98.98468}}, {'city': 'Khon Kaen', 'country': 'Thailand', 'geoPoint': {'lat': 16.44671, 'lon': 102.833}}, {'city': 'Pathumthani', 'country': 'Thailand', 'geoPoint': {'lat': 14.01346, 'lon': 100.53049}}]}}, 'resultsSection': {'participantFlowModule': {'preAssignmentDetails': 'Participants with a diagnosis of essential hypertension and type 2 diabetes mellitus (T2DM) were enrolled to receive azilsartan medoxomil at a starting dose of 40 mg increased to 80 mg if blood pressure of \\\\<140/85 mmHg was not achieved at Week 6.', 'recruitmentDetails': 'Participants took part in the study at 34 investigative sites in Hong Kong, Taiwan and Thailand from 13 July 2015 to 25 November 2016.', 'groups': [{'id': 'FG000', 'title': 'Azilsartan Medoxomil (Switched)', 'description': 'Azilsartan medoxomil 40 mg, tablets, orally, once, daily, for 12 weeks. Azilsartan medoxomil dose may be increased to 80 mg once daily if blood pressure has not reach BP goal of \\\\<140/85 mmHg at Week 6. Switched includes participants who switched from their baseline hypertension therapy to azilsartan medoxomil.'}, {'id': 'FG001', 'title': 'Azilsartan Medoxomil (Add-On)', 'description': 'Azilsartan medoxomil 40 mg, tablets, orally, once, daily, for 12 weeks. Azilsartan medoxomil dose may be increased to 80 mg once daily if blood pressure has not reach BP goal of \\\\<140/85 mmHg at Week 6. Add-On includes participants who added azilsartan medoxomil to their baseline hypertension therapy.'}, {'id': 'FG002', 'title': 'Azilsartan Medoxomil (Treatment-Naïve)', 'description': 'Azilsartan medoxomil 40 mg, tablets, orally, once, daily, for 12 weeks. Azilsartan medoxomil dose may be increased to 80 mg once daily if blood pressure has not reach BP goal of \\\\<140/85 mmHg at Week 6. Treatment-naïve includes participants never treated with antihypertensive therapy or participants who did not receive hypertension therapy for at least 4 weeks prior to screening.'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '289'}, {'groupId': 'FG001', 'numSubjects': '90'}, {'groupId': 'FG002', 'numSubjects': '1'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '269'}, {'groupId': 'FG001', 'numSubjects': '84'}, {'groupId': 'FG002', 'numSubjects': '1'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '20'}, {'groupId': 'FG001', 'numSubjects': '6'}, {'groupId': 'FG002', 'numSubjects': '0'}]}], 'dropWithdraws': [{'type': 'Pretreatment Event/Adverse Event', 'reasons': [{'groupId': 'FG000', 'numSubjects': '9'}, {'groupId': 'FG001', 'numSubjects': '2'}, {'groupId': 'FG002', 'numSubjects': '0'}]}, {'type': 'Significant Protocol Deviation', 'reasons': [{'groupId': 'FG000', 'numSubjects': '4'}, {'groupId': 'FG001', 'numSubjects': '1'}, {'groupId': 'FG002', 'numSubjects': '0'}]}, {'type': 'Lost to Follow-up', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}]}, {'type': 'Voluntary Withdrawal', 'reasons': [{'groupId': 'FG000', 'numSubjects': '2'}, {'groupId': 'FG001', 'numSubjects': '2'}, {'groupId': 'FG002', 'numSubjects': '0'}]}, {'type': 'Investigator Decision', 'reasons': [{'groupId': 'FG000', 'numSubjects': '2'}, {'groupId': 'FG001', 'numSubjects': '1'}, {'groupId': 'FG002', 'numSubjects': '0'}]}, {'type': 'Reason not specified', 'reasons': [{'groupId': 'FG000', 'numSubjects': '2'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}]}]}]}, 'baselineCharacteristicsModule': {'populationDescription': 'Safety analysis set included all participants who took at least 1 dose of azilsartan medoxomil.', 'groups': [{'id': 'BG000', 'title': 'Azilsartan Medoxomil', 'description': 'Azilsartan medoxomil 40 mg, tablets, orally, once, daily, for 12 weeks. Azilsartan medoxomil dose may be increased to 80 mg once daily if blood pressure has not reach BP goal of \\\\<140/85 mmHg at Week 6.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'BG000', 'value': '380'}]}], 'measures': [{'title': 'Age, Continuous', 'paramType': 'MEAN', 'dispersionType': 'STANDARD_DEVIATION', 'unitOfMeasure': 'years', 'classes': [{'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'BG000', 'value': '380'}]}], 'categories': [{'measurements': [{'groupId': 'BG000', 'value': '61.6', 'spread': '9.77'}]}]}]}, {'title': 'Age, Customized', 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'classes': [{'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'BG000', 'value': '380'}]}], 'categories': [{'title': '< 65 years old', 'measurements': [{'groupId': 'BG000', 'value': '221'}]}, {'title': '>=65 to <75 years old', 'measurements': [{'groupId': 'BG000', 'value': '159'}]}]}]}, {'title': 'Sex: Female, Male', 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'classes': [{'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'BG000', 'value': '380'}]}], 'categories': [{'title': 'Female', 'measurements': [{'groupId': 'BG000', 'value': '197'}]}, {'title': 'Male', 'measurements': [{'groupId': 'BG000', 'value': '183'}]}]}]}, {'title': 'Race/Ethnicity, Customized', 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'classes': [{'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'BG000', 'value': '380'}]}], 'categories': [{'title': 'Asian', 'measurements': [{'groupId': 'BG000', 'value': '380'}]}]}]}, {'title': 'Region of Enrollment', 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'classes': [{'title': 'Taiwan, Province Of China', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'BG000', 'value': '380'}]}], 'categories': [{'measurements': [{'groupId': 'BG000', 'value': '139'}]}]}, {'title': 'Thailand', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'BG000', 'value': '380'}]}], 'categories': [{'measurements': [{'groupId': 'BG000', 'value': '219'}]}]}, {'title': 'Hong Kong', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'BG000', 'value': '380'}]}], 'categories': [{'measurements': [{'groupId': 'BG000', 'value': '22'}]}]}]}, {'title': 'Height', 'paramType': 'MEAN', 'dispersionType': 'STANDARD_DEVIATION', 'unitOfMeasure': 'cm', 'classes': [{'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'BG000', 'value': '380'}]}], 'categories': [{'measurements': [{'groupId': 'BG000', 'value': '161.1', 'spread': '9.57'}]}]}]}, {'title': 'Weight', 'populationDescription': 'Here number analyzed is the number of participants who were evaluated for weight at baseline.', 'paramType': 'MEAN', 'dispersionType': 'STANDARD_DEVIATION', 'unitOfMeasure': 'kg', 'classes': [{'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'BG000', 'value': '374'}]}], 'categories': [{'measurements': [{'groupId': 'BG000', 'value': '72.04', 'spread': '15.072'}]}]}]}, {'title': 'Body Mass Index (BMI)', 'populationDescription': 'Here number analyzed is the number of participants who were evaluated for BMI at baseline.', 'paramType': 'MEAN', 'dispersionType': 'STANDARD_DEVIATION', 'unitOfMeasure': 'kg/m^2', 'classes': [{'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'BG000', 'value': '374'}]}], 'categories': [{'measurements': [{'groupId': 'BG000', 'value': '27.64', 'spread': '4.354'}]}]}]}, {'title': 'Smoking history', 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'classes': [{'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'BG000', 'value': '380'}]}], 'categories': [{'title': 'The participant has never smoked', 'measurements': [{'groupId': 'BG000', 'value': '279'}]}, {'title': 'The participant is an ex-smoker', 'measurements': [{'groupId': 'BG000', 'value': '75'}]}, {'title': 'The participant is a current smoker', 'measurements': [{'groupId': 'BG000', 'value': '26'}]}]}]}, {'title': 'Baseline Antihypertensive Treatment Status', 'description': 'Participants were counted more than once according to the antihypertensive treatment status. Antihypertensive treatment includes Angiotensin Converting Enzyme (ACE) inhibitor, Angiotensin Receptor Blocker (ARB), Calcium Channel Blocker (CCB), Thiazides and/or other treatments.', 'paramType': 'NUMBER', 'unitOfMeasure': 'participants', 'classes': [{'title': 'Treated with ACE inhibitor or ARB before Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'BG000', 'value': '380'}]}], 'categories': [{'measurements': [{'groupId': 'BG000', 'value': '202'}]}]}, {'title': 'Treated with CCB before Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'BG000', 'value': '380'}]}], 'categories': [{'measurements': [{'groupId': 'BG000', 'value': '112'}]}]}, {'title': 'Treated with Thiazide before Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'BG000', 'value': '380'}]}], 'categories': [{'measurements': [{'groupId': 'BG000', 'value': '30'}]}]}, {'title': 'Other', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'BG000', 'value': '380'}]}], 'categories': [{'measurements': [{'groupId': 'BG000', 'value': '121'}]}]}]}, {'title': 'Glycosylated Hemoglobin (HbA1c)', 'populationDescription': 'Only 374 participants were evaluated for this baseline characteristic.', 'paramType': 'MEAN', 'dispersionType': 'STANDARD_DEVIATION', 'unitOfMeasure': 'mmoL/moL', 'classes': [{'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'BG000', 'value': '374'}]}], 'categories': [{'measurements': [{'groupId': 'BG000', 'value': '7.00', 'spread': '0.875'}]}]}]}]}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Percentage of Participants With Blood Pressure (BP) <140/85 mmHg (Systolic BP <140 mmHg and Diastolic BP <85 mmHg) by Clinic-Measured Sitting BP at Week 12', 'description': 'Three serial BP measurements were determined while the participant was seated, with a sphygmomanometer.', 'populationDescription': 'Full analysis set (FAS) included all participants who took at least 1 dose of azilsartan medoxomil. Missing data was computed using last observation carried forward (LOCF) method. Here, number of participants analyzed is the total number of participants who were evaluable for this outcome measure.', 'reportingStatus': 'POSTED', 'paramType': 'NUMBER', 'dispersionType': '99% Confidence Interval', 'unitOfMeasure': 'percentage of participants', 'timeFrame': 'Week 12', 'groups': [{'id': 'OG000', 'title': 'Azilsartan Medoxomil (Switched)', 'description': 'Azilsartan medoxomil 40 mg, tablets, orally, once, daily, for 12 weeks. Azilsartan medoxomil dose may be increased to 80 mg once daily if blood pressure has not reach BP goal of \\\\<140/85 mmHg at Week 6. Switched includes participants who switched from their baseline hypertension therapy to azilsartan medoxomil.'}, {'id': 'OG001', 'title': 'Azilsartan Medoxomil (Add-On)', 'description': 'Azilsartan medoxomil 40 mg, tablets, orally, once, daily, for 12 weeks. Azilsartan medoxomil dose may be increased to 80 mg once daily if blood pressure has not reach BP goal of \\\\<140/85 mmHg at Week 6. Add-On includes participants who added azilsartan medoxomil to their baseline hypertension therapy.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '276'}, {'groupId': 'OG001', 'value': '85'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '59.8', 'lowerLimit': '43.40', 'upperLimit': '63.08'}, {'groupId': 'OG001', 'value': '65.9', 'lowerLimit': '44.07', 'upperLimit': '75.70'}]}]}]}, {'type': 'SECONDARY', 'title': 'Percentage of \"Treatment-Naïve\" Participants Reaching BP <140/85 mmHg', 'description': 'Treatment-naïve participants are defined as participants who have not received anti-hypertensive treatment for at least four weeks prior to screening. At each visit 3 serial BP measurements were determined while the participant was seated, with a sphygmomanometer.', 'populationDescription': 'FAS included all participants who took at least 1 dose of azilsartan medoxomil.', 'reportingStatus': 'POSTED', 'paramType': 'NUMBER', 'dispersionType': '99% Confidence Interval', 'unitOfMeasure': 'percentage of participants', 'timeFrame': 'Up to Week 12', 'groups': [{'id': 'OG000', 'title': 'Azilsartan Medoxomil (Treatment-Naïve)', 'description': 'Azilsartan medoxomil 40 mg, tablets, orally, once, daily, for 12 weeks. Azilsartan medoxomil dose may be increased to 80 mg once daily if blood pressure has not reach BP goal of \\\\<140/85 mmHg at Week 6. Treatment-naïve includes participants never treated with antihypertensive therapy or participants who did not receive hypertension therapy for at least 4 weeks prior to screening.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '1'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '0.0', 'lowerLimit': 'NA', 'upperLimit': 'NA', 'comment': 'CI was not calculated as there was only one participant in this group.'}]}]}]}, {'type': 'SECONDARY', 'title': 'Percentage of Participants Treated With Calcium Channel Blocker (CCB) Before Baseline Reaching BP<140/85 mmHg', 'description': 'At each visit three serial BP measurements were determined while the participant was seated, with a sphygmomanometer.', 'populationDescription': 'FAS included all participants who took at least 1 dose of azilsartan medoxomil. Missing data was computed using LOCF method. Here, number of participants analyzed is the participants who received CCB before baseline and are evaluable for this outcome measure.', 'reportingStatus': 'POSTED', 'paramType': 'NUMBER', 'dispersionType': '99% Confidence Interval', 'unitOfMeasure': 'percentage of participants', 'timeFrame': 'Weeks 6 and 12', 'groups': [{'id': 'OG000', 'title': 'Azilsartan Medoxomil', 'description': 'Azilsartan medoxomil 40 mg, tablets, orally, once, daily, for 12 weeks. Azilsartan medoxomil dose may be increased to 80 mg once daily if blood pressure has not reach BP goal of \\\\<140/85 mmHg at Week 6.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '109'}]}], 'classes': [{'title': 'Week 6', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '57.8', 'lowerLimit': '45.36', 'upperLimit': '71.12'}]}]}, {'title': 'Week 12', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '52.3', 'lowerLimit': '39.75', 'upperLimit': '65.08'}]}]}]}, {'type': 'SECONDARY', 'title': 'Percentage of Participants Treated With Angiotensin Converting Enzyme (ACE) Inhibitors or Other Angiotensin Receptor Blockers (ARBs) Before Baseline Reaching BP <140/85 mmHg', 'description': 'At each visit 3 serial BP measurements were determined while the participant was seated, with a sphygmomanometer.', 'populationDescription': 'FAS included all participants who took at least 1 dose of azilsartan medoxomil. Missing data was computed using LOCF method. Here, number of participants analyzed is the participants who received ACE inhibitors or other ARBs before baseline and are evaluable for this outcome measure.', 'reportingStatus': 'POSTED', 'paramType': 'NUMBER', 'dispersionType': '99% Confidence Interval', 'unitOfMeasure': 'percentage of participants', 'timeFrame': 'Weeks 6 and 12', 'groups': [{'id': 'OG000', 'title': 'Azilsartan Medoxomil', 'description': 'Azilsartan medoxomil 40 mg, tablets, orally, once, daily, for 12 weeks. Azilsartan medoxomil dose may be increased to 80 mg once daily if blood pressure has not reach BP goal of \\\\<140/85 mmHg at Week 6.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '193'}]}], 'classes': [{'title': 'Week 6', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '63.7', 'lowerLimit': '44.83', 'upperLimit': '68.92'}]}]}, {'title': 'Week 12', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '63.7', 'lowerLimit': '44.73', 'upperLimit': '69.01'}]}]}]}, {'type': 'SECONDARY', 'title': 'Percentage of Participants Treated With Thiazides Before Baseline Reaching BP <140/85 mmHg', 'description': 'At each visit three serial BP measurements were determined while the participant was seated, with a sphygmomanometer.', 'populationDescription': 'FAS included all participants who took at least 1 dose of azilsartan medoxomil. Missing data was computed using LOCF method. Here, number of participants analyzed is the participants who received thiazides before baseline and are evaluable for this outcome measure.', 'reportingStatus': 'POSTED', 'paramType': 'NUMBER', 'dispersionType': '99% Confidence Interval', 'unitOfMeasure': 'percentage of participants', 'timeFrame': 'Weeks 6 and 12', 'groups': [{'id': 'OG000', 'title': 'Azilsartan Medoxomil', 'description': 'Azilsartan medoxomil 40 mg, tablets, orally, once, daily, for 12 weeks. Azilsartan medoxomil dose may be increased to 80 mg once daily if blood pressure has not reach BP goal of \\\\<140/85 mmHg at Week 6.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '29'}]}], 'classes': [{'title': 'Week 6', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '79.3', 'lowerLimit': '45.97', 'upperLimit': '89.46'}]}]}, {'title': 'Week 12', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '86.2', 'lowerLimit': '43.81', 'upperLimit': '97.18'}]}]}]}, {'type': 'SECONDARY', 'title': 'Percentage of \"Treatment-Naïve\" Participants Reaching BP <130/80 mmHg', 'description': 'Treatment-naïve participants are defined as participants who have not received anti-hypertensive treatment for at least four weeks prior to screening. At each visit 3 serial BP measurements were determined while the participant was seated, with a sphygmomanometer.', 'populationDescription': 'FAS included all participants who took at least 1 dose of azilsartan medoxomil.', 'reportingStatus': 'POSTED', 'paramType': 'NUMBER', 'dispersionType': '99% Confidence Interval', 'unitOfMeasure': 'percentage of participants', 'timeFrame': 'Up to Week 12', 'groups': [{'id': 'OG000', 'title': 'Azilsartan Medoxomil (Treatment-Naïve)', 'description': 'Azilsartan medoxomil 40 mg, tablets, orally, once, daily, for 12 weeks. Azilsartan medoxomil dose may be increased to 80 mg once daily if blood pressure has not reach BP goal of \\\\<140/85 mmHg at Week 6. Treatment-naïve includes participants never treated with antihypertensive therapy or participants who did not receive hypertension therapy for at least 4 weeks prior to screening.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '1'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '0.0', 'lowerLimit': 'NA', 'upperLimit': 'NA', 'comment': 'CI was not calculated as there was only one participant in this group.'}]}]}]}, {'type': 'SECONDARY', 'title': 'Percentage of Participants Treated With CCB Before Baseline Reaching BP <130/80 mmHg', 'description': 'At each visit 3 serial BP measurements were determined while the participant was seated, with a sphygmomanometer.', 'populationDescription': 'FAS included all participants who took at least 1 dose of azilsartan medoxomil. Missing data was computed using LOCF method. Here, number of participants analyzed is the participants who received CCB before baseline and are evaluable for this outcome measure.', 'reportingStatus': 'POSTED', 'paramType': 'NUMBER', 'dispersionType': '99% Confidence Interval', 'unitOfMeasure': 'percentage of participants', 'timeFrame': 'Weeks 6 and 12', 'groups': [{'id': 'OG000', 'title': 'Azilsartan Medoxomil', 'description': 'Azilsartan medoxomil 40 mg, tablets, orally, once, daily, for 12 weeks. Azilsartan medoxomil dose may be increased to 80 mg once daily if blood pressure has not reach BP goal of \\\\<140/85 mmHg at Week 6.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '109'}]}], 'classes': [{'title': 'Week 6', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '26.6', 'lowerLimit': '14.73', 'upperLimit': '36.50'}]}]}, {'title': 'Week 12', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '27.5', 'lowerLimit': '15.73', 'upperLimit': '37.10'}]}]}]}, {'type': 'SECONDARY', 'title': 'Percentage of Participants Treated With ACE Inhibitors or Other ARBs Before Baseline Reaching BP <130/80 mmHg', 'description': 'At each visit 3 serial BP measurements were determined while the participant was seated, with a sphygmomanometer.', 'populationDescription': 'FAS included all participants who took at least 1 dose of azilsartan medoxomil. Missing data was computed using LOCF method. Here, number of participants analyzed is the participants who received ACE inhibitors or other ARBs before baseline and are evaluable for this outcome measure.', 'reportingStatus': 'POSTED', 'paramType': 'NUMBER', 'dispersionType': '99% Confidence Interval', 'unitOfMeasure': 'percentage of participants', 'timeFrame': 'Weeks 6 and 12', 'groups': [{'id': 'OG000', 'title': 'Azilsartan Medoxomil', 'description': 'Azilsartan medoxomil 40 mg, tablets, orally, once, daily, for 12 weeks. Azilsartan medoxomil dose may be increased to 80 mg once daily if blood pressure has not reach BP goal of \\\\<140/85 mmHg at Week 6.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '193'}]}], 'classes': [{'title': 'Week 6', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '31.1', 'lowerLimit': '10.05', 'upperLimit': '33.20'}]}]}, {'title': 'Week 12', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '35.2', 'lowerLimit': '12.18', 'upperLimit': '37.37'}]}]}]}, {'type': 'SECONDARY', 'title': 'Percentage of Participants Treated With Thiazides Before Baseline Reaching BP <130/80 mmHg', 'description': 'At each visit 3 serial BP measurements were determined while the participant was seated, with a sphygmomanometer.', 'populationDescription': 'FAS included all participants who took at least 1 dose of azilsartan medoxomil. Missing data was computed using LOCF method. Here, number of participants analyzed is the participants who received thiazides before baseline and are evaluable for this outcome measure.', 'reportingStatus': 'POSTED', 'paramType': 'NUMBER', 'dispersionType': '99% Confidence Interval', 'unitOfMeasure': 'percentage of participants', 'timeFrame': 'Weeks 6 and 12', 'groups': [{'id': 'OG000', 'title': 'Azilsartan Medoxomil', 'description': 'Azilsartan medoxomil 40 mg, tablets, orally, once, daily, for 12 weeks. Azilsartan medoxomil dose may be increased to 80 mg once daily if blood pressure has not reach BP goal of \\\\<140/85 mmHg at Week 6.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '29'}]}], 'classes': [{'title': 'Week 6', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '41.4', 'lowerLimit': '21.13', 'upperLimit': '65.05'}]}]}, {'title': 'Week 12', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '51.7', 'lowerLimit': '29.12', 'upperLimit': '73.67'}]}]}]}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With Systolic Blood Pressure (SBP) <140 mmHg at Week 12', 'description': 'Three serial BP measurements were determined while the participant was seated, with a sphygmomanometer.', 'populationDescription': 'FAS included all participants who took at least 1 dose of azilsartan medoxomil. Missing data was computed using LOCF method. Here, number of participants analyzed is the total number of participants who were evaluable for this outcome measure.', 'reportingStatus': 'POSTED', 'paramType': 'NUMBER', 'dispersionType': '99% Confidence Interval', 'unitOfMeasure': 'percentage of participants', 'timeFrame': 'Week 12', 'groups': [{'id': 'OG000', 'title': 'Azilsartan Medoxomil (Switched)', 'description': 'Azilsartan medoxomil 40 mg, tablets, orally, once, daily, for 12 weeks. Azilsartan medoxomil dose may be increased to 80 mg once daily if blood pressure has not reach BP goal of \\\\<140/85 mmHg at Week 6. Switched includes participants who switched from their baseline hypertension therapy to azilsartan medoxomil.'}, {'id': 'OG001', 'title': 'Azilsartan Medoxomil (Add-On)', 'description': 'Azilsartan medoxomil 40 mg, tablets, orally, once, daily, for 12 weeks. Azilsartan medoxomil dose may be increased to 80 mg once daily if blood pressure has not reach BP goal of \\\\<140/85 mmHg at Week 6. Add-On includes participants who added azilsartan medoxomil to their baseline hypertension therapy.'}, {'id': 'OG002', 'title': 'Azilsartan Medoxomil (Treatment-Naïve)', 'description': 'Azilsartan medoxomil 40 mg, tablets, orally, once, daily, for 12 weeks. Azilsartan medoxomil dose may be increased to 80 mg once daily if blood pressure has not reach BP goal of \\\\<140/85 mmHg at Week 6. Treatment-naïve includes participants never treated with antihypertensive therapy or participants who did not receive hypertension therapy for at least 4 weeks prior to screening.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '276'}, {'groupId': 'OG001', 'value': '85'}, {'groupId': 'OG002', 'value': '1'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '68.8', 'lowerLimit': '57.57', 'upperLimit': '75.78'}, {'groupId': 'OG001', 'value': '70.6', 'lowerLimit': '52.49', 'upperLimit': '83.94'}, {'groupId': 'OG002', 'value': '0.0', 'lowerLimit': 'NA', 'upperLimit': 'NA', 'comment': 'CI was not calculated as there was only one participant in this group.'}]}]}]}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With Diastolic Blood Pressure (DBP) <85 mmHg at Week 12', 'description': 'Three serial BP measurements were determined while the participant was seated, with a sphygmomanometer.', 'populationDescription': 'FAS included all participants who took at least 1 dose of azilsartan medoxomil. Missing data was computed using LOCF method. Here, number of participants analyzed is the total number of participants who were evaluable for this outcome measure.', 'reportingStatus': 'POSTED', 'paramType': 'NUMBER', 'dispersionType': '99% Confidence Interval', 'unitOfMeasure': 'percentage of participants', 'timeFrame': 'Week 12', 'groups': [{'id': 'OG000', 'title': 'Azilsartan Medoxomil (Switched)', 'description': 'Azilsartan medoxomil 40 mg, tablets, orally, once, daily, for 12 weeks. Azilsartan medoxomil dose may be increased to 80 mg once daily if blood pressure has not reach BP goal of \\\\<140/85 mmHg at Week 6. Switched includes participants who switched from their baseline hypertension therapy to azilsartan medoxomil.'}, {'id': 'OG001', 'title': 'Azilsartan Medoxomil (Add-On)', 'description': 'Azilsartan medoxomil 40 mg, tablets, orally, once, daily, for 12 weeks. Azilsartan medoxomil dose may be increased to 80 mg once daily if blood pressure has not reach BP goal of \\\\<140/85 mmHg at Week 6. Add-On includes participants who added azilsartan medoxomil to their baseline hypertension therapy.'}, {'id': 'OG002', 'title': 'Azilsartan Medoxomil (Treatment-Naïve)', 'description': 'Azilsartan medoxomil 40 mg, tablets, orally, once, daily, for 12 weeks. Azilsartan medoxomil dose may be increased to 80 mg once daily if blood pressure has not reach BP goal of \\\\<140/85 mmHg at Week 6. Treatment-naïve includes participants never treated with antihypertensive therapy or participants who did not receive hypertension therapy for at least 4 weeks prior to screening.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '276'}, {'groupId': 'OG001', 'value': '85'}, {'groupId': 'OG002', 'value': '1'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '74.6', 'lowerLimit': '64.86', 'upperLimit': '81.66'}, {'groupId': 'OG001', 'value': '81.2', 'lowerLimit': '67.40', 'upperLimit': '91.05'}, {'groupId': 'OG002', 'value': '0.0', 'lowerLimit': 'NA', 'upperLimit': 'NA', 'comment': 'CI was not calculated as there was only one participant in this group.'}]}]}]}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With DBP <90 mmHg at Week 12', 'description': 'Three serial BP measurements were determined while the participant was seated, with a sphygmomanometer.', 'populationDescription': 'FAS included all participants who took at least 1 dose of azilsartan medoxomil. Missing data was computed using LOCF method. Here, number of participants analyzed is the total number of participants who were evaluable for this outcome measure.', 'reportingStatus': 'POSTED', 'paramType': 'NUMBER', 'dispersionType': '99% Confidence Interval', 'unitOfMeasure': 'percentage of participants', 'timeFrame': 'Week 12', 'groups': [{'id': 'OG000', 'title': 'Azilsartan Medoxomil (Switched)', 'description': 'Azilsartan medoxomil 40 mg, tablets, orally, once, daily, for 12 weeks. Azilsartan medoxomil dose may be increased to 80 mg once daily if blood pressure has not reach BP goal of \\\\<140/85 mmHg at Week 6. Switched includes participants who switched from their baseline hypertension therapy to azilsartan medoxomil.'}, {'id': 'OG001', 'title': 'Azilsartan Medoxomil (Add-On)', 'description': 'Azilsartan medoxomil 40 mg, tablets, orally, once, daily, for 12 weeks. Azilsartan medoxomil dose may be increased to 80 mg once daily if blood pressure has not reach BP goal of \\\\<140/85 mmHg at Week 6. Add-On includes participants who added azilsartan medoxomil to their baseline hypertension therapy.'}, {'id': 'OG002', 'title': 'Azilsartan Medoxomil (Treatment-Naïve)', 'description': 'Azilsartan medoxomil 40 mg, tablets, orally, once, daily, for 12 weeks. Azilsartan medoxomil dose may be increased to 80 mg once daily if blood pressure has not reach BP goal of \\\\<140/85 mmHg at Week 6. Treatment-naïve includes participants never treated with antihypertensive therapy or participants who did not receive hypertension therapy for at least 4 weeks prior to screening.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '276'}, {'groupId': 'OG001', 'value': '85'}, {'groupId': 'OG002', 'value': '1'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '87.3', 'lowerLimit': '85.11', 'upperLimit': '95.34'}, {'groupId': 'OG001', 'value': '87.1', 'lowerLimit': '79.97', 'upperLimit': '96.46'}, {'groupId': 'OG002', 'value': '0.0', 'lowerLimit': 'NA', 'upperLimit': 'NA', 'comment': 'CI was not calculated as there was only one participant in this group.'}]}]}]}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With BP <130/80 mmHg at Week 12', 'description': 'Three serial BP measurements were determined while the participant was seated, with a sphygmomanometer.', 'populationDescription': 'FAS included all participants who took at least 1 dose of azilsartan medoxomil. Missing data was computed using LOCF method. Here, number of participants analyzed is the total number of participants who were evaluable for this outcome measure.', 'reportingStatus': 'POSTED', 'paramType': 'NUMBER', 'dispersionType': '99% Confidence Interval', 'unitOfMeasure': 'percentage of participants', 'timeFrame': 'Week 12', 'groups': [{'id': 'OG000', 'title': 'Azilsartan Medoxomil (Switched)', 'description': 'Azilsartan medoxomil 40 mg, tablets, orally, once, daily, for 12 weeks. Azilsartan medoxomil dose may be increased to 80 mg once daily if blood pressure has not reach BP goal of \\\\<140/85 mmHg at Week 6. Switched includes participants who switched from their baseline hypertension therapy to azilsartan medoxomil.'}, {'id': 'OG001', 'title': 'Azilsartan Medoxomil (Add-On)', 'description': 'Azilsartan medoxomil 40 mg, tablets, orally, once, daily, for 12 weeks. Azilsartan medoxomil dose may be increased to 80 mg once daily if blood pressure has not reach BP goal of \\\\<140/85 mmHg at Week 6. Add-On includes participants who added azilsartan medoxomil to their baseline hypertension therapy.'}, {'id': 'OG002', 'title': 'Azilsartan Medoxomil (Treatment-Naïve)', 'description': 'Azilsartan medoxomil 40 mg, tablets, orally, once, daily, for 12 weeks. Azilsartan medoxomil dose may be increased to 80 mg once daily if blood pressure has not reach BP goal of \\\\<140/85 mmHg at Week 6. Treatment-naïve includes participants never treated with antihypertensive therapy or participants who did not receive hypertension therapy for at least 4 weeks prior to screening.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '276'}, {'groupId': 'OG001', 'value': '85'}, {'groupId': 'OG002', 'value': '1'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '33.7', 'lowerLimit': '17.01', 'upperLimit': '37.26'}, {'groupId': 'OG001', 'value': '40.0', 'lowerLimit': '18.66', 'upperLimit': '48.66'}, {'groupId': 'OG002', 'value': '0.0', 'lowerLimit': 'NA', 'upperLimit': 'NA', 'comment': 'CI was not calculated as there was only one participant in this group.'}]}]}]}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With SBP <130 mmHg at Week 12', 'description': 'Three serial BP measurements were determined while the participant was seated, with a sphygmomanometer.', 'populationDescription': 'FAS included all participants who took at least 1 dose of azilsartan medoxomil. Missing data was computed using LOCF method. Here, number of participants analyzed is the total number of participants who were evaluable for this outcome measure.', 'reportingStatus': 'POSTED', 'paramType': 'NUMBER', 'dispersionType': '99% Confidence Interval', 'unitOfMeasure': 'percentage of participants', 'timeFrame': 'Week 12', 'groups': [{'id': 'OG000', 'title': 'Azilsartan Medoxomil (Switched)', 'description': 'Azilsartan medoxomil 40 mg, tablets, orally, once, daily, for 12 weeks. Azilsartan medoxomil dose may be increased to 80 mg once daily if blood pressure has not reach BP goal of \\\\<140/85 mmHg at Week 6. Switched includes participants who switched from their baseline hypertension therapy to azilsartan medoxomil.'}, {'id': 'OG001', 'title': 'Azilsartan Medoxomil (Add-On)', 'description': 'Azilsartan medoxomil 40 mg, tablets, orally, once, daily, for 12 weeks. Azilsartan medoxomil dose may be increased to 80 mg once daily if blood pressure has not reach BP goal of \\\\<140/85 mmHg at Week 6. Add-On includes participants who added azilsartan medoxomil to their baseline hypertension therapy.'}, {'id': 'OG002', 'title': 'Azilsartan Medoxomil (Treatment-Naïve)', 'description': 'Azilsartan medoxomil 40 mg, tablets, orally, once, daily, for 12 weeks. Azilsartan medoxomil dose may be increased to 80 mg once daily if blood pressure has not reach BP goal of \\\\<140/85 mmHg at Week 6. Treatment-naïve includes participants never treated with antihypertensive therapy or participants who did not receive hypertension therapy for at least 4 weeks prior to screening.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '276'}, {'groupId': 'OG001', 'value': '85'}, {'groupId': 'OG002', 'value': '1'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '41.3', 'lowerLimit': '22.25', 'upperLimit': '43.20'}, {'groupId': 'OG001', 'value': '43.5', 'lowerLimit': '20.17', 'upperLimit': '50.31'}, {'groupId': 'OG002', 'value': '0.0', 'lowerLimit': 'NA', 'upperLimit': 'NA', 'comment': 'CI was not calculated as there was only one participant in this group.'}]}]}]}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With DBP <80 mmHg at Week 12', 'description': 'Three serial BP measurements were determined while the participant was seated, with a sphygmomanometer.', 'populationDescription': 'FAS included all participants who took at least 1 dose of azilsartan medoxomil. Missing data was computed using LOCF method. Here, number of participants analyzed is the total number of participants who were evaluable for this outcome measure.', 'reportingStatus': 'POSTED', 'paramType': 'NUMBER', 'dispersionType': '99% Confidence Interval', 'unitOfMeasure': 'percentage of participants', 'timeFrame': 'Week 12', 'groups': [{'id': 'OG000', 'title': 'Azilsartan Medoxomil (Switched)', 'description': 'Azilsartan medoxomil 40 mg, tablets, orally, once, daily, for 12 weeks. Azilsartan medoxomil dose may be increased to 80 mg once daily if blood pressure has not reach BP goal of \\\\<140/85 mmHg at Week 6. Switched includes participants who switched from their baseline hypertension therapy to azilsartan medoxomil.'}, {'id': 'OG001', 'title': 'Azilsartan Medoxomil (Add-On)', 'description': 'Azilsartan medoxomil 40 mg, tablets, orally, once, daily, for 12 weeks. Azilsartan medoxomil dose may be increased to 80 mg once daily if blood pressure has not reach BP goal of \\\\<140/85 mmHg at Week 6. Add-On includes participants who added azilsartan medoxomil to their baseline hypertension therapy.'}, {'id': 'OG002', 'title': 'Azilsartan Medoxomil (Treatment-Naïve)', 'description': 'Azilsartan medoxomil 40 mg, tablets, orally, once, daily, for 12 weeks. Azilsartan medoxomil dose may be increased to 80 mg once daily if blood pressure has not reach BP goal of \\\\<140/85 mmHg at Week 6. Treatment-naïve includes participants never treated with antihypertensive therapy or participants who did not receive hypertension therapy for at least 4 weeks prior to screening.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '276'}, {'groupId': 'OG001', 'value': '85'}, {'groupId': 'OG002', 'value': '1'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '57.6', 'lowerLimit': '36.82', 'upperLimit': '59.95'}, {'groupId': 'OG001', 'value': '65.9', 'lowerLimit': '41.33', 'upperLimit': '75.07'}, {'groupId': 'OG002', 'value': '0.0', 'lowerLimit': 'NA', 'upperLimit': 'NA', 'comment': 'CI was not calculated as there was only one participant in this group.'}]}]}]}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With BP <140/90 mmHg at Week 12', 'description': 'Three serial BP measurements were determined while the participant was seated, with a sphygmomanometer.', 'populationDescription': 'FAS included all participants who took at least 1 dose of azilsartan medoxomil. Missing data was computed using LOCF method. Here, number of participants analyzed is the total number of participants who were evaluable for this outcome measure.', 'reportingStatus': 'POSTED', 'paramType': 'NUMBER', 'dispersionType': '99% Confidence Interval', 'unitOfMeasure': 'percentage of participants', 'timeFrame': 'Week 12', 'groups': [{'id': 'OG000', 'title': 'Azilsartan Medoxomil (Switched)', 'description': 'Azilsartan medoxomil 40 mg, tablets, orally, once, daily, for 12 weeks. Azilsartan medoxomil dose may be increased to 80 mg once daily if blood pressure has not reach BP goal of \\\\<140/85 mmHg at Week 6. Switched includes participants who switched from their baseline hypertension therapy to azilsartan medoxomil.'}, {'id': 'OG001', 'title': 'Azilsartan Medoxomil (Add-On)', 'description': 'Azilsartan medoxomil 40 mg, tablets, orally, once, daily, for 12 weeks. Azilsartan medoxomil dose may be increased to 80 mg once daily if blood pressure has not reach BP goal of \\\\<140/85 mmHg at Week 6. Add-On includes participants who added azilsartan medoxomil to their baseline hypertension therapy.'}, {'id': 'OG002', 'title': 'Azilsartan Medoxomil (Treatment-Naïve)', 'description': 'Azilsartan medoxomil 40 mg, tablets, orally, once, daily, for 12 weeks. Azilsartan medoxomil dose may be increased to 80 mg once daily if blood pressure has not reach BP goal of \\\\<140/85 mmHg at Week 6. Treatment-naïve includes participants never treated with antihypertensive therapy or participants who did not receive hypertension therapy for at least 4 weeks prior to screening.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '276'}, {'groupId': 'OG001', 'value': '85'}, {'groupId': 'OG002', 'value': '1'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '65.9', 'lowerLimit': '52.51', 'upperLimit': '71.04'}, {'groupId': 'OG001', 'value': '68.2', 'lowerLimit': '48.42', 'upperLimit': '79.92'}, {'groupId': 'OG002', 'value': '0.0', 'lowerLimit': 'NA', 'upperLimit': 'NA', 'comment': 'CI was not calculated as there was only one participant in this group.'}]}]}]}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Trough Sitting SBP at Week 12', 'description': 'At each visit 3 serial BP measurements were determined while the participant was seated, with a sphygmomanometer. Change from Baseline was estimated using an ANCOVA model with fixed effects, country, baseline hypertension therapy (BHT) and baseline SBP (or DBP) included as a covariate. A negative change from baseline indicates improvement.', 'populationDescription': 'FAS included all participants who took at least 1 dose of azilsartan medoxomil. Missing data was computed using LOCF method. Here, number of participants analyzed is the total number of participants who were evaluable for this outcome measure.', 'reportingStatus': 'POSTED', 'paramType': 'LEAST_SQUARES_MEAN', 'dispersionType': 'Standard Error', 'unitOfMeasure': 'mmHg', 'timeFrame': 'Baseline and Week 12', 'groups': [{'id': 'OG000', 'title': 'Azilsartan Medoxomil (Switched)', 'description': 'Azilsartan medoxomil 40 mg, tablets, orally, once, daily, for 12 weeks. Azilsartan medoxomil dose may be increased to 80 mg once daily if blood pressure has not reach BP goal of \\\\<140/85 mmHg at Week 6. Switched includes participants who switched from their baseline hypertension therapy to azilsartan medoxomil.'}, {'id': 'OG001', 'title': 'Azilsartan Medoxomil (Add-On)', 'description': 'Azilsartan medoxomil 40 mg, tablets, orally, once, daily, for 12 weeks. Azilsartan medoxomil dose may be increased to 80 mg once daily if blood pressure has not reach BP goal of \\\\<140/85 mmHg at Week 6. Add-On includes participants who added azilsartan medoxomil to their baseline hypertension therapy.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '276'}, {'groupId': 'OG001', 'value': '90'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-14.1', 'spread': '1.39'}, {'groupId': 'OG001', 'value': '-13.3', 'spread': '2.12'}]}]}]}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Trough Sitting SBP at Week 12 in \"Treatment-Naïve\" Participants', 'description': 'At each visit 3 serial BP measurements were determined while the participant was seated, with a sphygmomanometer. Change from Baseline was estimated using an ANCOVA model with fixed effects, country, baseline hypertension therapy (BHT) and baseline SBP (or DBP) included as a covariate. A negative change from baseline indicates improvement.', 'populationDescription': 'FAS included all participants who took at least 1 dose of azilsartan medoxomil. Missing data was computed using LOCF method. Here, number of participants analyzed is the total number of participants who were evaluable for this outcome measure.', 'reportingStatus': 'POSTED', 'paramType': 'MEAN', 'dispersionType': 'Standard Deviation', 'unitOfMeasure': 'mmHg', 'timeFrame': 'Baseline and Week 12', 'groups': [{'id': 'OG000', 'title': 'Azilsartan Medoxomil (Treatment-Naïve)', 'description': 'Azilsartan medoxomil 40 mg, tablets, orally, once, daily, for 12 weeks. Azilsartan medoxomil dose may be increased to 80 mg once daily if blood pressure has not reach BP goal of \\\\<140/85 mmHg at Week 6. Treatment-naïve includes participants never treated with antihypertensive therapy or participants who did not receive hypertension therapy for at least 4 weeks prior to screening.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '1'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-7', 'spread': 'NA', 'comment': 'Standard deviation was not calculated as there was only one participant who was evaluated.'}]}]}]}, {'type': 'SECONDARY', 'title': 'Change From Baseline in DBP at Week 12', 'description': 'At each visit 3 serial BP measurements were determined while the participant was seated, with a sphygmomanometer. Change from Baseline was estimated using an ANCOVA model with fixed effects, country, BHT and baseline SBP (or DBP) included as a covariate. A negative change from baseline indicates improvement.', 'populationDescription': 'FAS included all participants who took at least 1 dose of azilsartan medoxomil. Missing data was computed using LOCF method. Here, number of participants analyzed is the total number of participants who were analysed for this outcome measure.', 'reportingStatus': 'POSTED', 'paramType': 'LEAST_SQUARES_MEAN', 'dispersionType': 'Standard Error', 'unitOfMeasure': 'mmHg', 'timeFrame': 'Baseline and Week 12', 'groups': [{'id': 'OG000', 'title': 'Azilsartan Medoxomil (Switched)', 'description': 'Azilsartan medoxomil 40 mg, tablets, orally, once, daily, for 12 weeks. Azilsartan medoxomil dose may be increased to 80 mg once daily if blood pressure has not reach BP goal of \\\\<140/85 mmHg at Week 6. Switched includes participants who switched from their baseline hypertension therapy to azilsartan medoxomil.'}, {'id': 'OG001', 'title': 'Azilsartan Medoxomil (Add-On)', 'description': 'Azilsartan medoxomil 40 mg, tablets, orally, once, daily, for 12 weeks. Azilsartan medoxomil dose may be increased to 80 mg once daily if blood pressure has not reach BP goal of \\\\<140/85 mmHg at Week 6. Add-On includes participants who added azilsartan medoxomil to their baseline hypertension therapy.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '276'}, {'groupId': 'OG001', 'value': '85'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-4.9', 'spread': '0.76'}, {'groupId': 'OG001', 'value': '-5.7', 'spread': '1.16'}]}]}]}, {'type': 'SECONDARY', 'title': 'Change From Baseline in DBP at Week 12 in \"Treatment-Naïve\" Participants', 'description': 'At each visit 3 serial BP measurements were determined while the participant was seated, with a sphygmomanometer. Change from Baseline was estimated using an ANCOVA model with fixed effects, country, BHT and baseline SBP (or DBP) included as a covariate. A negative change from baseline indicates improvement.', 'populationDescription': 'FAS included all participants who took at least 1 dose of azilsartan medoxomil. Missing data was computed using LOCF method. Here, number of participants analyzed is the total number of participants who were analysed for this outcome measure.', 'reportingStatus': 'POSTED', 'paramType': 'MEAN', 'dispersionType': 'Standard Deviation', 'unitOfMeasure': 'mmHg', 'timeFrame': 'Baseline and Week 12', 'groups': [{'id': 'OG000', 'title': 'Azilsartan Medoxomil (Treatment-Naïve)', 'description': 'Azilsartan medoxomil 40 mg, tablets, orally, once, daily, for 12 weeks. Azilsartan medoxomil dose may be increased to 80 mg once daily if blood pressure has not reach BP goal of \\\\<140/85 mmHg at Week 6. Treatment-naïve includes participants never treated with antihypertensive therapy or participants who did not receive hypertension therapy for at least 4 weeks prior to screening.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '1'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '20', 'spread': 'NA', 'comment': 'Standard deviation was not calculated as there was only one participant who was evaluated.'}]}]}]}]}, 'adverseEventsModule': {'frequencyThreshold': '5', 'timeFrame': 'From first dose of study drug up to 14 days after the date of the last dose of study drug (up to 14 weeks)', 'description': 'At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment. Adverse Events are reported as per dose received.', 'eventGroups': [{'id': 'EG000', 'title': 'Before Week 6 Azilsartan Medoxomil 40 mg', 'description': 'Azilsartan medoxomil 40 mg, tablets, orally, once, daily, for 6 weeks.', 'seriousNumAffected': 4, 'seriousNumAtRisk': 380, 'otherNumAffected': 0, 'otherNumAtRisk': 380}, {'id': 'EG001', 'title': 'After Week 6 Azilsartan Medoxomil 40 mg', 'description': 'Azilsartan medoxomil 40 mg, tablets, orally, once, daily, for Week 6 up to Week 12.', 'seriousNumAffected': 3, 'seriousNumAtRisk': 258, 'otherNumAffected': 0, 'otherNumAtRisk': 258}, {'id': 'EG002', 'title': 'After Week 6 Azilsartan Medoxomil 80 mg', 'description': 'Azilsartan medoxomil 80 mg, tablets, orally, once, daily, for Week 6 up to Week 12.', 'seriousNumAffected': 1, 'seriousNumAtRisk': 97, 'otherNumAffected': 0, 'otherNumAtRisk': 97}], 'seriousEvents': [{'term': 'Acute myocardial infarction', 'organSystem': 'Cardiac disorders', 'sourceVocabulary': 'MedDRA version 19.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 380}, {'groupId': 'EG001', 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 97}]}, {'term': 'Cardiac failure', 'organSystem': 'Cardiac disorders', 'sourceVocabulary': 'MedDRA version 19.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 1, 'numAtRisk': 380}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 97}]}, {'term': 'Pneumonia', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA version 19.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 380}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 97}]}, {'term': 'Sepsis', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA version 19.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 380}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 97}]}, {'term': 'Breast cancer', 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'sourceVocabulary': 'MedDRA version 19.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 380}, {'groupId': 'EG001', 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 97}]}, {'term': 'Acute kidney injury', 'organSystem': 'Renal and urinary disorders', 'sourceVocabulary': 'MedDRA version 19.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 1, 'numAtRisk': 380}, {'groupId': 'EG001', 'numAffected': 1, 'numAtRisk': 258}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 97}]}, {'term': 'Respiratory failure', 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'sourceVocabulary': 'MedDRA version 19.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 1, 'numAtRisk': 380}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 97}]}, {'term': 'Hypotension', 'organSystem': 'Vascular disorders', 'sourceVocabulary': 'MedDRA version 19.0', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 1, 'numAtRisk': 380}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 258}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 97}]}]}, 'moreInfoModule': {'certainAgreement': {'piSponsorEmployee': False, 'restrictionType': 'OTHER', 'restrictiveAgreement': True, 'otherDetails': 'The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.'}, 'pointOfContact': {'title': 'Medical Director', 'organization': 'Takeda', 'email': 'trialdisclosures@takeda.com', 'phone': '+1-877-825-3327'}}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2024-11-22'}, 'conditionBrowseModule': {'meshes': [{'id': 'D006973', 'term': 'Hypertension'}, {'id': 'D000075222', 'term': 'Essential Hypertension'}, {'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D003924', 'term': 'Diabetes Mellitus, Type 2'}], 'ancestors': [{'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}, {'id': 'D014652', 'term': 'Vascular Diseases'}, {'id': 'D002318', 'term': 'Cardiovascular Diseases'}], 'browseLeaves': [{'id': 'M7119', 'name': 'Diabetes Mellitus, Type 2', 'asFound': 'Type 2 Diabetes', 'relevance': 'HIGH'}, {'id': 'M7115', 'name': 'Diabetes Mellitus', 'asFound': 'Diabetes', 'relevance': 'HIGH'}, {'id': 'M10024', 'name': 'Hypertension', 'asFound': 'Hypertension', 'relevance': 'HIGH'}, {'id': 'M1470', 'name': 'Essential Hypertension', 'asFound': 'Essential Hypertension', 'relevance': 'HIGH'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}, {'id': 'M17400', 'name': 'Vascular Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC14', 'name': 'Heart and Blood Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C557413', 'term': 'Azilsartan medoxomil'}], 'ancestors': [{'id': 'D047228', 'term': 'Angiotensin II Type 1 Receptor Blockers'}, {'id': 'D057911', 'term': 'Angiotensin Receptor Antagonists'}, {'id': 'D045504', 'term': 'Molecular Mechanisms of Pharmacological Action'}], 'browseLeaves': [{'id': 'M256876', 'name': 'Azilsartan medoxomil', 'asFound': 'Insurance', 'relevance': 'HIGH'}, {'id': 'M4132', 'name': 'Angiotensin II', 'relevance': 'LOW'}, {'id': 'M289354', 'name': 'Giapreza', 'relevance': 'LOW'}, {'id': 'M4135', 'name': 'Angiotensinogen', 'relevance': 'LOW'}, {'id': 'M25789', 'name': 'Angiotensin II Type 1 Receptor Blockers', 'relevance': 'LOW'}, {'id': 'M28916', 'name': 'Angiotensin Receptor Antagonists', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'All', 'name': 'All Drugs and Chemicals'}, {'abbrev': 'VaCoAg', 'name': 'Vasoconstrictor Agents'}]}}, 'hasResults': True}, {'protocolSection': {'identificationModule': {'nctId': 'NCT06220773', 'orgStudyIdInfo': {'id': 'BR-FDC-CT-301'}, 'organization': {'fullName': 'Boryung Pharmaceutical Co., Ltd', 'class': 'INDUSTRY'}, 'briefTitle': 'A Study to Evaluate the Efficacy and Safety of BR1019A and BR1019B Combination Therapy', 'officialTitle': 'A Randomized, Double-blind, Multi-center, Phase 3 Study to Evaluate the Efficacy and Safety of BR1019A and BR1019B Combination Therapy in Patients With Essential Hypertension and Type 2 Diabetes Mellitus'}, 'statusModule': {'statusVerifiedDate': '2024-05', 'overallStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2024-05-21', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2025-04', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2025-04', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2024-01-14', 'studyFirstSubmitQcDate': '2024-01-14', 'studyFirstPostDateStruct': {'date': '2024-01-24', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2024-05-21', 'lastUpdatePostDateStruct': {'date': '2024-05-22', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Boryung Pharmaceutical Co., Ltd', 'class': 'INDUSTRY'}}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'The objective of this clinical study is to Evaluate the Efficacy and Safety of BR1019A and BR1019B combination therapy in Patients with Essential Hypertension and Type 2 Diabetes Mellitus'}, 'conditionsModule': {'conditions': ['Essential Hypertension', 'Type 2 Diabetes Mellitus']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE3'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'DOUBLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR']}}, 'enrollmentInfo': {'count': 276, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'BR1019A + BR1019B + BR1019C-1', 'type': 'EXPERIMENTAL', 'interventionNames': ['Drug: BR1019A', 'Drug: BR1019B', 'Drug: BR1019C-1']}, {'label': 'BR1019A + BR1019B-1 + BR1019C-1', 'type': 'ACTIVE_COMPARATOR', 'interventionNames': ['Drug: BR1019A', 'Drug: BR1019B-1', 'Drug: BR1019C-1']}, {'label': 'BR1019A-1 + BR1019B + BR1019C-1', 'type': 'ACTIVE_COMPARATOR', 'interventionNames': ['Drug: BR1019B', 'Drug: BR1019A-1', 'Drug: BR1019C-1']}, {'label': 'BR1019A-1 + BR1019B + BR1019C', 'type': 'OTHER', 'interventionNames': ['Drug: BR1019B', 'Drug: BR1019C', 'Drug: BR1019A-1']}], 'interventions': [{'type': 'DRUG', 'name': 'BR1019A', 'description': 'Subjects take the investigational products once a day for 12 weeks.', 'armGroupLabels': ['BR1019A + BR1019B + BR1019C-1', 'BR1019A + BR1019B-1 + BR1019C-1']}, {'type': 'DRUG', 'name': 'BR1019B', 'description': 'Subjects take the investigational products once a day for 12 weeks.', 'armGroupLabels': ['BR1019A + BR1019B + BR1019C-1', 'BR1019A-1 + BR1019B + BR1019C', 'BR1019A-1 + BR1019B + BR1019C-1']}, {'type': 'DRUG', 'name': 'BR1019C', 'description': 'Subjects take the investigational products once a day for 12 weeks.', 'armGroupLabels': ['BR1019A-1 + BR1019B + BR1019C']}, {'type': 'DRUG', 'name': 'BR1019A-1', 'description': 'Subjects take the investigational products once a day for 12 weeks.', 'armGroupLabels': ['BR1019A-1 + BR1019B + BR1019C', 'BR1019A-1 + BR1019B + BR1019C-1']}, {'type': 'DRUG', 'name': 'BR1019B-1', 'description': 'Subjects take the investigational products once a day for 12 weeks.', 'armGroupLabels': ['BR1019A + BR1019B-1 + BR1019C-1']}, {'type': 'DRUG', 'name': 'BR1019C-1', 'description': 'Subjects take the investigational products once a day for 12 weeks.', 'armGroupLabels': ['BR1019A + BR1019B + BR1019C-1', 'BR1019A + BR1019B-1 + BR1019C-1', 'BR1019A-1 + BR1019B + BR1019C-1']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'The change of mean sitting systolic blood pressure from baseline in BR1019A+BR1019B+BR1019C-1 at Week 12 compared to BR1019A-1+BR1019B+BR1019C-1', 'timeFrame': '12 weeks from Baseline Visit'}, {'measure': 'The change of HbA1c from baseline in BR1019A+BR1019B+BR1019C-1 at Week 12 compared to BR1019A+BR1019B-1+BR1019C-1', 'timeFrame': '12 weeks from Baseline Visit'}]}, 'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\n\\n* Those with type 2 diabetes mellitus \\\\& essential hypertension\\n* Those who agree to discontinue existing antihypertensive and/or oral hypoglycemic drugs during the clinical trial\\n* Those who are judged medically reasonable by investigator to be able to discontinue existing antihypertensive and/or oral hypoglycemic drugs(except for Metformin) during the clinical trial\\n\\nExclusion Criteria:\\n\\n* Those who meet the following criteria\\n\\n  * Those with a history of secondary hypertension or suspected secondary hypertension; (Including but not limited to; e.g., renovascular disease, adrenal medullary and cortical hyperfunctions, coarctation of the aorta, primary hyperaldosteronism, unilateral or bilateral renal artery stenosis, Cushing's syndrome, pheochromocytoma and polycystic kidney disease, etc.)\\n  * Those with clinical significant orthostatic hypotension accompanied by symptoms\\n  * Those with diabetes mellitus taking renin inhibitors(Aliskiren) or moderate to severe renal impairment\\n  * Those with diabetic nephropathy taking ACE inhibitors\\n  * Those with type 1 diabetes mellitus, secondary diabetes mellitus, severe insulin-dependent diabetes, diabetic ketoacidosis or lactic acidosis\\n  * Those with uncontrolled, severe diabetic complications (Micro-vascular complications(e.g., nephropathy, retinopathy, neuropathy, etc.), Macro-vascular complications)\\n  * Diabetic coma or pre-coma\", 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '19 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Shin-young Oh', 'role': 'CONTACT', 'phone': '+82-2-708-8000', 'email': 'syoh@boryung.co.kr'}], 'locations': [{'facility': 'Severance Hospital', 'status': 'RECRUITING', 'city': 'Seoul', 'country': 'Korea, Republic of', 'contacts': [{'name': 'Seok-min Kang, M.D., Ph.D.', 'role': 'CONTACT'}], 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'facility': 'Severance Hospital', 'status': 'RECRUITING', 'city': 'Seoul', 'country': 'Korea, Republic of', 'contacts': [{'name': 'Bong-Soo Cha, M.D., Ph.D.', 'role': 'CONTACT'}], 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2024-11-22'}, 'conditionBrowseModule': {'meshes': [{'id': 'D006973', 'term': 'Hypertension'}, {'id': 'D000075222', 'term': 'Essential Hypertension'}, {'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D003924', 'term': 'Diabetes Mellitus, Type 2'}], 'ancestors': [{'id': 'D014652', 'term': 'Vascular Diseases'}, {'id': 'D002318', 'term': 'Cardiovascular Diseases'}, {'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}], 'browseLeaves': [{'id': 'M7119', 'name': 'Diabetes Mellitus, Type 2', 'asFound': 'Type 2 Diabetes Mellitus', 'relevance': 'HIGH'}, {'id': 'M7115', 'name': 'Diabetes Mellitus', 'asFound': 'Diabetes Mellitus', 'relevance': 'HIGH'}, {'id': 'M10024', 'name': 'Hypertension', 'asFound': 'Hypertension', 'relevance': 'HIGH'}, {'id': 'M1470', 'name': 'Essential Hypertension', 'asFound': 'Essential Hypertension', 'relevance': 'HIGH'}, {'id': 'M17400', 'name': 'Vascular Diseases', 'relevance': 'LOW'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC14', 'name': 'Heart and Blood Diseases'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT06258473', 'orgStudyIdInfo': {'id': 'IRB-16 November-23-041'}, 'organization': {'fullName': 'BRAC University', 'class': 'OTHER'}, 'briefTitle': 'Addressing Gaps in the Hypertension and Diabetes Care Continuum in Rural Bangladesh: The Dinajpur Study', 'officialTitle': 'Addressing Gaps in the Hypertension and Diabetes Care Continuum in Rural Bangladesh Through mHealth and Decentralized Primary Care: The Dinajpur Study'}, 'statusModule': {'statusVerifiedDate': '2024-02', 'overallStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2024-01-01', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2026-09-30', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2026-09-30', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2024-02-06', 'studyFirstSubmitQcDate': '2024-02-06', 'studyFirstPostDateStruct': {'date': '2024-02-14', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2024-02-06', 'lastUpdatePostDateStruct': {'date': '2024-02-14', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'BRAC University', 'class': 'OTHER'}, 'collaborators': [{'name': 'Imperial College London', 'class': 'OTHER'}, {'name': 'Nanyang Technological University', 'class': 'OTHER'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'In the present implementation study, we aim to document the experience of implementing integrated, decentralized primary care in rural Bangladesh, including components of healthcare provider training, mHealth, decentralization with task shifting, and community-based care, and to generate data on the effectiveness and cost-effectiveness of the multicomponent integrated care as compared to usual care and to mHealth intervention alone. We will also Investigate the factors that explain how the interventions influence hypertension and diabetes management and explore barriers/facilitators to delivering and sustaining intervention. We will conduct mixed-methods research to understand how the intervention influences treatment and prevention in this patient population. Particularly, we will assess lifestyle changes (i.e., smoking, dietary salt intake, physical activity, alcohol consumption), and burden for patients (e.g., waiting time, travel-related cost) at individual and community level. Qualitative data will shed light on facilitators and barriers to hypertension and diabetes prevention and control from the perspectives of patients (and their families), primary care providers, public health officials, and other stakeholders. Additionally, we will undertake a health economic evaluation of the interventions for primary care systems. A comprehensive evaluation of cost and effectiveness will be important for the models tested, providing necessary evidence for policymakers and stakeholders to scale up the interventions. We hypothesize that compared with usual care, the multicomponent decentralized primary care will improve all steps along hypertension and diabetes care continuum. On the other hand, we hypothesize that the mHealth intervention alone (Simple App) may improve BP and glycemic control compared with usual care but will have a limited impact on rates of screening, diagnosis, and treatment. We also hypothesize that the multicomponent integrated care will lead to a higher treatment success rate relative to mHealth intervention alone.', 'detailedDescription': 'Background:\\n\\nHypertension is the predominant risk factor for cardiovascular diseases (CVDs) - the leading cause of death worldwide. In 2015, 1 in 5 adult women and close to 1 in 4 adult men had elevated blood pressure. The estimated number of adults with elevated blood pressure increased from 594 million in 1975 to 1.13 billion in 2015, largely due to increases in low- and middle-income countries (LMICs).3 Globally, 10.5% adult population has diabetes, with almost half unaware of the condition they are living with. Complications of persistently elevated blood pressure and poor glycemic control, such as heart disease, stroke, chronic kidney disease, blindness, are well documented. Compared with patients with controlled blood pressure, hypertension patients without treatment and those treated but with uncontrolled blood pressure have substantially higher risk of all-cause and CVD mortality. The factors underlying the gaps in hypertension and diabetes care continuum (i.e., screening, diagnosis, treatment, control) are complex and multifactorial, reflecting the vulnerabilities at individual, community, and healthcare system levels in LMICs.Few studies have examined the strategy to address shortage of healthcare human resources and NCD care accessibility through decentralization with task shifting (or task sharing), which has been shown a viable strategy to rapidly scale-up antiretroviral therapy for HIV/AIDS care in resource-limited settings. Like many other LMICs, Bangladesh is experiencing rapid demographic and epidemiologic transitions. In the recent years, NCD replaced infectious disease and maternal and neonatal conditions as the leading cause of death, accounting for 71% of all deaths in Bangladesh. An estimated 27.4% of Bangladeshi adults have hypertension and 9.8% have diabetes. According to 2017-2018 Bangladesh Demographic and Health Survey, only 36.7% of Bangladeshi adults with hypertension were aware that they had hypertension, and only 31.1% were on treatment and 12.7% had blood pressure controlled. The awareness, treatment, and control rates for diabetes were estimated to be 30.9%, 28.2%, and 26.5%, respectively. Tobacco use, insufficient fruit/vegetable intake, overweight/obese, are highly prevalent. Over the past decade, the Government of Bangladesh has promoted improved NCD care through national multisectoral actions, most notably through the establishment of dedicated noncommunicable disease facilities (\"NCD Corners\") at subdistrict hospitals since 2011. These NCD Corners were designed to provide preventive and clinical care for common NCDs. Despite the initiative, NCD corners remained nascent due to a lack of specific guidelines, trained workforce, appropriate medicines and supplies, adequate laboratory facilities, and poor record-keeping and reporting.\\n\\nIn the present study, we aim to document the experience of implementing a multicomponent, decentralized primary care in rural Bangladesh, including components of healthcare provider training, mHealth, decentralization with task shifting, and community-based care, and to generate data on the effectiveness and cost-effectiveness of the multicomponent integrated care as compared to usual care and to mHealth intervention alone.\\n\\nStudy design\\n\\nThis is a type 2 effectiveness-implementation hybrid study with a dual focus on testing of effectiveness of interventions and implementation strategies.41 A three-arm mixed-methods quasi-experimental design will be used to achieve the aims specified before. Two intervention subdistricts (i.e., mHealth only and mHealth plus task sharing, decentralization, and community-based care) and one reference subdistrict from Dinajpur district, Rangpur division in Northern Bangladesh (Figure 1) will be selected to implement the study. While the key outcomes will be evaluated with community-based repeated cross-sectional surveys with independent samples, we will also make use of facility-based prospective cohort data to supplement community-based surveys. We will employ a mixed methods approach to generate rich data on changes in primary and secondary outcomes, and quantitative and qualitative data for process evaluation. The project duration is 36 months.\\n\\nSpecific objectives and hypothesis of the study\\n\\nSA1: Document the experience of implementing a multicomponent decentralized care in public primary care system for hypertension and diabetes and evaluate the effectiveness of the package compared with usual care and mHealth intervention alone. The findings will not only shed light on the effectiveness of the interventions on treatment outcomes, but will also informing approaches to improve screening, diagnosis, and management of these conditions. Among the first, we expect to provide data on the role of decentralization for expanding NCD care in resource limited settings.\\n\\nSA2: Investigate the factors that explain how the interventions influences hypertension and diabetes management and explore barriers/facilitators to deliver and sustaining intervention. We will conduct mixed methods research to understand how the intervention influences treatment and prevention in this patient population. Particularly, we will assess changes in lifestyle (i.e., smoking, dietary salt intake, physical activity, alcohol consumption), burden for patients (e.g., waiting time, travel-related cost) at individual and community level. Qualitative data will shed light on facilitators and barriers to hypertension and diabetes prevention and control from perspectives of patients (and their families), primary care providers, and public health officials, and other stakeholders.\\n\\nSA3: Undertake a health economic evaluation of the interventions for primary care systems. A comprehensive evaluation of cost and effectiveness will be important for the models tested, providing necessary evidence for policy makes and stakeholders to scale up the interventions.\\n\\nWe hypothesize that compared with usual care, the multicomponent decentralized primary care will improve all steps along the hypertension and diabetes care continuum. On the other hand, we hypothesize that the mHealth intervention alone (Simple App) may improve BP and glycemic control compared with usual care but will have limited impact on rates of screening, diagnosis, and treatment. We also hypothesize that the multicomponent integrated care will lead to higher treatment success rate relative to mHealth intervention alone.\\n\\nStudy population and settings:\\n\\nIn rural Bangladesh, a subdistrict (Upazila) is the second lowest tier of administration, while union is the lowest rural administrative unit, and each union is made up of nine wards (usually one village is designated as a ward). The primary healthcare system in rural areas consist of a subdistrict level hospital (Upazila Health Complexes), union health (sub)centers, and community clinics which cover 2 to 4 villages. A Upazila Health Complex lies at the top of the primary care system. It is typically a 50-bed hospital, serving a population of a few hundred thousand.\\n\\nCommunity clinics are at the lowest level of the healthcare facility hierarchy. With two rooms and drinking-water and lavatory facilities under a covered waiting area, community clinics were designed to be accessible for more than 80% of rural population within less than 30-minute walking distance.42 Community clinics are staffed by a Community Health Care Provider (CHCP), who usually receive 4-month medical training.\\n\\nInterventions\\n\\nBuilt upon assessment of barriers to hypertension and diabetes management at patient, provider, and health system levels and previous interventional studies, a multicomponent intervention package was designed to increase access to primary care, and to improve care quality and patient retention. The intervention package includes mHealth, decentralization with task sharing, community-based care, and supportive monitoring visits. The effectiveness of the intervention package is compared with mHealth only intervention and usual care.\\n\\nDescription of the interventions Multicomponent decentralized care\\n\\nIt will include both government model and mHealth for patient management and some other components like supportive supervisions. In line with Bangladesh government\\'s recommendation, Simple App will be used by primary care facilities for coordinated NCD management. The Simple App was developed and is actively maintained by Resolve to Save Lives (more details about the app can be found from the website https://www.simple.org). The app was designed to tackle two major factors contribute to blood pressure and glycemic control among treated patients with hypertension and diabetes, namely timely titration and adherence with therapy. To accommodate the context of busy primary care facilities, data collection is limited to a few key variables such as prescription, follow-up visit, and changes in blood pressure and blood glucose. Using unique patient ID, the app allows seamless transferring of electronic health records among primary care facilities and thus ensure continuity of the process.\\n\\nEngaging community health workers in NCD care: Integrating hypertension and diabetes care into the community by training CHWs to provide screening, counselling, and follow-up has been shown to improve hypertension and diabetes care management in many LMICs, including countries from South Asia. In line with previous studies, we will enlist CHWs in case finding, counselling, referral, and follow-up. Existing CHWs will be trained and provided with necessary equipment and health education materials and tools to carry out these tasks. Initial training will cover topics including basics of hypertension and diabetes, lifestyle risk factors counselling, patient self-management, and collaboration with CHCPs. A refresher training will be done at 6 months of implementation. CHWs will not be compensated for the activities performed to be consistent with Bangladesh government\\'s plan considering scalability.\\n\\nSupportive monitoring and supervision: Quarterly supervision by higher level health administrators and medical professionals will be organized to NCD corner to help solve issues with patient managements, medication supply etc. Visits may be informed by performance summary made available by Simple App dashboard. Similarly, quarterly supervision to CCs by NCD corner medical staff and subdistrict health officials will be done. Supportive visits by study team will be organized to help NCD corners and CCs solve technical issues with Simple App.\\n\\nmHealth only\\n\\nIn subdistrict with mHealth intervention only, training and support to use Simple App for hypertension and diabetes management will be provided. The healthcare providers at NCD corner will decide how they react to the information made available by the digital tool, and similarly the patient component will not be included. Patient pathways remain the same as usual care.\\n\\nUsual care\\n\\nExisting usual care provided by government primary care system including screening, treatment initiating, drug refill, and routine follow-up, at subdistrict NCD corner. Community clinics and CHWs have less involvement in NCD care provision.'}, 'conditionsModule': {'conditions': ['Hypertension', 'Diabetes'], 'keywords': ['Hypertension', 'Diabetes', 'Care continumm', 'mHealth', 'Decentralized Primary Care', 'Rural Bangladesh']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE1'], 'designInfo': {'allocation': 'NON_RANDOMIZED', 'interventionModel': 'SINGLE_GROUP', 'primaryPurpose': 'SUPPORTIVE_CARE', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 6750, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Multicomponent decentralized care', 'type': 'EXPERIMENTAL', 'description': 'mHealth plus decentralized primary care The multi-component intervention aims to increase access to primary care, and to improve care quality and patient retention. The intervention package includes mHealth, decentralization with task sharing, community-based care, and supportive monitoring visits', 'interventionNames': ['Combination Product: Multicomponent decentralized care', 'Combination Product: mHealth']}, {'label': 'mHealth', 'type': 'ACTIVE_COMPARATOR', 'description': 'In subdistrict with mHealth intervention only, we will provide the same training on hypertension and diabetes care to physicians and nurses at NCD corner in UHC, and training to use Simple App for hypertension and diabetes management. Quarterly supervision by higher-level health administrators and medical professionals to NCD corner helps solve issues with patient management, medication supply, etc. Visits may be informed by a performance summary made available by the Simple App dashboard. Two supportive visits by the study team will be organized to help NCD Corner solve technical issues with Simple App. The healthcare providers at NCD Corner will decide how they react to the information made available by the digital tool, and similarly, the patient component will not be included. Patient pathways remain the same as usual care.', 'interventionNames': ['Combination Product: mHealth']}, {'label': 'Usual care', 'type': 'NO_INTERVENTION', 'description': 'Existing usual care provided by government primary care system including screening, treatment initiating, drug refill, and routine follow-up, at subdistrict NCD corner. Community clinics and CHWs have less involvement in NCD care provision.'}], 'interventions': [{'type': 'COMBINATION_PRODUCT', 'name': 'Multicomponent decentralized care', 'description': '1. Training and support on Simple app for HTN/DM management \\\\& training NCD corner clinicians on clinical guidelines and establish team-based care for Upazila level NCD corner\\n2. CHCPs conduct BP/BG screening, monitoring, lifestyle counseling, dispensing of medications, follow-up overdue patients at CCs \\\\& CHCP care coordination supported by Simple app at community clinics\\n3. CHWs assist in screening, counselling, referral, and follow-up for CHW at village level', 'armGroupLabels': ['Multicomponent decentralized care']}, {'type': 'COMBINATION_PRODUCT', 'name': 'mHealth', 'description': 'Training and support on Simple app for HTN/DM patient management \\\\& training NCD corner clinicians on clinical guidelines of Upazila Health complex', 'armGroupLabels': ['Multicomponent decentralized care', 'mHealth']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Hypertension and Diabetes control', 'description': 'The primary outcome will be the proportion of patients treated for NCDs who achieved or maintained disease-specific controlled status, according to national or WHO PEN protocols. Hypertension is considered controlled if SBP\\\\<140 mmHg and DBP\\\\<90 mmHg for most patients, and if SBP\\\\<130 mmHg and DBP\\\\<80 mmHg for patients who have comorbidities (diabetes, heart disease, stroke, chronic kidney disease) or having 10-year CVD risk ≥ 30%. Goal for glycemic control is fasting plasma glucose 4.4-7.2 mmol/L, or random plasma glucose \\\\<11.1 mmol/L. The effectiveness will be assessed primarily using repeated independent community-based surveys.', 'timeFrame': '2 years and 9 months'}], 'secondaryOutcomes': [{'measure': 'Hypertension and diabetes care cascade', 'description': 'Secondary outcomes include hypertension and diabetes care cascade (i.e. % of patients aware of their condition, % of diagnosed patients on treatment), smoking cessation among HTN/DM patients, and meeting recommended physical activity level.', 'timeFrame': '2 years and 9 months'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* All participants aged 40 or above\\n* With hypertension and diabetes\\n* Residents of specific study areas\\n* Willing to participate\\n\\nExclusion Criteria:\\n\\n* Adults aged less than 40 years\\n* Children\\n* Pregnant women\\n* Severely ill\\n* Having severe disabilities both physical and mental)', 'healthyVolunteers': True, 'sex': 'ALL', 'minimumAge': '40 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Malay K Mridha, PhD', 'role': 'CONTACT', 'phone': '+8801715190573', 'email': 'malay.mridha@bracu.ac.bd'}, {'name': 'Wubin Xie, DrPH', 'role': 'CONTACT', 'email': 'wubin.xie@ntu.edu.sg'}], 'overallOfficials': [{'name': 'Malay K Mridha, PhD', 'affiliation': 'BRAC University - School of Public Health', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'John C Chambers, PhD', 'affiliation': 'Imperial College London', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'BRAC James P Grant School of Public Health', 'status': 'RECRUITING', 'city': 'Dhaka', 'zip': '1213', 'country': 'Bangladesh', 'contacts': [{'name': 'Malay K Mridha, PhD', 'role': 'CONTACT', 'phone': '+8801715190573', 'email': 'malay.mridha@bracu.ac.bd'}], 'geoPoint': {'lat': 23.7104, 'lon': 90.40744}}]}, 'referencesModule': {'references': [{'pmid': '34879977', 'type': 'BACKGROUND', 'citation': 'Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, Stein C, Basit A, Chan JCN, Mbanya JC, Pavkov ME, Ramachandaran A, Wild SH, James S, Herman WH, Zhang P, Bommer C, Kuo S, Boyko EJ, Magliano DJ. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022 Jan;183:109119. doi: 10.1016/j.diabres.2021.109119. Epub 2021 Dec 6. Erratum In: Diabetes Res Clin Pract. 2023 Oct;204:110945. doi: 10.1016/j.diabres.2023.110945.'}, {'pmid': '33309175', 'type': 'BACKGROUND', 'citation': 'Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, Barengo NC, Beaton AZ, Benjamin EJ, Benziger CP, Bonny A, Brauer M, Brodmann M, Cahill TJ, Carapetis J, Catapano AL, Chugh SS, Cooper LT, Coresh J, Criqui M, DeCleene N, Eagle KA, Emmons-Bell S, Feigin VL, Fernandez-Sola J, Fowkes G, Gakidou E, Grundy SM, He FJ, Howard G, Hu F, Inker L, Karthikeyan G, Kassebaum N, Koroshetz W, Lavie C, Lloyd-Jones D, Lu HS, Mirijello A, Temesgen AM, Mokdad A, Moran AE, Muntner P, Narula J, Neal B, Ntsekhe M, Moraes de Oliveira G, Otto C, Owolabi M, Pratt M, Rajagopalan S, Reitsma M, Ribeiro ALP, Rigotti N, Rodgers A, Sable C, Shakil S, Sliwa-Hahnle K, Stark B, Sundstrom J, Timpel P, Tleyjeh IM, Valgimigli M, Vos T, Whelton PK, Yacoub M, Zuhlke L, Murray C, Fuster V; GBD-NHLBI-JACC Global Burden of Cardiovascular Diseases Writing Group. Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study. J Am Coll Cardiol. 2020 Dec 22;76(25):2982-3021. doi: 10.1016/j.jacc.2020.11.010. Erratum In: J Am Coll Cardiol. 2021 Apr 20;77(15):1958-1959. doi: 10.1016/j.jacc.2021.02.039.'}, {'pmid': '27863813', 'type': 'BACKGROUND', 'citation': 'NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19.1 million participants. Lancet. 2017 Jan 7;389(10064):37-55. doi: 10.1016/S0140-6736(16)31919-5. Epub 2016 Nov 16. Erratum In: Lancet. 2020 Sep 26;396(10255):886. doi: 10.1016/S0140-6736(20)31972-3.'}, {'pmid': '19851295', 'type': 'BACKGROUND', 'citation': 'Gu Q, Dillon CF, Burt VL, Gillum RF. Association of hypertension treatment and control with all-cause and cardiovascular disease mortality among US adults with hypertension. Am J Hypertens. 2010 Jan;23(1):38-45. doi: 10.1038/ajh.2009.191. Epub 2009 Oct 22.'}, {'pmid': '18261929', 'type': 'BACKGROUND', 'citation': 'Gu Q, Burt VL, Paulose-Ram R, Yoon S, Gillum RF. High blood pressure and cardiovascular disease mortality risk among U.S. adults: the third National Health and Nutrition Examination Survey mortality follow-up study. Ann Epidemiol. 2008 Apr;18(4):302-9. doi: 10.1016/j.annepidem.2007.11.013. Epub 2008 Feb 8. Erratum In: Ann Epidemiol. 2008 Jun;18(6):515.'}, {'pmid': '30822339', 'type': 'BACKGROUND', 'citation': 'Manne-Goehler J, Geldsetzer P, Agoudavi K, Andall-Brereton G, Aryal KK, Bicaba BW, Bovet P, Brian G, Dorobantu M, Gathecha G, Singh Gurung M, Guwatudde D, Msaidie M, Houehanou C, Houinato D, Jorgensen JMA, Kagaruki GB, Karki KB, Labadarios D, Martins JS, Mayige MT, McClure RW, Mwalim O, Mwangi JK, Norov B, Quesnel-Crooks S, Silver BK, Sturua L, Tsabedze L, Wesseh CS, Stokes A, Marcus M, Ebert C, Davies JI, Vollmer S, Atun R, Barnighausen TW, Jaacks LM. Health system performance for people with diabetes in 28 low- and middle-income countries: A cross-sectional study of nationally representative surveys. PLoS Med. 2019 Mar 1;16(3):e1002751. doi: 10.1371/journal.pmed.1002751. eCollection 2019 Mar.'}, {'pmid': '31327566', 'type': 'BACKGROUND', 'citation': 'Geldsetzer P, Manne-Goehler J, Marcus ME, Ebert C, Zhumadilov Z, Wesseh CS, Tsabedze L, Supiyev A, Sturua L, Bahendeka SK, Sibai AM, Quesnel-Crooks S, Norov B, Mwangi KJ, Mwalim O, Wong-McClure R, Mayige MT, Martins JS, Lunet N, Labadarios D, Karki KB, Kagaruki GB, Jorgensen JMA, Hwalla NC, Houinato D, Houehanou C, Msaidie M, Guwatudde D, Gurung MS, Gathecha G, Dorobantu M, Damasceno A, Bovet P, Bicaba BW, Aryal KK, Andall-Brereton G, Agoudavi K, Stokes A, Davies JI, Barnighausen T, Atun R, Vollmer S, Jaacks LM. The state of hypertension care in 44 low-income and middle-income countries: a cross-sectional study of nationally representative individual-level data from 1.1 million adults. Lancet. 2019 Aug 24;394(10199):652-662. doi: 10.1016/S0140-6736(19)30955-9. Epub 2019 Jul 18.'}, {'pmid': '34050340', 'type': 'BACKGROUND', 'citation': 'Zhou B, Perel P, Mensah GA, Ezzati M. Global epidemiology, health burden and effective interventions for elevated blood pressure and hypertension. Nat Rev Cardiol. 2021 Nov;18(11):785-802. doi: 10.1038/s41569-021-00559-8. Epub 2021 May 28.'}, {'pmid': '31327564', 'type': 'BACKGROUND', 'citation': 'NCD Risk Factor Collaboration (NCD-RisC). Long-term and recent trends in hypertension awareness, treatment, and control in 12 high-income countries: an analysis of 123 nationally representative surveys. Lancet. 2019 Aug 24;394(10199):639-651. doi: 10.1016/S0140-6736(19)31145-6. Epub 2019 Jul 18.'}, {'pmid': '12377092', 'type': 'BACKGROUND', 'citation': 'Bodenheimer T, Wagner EH, Grumbach K. Improving primary care for patients with chronic illness: the chronic care model, Part 2. JAMA. 2002 Oct 16;288(15):1909-14. doi: 10.1001/jama.288.15.1909.'}, {'pmid': '35140165', 'type': 'BACKGROUND', 'citation': 'Kabir A, Karim MN, Islam RM, Romero L, Billah B. Health system readiness for non-communicable diseases at the primary care level: a systematic review. BMJ Open. 2022 Feb 9;12(2):e060387. doi: 10.1136/bmjopen-2021-060387.'}, {'pmid': '25602898', 'type': 'BACKGROUND', 'citation': 'Kruk ME, Nigenda G, Knaul FM. Redesigning primary care to tackle the global epidemic of noncommunicable disease. Am J Public Health. 2015 Mar;105(3):431-7. doi: 10.2105/AJPH.2014.302392. Epub 2015 Jan 20.'}, {'pmid': '30196093', 'type': 'BACKGROUND', 'citation': 'Kruk ME, Gage AD, Arsenault C, Jordan K, Leslie HH, Roder-DeWan S, Adeyi O, Barker P, Daelmans B, Doubova SV, English M, Garcia-Elorrio E, Guanais F, Gureje O, Hirschhorn LR, Jiang L, Kelley E, Lemango ET, Liljestrand J, Malata A, Marchant T, Matsoso MP, Meara JG, Mohanan M, Ndiaye Y, Norheim OF, Reddy KS, Rowe AK, Salomon JA, Thapa G, Twum-Danso NAY, Pate M. High-quality health systems in the Sustainable Development Goals era: time for a revolution. Lancet Glob Health. 2018 Nov;6(11):e1196-e1252. doi: 10.1016/S2214-109X(18)30386-3. Epub 2018 Sep 5. No abstract available. Erratum In: Lancet Glob Health. 2018 Nov;6(11):e1162. doi: 10.1016/S2214-109X(18)30438-8. Lancet Glob Health. 2018 Nov;6(11):e1162. doi: 10.1016/S2214-109X(18)30456-X. Lancet Glob Health. 2021 Aug;9(8):e1067. doi: 10.1016/S2214-109X(21)00250-3.'}, {'pmid': '21112623', 'type': 'BACKGROUND', 'citation': 'Frenk J, Chen L, Bhutta ZA, Cohen J, Crisp N, Evans T, Fineberg H, Garcia P, Ke Y, Kelley P, Kistnasamy B, Meleis A, Naylor D, Pablos-Mendez A, Reddy S, Scrimshaw S, Sepulveda J, Serwadda D, Zurayk H. Health professionals for a new century: transforming education to strengthen health systems in an interdependent world. Lancet. 2010 Dec 4;376(9756):1923-58. doi: 10.1016/S0140-6736(10)61854-5. Epub 2010 Nov 26. No abstract available.'}, {'pmid': '35171912', 'type': 'BACKGROUND', 'citation': 'Chowdhury HA, Paromita P, Mayaboti CA, Rakhshanda S, Rahman FN, Abedin M, Rahman AKMF, Mashreky SR. Assessing service availability and readiness of healthcare facilities to manage diabetes mellitus in Bangladesh: Findings from a nationwide survey. PLoS One. 2022 Feb 16;17(2):e0263259. doi: 10.1371/journal.pone.0263259. eCollection 2022.'}, {'pmid': '36101774', 'type': 'BACKGROUND', 'citation': 'Islam K, Huque R, Saif-Ur-Rahman KM, Ehtesham Kabir ANM, Enayet Hussain AHM. Implementation status of non-communicable disease control program at primary health care level in Bangladesh: Findings from a qualitative research. Public Health Pract (Oxf). 2022 May 10;3:100271. doi: 10.1016/j.puhip.2022.100271. eCollection 2022 Jun.'}, {'pmid': '31752801', 'type': 'BACKGROUND', 'citation': 'Correia JC, Lachat S, Lagger G, Chappuis F, Golay A, Beran D; COHESION Project. Interventions targeting hypertension and diabetes mellitus at community and primary healthcare level in low- and middle-income countries:a scoping review. BMC Public Health. 2019 Nov 21;19(1):1542. doi: 10.1186/s12889-019-7842-6.'}, {'pmid': '36066896', 'type': 'BACKGROUND', 'citation': 'Ye J, Orji IA, Baldridge AS, Ojo TM, Shedul G, Ugwuneji EN, Egenti NB, Aluka-Omitiran K, Okoli RCB, Eze H, Nwankwo A, Hirschhorn LR, Chopra A, Ale BM, Shedul GL, Tripathi P, Kandula NR, Huffman MD, Ojji DB; Hypertension Treatment in Nigeria Program Investigators. Characteristics and Patterns of Retention in Hypertension Care in Primary Care Settings From the Hypertension Treatment in Nigeria Program. JAMA Netw Open. 2022 Sep 1;5(9):e2230025. doi: 10.1001/jamanetworkopen.2022.30025.'}, {'pmid': '21144064', 'type': 'BACKGROUND', 'citation': 'Labhardt ND, Balo JR, Ndam M, Grimm JJ, Manga E. Task shifting to non-physician clinicians for integrated management of hypertension and diabetes in rural Cameroon: a programme assessment at two years. BMC Health Serv Res. 2010 Dec 14;10:339. doi: 10.1186/1472-6963-10-339.'}, {'pmid': '34385229', 'type': 'BACKGROUND', 'citation': 'Deo S, Singh P. Community health worker-led, technology-enabled private sector intervention for diabetes and hypertension management among urban poor: a retrospective cohort study from large Indian metropolitan city. BMJ Open. 2021 Aug 12;11(8):e045246. doi: 10.1136/bmjopen-2020-045246.'}, {'pmid': '30390686', 'type': 'BACKGROUND', 'citation': 'Labrique AB, Wadhwani C, Williams KA, Lamptey P, Hesp C, Luk R, Aerts A. Best practices in scaling digital health in low and middle income countries. Global Health. 2018 Nov 3;14(1):103. doi: 10.1186/s12992-018-0424-z.'}, {'pmid': '25559011', 'type': 'BACKGROUND', 'citation': 'Anchala R, Kaptoge S, Pant H, Di Angelantonio E, Franco OH, Prabhakaran D. Evaluation of effectiveness and cost-effectiveness of a clinical decision support system in managing hypertension in resource constrained primary health care settings: results from a cluster randomized trial. J Am Heart Assoc. 2015 Jan 5;4(1):e001213. doi: 10.1161/JAHA.114.001213.'}, {'pmid': '30586732', 'type': 'BACKGROUND', 'citation': 'Prabhakaran D, Jha D, Prieto-Merino D, Roy A, Singh K, Ajay VS, Jindal D, Gupta P, Kondal D, Goenka S, Jacob P, Singh R, Kumar BGP, Perel P, Tandon N, Patel V; Members of the Research Steering Committee,Investigators,Members of the Data Safety and Monitoring Board. Effectiveness of an mHealth-Based Electronic Decision Support System for Integrated Management of Chronic Conditions in Primary Care: The mWellcare Cluster-Randomized Controlled Trial. Circulation. 2019 Jan 15;139(3):380-391. doi: 10.1161/CIRCULATIONAHA.118.038192. Epub 2018 Nov 10.'}, {'pmid': '31139453', 'type': 'BACKGROUND', 'citation': 'Kumar A, Schwarz D, Acharya B, Agrawal P, Aryal A, Choudhury N, Citrin D, Dangal B, Deukmedjian G, Dhimal M, Dhungana S, Gauchan B, Gupta T, Halliday S, Jha D, Kalaunee SP, Karmacharya B, Kishore S, Koirala B, Kunwar L, Mahar R, Maru S, Mehanni S, Nirola I, Pandey S, Pant B, Pathak M, Poudel S, Rajbhandari I, Raut A, Rimal P, Schwarz R, Shrestha A, Thapa A, Thapa P, Thapa R, Wong L, Maru D. Designing and implementing an integrated non-communicable disease primary care intervention in rural Nepal. BMJ Glob Health. 2019 Apr 29;4(2):e001343. doi: 10.1136/bmjgh-2018-001343. eCollection 2019.'}, {'pmid': '28975305', 'type': 'BACKGROUND', 'citation': 'He J, Irazola V, Mills KT, Poggio R, Beratarrechea A, Dolan J, Chen CS, Gibbons L, Krousel-Wood M, Bazzano LA, Nejamis A, Gulayin P, Santero M, Augustovski F, Chen J, Rubinstein A; HCPIA Investigators. Effect of a Community Health Worker-Led Multicomponent Intervention on Blood Pressure Control in Low-Income Patients in Argentina: A Randomized Clinical Trial. JAMA. 2017 Sep 19;318(11):1016-1025. doi: 10.1001/jama.2017.11358.'}, {'pmid': '32074419', 'type': 'BACKGROUND', 'citation': 'Jafar TH, Gandhi M, de Silva HA, Jehan I, Naheed A, Finkelstein EA, Turner EL, Morisky D, Kasturiratne A, Khan AH, Clemens JD, Ebrahim S, Assam PN, Feng L; COBRA-BPS Study Group. A Community-Based Intervention for Managing Hypertension in Rural South Asia. N Engl J Med. 2020 Feb 20;382(8):717-726. doi: 10.1056/NEJMoa1911965.'}, {'pmid': '31488369', 'type': 'BACKGROUND', 'citation': 'Schwalm JD, McCready T, Lopez-Jaramillo P, Yusoff K, Attaran A, Lamelas P, Camacho PA, Majid F, Bangdiwala SI, Thabane L, Islam S, McKee M, Yusuf S. A community-based comprehensive intervention to reduce cardiovascular risk in hypertension (HOPE 4): a cluster-randomised controlled trial. Lancet. 2019 Oct 5;394(10205):1231-1242. doi: 10.1016/S0140-6736(19)31949-X. Epub 2019 Sep 2.'}, {'pmid': '21997488', 'type': 'BACKGROUND', 'citation': 'Brennan AT, Long L, Maskew M, Sanne I, Jaffray I, MacPhail P, Fox MP. Outcomes of stable HIV-positive patients down-referred from a doctor-managed antiretroviral therapy clinic to a nurse-managed primary health clinic for monitoring and treatment. AIDS. 2011 Oct 23;25(16):2027-36. doi: 10.1097/QAD.0b013e32834b6480.'}, {'pmid': '20557927', 'type': 'BACKGROUND', 'citation': 'Sanne I, Orrell C, Fox MP, Conradie F, Ive P, Zeinecker J, Cornell M, Heiberg C, Ingram C, Panchia R, Rassool M, Gonin R, Stevens W, Truter H, Dehlinger M, van der Horst C, McIntyre J, Wood R; CIPRA-SA Study Team. Nurse versus doctor management of HIV-infected patients receiving antiretroviral therapy (CIPRA-SA): a randomised non-inferiority trial. Lancet. 2010 Jul 3;376(9734):33-40. doi: 10.1016/S0140-6736(10)60894-X. Erratum In: Lancet. 2010 Sep 25;376(9746):1054.'}, {'pmid': '19545398', 'type': 'BACKGROUND', 'citation': 'Lehmann U, Van Damme W, Barten F, Sanders D. Task shifting: the answer to the human resources crisis in Africa? Hum Resour Health. 2009 Jun 21;7:49. doi: 10.1186/1478-4491-7-49.'}, {'pmid': '23807693', 'type': 'BACKGROUND', 'citation': 'Kredo T, Ford N, Adeniyi FB, Garner P. Decentralising HIV treatment in lower- and middle-income countries. Cochrane Database Syst Rev. 2013 Jun 27;2013(6):CD009987. doi: 10.1002/14651858.CD009987.pub2.'}, {'pmid': '35945426', 'type': 'BACKGROUND', 'citation': 'Kaur P, Kunwar A, Sharma M, Durgad K, Gupta S; India Hypertension Control Initiative collaboration; Bhargava B. The India Hypertension Control Initiative-early outcomes in 26 districts across five states of India, 2018-2020. J Hum Hypertens. 2023 Jul;37(7):560-567. doi: 10.1038/s41371-022-00742-5. Epub 2022 Aug 9.'}, {'pmid': '33168004', 'type': 'BACKGROUND', 'citation': 'Patel SA, Sharma H, Mohan S, Weber MB, Jindal D, Jarhyan P, Gupta P, Sharma R, Ali M, Ali MK, Narayan KMV, Prabhakaran D, Gupta Y, Roy A, Tandon N. The Integrated Tracking, Referral, and Electronic Decision Support, and Care Coordination (I-TREC) program: scalable strategies for the management of hypertension and diabetes within the government healthcare system of India. BMC Health Serv Res. 2020 Nov 9;20(1):1022. doi: 10.1186/s12913-020-05851-w.'}, {'pmid': '33069326', 'type': 'BACKGROUND', 'citation': 'GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020 Oct 17;396(10258):1204-1222. doi: 10.1016/S0140-6736(20)30925-9. Erratum In: Lancet. 2020 Nov 14;396(10262):1562. doi: 10.1016/S0140-6736(20)32226-1.'}, {'pmid': '35685557', 'type': 'BACKGROUND', 'citation': 'Khan N, Oldroyd JC, Hossain MB, Islam RM. Awareness, Treatment, and Control of Diabetes in Bangladesh: Evidence from the Bangladesh Demographic and Health Survey 2017/18. Int J Clin Pract. 2022 Apr 22;2022:8349160. doi: 10.1155/2022/8349160. eCollection 2022.'}, {'pmid': '34492733', 'type': 'BACKGROUND', 'citation': 'Khan MN, Oldroyd JC, Chowdhury EK, Hossain MB, Rana J, Renzetti S, Islam RM. Prevalence, awareness, treatment, and control of hypertension in Bangladesh: Findings from National Demographic and Health Survey, 2017-2018. J Clin Hypertens (Greenwich). 2021 Oct;23(10):1830-1842. doi: 10.1111/jch.14363. Epub 2021 Sep 7.'}, {'pmid': '33247026', 'type': 'BACKGROUND', 'citation': 'Riaz BK, Islam MZ, Islam ANMS, Zaman MM, Hossain MA, Rahman MM, Khanam F, Amin KMB, Noor IN. Risk factors for non-communicable diseases in Bangladesh: findings of the population-based cross-sectional national survey 2018. BMJ Open. 2020 Nov 27;10(11):e041334. doi: 10.1136/bmjopen-2020-041334.'}, {'pmid': '36639189', 'type': 'BACKGROUND', 'citation': 'Burka D, Gupta R, Moran AE, Cohn J, Choudhury SR, Cheadle T, Mullick R, Frieden TR. Keep it simple: designing a user-centred digital information system to support chronic disease management in low/middle-income countries. BMJ Health Care Inform. 2023 Jan;30(1):e100641. doi: 10.1136/bmjhci-2022-100641.'}, {'pmid': '22310560', 'type': 'BACKGROUND', 'citation': 'Curran GM, Bauer M, Mittman B, Pyne JM, Stetler C. Effectiveness-implementation hybrid designs: combining elements of clinical effectiveness and implementation research to enhance public health impact. Med Care. 2012 Mar;50(3):217-26. doi: 10.1097/MLR.0b013e3182408812.'}, {'pmid': '24268002', 'type': 'BACKGROUND', 'citation': 'Chowdhury AM, Bhuiya A, Chowdhury ME, Rasheed S, Hussain Z, Chen LC. The Bangladesh paradox: exceptional health achievement despite economic poverty. Lancet. 2013 Nov 23;382(9906):1734-45. doi: 10.1016/S0140-6736(13)62148-0. Epub 2013 Nov 21.'}, {'pmid': '26903017', 'type': 'BACKGROUND', 'citation': 'Schwalm JD, McKee M, Huffman MD, Yusuf S. Resource Effective Strategies to Prevent and Treat Cardiovascular Disease. Circulation. 2016 Feb 23;133(8):742-55. doi: 10.1161/CIRCULATIONAHA.115.008721.'}, {'pmid': '30147302', 'type': 'BACKGROUND', 'citation': 'Naheed A, Haldane V, Jafar TH, Chakma N, Legido-Quigley H. Patient pathways and perceptions of hypertension treatment, management, and control in rural Bangladesh: a qualitative study. Patient Prefer Adherence. 2018 Aug 14;12:1437-1449. doi: 10.2147/PPA.S163385. eCollection 2018.'}, {'pmid': '30682093', 'type': 'BACKGROUND', 'citation': \"Legido-Quigley H, Naheed A, de Silva HA, Jehan I, Haldane V, Cobb B, Tavajoh S, Chakma N, Kasturiratne A, Siddiqui S, Jafar TH; for COBRA-BPS Study group. Patients' experiences on accessing health care services for management of hypertension in rural Bangladesh, Pakistan and Sri Lanka: A qualitative study. PLoS One. 2019 Jan 25;14(1):e0211100. doi: 10.1371/journal.pone.0211100. eCollection 2019.\"}, {'pmid': '21382643', 'type': 'BACKGROUND', 'citation': 'Nam S, Chesla C, Stotts NA, Kroon L, Janson SL. Barriers to diabetes management: patient and provider factors. Diabetes Res Clin Pract. 2011 Jul;93(1):1-9. doi: 10.1016/j.diabres.2011.02.002. Epub 2011 Mar 5.'}, {'pmid': '30920917', 'type': 'BACKGROUND', 'citation': 'Burnier M, Egan BM. Adherence in Hypertension. Circ Res. 2019 Mar 29;124(7):1124-1140. doi: 10.1161/CIRCRESAHA.118.313220.'}, {'pmid': '25754566', 'type': 'BACKGROUND', 'citation': 'Abrahams-Gessel S, Denman CA, Montano CM, Gaziano TA, Levitt N, Rivera-Andrade A, Carrasco DM, Zulu J, Khanam MA, Puoane T. The training and fieldwork experiences of community health workers conducting population-based, noninvasive screening for CVD in LMIC. Glob Heart. 2015 Mar;10(1):45-54. doi: 10.1016/j.gheart.2014.12.008.'}, {'pmid': '29221543', 'type': 'BACKGROUND', 'citation': 'Alaofe H, Asaolu I, Ehiri J, Moretz H, Asuzu C, Balogun M, Abosede O, Ehiri J. Community Health Workers in Diabetes Prevention and Management in Developing Countries. Ann Glob Health. 2017 May-Aug;83(3-4):661-675. doi: 10.1016/j.aogh.2017.10.009. Epub 2017 Nov 22.'}, {'pmid': '31097278', 'type': 'BACKGROUND', 'citation': 'Anand TN, Joseph LM, Geetha AV, Prabhakaran D, Jeemon P. Task sharing with non-physician health-care workers for management of blood pressure in low-income and middle-income countries: a systematic review and meta-analysis. Lancet Glob Health. 2019 Jun;7(6):e761-e771. doi: 10.1016/S2214-109X(19)30077-4. Erratum In: Lancet Glob Health. 2019 Nov;7(11):e1499. doi: 10.1016/S2214-109X(19)30367-5.'}, {'pmid': '26187361', 'type': 'BACKGROUND', 'citation': \"Gaziano TA, Abrahams-Gessel S, Denman CA, Montano CM, Khanam M, Puoane T, Levitt NS. An assessment of community health workers' ability to screen for cardiovascular disease risk with a simple, non-invasive risk assessment instrument in Bangladesh, Guatemala, Mexico, and South Africa: an observational study. Lancet Glob Health. 2015 Sep;3(9):e556-63. doi: 10.1016/S2214-109X(15)00143-6. Epub 2015 Jul 14.\"}, {'pmid': '31996250', 'type': 'BACKGROUND', 'citation': 'Schwarz D, Dhungana S, Kumar A, Acharya B, Agrawal P, Aryal A, Baum A, Choudhury N, Citrin D, Dangal B, Dhimal M, Gauchan B, Gupta T, Halliday S, Karmacharya B, Kishore S, Koirala B, Kshatriya U, Levine E, Maru S, Rimal P, Sapkota S, Schwarz R, Shrestha A, Thapa A, Maru D. An integrated intervention for chronic care management in rural Nepal: protocol of a type 2 hybrid effectiveness-implementation study. Trials. 2020 Jan 29;21(1):119. doi: 10.1186/s13063-020-4063-3.'}, {'pmid': '34143882', 'type': 'BACKGROUND', 'citation': 'Song P, Gupta A, Goon IY, Hasan M, Mahmood S, Pradeepa R, Siddiqui S, Frost GS, Kusuma D, Miraldo M, Sassi F, Wareham NJ, Ahmed S, Anjana RM, Brage S, Forouhi NG, Jha S, Kasturiratne A, Katulanda P, Khawaja KI, Loh M, Mridha MK, Wickremasinghe AR, Kooner JS, Chambers JC; South Asia Biobank. Remaining authors are listed at the end of the article. Data Resource Profile: Understanding the patterns and determinants of health in South Asians-the South Asia Biobank. Int J Epidemiol. 2021 Jul 9;50(3):717-718e. doi: 10.1093/ije/dyab029. No abstract available.'}, {'pmid': '30486858', 'type': 'BACKGROUND', 'citation': 'Gandhi M, Assam PN, Turner EL, Morisky DE, Chan E, Jafar TH; COBRA-BPS Study Group. Statistical analysis plan for the control of blood pressure and risk attenuation-rural Bangladesh, Pakistan, Sri Lanka (COBRA-BPS) trial: a cluster randomized trial for a multicomponent intervention versus usual care in hypertensive patients. Trials. 2018 Nov 29;19(1):658. doi: 10.1186/s13063-018-3022-8.'}, {'pmid': '37984955', 'type': 'BACKGROUND', 'citation': 'Xie W, Paul RR, Goon IY, Anan A, Rahim A, Hossain MM, Hersch F, Oldenburg B, Chambers J, Mridha MK. Enhancing care quality and accessibility through digital technology-supported decentralisation of hypertension and diabetes management: a proof-of-concept study in rural Bangladesh. BMJ Open. 2023 Nov 19;13(11):e073743. doi: 10.1136/bmjopen-2023-073743.'}, {'pmid': '7580713', 'type': 'BACKGROUND', 'citation': 'Campbell MJ, Julious SA, Altman DG. Estimating sample sizes for binary, ordered categorical, and continuous outcomes in two group comparisons. BMJ. 1995 Oct 28;311(7013):1145-8. doi: 10.1136/bmj.311.7013.1145. Erratum In: BMJ 1996 Jan 13;312(7023):96.'}, {'pmid': '20335814', 'type': 'BACKGROUND', 'citation': 'Lipsitch M, Tchetgen Tchetgen E, Cohen T. Negative controls: a tool for detecting confounding and bias in observational studies. Epidemiology. 2010 May;21(3):383-8. doi: 10.1097/EDE.0b013e3181d61eeb. Erratum In: Epidemiology. 2010 Jul;21(4):589.'}, {'pmid': '22072596', 'type': 'BACKGROUND', 'citation': 'Zou GY, Donner A. Extension of the modified Poisson regression model to prospective studies with correlated binary data. Stat Methods Med Res. 2013 Dec;22(6):661-70. doi: 10.1177/0962280211427759. Epub 2011 Nov 8.'}, {'pmid': '21841157', 'type': 'BACKGROUND', 'citation': 'Yelland LN, Salter AB, Ryan P. Performance of the modified Poisson regression approach for estimating relative risks from clustered prospective data. Am J Epidemiol. 2011 Oct 15;174(8):984-92. doi: 10.1093/aje/kwr183. Epub 2011 Aug 12.'}, {'pmid': '33404857', 'type': 'BACKGROUND', 'citation': 'Xu X, Lazar CM, Ruger JP. Micro-costing in health and medicine: a critical appraisal. Health Econ Rev. 2021 Jan 6;11(1):1. doi: 10.1186/s13561-020-00298-5.'}, {'pmid': '27623463', 'type': 'BACKGROUND', 'citation': 'Sanders GD, Neumann PJ, Basu A, Brock DW, Feeny D, Krahn M, Kuntz KM, Meltzer DO, Owens DK, Prosser LA, Salomon JA, Sculpher MJ, Trikalinos TA, Russell LB, Siegel JE, Ganiats TG. Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine. JAMA. 2016 Sep 13;316(10):1093-103. doi: 10.1001/jama.2016.12195. Erratum In: JAMA. 2016 Nov 8;316(18):1924. doi: 10.1001/jama.2016.15518.'}, {'pmid': '27429489', 'type': 'BACKGROUND', 'citation': 'Oti SO, van de Vijver S, Gomez GB, Agyemang C, Egondi T, Kyobutungi C, Stronks K. Outcomes and costs of implementing a community-based intervention for hypertension in an urban slum in Kenya. Bull World Health Organ. 2016 Jul 1;94(7):501-9. doi: 10.2471/BLT.15.156513. Epub 2016 Apr 26.'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2024-11-22'}, 'conditionBrowseModule': {'meshes': [{'id': 'D006973', 'term': 'Hypertension'}, {'id': 'D003920', 'term': 'Diabetes Mellitus'}], 'ancestors': [{'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}, {'id': 'D014652', 'term': 'Vascular Diseases'}, {'id': 'D002318', 'term': 'Cardiovascular Diseases'}], 'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'asFound': 'Diabetes', 'relevance': 'HIGH'}, {'id': 'M10024', 'name': 'Hypertension', 'asFound': 'Hypertension', 'relevance': 'HIGH'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}, {'id': 'M17400', 'name': 'Vascular Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC14', 'name': 'Heart and Blood Diseases'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT00123227', 'orgStudyIdInfo': {'id': '02-210'}, 'organization': {'fullName': 'Royal Brompton & Harefield NHS Foundation Trust', 'class': 'OTHER'}, 'briefTitle': 'Rosiglitazone Plaque Study', 'officialTitle': 'A Randomised, Double-Blind, Placebo-Controlled, Cardiovascular Magnetic Resonance (CMR) Study to Evaluate the Effect of Rosiglitazone on Carotid Atherosclerotic Plaques in Type 2 Diabetics With Vascular Disease or Hypertension'}, 'statusModule': {'statusVerifiedDate': '2005-05', 'overallStatus': 'UNKNOWN', 'lastKnownStatus': 'ACTIVE_NOT_RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2002-10'}, 'completionDateStruct': {'date': '2005-05'}, 'studyFirstSubmitDate': '2005-07-19', 'studyFirstSubmitQcDate': '2005-07-19', 'studyFirstPostDateStruct': {'date': '2005-07-22', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2005-07-29', 'lastUpdatePostDateStruct': {'date': '2005-08-01', 'type': 'ESTIMATED'}}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Royal Brompton & Harefield NHS Foundation Trust', 'class': 'OTHER'}, 'collaborators': [{'name': 'GlaxoSmithKline', 'class': 'INDUSTRY'}, {'name': 'CORDA, The Heart Charity', 'class': 'OTHER'}]}, 'descriptionModule': {'briefSummary': 'The purpose of this study is to determine whether rosiglitazone, a peroxisome proliferator activated receptor gamma (PPAR-gamma) agonist, induces regression in carotid atherosclerotic plaques in diabetic patients with vascular disease and/or hypertension over a 12 month period.', 'detailedDescription': 'Rosiglitazone is a new member of the thiazolidinediones (TZDs), a class of drugs which act by binding to peroxisome proliferator activated receptor gamma (PPAR-gamma). It has been suggested that the TZD class od anti-diabetic drug may exhibit anti-atherosclerotic effects. The aim of this study is to evaluate over a 12 month period the potential benefits of rosiglitazone on carotid artery atherosclerotic plaques in the type 2 diabetic population with coexisting vascular disease or hypertension. It is hypothesised that treatment with rosiglitazone will lead to a decrease in plaque size. In addition it is hoped that rosiglitazone will have a positive effect on the plaque composition and stability.\\n\\nThe primary endpoint will be the plaque volume change over 12 months as assessed by cardiovascular magnetic resonance (CMR). The effectiveness of this modality to evaluate the effects of pharmacological agents on atherosclerosis in vivo has been demonstrated in previous studies using statins.\\n\\nThe secondary endpoints will be to define the changes in plaque lipid content, fibrous cap thickness and gadolinium enhancement as a measure of fibrous cap inflammation and plaque neovascularisation.'}, 'conditionsModule': {'conditions': ['Diabetes Mellitus, Type 2', 'Vascular Diseases', 'Hypertension'], 'keywords': ['Randomised controlled trial', 'Rosiglitazone', 'Cardiovascular magnetic resonance', 'Diabetes Mellitus', 'Vascular Diseases', 'Hypertension']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE3'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'SINGLE_GROUP', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'DOUBLE'}}, 'enrollmentInfo': {'count': 60}}, 'armsInterventionsModule': {'interventions': [{'type': 'DRUG', 'name': 'Rosiglitazone'}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Plaque volume change over 12 months as assessed by cardiovascular magnetic resonance (CMR)'}], 'secondaryOutcomes': [{'measure': 'Change in plaque lipid content'}, {'measure': 'Change in plaque fibrous cap thickness'}, {'measure': 'Change in plaque gadolinium enhancement as a measure of fibrous cap inflammation and plaque neovascularisation'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* Patients with type 2 diabetes as defined by the World Health Organization (WHO) criteria\\n* Male or female patient who is 30 to 75 years of age at screening\\n* Patients with coexisting vascular disease (previous myocardial infarction, cerebrovascular accident or peripheral vascular disease) or hypertension (BP \\\\> 150/90)\\n* Patients who have initiated statin and fibrate therapy at least 6 months prior to screening, and have been receiving a stable dose for at least 3 months prior to screening. \\\\[Note: patients not receiving statin or fibrate therapy will be allowed to enter the study providing that this method of treatment is not required as active treatment for their medical condition at the time of screening; if any of these patients develop the need for statin or fibrate therapy during the course of the study, therapy will be started without the need to withdraw the patient from the study.\\\\]\\n* Female patients must be post-menopausal, surgically sterile, or using effective contraceptive measures. Women of childbearing age must use effective contraceptive measures for at least 1 month prior to visit 1 (screening), and should continue to use the same contraceptive method during the study and for 30 days after discontinuing study treatment.\\n* Patients who give their signed informed consent to participate.\\n* Patients with an HbA1c value \\\\< 10% at screening visit.\\n* Patients with evidence of at least one atheromatous plaque causing narrowing of internal carotid artery between 10 and 95%. Diagnosis to be performed prior to randomisation by colour duplex examination.\\n\\nExclusion Criteria:\\n\\n* Patients who have taken \\\\>2 concomitant oral anti-hypertensive agents (i.e. oral combination) within the 3 months prior to the screening visit (visit 1)\\n* Previous exposure to a thiazolidinedione (TZD) or other PPAR-gamma agonist (e.g. rosiglitazone, troglitazone, pioglitazone, GI262570) or participation in a double-blind clinical study involving a TZD or PPAR-gamma agonist where the randomisation code has not been broken prior to visit 1 (screening) of this study.\\n* Patients who have required the chronic use of insulin for glycaemic control at any time in the past (with the exception of those who have needed short-term insulin use to maintain glycaemic control during a hospitalisation, during pregnancy or during a medical procedure or intervention) or patients with a history of ketoacidosis.\\n* Use of any investigational drug within 30 days of 5 half-lives preceding the first dose of medication at the start of the study.\\n* Systolic blood pressure \\\\>170 mmHg or diastolic blood pressure \\\\> 100mHg.\\n* Patients with unstable or severe angina or congestive heart failure (New York Heart Association \\\\[NYHA\\\\] class I-IV)\\n* History of gangrene or transient ischaemic attack (TIA)\\n* History of stroke within the previous year.\\n* Presence of clinically significant hepatic disease (i.e. patients with ALT, total bilirubin, or alkaline phosphatase \\\\> 2.5 times the upper limit of the normal laboratory range)\\n* Any pre-existing condition or clinically significant abnormality identified in the screening (visit 1) physical examination, electrocardiogram, ultrasound examination or laboratory tests which, in the judgement of the investigator, would preclude safe completion of the study.\\n* Clinically significant anaemia defined by haemoglobin concentration \\\\<11g/dL for males, or \\\\<10 g/dL for females\\n* Patients with creatinine \\\\> 150 umol/L.\\n* Women who are lactating, pregnant, or planning to become pregnant during the course of the study.\\n* Alcohol or drug abuse within the last 6 months.\\n* Previous surgery to carotid arteries.\\n* Pacemakers, cerebral aneurysm clips, claustrophobia or any implantable devices incompatible with magnetic resonance imaging.\\n* Patients exhibiting total occlusion of the internal carotid artery (when assessed by colour duplex examination performed).\\n* Patients unable to lie supine for 60 minutes.', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '30 Years', 'maximumAge': '75 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Dudley J Pennell, MD FRCP FACC', 'affiliation': 'Cardiovascular Magnetic Resonance Unit, Royal Brompton Hospital, London UK / National Heart and Lung Institute, Imperial College, London UK', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'Cardiovascular Magnetic Resonance Unit, Royal Brompton Hospital', 'city': 'London', 'zip': 'SW3 6NP', 'country': 'United Kingdom', 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}, {'facility': \"St Mary's NHS Trust\", 'city': 'London', 'zip': 'W2 1NY', 'country': 'United Kingdom', 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2024-11-22'}, 'conditionBrowseModule': {'meshes': [{'id': 'D006973', 'term': 'Hypertension'}, {'id': 'D014652', 'term': 'Vascular Diseases'}, {'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D003924', 'term': 'Diabetes Mellitus, Type 2'}], 'ancestors': [{'id': 'D002318', 'term': 'Cardiovascular Diseases'}, {'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}], 'browseLeaves': [{'id': 'M7119', 'name': 'Diabetes Mellitus, Type 2', 'asFound': 'Diabetes Mellitus, Type 2', 'relevance': 'HIGH'}, {'id': 'M17400', 'name': 'Vascular Diseases', 'asFound': 'Vascular Disease', 'relevance': 'HIGH'}, {'id': 'M7115', 'name': 'Diabetes Mellitus', 'asFound': 'Diabetes Mellitus', 'relevance': 'HIGH'}, {'id': 'M10024', 'name': 'Hypertension', 'asFound': 'Hypertension', 'relevance': 'HIGH'}, {'id': 'M29003', 'name': 'Plaque, Atherosclerotic', 'relevance': 'LOW'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC14', 'name': 'Heart and Blood Diseases'}, {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D000077154', 'term': 'Rosiglitazone'}], 'ancestors': [{'id': 'D007004', 'term': 'Hypoglycemic Agents'}, {'id': 'D045505', 'term': 'Physiological Effects of Drugs'}], 'browseLeaves': [{'id': 'M1677', 'name': 'Rosiglitazone', 'asFound': 'Muscle strength', 'relevance': 'HIGH'}, {'id': 'M10054', 'name': 'Hypoglycemic Agents', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'Hypo', 'name': 'Hypoglycemic Agents'}, {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT03539627', 'orgStudyIdInfo': {'id': 'IISR-2017-102380'}, 'organization': {'fullName': 'Research Institute for Complex Problems of Cardiovascular Diseases, Russia', 'class': 'OTHER'}, 'briefTitle': 'Azilsartan Medoxomil in Hypertensive pAtients With Stable Ischemic Heart Disease and DiabEtes MEllitus.', 'officialTitle': 'One-center, Observational, Non-interventional, Prospective Study of the Efficacy of Azilsartan Medoxomil in Patients With Arterial Hypertension Associated With Stable Ischemic Heart Disease and Type 2 Diabetes Mellitus.', 'acronym': 'AcADEME'}, 'statusModule': {'statusVerifiedDate': '2022-10', 'overallStatus': 'COMPLETED', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2018-11-07', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2022-04-29', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2022-04-29', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2018-05-02', 'studyFirstSubmitQcDate': '2018-05-16', 'studyFirstPostDateStruct': {'date': '2018-05-29', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2022-10-24', 'lastUpdatePostDateStruct': {'date': '2022-10-26', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorFullName': 'Olga Barbarash', 'investigatorTitle': 'Professor', 'investigatorAffiliation': 'Research Institute for Complex Problems of Cardiovascular Diseases, Russia'}, 'leadSponsor': {'name': 'Research Institute for Complex Problems of Cardiovascular Diseases, Russia', 'class': 'OTHER'}}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False, 'isUsExport': False}, 'descriptionModule': {'briefSummary': 'One-center, observational, non-interventional, prospective study of the efficacy of azilsartan medoxomil in patients with arterial hypertension associated with stable ischemic heart disease and type 2 diabetes mellitus.', 'detailedDescription': 'One-center, observational, non-interventional, prospective study of the efficacy of azilsartan medoxomil in patients with arterial hypertension associated with stable ischemic heart disease and type 2 diabetes mellitus.\\n\\nDuring the study 5 visits to the research center are planned. At each visit, a physical examination, sampling of bio-samples for evaluation in the local laboratory, and collection of information on adverse events will be performed. 24-hours monitoring of blood pressure will be performed at screening, after 1 months of therapy and at the final visit (6 months of therapy).\\n\\nData will be collected during 5 consecutive visits to the research center. The observation period will be about 6 months, the active treatment period will be at least 6 months (24 weeks). Patients included in the study will be observed in an outpatient clinic according to the local practice of the research center.\\n\\nIt is planned that potentially eligible patients will be invited to the screening visit. Based on the results of daily monitoring of blood pressure, a final decision will be made about the suitability of the patient to participate in the study. Patients who have not reached the target values of blood pressure will start taking the study drug (Edarbi). By not achieving the target values of blood pressure, the mean daily systolic blood pressure is more than 130 mm Hg and the diastolic blood pressure is more than 90 mm Hg. The length of time between Visit 1 and Visit 2 is suspected to be no longer than 2 weeks.\\n\\nAll examinations (examination and evaluation of vital functions, laboratory tests, instrumental examinations) will be performed in accordance with the general standards of medical practice and in accordance with the routine practice of the institution.\\n\\nBased on the number of patients hospitalized in the Research Institute For Complex Issues Of Cardiovascular Diseases (1500 patients), as well as the data on the prevalence of type 2 diabetes in this group (23.5%, 353 patients), the required sample size will be 184 patients (Confidence interval ± 5 %, the confidence probability is 95%).\\n\\nSS = Z2 \\\\* (p) \\\\* (1-p) C2 where: Z = Z factor (1,96 for 95% confidence interval) p = percentage of respondents required, in decimal form (0,5 by default) c = confidence interval, in decimal form (for example, 0,04 = ±4%).'}, 'conditionsModule': {'conditions': ['Arterial Hypertension', 'Diabetes Mellitus', 'Stable Chronic Angina'], 'keywords': ['diabetes mellitus', 'Edarbi', 'hypertension']}, 'designModule': {'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'COHORT', 'timePerspective': 'PROSPECTIVE'}, 'bioSpec': {'retention': 'SAMPLES_WITHOUT_DNA', 'description': 'Serum, urine'}, 'enrollmentInfo': {'count': 184, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'patients with hypertension, CAD and diabetes', 'description': 'Patients with hypertension associated with stable CAD and diabetes on azilsartan medoxomil (Edarbi) therapy', 'interventionNames': ['Drug: Azilsartan Medoxomil 40 MG Oral Tablet [Edarbi]']}], 'interventions': [{'type': 'DRUG', 'name': 'Azilsartan Medoxomil 40 MG Oral Tablet [Edarbi]', 'description': 'patients are to receive azilsartan medoxomil', 'armGroupLabels': ['patients with hypertension, CAD and diabetes']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Systolic blood pressure', 'description': 'Dynamics of clinical SBP from the baseline against the background of therapy with Edarbi®', 'timeFrame': 'interval: up to 24 weeks'}], 'secondaryOutcomes': [{'measure': 'Diastolic blood pressure', 'description': 'Dynamics of clinical DBP from the baseline against the background of therapy with Edarbi® (interval: Visit of inclusion - Visit 5);', 'timeFrame': 'interval: up to 24 weeks'}, {'measure': 'Dynamics of renal function (filtration)', 'description': 'Dynamics of eGFR', 'timeFrame': 'interval: up to 24 weeks'}, {'measure': 'Edarbi® efficacy', 'description': 'proportion of patients who respond to Edarbi® therapy (defined as decrease of SBP≥ 20 mm Hg or decrease of DBP≥10 mm Hg)', 'timeFrame': 'interval: up to 24 weeks'}, {'measure': 'Dynamics of renal function (evidence of kidney injury)', 'description': 'N-GAL-dynamics', 'timeFrame': 'interval: up to 24 weeks'}, {'measure': 'Dynamics of renal function (proteinuria detecton)', 'description': 'UACR dynamics', 'timeFrame': 'interval: up to 24 weeks'}]}, 'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\n\\n1. Informed consent signed by the patient.\\n2. Men and women aged 18 years and older with a previously diagnosed hypertension and type 2 diabetes mellitus and stable ischemic heart disease.\\n3. Stable therapy of hypertension, T2DM and ischemic heart disease for at least 12 weeks before screening.\\n4. Not achievement of target values \\\\* of blood pressure against the background of previously prescribed and steadily accepted antihypertensive therapy.\\n\\n   \\\\* not reaching the target figures of arterial pressure means mean systolic blood pressure more than 130 mm Hg and / or an average diastolic blood pressure more than 90 mmHg.\\n5. Investigator's decision on the advisability of correction of previously prescribed therapy with the replacement of ACE inhibitors or other ARBs with azilsartan medoxomil.\\n\\nExclusion Criteria:\\n\\n1. Contraindications to the azilsartan medoxomil in accordance with instruction for use, including information on the individual intolerance of the drug.\\n2. Any circumstances in the opinion of the investigator that interfere with the participation of the patient in the study.\\n3. The patient included in the study is an employee of the center or a relative of the investigator.\\n4. Participation in other clinical trials. Participation in register studies is allowed.\\n5. Any disease or condition that leads to a decrease in the patient's life expectancy.\", 'healthyVolunteers': False, 'sex': 'ALL', 'genderBased': True, 'genderDescription': 'adult patients only', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'studyPopulation': 'Patients with arterial hypertension associated with stable ischemic heart disease and type 2 diabetes mellitus', 'samplingMethod': 'NON_PROBABILITY_SAMPLE'}, 'contactsLocationsModule': {'locations': [{'facility': 'Anastasia Kochergina', 'city': 'Kemerovo', 'zip': '650002', 'country': 'Russian Federation', 'geoPoint': {'lat': 55.33333, 'lon': 86.08333}}]}, 'referencesModule': {'seeAlsoLinks': [{'label': 'Kochergina A.M., Barbarash O.L. Azilsartan medoxomil: opportunities and prospects in diabetes mellitus. \"Arterial\\'naya Gipertenziya\" (\"Arterial Hypertension\"). 2021;27(2):247-254. (In Russ.)', 'url': 'https://htn.almazovcentre.ru/jour/article/view/2079'}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2024-11-22'}, 'conditionBrowseModule': {'meshes': [{'id': 'D006973', 'term': 'Hypertension'}, {'id': 'D006331', 'term': 'Heart Diseases'}, {'id': 'D017202', 'term': 'Myocardial Ischemia'}, {'id': 'D003324', 'term': 'Coronary Artery Disease'}, {'id': 'D060050', 'term': 'Angina, Stable'}, {'id': 'D003920', 'term': 'Diabetes Mellitus'}], 'ancestors': [{'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}, {'id': 'D014652', 'term': 'Vascular Diseases'}, {'id': 'D002318', 'term': 'Cardiovascular Diseases'}, {'id': 'D003327', 'term': 'Coronary Disease'}, {'id': 'D001161', 'term': 'Arteriosclerosis'}, {'id': 'D001157', 'term': 'Arterial Occlusive Diseases'}, {'id': 'D000787', 'term': 'Angina Pectoris'}, {'id': 'D002637', 'term': 'Chest Pain'}, {'id': 'D010146', 'term': 'Pain'}, {'id': 'D009461', 'term': 'Neurologic Manifestations'}], 'browseLeaves': [{'id': 'M10543', 'name': 'Ischemia', 'relevance': 'LOW'}, {'id': 'M9419', 'name': 'Heart Diseases', 'asFound': 'Heart Disease', 'relevance': 'HIGH'}, {'id': 'M6546', 'name': 'Coronary Artery Disease', 'asFound': 'Ischemic Heart Disease', 'relevance': 'HIGH'}, {'id': 'M19506', 'name': 'Myocardial Ischemia', 'asFound': 'Ischemic Heart Disease', 'relevance': 'HIGH'}, {'id': 'M7119', 'name': 'Diabetes Mellitus, Type 2', 'relevance': 'LOW'}, {'id': 'M7115', 'name': 'Diabetes Mellitus', 'asFound': 'Diabetes Mellitus', 'relevance': 'HIGH'}, {'id': 'M10024', 'name': 'Hypertension', 'asFound': 'Hypertension', 'relevance': 'HIGH'}, {'id': 'M4117', 'name': 'Angina Pectoris', 'relevance': 'LOW'}, {'id': 'M29575', 'name': 'Angina, Stable', 'asFound': 'Stable Chronic Angina', 'relevance': 'HIGH'}, {'id': 'M6549', 'name': 'Coronary Disease', 'relevance': 'LOW'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}, {'id': 'M17400', 'name': 'Vascular Diseases', 'relevance': 'LOW'}, {'id': 'M4469', 'name': 'Arteriosclerosis', 'relevance': 'LOW'}, {'id': 'M4465', 'name': 'Arterial Occlusive Diseases', 'relevance': 'LOW'}, {'id': 'M13066', 'name': 'Pain', 'relevance': 'LOW'}, {'id': 'M5882', 'name': 'Chest Pain', 'relevance': 'LOW'}, {'id': 'M12404', 'name': 'Neurologic Manifestations', 'relevance': 'LOW'}, {'id': 'T1303', 'name': 'Chronic Graft Versus Host Disease', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC14', 'name': 'Heart and Blood Diseases'}, {'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'BC10', 'name': 'Nervous System Diseases'}, {'abbrev': 'Rare', 'name': 'Rare Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C557413', 'term': 'Azilsartan medoxomil'}], 'ancestors': [{'id': 'D047228', 'term': 'Angiotensin II Type 1 Receptor Blockers'}, {'id': 'D057911', 'term': 'Angiotensin Receptor Antagonists'}, {'id': 'D045504', 'term': 'Molecular Mechanisms of Pharmacological Action'}], 'browseLeaves': [{'id': 'M256876', 'name': 'Azilsartan medoxomil', 'asFound': 'Insurance', 'relevance': 'HIGH'}, {'id': 'M4132', 'name': 'Angiotensin II', 'relevance': 'LOW'}, {'id': 'M289354', 'name': 'Giapreza', 'relevance': 'LOW'}, {'id': 'M4135', 'name': 'Angiotensinogen', 'relevance': 'LOW'}, {'id': 'M25789', 'name': 'Angiotensin II Type 1 Receptor Blockers', 'relevance': 'LOW'}, {'id': 'M28916', 'name': 'Angiotensin Receptor Antagonists', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'All', 'name': 'All Drugs and Chemicals'}, {'abbrev': 'VaCoAg', 'name': 'Vasoconstrictor Agents'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT01416766', 'orgStudyIdInfo': {'id': 'CONDUIT-001'}, 'secondaryIdInfos': [{'id': 'R18HS018461', 'type': 'AHRQ', 'link': 'https://reporter.nih.gov/quickSearch/R18HS018461'}], 'organization': {'fullName': 'University of Massachusetts, Worcester', 'class': 'OTHER'}, 'briefTitle': 'CONtrolling Disease Using Inexpensive IT - Hypertension in Diabetes', 'officialTitle': 'CONtrolling Disease Using Inexpensive IT - Hypertension in Diabetes', 'acronym': 'CONDUIT-HID'}, 'statusModule': {'statusVerifiedDate': '2015-09', 'overallStatus': 'COMPLETED', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2011-08'}, 'primaryCompletionDateStruct': {'date': '2014-10', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2015-07', 'type': 'ACTUAL'}, 'studyFirstSubmitDate': '2011-08-03', 'studyFirstSubmitQcDate': '2011-08-12', 'studyFirstPostDateStruct': {'date': '2011-08-15', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2015-09-15', 'lastUpdatePostDateStruct': {'date': '2015-09-16', 'type': 'ESTIMATED'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorFullName': 'Barry Saver', 'investigatorTitle': 'Principal Investigator', 'investigatorAffiliation': 'University of Massachusetts, Worcester'}, 'leadSponsor': {'name': 'University of Massachusetts, Worcester', 'class': 'OTHER'}, 'collaborators': [{'name': 'Reliant Medical Group', 'class': 'OTHER'}, {'name': 'University of Massachusetts, Amherst', 'class': 'OTHER'}]}, 'oversightModule': {'oversightHasDmc': True}, 'descriptionModule': {'briefSummary': 'This project will develop and test a low-cost approach to using health information technology and home monitoring aimed at improving care for chronic conditions, with low barriers to adoption in a wide variety of settings - from large group practices using state-of-the-art electronic health records to small practices with no more than a computer with internet access. Success will lead to a cost-effective approach to improving control of hypertension, both among individuals with diabetes and among non-diabetics, which can make a substantial contribution to the health of the population of the United States as improving hypertension control is estimated to have a greater population health benefit than most other health interventions. Success will also set the stage for adaptation of this intervention to a variety of other chronic health conditions and further substantial improvements in the health of millions of Americans.', 'detailedDescription': 'This project will develop and test a low-cost approach to using health information technology (HIT), aimed at improving the effectiveness and cost-effectiveness of care for chronic health conditions that are amenable to home self-monitoring, that is easy to disseminate. In contrast to many other HIT-based interventions, the investigators will utilize commercial, off-the-shelf technology rather than custom, expensive HIT. The investigators are using hypertension control among persons with diabetes as our test case because there is documented need for improving control of hypertension in this high-risk population and studies estimate that improving hypertension control in diabetes is more cost-effective than most other medical interventions and possibly even cost-saving in direct health care dollars. This high-value return on investment is important for encouraging adoption, expansion, and dissemination of HIT innovations. Our intervention will involve recruiting 400 persons with diabetes and uncontrolled hypertension receiving care through Reliant Medical Group (RMG - formerly called Fallon Clinic). MODIFICATION (2/13) - Due smaller than anticipated numbers of eligible persons and low enrollment, we are expanding eligibility to include \"prediabetics\". Half of them will be randomly assigned to receive an automated blood pressure (BP) monitor capable of uploading readings through a computer, plus instruction on how to connect their monitors at home or in the clinic to upload their information into a popular and free commercial personal health record (PHR) system. These blood pressure data from the PHR will be transferred automatically into RMG\\'s electronic health record (EHR) system and will alert RMG\\'s existing team of care management nurses. Subjects whose blood pressure is uncontrolled will have their medication regimens intensified by these nurses according to protocols. Intervention subjects will receive regular outreach calls from the care management nurses if their blood pressure remains uncontrolled or they are not periodically uploading blood pressure readings. After one year, the investigators will compare outcomes between control and intervention subjects. Our primary outcomes will be change in mean blood pressure and proportion of subjects with controlled blood pressure. The investigators will also measure a range of secondary outcomes including costs of the intervention, medication utilization, and a variety of patient-reported outcomes. Furthermore, the investigators will interview and observe study subjects and care providers to gain a better understanding of factors affecting uptake and use of the intervention. The investigators will examine continued use of the intervention after formal study participation ends and will also measure uptake of the intervention by control subjects offered delayed entry at the end of the formal study. Lastly, the investigators will compare our study and findings to other, recent studies using HIT to improve hypertension control and develop a set of best practices and recommendations for future efforts in this area.'}, 'conditionsModule': {'conditions': ['Hypertension', 'Diabetes Mellitus'], 'keywords': ['Blood Pressure Monitors', 'Medical Informatics', 'Disease Management', 'Comparative Effectiveness Research']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'HEALTH_SERVICES_RESEARCH', 'maskingInfo': {'masking': 'SINGLE', 'whoMasked': ['OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 196, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Control', 'type': 'NO_INTERVENTION', 'description': 'Control participants will receive usual care during their year of enrollment. At enrollment, prior to randomization, they will be informed that, if randomized to control status, they will be offered a free BP monitor and the opportunity to receive the study intervention after completing the exit interview in 1 year.'}, {'label': 'Intervention', 'type': 'EXPERIMENTAL', 'description': 'Self-monitoring-nurse-primary care provider feedback loop After randomization, intervention participants will receive the intervention (free home BP monitor, assistance setting up to upload BP readings from home/work or clinic computer; feedback loop with nurse-driven protocols to manage uncontrolled hypertension and maintain control once attained).', 'interventionNames': ['Other: Self-monitoring-nurse-primary care provider feedback loop']}], 'interventions': [{'type': 'OTHER', 'name': 'Self-monitoring-nurse-primary care provider feedback loop', 'description': \"Intervention participants will receive an Omron BP monitor and assistance in setting it up to upload BP data to Reliant Medical Group from a home/work or clinic-based computer. They will be encouraged to upload readings at least once/month. Diabetes management nurses will receive the readings and, if a participant's mean BP is not at target, will follow protocols to address this, contacting PCPs as indicated by protocols.\", 'armGroupLabels': ['Intervention'], 'otherNames': ['CONDUIT blood pressure intervention']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Change in blood pressure (BP)', 'description': 'We will assess differences in changes in systolic BP (SBP) and diastolic BP (DBP) measured at study intake and 1 year later at exit. We will also evaluate changes in mean EHR BP readings prior to study entry and in the 3 months before study exit. We will also assess the primary outcome in terms of % of intervention vs. control participants achieving control (originally proposed as mean of 3 exit readings \\\\<130 SBP and 80 DBP but now revised to 140 SBP and 80 DBP due to new evidence and change in the Healthcare Effectiveness Data and Information Set (HEDIS) measure for 2011). NOTE: For eligible participant group added 2/13, \"prediabetic\" patients, DBP control will be judged as mean \\\\<90mmHg as target BP for these groups is 140/90.', 'timeFrame': 'At entry (day 1) and 1 year later; secondarily, electronic health record (EHR)-based readings prior to entry and one year later'}], 'secondaryOutcomes': [{'measure': 'Refill adherence', 'description': 'We will compare changes in the Medication Possession Ratio for antihypertensive medications for the 6 months prior to study entry and the 6 months prior to study exit for the subset of participants for whom insurance claims give us complete data on prescription fills.', 'timeFrame': '6 months prior to study entry and 6 months prior to study exit'}, {'measure': 'Self-reported medication adherence', 'description': 'Change in self-reported medication adherence, based on: 1) the modified Morisky scale and 2) a visual analog scale (Walsh).', 'timeFrame': 'At entry (day 1) and 1 year later, at exit'}, {'measure': 'Technology use', 'description': 'We will measure use of home/office/other personal computers to upload BP readings over the internet vs. bringing BP monitor to clinic and uploading data vs. calling/mailing/faxing readings (offered to those not doing either of the first 2 after 2-3 months). We intend to offer delayed entry after the exit to control subjects and will assess their use over the next 3-6 months.', 'timeFrame': 'Continuous over course of study; final measurement at exit interview for intervention subjects & 6 mos. after exit for controls'}, {'measure': 'Health care utilization', 'description': 'We will measure counts of Reliant Medical Group visits and hospitalizations. Number of antihypertensive medications and post/pre change will be compared for control vs. intervention participants. We will also compare health care costs, as represented by billed charges; complete charges are expected to be available for \\\\~70% of participants; clinic-only charges will be compared for the remainder.', 'timeFrame': 'Enrollment through exit 1 year later'}, {'measure': 'Satisfaction', 'description': 'Participant satisfaction with care will be measured using Consumer Assessment of Healthcare Providers and Systems (CAHPS) clinician and group survey questions.', 'timeFrame': 'At entry (day 1) and 1 year later, at exit'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* diagnoses of both diabetes mellitus (MODIFICATION 2/13: prediabetes) and hypertension\\n* uncontrolled hypertension (mean of up to most recent 3 clinic BPs in previous 6 months with SBP\\\\>=145 and/or DBP\\\\>=85) AND mean of 3 readings taken at intake visit meeting same criterion\\n\\nExclusion Criteria:\\n\\n* end-stage renal disease\\n* management of blood pressure by provider other than primary care provider (PCP)\\n* pregnancy/gestational diabetes\\n* terminal illness\\n* diagnosed or probable (based on screen) dementia\\n* active psychosis\\n* moderate-severe mental retardation\\n* indication by PCP that patient would be inappropriate for study\\n* planning to leave Reliant Medical Group (formerly Fallon Clinic) during the coming year\\n\\nMODIFICATIONS: due to a smaller pool of eligible participants and lower enrollment than anticipated, eligibility for the study has been expanded as of February 2013 to include persons with \"prediabetes,\" defined by either a coded diagnosis of abnormal glucose (International Classification of Diseases \\\\[ICD\\\\] 9-CM codes 790.2x) or a hemoglobin A1c laboratory value from 6.0%-6.4%. For this group, the DBP eligibility criterion will be a mean, as defined above, of \\\\>=95, as target BP for this group is 140/90, not 140/80.', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'maximumAge': '80 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Barry G Saver, MD, MPH', 'affiliation': 'University of Massachusetts, Worcester', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'Reliant Medical Group', 'city': 'Worcester', 'state': 'Massachusetts', 'zip': '01605', 'country': 'United States', 'geoPoint': {'lat': 42.26259, 'lon': -71.80229}}]}, 'referencesModule': {'references': [{'pmid': '23800678', 'type': 'RESULT', 'citation': 'Marquard JL, Garber L, Saver B, Amster B, Kelleher M, Preusse P. Overcoming challenges integrating patient-generated data into the clinical EHR: lessons from the CONtrolling Disease Using Inexpensive IT--Hypertension in Diabetes (CONDUIT-HID) Project. Int J Med Inform. 2013 Oct;82(10):903-10. doi: 10.1016/j.ijmedinf.2013.04.009. Epub 2013 Jun 22.'}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2024-11-22'}, 'conditionBrowseModule': {'meshes': [{'id': 'D006973', 'term': 'Hypertension'}, {'id': 'D003920', 'term': 'Diabetes Mellitus'}], 'ancestors': [{'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}, {'id': 'D014652', 'term': 'Vascular Diseases'}, {'id': 'D002318', 'term': 'Cardiovascular Diseases'}], 'browseLeaves': [{'id': 'M7115', 'name': 'Diabetes Mellitus', 'asFound': 'Diabetes', 'relevance': 'HIGH'}, {'id': 'M10024', 'name': 'Hypertension', 'asFound': 'Hypertension', 'relevance': 'HIGH'}, {'id': 'M11639', 'name': 'Metabolic Diseases', 'relevance': 'LOW'}, {'id': 'M25403', 'name': 'Glucose Metabolism Disorders', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}, {'id': 'M17400', 'name': 'Vascular Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC14', 'name': 'Heart and Blood Diseases'}]}, 'interventionBrowseModule': {'browseLeaves': [{'id': 'M4854', 'name': 'Benzocaine', 'relevance': 'LOW'}, {'id': 'T433', 'name': 'Tannic Acid', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'CNSDep', 'name': 'Central Nervous System Depressants'}, {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}, {'abbrev': 'Ot', 'name': 'Other Dietary Supplements'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT05198674', 'orgStudyIdInfo': {'id': 'MDT20044RDN004'}, 'organization': {'fullName': 'Medtronic Vascular', 'class': 'INDUSTRY'}, 'briefTitle': 'SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN', 'officialTitle': 'The SPYRAL AFFIRM Global Clinical Study of Renal Denervation With the Symplicity Spyral Renal Denervation System in Subjects With Uncontrolled Hypertension (SPYRAL AFFIRM)'}, 'statusModule': {'statusVerifiedDate': '2024-11', 'overallStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2021-10-20', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2026-11-30', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2029-11-30', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2021-11-05', 'studyFirstSubmitQcDate': '2022-01-06', 'studyFirstPostDateStruct': {'date': '2022-01-20', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2024-11-19', 'lastUpdatePostDateStruct': {'date': '2024-11-20', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Medtronic Vascular', 'class': 'INDUSTRY'}}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': True, 'isUnapprovedDevice': True}, 'descriptionModule': {'briefSummary': 'The purpose of this single-arm interventional study is to evaluate the long-term safety, efficacy, and durability of the Symplicity Spyral system in subjects treated with renal denervation.\\n\\nAdditionally, long-term follow-up data will also be collected from eligible subjects previously treated in the SPYRAL PIVOTAL-SPYRAL HTN-OFF MED and SPYRAL HTN-ON MED studies.'}, 'conditionsModule': {'conditions': ['Hypertension', 'Vascular Diseases', 'Cardiovascular Diseases', 'Chronic Kidney Diseases', 'Diabetes Mellitus']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 1400, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Main Cohort: Renal Denervation', 'type': 'EXPERIMENTAL', 'description': 'Renal angiography and Renal Denervation (Symplicity Spyral™ multi-electrode renal denervation system)', 'interventionNames': ['Device: Renal Denervation (Symplicity Spyral™)']}], 'interventions': [{'type': 'DEVICE', 'name': 'Renal Denervation (Symplicity Spyral™)', 'description': 'Device: Symplicity Spyral™ multi-electrode renal denervation system. After a renal angiography according to standard procedures, subjects are treated with the renal denervation procedure.', 'armGroupLabels': ['Main Cohort: Renal Denervation'], 'otherNames': ['Renal Angiography', 'Renal Denervation']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'The Primary endpoint of office Systolic Blood Pressure (SBP) change at 6 months.', 'description': 'The Primary endpoint of office Systolic Blood Pressure (SBP) change at 6 months will be assessed for all patients in the Main Study Cohort', 'timeFrame': '6 months'}], 'secondaryOutcomes': [{'measure': 'Office Systolic Blood Pressure change', 'timeFrame': 'From baseline to 1, 3, 6, 12, 24, and 36 months post-procedure'}, {'measure': 'Home Blood Pressure change (Main Cohort Only)', 'timeFrame': 'From baseline to 1, 3, 6, 12, 24, and 36 months post-procedure'}, {'measure': 'Change in blood pressure as measured by 24-hour ABPM', 'timeFrame': 'From baseline to 1, 3, 6, 12, 24, and 36 months post-procedure'}, {'measure': 'Percent of subjects achieving blood pressure control as measured by OBP, HBP and ABPM', 'timeFrame': 'From baseline to 1, 3, 6, 12, 24, and 36 months post-procedure'}, {'measure': \"Time subject's blood pressure is controlled\", 'timeFrame': 'Procedure to 36 months post-procedure'}, {'measure': 'Change in number of anti-hypertensive medications taken from baseline', 'timeFrame': 'From baseline to 1, 3, 6, 12, 24, and 36 months post-procedure'}, {'measure': 'Change from baseline in EQ-5D quality of life score', 'timeFrame': 'From baseline to 1, 3, 6, 12, 24, and 36 months post-procedure'}, {'measure': 'Change from baseline in hypertension health status score', 'timeFrame': 'From baseline to 1, 3, 6, 12, 24, and 36 months post-procedure'}, {'measure': 'Evaluate pre-specified subgroups (Chronic Kidney Disease, Diabetes Mellitus Type II, etc) as predictors for change in blood pressure as measured by OBP, HBP and ABPM', 'timeFrame': 'From baseline to 1, 3, 6, 12, 24, and 36 months post-procedure'}, {'measure': 'Evaluation of slope of eGFR', 'timeFrame': 'From baseline to 1, 3, 6, 12, 24, and 36 months post-procedure'}, {'measure': 'Incidence of events, including major adverse events', 'timeFrame': 'From baseline to 1, 3, 6, 12, 24, and 36 months post-procedure'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n1. Individual is diagnosed with hypertension and has a baseline office systolic blood pressure ≥140 mmHg\\n2. Individual has a baseline office diastolic blood pressure ≥ 90 mmHg\\n3. Individual has an average systolic baseline home blood pressure ≥135 mmHg\\n\\nExclusion Criteria:\\n\\n1. Individual lacks appropriate renal artery anatomy\\n2. Individual has undergone prior renal denervation\\n3. Individual has a documented condition that would prohibit or interfere with ability to obtain an accurate blood pressure measurement\\n4. Individual requires chronic oxygen support or mechanical ventilation other than nocturnal respiratory support for sleep apnea\\n5. Individual has an estimated glomerular filtration rate (eGFR) of \\\\<45\\n6. Individual has one or more episode(s) of orthostatic hypotension\\n7. Individual is pregnant, nursing or planning to become pregnant\\n8. Individual has primary pulmonary hypertension\\n9. Individual has documented type 1 diabetes mellitus or poorly-controlled type 2 diabetes mellitus with glycosylated hemoglobin greater than 8.0%', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Kelsey Anderson', 'role': 'CONTACT', 'phone': '+17635149730', 'email': 'kelsey.m.anderson@medtronic.com'}], 'overallOfficials': [{'name': 'David Kandzari, MD', 'affiliation': 'Piedmont Heart Institute', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'Felix Mahfoud, MD', 'affiliation': 'Saarland University Hospital', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'University of Alabama at Birmingham (UAB) Hospital', 'status': 'RECRUITING', 'city': 'Birmingham', 'state': 'Alabama', 'zip': '35233', 'country': 'United States', 'contacts': [{'name': 'Alisha Hitt, RN', 'role': 'CONTACT', 'phone': '205-539-2908', 'email': 'aghitt@uabmc.edu'}, {'name': 'Katherine Phillips', 'role': 'CONTACT', 'phone': '205-975-1888', 'email': 'kcphillips@uabmc.edu'}, {'name': 'Mustafa Ahmed, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'Hussein Abu Daya, MD', 'role': 'SUB_INVESTIGATOR'}], 'geoPoint': {'lat': 33.52066, 'lon': -86.80249}}, {'facility': 'Banner Heart Hospital', 'status': 'RECRUITING', 'city': 'Mesa', 'state': 'Arizona', 'zip': '85206', 'country': 'United States', 'contacts': [{'name': 'Robert Flynn', 'role': 'CONTACT', 'phone': '480-412-6859'}, {'name': 'Jaskamal Kahlon', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 33.42227, 'lon': -111.82264}}, {'facility': 'Abrazo Arizona Heart Hospital/Biltmore Cardiology', 'status': 'RECRUITING', 'city': 'Phoenix', 'state': 'Arizona', 'zip': '85016', 'country': 'United States', 'contacts': [{'name': 'Jessica Byrne, BsC', 'role': 'CONTACT', 'phone': '602-952-0002', 'phoneExt': '7349', 'email': 'jessicabyrne@pcrg.hush.com'}, {'name': 'Timothy Byrne', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'Akram Ibrahim', 'role': 'SUB_INVESTIGATOR'}], 'geoPoint': {'lat': 33.44838, 'lon': -112.07404}}, {'facility': 'HonorHealth Research Institute', 'status': 'RECRUITING', 'city': 'Scottsdale', 'state': 'Arizona', 'zip': '85258', 'country': 'United States', 'contacts': [{'name': 'Devin Howard, RN', 'role': 'CONTACT', 'phone': '480-323-1046', 'email': 'devihoward@honorhealth.com'}, {'name': 'Alisha Vandriel', 'role': 'CONTACT', 'phone': '480) 323-1046', 'email': 'avandriel@honorhealth.com'}, {'name': 'Taral Patel, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'Mayurkumar Bhakta, MD', 'role': 'SUB_INVESTIGATOR'}], 'geoPoint': {'lat': 33.50921, 'lon': -111.89903}}, {'facility': 'Arkansas Cardiology', 'status': 'RECRUITING', 'city': 'Little Rock', 'state': 'Arkansas', 'zip': '72205', 'country': 'United States', 'contacts': [{'name': 'Bobbi Philips', 'role': 'CONTACT', 'phone': '501-227-7596', 'phoneExt': '1263', 'email': 'bphillips@arcard.org'}, {'name': 'Stacy Canerday, RN', 'role': 'CONTACT', 'email': 'scanerday@arcard.org'}, {'name': 'Dwight Chrisman, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 34.74648, 'lon': -92.28959}}, {'facility': 'Scripps Memorial Hospital', 'status': 'RECRUITING', 'city': 'La Jolla', 'state': 'California', 'zip': '92037', 'country': 'United States', 'contacts': [{'name': 'Janet Lawrence, BA, CCRC', 'role': 'CONTACT', 'phone': '858-824-4168'}, {'name': 'Christina Nava, CCRP', 'role': 'CONTACT', 'phone': '858-824-5244'}, {'name': 'Paul S. Teirstein, MD, FACC', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'Curtiss T. Stinis, MS FACC FSCAI', 'role': 'SUB_INVESTIGATOR'}], 'geoPoint': {'lat': 32.84727, 'lon': -117.2742}}, {'facility': 'Stanford Hospital and Clinics', 'status': 'RECRUITING', 'city': 'Stanford', 'state': 'California', 'zip': '94305', 'country': 'United States', 'contacts': [{'name': 'Maria Perlas, RN', 'role': 'CONTACT', 'phone': '650-723-2094', 'email': 'mperlas@stanford.edu'}, {'name': 'Arohi Bapat, CRC', 'role': 'CONTACT', 'phone': '650-725-2382', 'email': 'arohi90@stanford.edu'}, {'name': 'David P. Lee, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'Alan C. Yeung, MD', 'role': 'SUB_INVESTIGATOR'}], 'geoPoint': {'lat': 37.42411, 'lon': -122.16608}}, {'facility': 'University of Colorado Anschutz Medical Campus', 'status': 'RECRUITING', 'city': 'Aurora', 'state': 'Colorado', 'zip': '80045', 'country': 'United States', 'contacts': [{'name': 'Tanner Bloks, PRA', 'role': 'CONTACT', 'phone': '303-724-3938', 'email': 'Tanner.bloks@cuanschutz.edu'}, {'name': 'Emanuel Gereab, PRA', 'role': 'CONTACT', 'phone': '303-724-5683', 'email': 'emanuel.gebreab@cuanschutz.edu'}, {'name': 'Kevin Rogers, Dr', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'Bricker Rory, Dr', 'role': 'SUB_INVESTIGATOR'}], 'geoPoint': {'lat': 39.72943, 'lon': -104.83192}}, {'facility': 'Colorado Heart and Vascular PC', 'status': 'RECRUITING', 'city': 'Lakewood', 'state': 'Colorado', 'zip': '80228', 'country': 'United States', 'contacts': [{'name': 'David Bailey', 'role': 'CONTACT', 'phone': '303-595-2619', 'email': 'dbailey@chvpc.com'}, {'name': 'Alec Timp', 'role': 'CONTACT', 'phone': '303-595-2619', 'email': 'atimp@chvpc.com'}, {'name': 'John Altman, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 39.70471, 'lon': -105.08137}}, {'facility': 'Hartford Hospital', 'status': 'RECRUITING', 'city': 'Hartford', 'state': 'Connecticut', 'zip': '06102', 'country': 'United States', 'contacts': [{'name': 'Joseph Ingrassia, MD', 'role': 'CONTACT', 'phone': '860-972-3570', 'email': 'Joseph.Ingrassia@hhchealth.org'}, {'name': 'Jadwiga Jerman, MD', 'role': 'CONTACT', 'phone': '860-972-9146', 'email': 'Jadwiga.Jerman@hhchealth.org'}, {'name': 'Joseph Ingrassia, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'Mohamad Firas Barbour', 'role': 'SUB_INVESTIGATOR'}], 'geoPoint': {'lat': 41.76371, 'lon': -72.68509}}, {'facility': 'MedStar Washington Hospital Center', 'status': 'RECRUITING', 'city': 'Washington', 'state': 'District of Columbia', 'zip': '20010', 'country': 'United States', 'contacts': [{'name': 'Suman Singh, MD,MPH,CCRC', 'role': 'CONTACT', 'phone': '202-877-8475', 'email': 'suman.singh@medstar.net'}, {'name': 'Kassaye Sesaba, MD', 'role': 'CONTACT', 'phone': '202-877-7452', 'email': 'kassaye.t.sesaba@medstar.net'}, {'name': 'Nelson Bernardo, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 38.89511, 'lon': -77.03637}}, {'facility': 'BayCare Health System', 'status': 'RECRUITING', 'city': 'Clearwater', 'state': 'Florida', 'zip': '33756', 'country': 'United States', 'contacts': [{'name': 'Parag Patel', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 27.96585, 'lon': -82.8001}}, {'facility': 'Clearwater Cardiovascular Consultants', 'status': 'RECRUITING', 'city': 'Clearwater', 'state': 'Florida', 'zip': '33756', 'country': 'United States', 'contacts': [{'name': 'Michele Cameron, RN', 'role': 'CONTACT', 'phone': '727-467-9393', 'email': 'cameronm@cccheart.com'}, {'name': 'Douglas Spriggs, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'Donald Kikta, MD', 'role': 'SUB_INVESTIGATOR'}], 'geoPoint': {'lat': 27.96585, 'lon': -82.8001}}, {'facility': 'Baptist Medical Center', 'status': 'RECRUITING', 'city': 'Jacksonville', 'state': 'Florida', 'zip': '32207', 'country': 'United States', 'contacts': [{'name': 'Salil Patel, Dr.', 'role': 'CONTACT', 'phone': '904-202-7312', 'email': 'BHRI@bmcjax.com'}], 'geoPoint': {'lat': 30.33218, 'lon': -81.65565}}, {'facility': 'University of Miami Hosptial', 'status': 'RECRUITING', 'city': 'Miami', 'state': 'Florida', 'zip': '33136', 'country': 'United States', 'contacts': [{'name': 'Karla Duarte', 'role': 'CONTACT', 'phone': '305-243-0256'}, {'name': 'Christian Marin y Kall, MD, MBA', 'role': 'CONTACT', 'phone': '(305)243-2119'}, {'name': 'Eduardo de Marchena, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 25.77427, 'lon': -80.19366}}, {'facility': 'AdventHealth Orlando', 'status': 'RECRUITING', 'city': 'Orlando', 'state': 'Florida', 'zip': '32803', 'country': 'United States', 'contacts': [{'name': 'Maggie Warrington, RN', 'role': 'CONTACT', 'phone': '407-303-7556'}, {'name': 'Nipun Arora, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 28.53834, 'lon': -81.37924}}, {'facility': 'Orlando Health Heart & Vascular Institute', 'status': 'RECRUITING', 'city': 'Orlando', 'state': 'Florida', 'zip': '32806', 'country': 'United States', 'contacts': [{'name': 'George M. Ngo, MSM', 'role': 'CONTACT', 'phone': '321-843-9657', 'email': 'george.ngo@orlandohealth.com'}, {'name': 'Gloryvee Hernandez-Pagan, MSN', 'role': 'CONTACT', 'phone': '321-841-3686', 'email': 'gloryvee.hernandezpagan@orlandohealth.com'}, {'name': 'Farhan J. Khawaja, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'Maxim Olivier, MD', 'role': 'SUB_INVESTIGATOR'}], 'geoPoint': {'lat': 28.53834, 'lon': -81.37924}}, {'facility': 'BayCare Medical Group', 'status': 'RECRUITING', 'city': 'Safety Harbor', 'state': 'Florida', 'zip': '34695', 'country': 'United States', 'contacts': [{'name': 'Martha Bunnell-Pollak, RN', 'role': 'CONTACT', 'phone': '727-723-6511', 'email': 'Martha.BunnellPollak@baycare.org'}, {'name': 'Valbone Vranica, BS, RN', 'role': 'CONTACT', 'phone': '(727) 723 -6527', 'email': 'valbone.vranica@baycare.org'}, {'name': 'Parag Patel, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 27.99085, 'lon': -82.69316}}, {'facility': 'Tallahassee Memorial Healthcare, Inc', 'status': 'RECRUITING', 'city': 'Tallahassee', 'state': 'Florida', 'zip': '32308', 'country': 'United States', 'contacts': [{'name': 'Katherine Gearld, LPN, CCRC', 'role': 'CONTACT', 'phone': '850-431-5024', 'email': 'katherine.gearld@tmh.org'}, {'name': 'Thomas Noel, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'Pablo Rengifo, MD', 'role': 'SUB_INVESTIGATOR'}], 'geoPoint': {'lat': 30.43826, 'lon': -84.28073}}, {'facility': 'Emory University Hospital Midtown', 'status': 'RECRUITING', 'city': 'Atlanta', 'state': 'Georgia', 'zip': '30308', 'country': 'United States', 'contacts': [{'name': 'Wei Xu, MD', 'role': 'CONTACT', 'phone': '404-686-6187', 'email': 'wei.xu@emory.edu'}, {'name': 'Chandan Devireddy, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 33.749, 'lon': -84.38798}}, {'facility': 'Piedmont Heart Institute', 'status': 'RECRUITING', 'city': 'Atlanta', 'state': 'Georgia', 'zip': '30309', 'country': 'United States', 'contacts': [{'name': 'David Kandzari, MD', 'role': 'CONTACT'}], 'geoPoint': {'lat': 33.749, 'lon': -84.38798}}, {'facility': 'Wellstar Research Institute', 'status': 'RECRUITING', 'city': 'Marietta', 'state': 'Georgia', 'zip': '30060', 'country': 'United States', 'contacts': [{'name': 'Stacey Mitchell', 'role': 'CONTACT', 'phone': '470-793-4042'}, {'name': 'Jen Cuvo', 'role': 'CONTACT', 'phone': '470-793-4063'}, {'name': 'Salvatore Mannino, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'Amar Patel, MD', 'role': 'SUB_INVESTIGATOR'}], 'geoPoint': {'lat': 33.9526, 'lon': -84.54993}}, {'facility': 'University of Chicago Medicine', 'status': 'RECRUITING', 'city': 'Chicago', 'state': 'Illinois', 'zip': '60637', 'country': 'United States', 'contacts': [{'name': 'Michaela K McSweeney, RN-BC', 'role': 'CONTACT', 'phone': '773-702-7308', 'email': 'mmcsweeney@bsd.uchciago.edu'}, {'name': 'Cynthia Arevalo', 'role': 'CONTACT', 'email': 'carevalo@bsd.uchicago.edu'}, {'name': 'Sandeep Nathan, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 41.85003, 'lon': -87.65005}}, {'facility': 'Loyola University Medical Center', 'status': 'RECRUITING', 'city': 'Maywood', 'state': 'Illinois', 'zip': '60153-3328', 'country': 'United States', 'contacts': [{'name': 'Bruce Lewis, MD', 'role': 'CONTACT', 'phone': '708-216-9447'}, {'name': 'Wendy Klein, RN', 'role': 'CONTACT', 'phone': '708-327-2761', 'email': 'wklein@luc.edu'}, {'name': 'Bruce Lewis, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 41.8792, 'lon': -87.84312}}, {'facility': 'Heart Care Centers of Illinois', 'status': 'RECRUITING', 'city': 'Palos Park', 'state': 'Illinois', 'zip': '60464', 'country': 'United States', 'contacts': [{'name': 'Ravi Ramana, MD', 'role': 'CONTACT'}], 'geoPoint': {'lat': 41.66725, 'lon': -87.83033}}, {'facility': 'St. Vincents Hospital', 'status': 'RECRUITING', 'city': 'Indianapolis', 'state': 'Indiana', 'zip': '46290', 'country': 'United States', 'geoPoint': {'lat': 39.76838, 'lon': -86.15804}}, {'facility': 'Mercy Medical Center', 'status': 'RECRUITING', 'city': 'West Des Moines', 'state': 'Iowa', 'zip': '50266-8209', 'country': 'United States', 'contacts': [{'name': 'Maria Marrazzo, MSN, RN', 'role': 'CONTACT', 'phone': '515-633-3845', 'email': 'maria.marrazzo@mercyone.org'}, {'name': 'Magdi Ghali, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'Daniel Shivapour, MD', 'role': 'SUB_INVESTIGATOR'}], 'geoPoint': {'lat': 41.57721, 'lon': -93.71133}}, {'facility': 'The Johns Hopkins Hospital', 'status': 'RECRUITING', 'city': 'Baltimore', 'state': 'Maryland', 'zip': '21287', 'country': 'United States', 'contacts': [{'name': 'Michele Fisher, LPN/RCS', 'role': 'CONTACT', 'phone': '410-955-6839', 'email': 'mfishe36@jhmi.edu'}, {'name': 'Mary Kate Dougherty, BS', 'role': 'CONTACT', 'email': 'Mdough10@jhu.edu'}, {'name': 'Rohan Kalathiya, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 39.29038, 'lon': -76.61219}}, {'facility': 'Saint Joseph Medical Center (Towson MD)', 'status': 'RECRUITING', 'city': 'Towson', 'state': 'Maryland', 'zip': '21204', 'country': 'United States', 'contacts': [{'name': 'Christine Rittase', 'role': 'CONTACT', 'phone': '410-427-2580', 'email': 'christine.rittase@umm.edu'}, {'name': 'Aja Janyavula', 'role': 'CONTACT', 'phone': '(410) 427-2580', 'email': 'ajanyavula@umm.edu'}, {'name': 'Daniel Ambinder, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 39.4015, 'lon': -76.60191}}, {'facility': 'Beth Israel Deaconess Medical Center', 'status': 'RECRUITING', 'city': 'Boston', 'state': 'Massachusetts', 'zip': '02215', 'country': 'United States', 'contacts': [{'name': 'Eric Secemsky, MD', 'role': 'CONTACT', 'phone': '617-667-8800'}, {'name': 'Jenifer Kaufman', 'role': 'CONTACT', 'phone': '617-632-8956'}, {'name': 'Eric Secemsky, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'Brett Carroll, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Anna Krawisz, MD', 'role': 'SUB_INVESTIGATOR'}], 'geoPoint': {'lat': 42.35843, 'lon': -71.05977}}, {'facility': 'University of Michigan', 'status': 'RECRUITING', 'city': 'Ann Arbor', 'state': 'Michigan', 'zip': '48109', 'country': 'United States', 'contacts': [{'name': 'Allison Schley', 'role': 'CONTACT', 'email': 'schleya@med.umich.edu'}, {'name': 'Paul Michael Grossman', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'Stanley Chetcuti', 'role': 'SUB_INVESTIGATOR'}], 'geoPoint': {'lat': 42.27756, 'lon': -83.74088}}, {'facility': 'Henry Ford Hospital', 'status': 'RECRUITING', 'city': 'Detroit', 'state': 'Michigan', 'zip': '48202', 'country': 'United States', 'contacts': [{'name': 'Michelle Butcher, RN, BS', 'role': 'CONTACT', 'phone': '313-916-0015', 'email': 'Mbutche1@hfhs.org'}, {'name': 'Melanee Schimmel, RN, BS', 'role': 'CONTACT', 'phone': '313-916-7614', 'email': 'Mschimm2@hfhs.org'}, {'name': 'Herbert Aronow, Dr.', 'role': 'SUB_INVESTIGATOR'}], 'geoPoint': {'lat': 42.33143, 'lon': -83.04575}}, {'facility': 'Henry Ford Saint John Hospital', 'status': 'RECRUITING', 'city': 'Detroit', 'state': 'Michigan', 'zip': '48236', 'country': 'United States', 'contacts': [{'name': 'Renee Bess, CCRP', 'role': 'CONTACT', 'phone': '313-343-4811', 'email': 'renee.bess@ascension.org'}, {'name': 'Rhonda Beauchemin, RN', 'role': 'CONTACT', 'phone': '313.343.7536', 'email': 'rhonda.beauchemin@ascension.org'}, {'name': 'Amir Kaki, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'Theodore Schreiber, MD', 'role': 'SUB_INVESTIGATOR'}], 'geoPoint': {'lat': 42.33143, 'lon': -83.04575}}, {'facility': 'Spectrum Health Hospitals', 'status': 'RECRUITING', 'city': 'Grand Rapids', 'state': 'Michigan', 'zip': '49503-2560', 'country': 'United States', 'geoPoint': {'lat': 42.96336, 'lon': -85.66809}}, {'facility': 'Saint Joseph Mercy Oakland', 'status': 'RECRUITING', 'city': 'Pontiac', 'state': 'Michigan', 'zip': '48341', 'country': 'United States', 'contacts': [{'name': 'Kiritkumar Patel', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 42.63892, 'lon': -83.29105}}, {'facility': 'Henry Ford Providence Southfield Hospital', 'status': 'RECRUITING', 'city': 'Southfield', 'state': 'Michigan', 'zip': '48075', 'country': 'United States', 'contacts': [{'name': 'Yulia Abidov, RN, CCRC', 'role': 'CONTACT', 'phone': '248-849-5328', 'email': 'yulia.abidov@ascension.org'}, {'name': 'Heather Hesano, RN, BSN', 'role': 'CONTACT', 'phone': '248-8492379', 'email': 'heather.hesano@ascension.org'}, {'name': 'Shukri David, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 42.47337, 'lon': -83.22187}}, {'facility': 'Metropolitan Heart and Vascular Institute (MHVI)', 'status': 'RECRUITING', 'city': 'Coon Rapids', 'state': 'Minnesota', 'zip': '55433', 'country': 'United States', 'contacts': [{'name': 'Brittany Renier, RN, BSN', 'role': 'CONTACT', 'phone': '763-236-9134', 'email': 'Brittany.Renier@mhvi.com'}, {'name': 'Derek Vang, MBSc, CCRC', 'role': 'CONTACT', 'phone': '763-236-9347', 'email': 'derek.vang@mhvi.com'}, {'name': 'Matthew Whitbeck, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'Daniel Dulas, MD', 'role': 'SUB_INVESTIGATOR'}], 'geoPoint': {'lat': 45.11997, 'lon': -93.28773}}, {'facility': 'CentraCare Heart & Vascular Center', 'status': 'RECRUITING', 'city': 'Saint Cloud', 'state': 'Minnesota', 'zip': '56303-1900', 'country': 'United States', 'contacts': [{'name': 'Kelly Kobylinski, BSN', 'role': 'CONTACT', 'phone': '320-251-2700', 'phoneExt': '58316', 'email': 'kelly.kobylinski@centracare.com'}, {'name': 'Jennifer Humbert, RN', 'role': 'CONTACT', 'phone': '320-251-2700', 'phoneExt': '57560', 'email': 'humbertj@centracare.com'}, {'name': 'Jacob Dutcher, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'Wade Schmidt, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Yaga Saine', 'role': 'SUB_INVESTIGATOR'}], 'geoPoint': {'lat': 45.5608, 'lon': -94.16249}}, {'facility': 'North Mississippi Medical Center', 'status': 'RECRUITING', 'city': 'Tupelo', 'state': 'Mississippi', 'zip': '38801', 'country': 'United States', 'contacts': [{'name': 'Brittany Cook, RN', 'role': 'CONTACT', 'phone': '662-620-6835', 'email': 'Brittany.cook@nmhs.net'}, {'name': 'Kristin Eads, RD, BSN', 'role': 'CONTACT', 'phone': '662-620-6875', 'email': 'keads@nmhs.net'}, {'name': 'Barry Bertolet, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 34.25807, 'lon': -88.70464}}, {'facility': 'University of Nebraska Medical Center', 'status': 'RECRUITING', 'city': 'Omaha', 'state': 'Nebraska', 'zip': '68105', 'country': 'United States', 'contacts': [{'name': \"Edward O'Leary, MD\", 'role': 'CONTACT', 'phone': '402-559-4874'}, {'name': 'Nichole Coltrain, RN', 'role': 'CONTACT', 'phone': '402 559-0232'}, {'name': \"Edward O'Leary, MD\", 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 41.25626, 'lon': -95.94043}}, {'facility': 'University Medical Center of Southern Nevada', 'status': 'RECRUITING', 'city': 'Las Vegas', 'state': 'Nevada', 'zip': '89102', 'country': 'United States', 'contacts': [{'name': 'Jennifer Robinson, CCRC', 'role': 'CONTACT', 'phone': '702-383-7842'}, {'name': 'Chowdhury Ahsan, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 36.17497, 'lon': -115.13722}}, {'facility': 'Dartmouth-Hitchcock', 'status': 'RECRUITING', 'city': 'Lebanon', 'state': 'New Hampshire', 'zip': '03756', 'country': 'United States', 'contacts': [{'name': 'Brian J. Aldrich, BS, BA, CCRP, CCRC, ACRP-MDP', 'role': 'CONTACT', 'phone': '6036506228', 'email': 'Brian.J.Aldrich@hitchcock.org'}, {'name': 'James DeVries, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'Michael Young, MD', 'role': 'SUB_INVESTIGATOR'}], 'geoPoint': {'lat': 43.64229, 'lon': -72.25176}}, {'facility': 'Virtua Medical Group', 'status': 'RECRUITING', 'city': 'Marlton', 'state': 'New Jersey', 'zip': '08053', 'country': 'United States', 'contacts': [{'name': 'Kristin Broderick', 'role': 'CONTACT', 'phone': '856-355-1225', 'email': 'KBroderick@virtua.org'}, {'name': 'Elizabeth Gaffney', 'role': 'CONTACT', 'email': 'egaffney@virtua.org'}, {'name': 'Kintur Sanghvi, MD', 'role': 'SUB_INVESTIGATOR'}], 'geoPoint': {'lat': 39.89122, 'lon': -74.92183}}, {'facility': 'Morristown Medical Center', 'status': 'RECRUITING', 'city': 'Morristown', 'state': 'New Jersey', 'zip': '07960', 'country': 'United States', 'contacts': [{'name': 'Dimitrios Karmpaliotis, MD', 'role': 'CONTACT'}], 'geoPoint': {'lat': 40.79677, 'lon': -74.48154}}, {'facility': 'Montefiore Medical Center', 'status': 'RECRUITING', 'city': 'Bronx', 'state': 'New York', 'zip': '10467', 'country': 'United States', 'contacts': [{'name': 'Mollie Machado', 'role': 'CONTACT', 'phone': '718-920-6509', 'email': 'momachado@montefiore.org'}, {'name': 'Mohamed Latib, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'Maday Gonzalez, MD', 'role': 'SUB_INVESTIGATOR'}], 'geoPoint': {'lat': 40.84985, 'lon': -73.86641}}, {'facility': 'SJH Cardiology Associates', 'status': 'RECRUITING', 'city': 'Liverpool', 'state': 'New York', 'zip': '13088', 'country': 'United States', 'contacts': [{'name': 'Laura R. Mowers, MS, CCRP', 'role': 'CONTACT', 'phone': '315-234-4412', 'email': 'laura.mowers@sjhcardiology.org'}, {'name': 'Ayman Iskander', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 43.10646, 'lon': -76.2177}}, {'facility': 'North Shore University Hospital', 'status': 'RECRUITING', 'city': 'Manhasset', 'state': 'New York', 'zip': '11030', 'country': 'United States', 'contacts': [{'name': 'Ian Dalangin', 'role': 'CONTACT', 'phone': '516-562-2457'}, {'name': 'Salome Elia Reddy', 'role': 'CONTACT', 'phone': '(516) 562-1385'}, {'name': 'Avneet Singh, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 40.79788, 'lon': -73.69957}}, {'facility': 'Weill Cornell Medical Center', 'status': 'RECRUITING', 'city': 'New York', 'state': 'New York', 'zip': '10021-9800', 'country': 'United States', 'contacts': [{'name': 'Pretti Singh, MS', 'role': 'CONTACT', 'phone': '212-746-2516', 'email': 'prs4008@med.cornell.edu'}, {'name': 'Dmitriy Feldman, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'facility': 'Saint Francis Hospital', 'status': 'RECRUITING', 'city': 'Roslyn', 'state': 'New York', 'zip': '11576-1348', 'country': 'United States', 'contacts': [{'name': 'Marion Cyriac', 'role': 'CONTACT', 'phone': '201-530-7967', 'email': 'marion.cyriac@chsli.org'}, {'name': 'Linda Bongiovanni', 'role': 'CONTACT', 'phone': '(516) 562-6788', 'email': 'linda.bongiovanni@chsli.org'}, {'name': 'Doosup Shin, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 40.79982, 'lon': -73.65096}}, {'facility': 'University of North Carolina', 'status': 'RECRUITING', 'city': 'Chapel Hill', 'state': 'North Carolina', 'zip': '27599', 'country': 'United States', 'contacts': [{'name': 'Geri Messinger, B.S.', 'role': 'CONTACT', 'phone': '919-843-8644', 'email': 'geri_messinger@med.unc.edu'}, {'name': 'Meghan Allen, MPH', 'role': 'CONTACT', 'phone': '919-843-1610', 'email': 'meghme@med.unc.edu'}, {'name': 'Rick Stouffer, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 35.9132, 'lon': -79.05584}}, {'facility': 'Duke University Medical Center', 'status': 'RECRUITING', 'city': 'Durham', 'state': 'North Carolina', 'zip': '27710', 'country': 'United States', 'contacts': [{'name': 'Oksana Zakharova', 'role': 'CONTACT', 'phone': '919-681-4959', 'email': 'Oksana.zakharova@duke.edu'}, {'name': 'Manesh Patel, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 35.99403, 'lon': -78.89862}}, {'facility': 'Sanford Medical Center', 'status': 'RECRUITING', 'city': 'Fargo', 'state': 'North Dakota', 'zip': '58102', 'country': 'United States', 'contacts': [{'name': 'Sanford Research', 'role': 'CONTACT', 'phone': '701-234-4218'}, {'name': 'Nichole Johnson, RN', 'role': 'CONTACT', 'phone': '701-234-4218', 'email': 'Nichole.Johnson3@SanfordHealth.org'}, {'name': 'Yasser Almanaseer', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 46.87719, 'lon': -96.7898}}, {'facility': 'The Lindner Center', 'status': 'RECRUITING', 'city': 'Cincinnati', 'state': 'Ohio', 'zip': '45219', 'country': 'United States', 'contacts': [{'name': 'Kasey Riffey, RN, BSN', 'role': 'CONTACT', 'phone': '513-585-1777', 'email': 'kasey.riffey@thechristhospital.com'}, {'name': 'John Corl, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 39.12713, 'lon': -84.51435}}, {'facility': 'University Hospitals Cleveland Medical Center', 'status': 'RECRUITING', 'city': 'Cleveland', 'state': 'Ohio', 'zip': '44106', 'country': 'United States', 'contacts': [{'name': 'Emily Mullenax, RN', 'role': 'CONTACT', 'phone': '216-844-3852', 'email': 'Emily.Mullenax@uhhospitals.org'}, {'name': 'Terence Semenec, RN', 'role': 'CONTACT', 'phone': '216-983-4724', 'email': 'Terence.Semenec@uhhospitals.org'}, {'name': 'Mehdi Shishehbor', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 41.4995, 'lon': -81.69541}}, {'facility': 'Cleveland Cl inic', 'status': 'RECRUITING', 'city': 'Cleveland', 'state': 'Ohio', 'zip': '44195', 'country': 'United States', 'contacts': [{'name': 'HVTI', 'role': 'CONTACT', 'email': 'hvtiresearch@ccf.org'}, {'name': 'Khaled Ziada', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 41.4995, 'lon': -81.69541}}, {'facility': 'Riverside Methodist Hospital', 'status': 'RECRUITING', 'city': 'Columbus', 'state': 'Ohio', 'zip': '43214', 'country': 'United States', 'contacts': [{'name': 'Joseph D. Campbell, MD', 'role': 'CONTACT', 'phone': '614-566-1250', 'email': 'joseph.campbell2@ohiohealth.com'}, {'name': 'Joseph D. Campbell, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'John A. Phillips, MD', 'role': 'SUB_INVESTIGATOR'}], 'geoPoint': {'lat': 39.96118, 'lon': -82.99879}}, {'facility': 'Oklahoma Heart Hospital', 'status': 'RECRUITING', 'city': 'Oklahoma City', 'state': 'Oklahoma', 'zip': '73120', 'country': 'United States', 'contacts': [{'name': 'Mohammad Ghani', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 35.46756, 'lon': -97.51643}}, {'facility': 'UPMC Harrisburg Hospital', 'status': 'RECRUITING', 'city': 'Harrisburg', 'state': 'Pennsylvania', 'zip': '17101', 'country': 'United States', 'contacts': [{'name': 'Gretchen C Meise, RN BSN', 'role': 'CONTACT', 'phone': '717-920-4464', 'email': 'meisegc@upmc.edu'}, {'name': 'Joanna L Miller, RN BSN', 'role': 'CONTACT', 'phone': '717 920 4463', 'email': 'Millerjl30@upmc.edu'}, {'name': 'William Bachinsky', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'Cleon Hubbard', 'role': 'SUB_INVESTIGATOR'}], 'geoPoint': {'lat': 40.2737, 'lon': -76.88442}}, {'facility': 'Hospital of the University of Pennsylvania', 'status': 'RECRUITING', 'city': 'Philadelphia', 'state': 'Pennsylvania', 'zip': '19104', 'country': 'United States', 'contacts': [{'name': 'Rianne Delacruz', 'role': 'CONTACT', 'phone': '215-349-8001', 'email': 'rianne.delacruz@pennmedicine.upenn.edu'}, {'name': 'Debbie Cohen, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'Taisei Kobayashi, MD', 'role': 'SUB_INVESTIGATOR'}], 'geoPoint': {'lat': 39.95233, 'lon': -75.16379}}, {'facility': 'Allegheny General Hospital', 'status': 'RECRUITING', 'city': 'Pittsburgh', 'state': 'Pennsylvania', 'zip': '15212', 'country': 'United States', 'contacts': [{'name': 'Ramzi Khalil, MD', 'role': 'CONTACT', 'phone': '412-359-4025'}, {'name': 'Tracy Spirk', 'role': 'CONTACT', 'phone': '412-359-4025'}, {'name': 'Ramzi Khalil, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'David Lasorda, MD', 'role': 'SUB_INVESTIGATOR'}], 'geoPoint': {'lat': 40.44062, 'lon': -79.99589}}, {'facility': 'Rhode Island Hospital and Health Services', 'status': 'RECRUITING', 'city': 'Providence', 'state': 'Rhode Island', 'zip': '02906', 'country': 'United States', 'contacts': [{'name': 'Lori-Ann DeSimone', 'role': 'CONTACT', 'email': 'ldesimone@lifespan.org'}, {'name': 'Bailey Nivens', 'role': 'CONTACT', 'email': 'Bnevins@lifespan.org'}, {'name': 'Omar Hyder, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 41.82399, 'lon': -71.41283}}, {'facility': 'AnMed Health Medical Center', 'status': 'RECRUITING', 'city': 'Anderson', 'state': 'South Carolina', 'zip': '29621', 'country': 'United States', 'contacts': [{'name': 'Melissa Frankum, MSN, RN', 'role': 'CONTACT', 'phone': '864-512-8519', 'email': 'melissa.frankum@anmedhealth.org'}, {'name': 'Sonya Bair', 'role': 'CONTACT', 'phone': '1-864-512-8733', 'email': 'Sonya.bair@anmedhealth.org'}, {'name': 'Brent McLaurin, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 34.50344, 'lon': -82.65013}}, {'facility': 'Centennial Medical Center', 'status': 'RECRUITING', 'city': 'Nashville', 'state': 'Tennessee', 'zip': '37203', 'country': 'United States', 'contacts': [{'name': 'Paul T. Dalecke, CCRC', 'role': 'CONTACT', 'phone': '615-329-7357', 'email': 'Paul.dalecke@hcahealthcare.com'}, {'name': 'Drew Quillen, CCRC/CCRP', 'role': 'CONTACT', 'phone': '615-417-1035', 'email': 'Cameron.quillen@hcahealthcare.com'}, {'name': 'Brian Jefferson, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'Bryan Doherty, MD', 'role': 'SUB_INVESTIGATOR'}], 'geoPoint': {'lat': 36.16589, 'lon': -86.78444}}, {'facility': 'Vanderbilt University Medical Center', 'status': 'RECRUITING', 'city': 'Nashville', 'state': 'Tennessee', 'zip': '37232', 'country': 'United States', 'contacts': [{'name': 'Carol A. Meisch, RN, BSN', 'role': 'CONTACT', 'phone': '615-343-4983', 'email': 'carol.meisch@vumc.org'}, {'name': 'Jaime N. Rich, MPH', 'role': 'CONTACT', 'phone': '615-936-1024', 'email': 'Jaime.Rich@vumc.org'}, {'name': 'Pete Fong, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 36.16589, 'lon': -86.78444}}, {'facility': 'Baylor Jack and Jane Hamilton Heart and Vascular Hospital', 'status': 'RECRUITING', 'city': 'Dallas', 'state': 'Texas', 'zip': '75226-1316', 'country': 'United States', 'contacts': [{'name': 'Robert Stoler, MD', 'role': 'CONTACT'}], 'geoPoint': {'lat': 32.78306, 'lon': -96.80667}}, {'facility': 'Houston Methodist', 'status': 'RECRUITING', 'city': 'Houston', 'state': 'Texas', 'zip': '77030', 'country': 'United States', 'contacts': [{'name': 'Rene Plascencia, BS', 'role': 'CONTACT', 'phone': '713-441-6548', 'email': 'rplascencia@houstonmethodist.org'}, {'name': 'Padmaja V. Naik, MBBS, MPH', 'role': 'CONTACT', 'phone': '281-615-9407', 'email': 'pvnaik@houstonmethodist.org'}, {'name': 'Alpesh Shah, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'Neal Kleiman, MD', 'role': 'SUB_INVESTIGATOR'}], 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}, {'facility': 'Baylor Scott & White The Heart Hospital Baylor Plano', 'status': 'RECRUITING', 'city': 'Plano', 'state': 'Texas', 'zip': '75093', 'country': 'United States', 'contacts': [{'name': 'Srinivasa Potluri, MD', 'role': 'CONTACT'}], 'geoPoint': {'lat': 33.01984, 'lon': -96.69889}}, {'facility': 'Methodist Hospital', 'status': 'RECRUITING', 'city': 'San Antonio', 'state': 'Texas', 'zip': '78229', 'country': 'United States', 'contacts': [{'name': 'Aliseiya Garza, BS', 'role': 'CONTACT', 'phone': '210-449-5026'}, {'name': 'Maurene Cantu, RN', 'role': 'CONTACT', 'phone': '210-218-4950'}, {'name': 'Jorge Alvarez, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'Abelardo Martinez-Rumayor, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Moises Bucay, MD', 'role': 'SUB_INVESTIGATOR'}], 'geoPoint': {'lat': 29.42412, 'lon': -98.49363}}, {'facility': 'The University of Texas at Tyler', 'status': 'RECRUITING', 'city': 'Tyler', 'state': 'Texas', 'zip': '75701', 'country': 'United States', 'contacts': [{'name': 'Kevin Thornton, LVN, CCRC', 'role': 'CONTACT', 'phone': '903-510-7295', 'email': 'kevin.thornton@uthet.com'}, {'name': 'Elizabeth Seal, CCRC', 'role': 'CONTACT', 'phone': '903-510-7291', 'email': 'eseal@uthet.com'}, {'name': 'Frank Navetta, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'Robert Smith, MD', 'role': 'SUB_INVESTIGATOR'}], 'geoPoint': {'lat': 32.35126, 'lon': -95.30106}}, {'facility': 'Intermountain Medical Center', 'status': 'RECRUITING', 'city': 'Murray', 'state': 'Utah', 'zip': '84107', 'country': 'United States', 'contacts': [{'name': 'Lindsey Bevan', 'role': 'CONTACT', 'phone': '801-507-4889', 'email': 'Lindsey.Bevan@imail.org'}, {'name': 'McKenna Jensen', 'role': 'CONTACT', 'phone': '801-507-4760', 'email': 'Mckenna.Jensen@imail.org'}, {'name': 'Kent Meredith, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'Edward Miner, MD', 'role': 'SUB_INVESTIGATOR'}], 'geoPoint': {'lat': 40.66689, 'lon': -111.88799}}, {'facility': 'University of Vermont Medical Center', 'status': 'RECRUITING', 'city': 'Burlington', 'state': 'Vermont', 'zip': '05401', 'country': 'United States', 'contacts': [{'name': 'Rony Lahoud, MD', 'role': 'CONTACT', 'phone': '802-847-3734'}, {'name': 'Amy Henderson', 'role': 'CONTACT', 'phone': '802-847-4746', 'email': 'amy.henderson@uvmhealth.org'}, {'name': 'Rony Lahoud, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'Dauerman Harold, MD', 'role': 'SUB_INVESTIGATOR'}], 'geoPoint': {'lat': 44.47588, 'lon': -73.21207}}, {'facility': 'UVA Medical Center', 'status': 'RECRUITING', 'city': 'Charlottesville', 'state': 'Virginia', 'zip': '22908', 'country': 'United States', 'contacts': [{'name': 'Kelly Parker, RN, CCRC', 'role': 'CONTACT', 'phone': '434-982-1058'}, {'name': 'Linda Bryceland, RN, CCRC', 'role': 'CONTACT', 'phone': '434-982-1058'}, {'name': 'Kanwar Singh', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 38.02931, 'lon': -78.47668}}, {'facility': 'Providence Regional Medical Center Everett', 'status': 'RECRUITING', 'city': 'Everett', 'state': 'Washington', 'zip': '98201', 'country': 'United States', 'contacts': [{'name': 'Catalina Danila', 'role': 'CONTACT', 'phone': '425-258-7273', 'email': 'mihaela.danila@providence.org'}, {'name': 'Dean Rocco', 'role': 'CONTACT'}, {'name': 'Mahesh Mulumudi, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'Apurva Badheka, MD', 'role': 'SUB_INVESTIGATOR'}], 'geoPoint': {'lat': 47.97898, 'lon': -122.20208}}, {'facility': 'West Virginia University', 'status': 'RECRUITING', 'city': 'Morgantown', 'state': 'West Virginia', 'zip': '26506', 'country': 'United States', 'contacts': [{'name': 'Ramesh Daggubati, MD', 'role': 'CONTACT', 'phone': '304-598-4478', 'email': 'ramesh.daggubati@wvumedicine.org'}, {'name': 'Kimberly Quedado, PhD', 'role': 'CONTACT', 'email': 'kimberly.quedado@wvumedicine.org'}, {'name': 'Ramesh Daggubati, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 39.62953, 'lon': -79.9559}}, {'facility': \"Advocate Aurora Health-Aurora St. Luke's Medical Center (ASLMC)\", 'status': 'RECRUITING', 'city': 'Milwaukee', 'state': 'Wisconsin', 'zip': '53215', 'country': 'United States', 'contacts': [{'name': 'Dena Burke, RN, CCRC', 'role': 'CONTACT', 'phone': '414-649-3490', 'email': 'dena.burke@aah.org'}, {'name': 'Donald Lobacz, RN, CCRC', 'role': 'CONTACT', 'phone': '414-649-3438', 'email': 'Donald.Lobacz@aah.org'}, {'name': 'Suhail Allaqaband, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'Fuad Jan, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Babak Haddadian, MD', 'role': 'SUB_INVESTIGATOR'}], 'geoPoint': {'lat': 43.0389, 'lon': -87.90647}}, {'facility': 'The Alfred Hospital', 'status': 'RECRUITING', 'city': 'Melbourne', 'state': 'Victoria', 'zip': '3004', 'country': 'Australia', 'contacts': [{'name': 'Brianna Davidson, Nurse', 'role': 'CONTACT', 'email': 'cardiactrials@alfred.org.au'}, {'name': 'Antony Walton, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'Yusuke Sata, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Liam Guiney, MD', 'role': 'SUB_INVESTIGATOR'}], 'geoPoint': {'lat': -37.814, 'lon': 144.96332}}, {'facility': 'Dobney Hypertension Centre', 'status': 'RECRUITING', 'city': 'Perth', 'state': 'Western Australia', 'zip': '6000', 'country': 'Australia', 'contacts': [{'name': 'Markus Schlaich, MD', 'role': 'CONTACT', 'phone': '+61 8 9224 0382', 'email': 'Markus.Schlaich@uwa.edu.au'}, {'name': 'Anu Joyson, Nurse', 'role': 'CONTACT', 'email': 'Anu.joyson@uwa.edu.au'}, {'name': 'Carl Schultz, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Sharad Shetty, MD', 'role': 'SUB_INVESTIGATOR'}], 'geoPoint': {'lat': -31.95224, 'lon': 115.8614}}, {'facility': 'Algemeen Stedelijk Ziekenhuis - R&D Hartziekten', 'status': 'RECRUITING', 'city': 'Aalst', 'state': 'Oost - Vlaanderen', 'zip': '9300', 'country': 'Belgium', 'contacts': [{'name': 'An Roets', 'role': 'CONTACT', 'phone': '+32 53764175', 'email': 'an.roets@asz.be'}, {'name': 'Lies DeHauwere', 'role': 'CONTACT', 'phone': '+32 53766735', 'email': 'lies.dehauwre@asz.be'}, {'name': 'Michael Rosseel, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 50.93604, 'lon': 4.0355}}, {'facility': 'AZ Sint Jan Brugge-Oostende av', 'status': 'RECRUITING', 'city': 'Brugge', 'zip': '8000', 'country': 'Belgium', 'contacts': [{'name': 'Jan van der Heyden, Dr', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 51.20892, 'lon': 3.22424}}, {'facility': 'Ziekenhuis Oost Limburg - Campus Sint-Jan', 'status': 'RECRUITING', 'city': 'Genk', 'zip': '3600', 'country': 'Belgium', 'geoPoint': {'lat': 50.965, 'lon': 5.50082}}, {'facility': 'University Hospital Ghent', 'status': 'RECRUITING', 'city': 'Gent', 'zip': '9000', 'country': 'Belgium', 'contacts': [{'name': 'Pieter Vervaet, MSc', 'role': 'CONTACT', 'email': 'pieter.vervaet@uzgent.be'}, {'name': 'Michaël Buysse', 'role': 'CONTACT', 'email': 'michael.buysse@uzgent.be'}, {'name': 'Benny Drieghe', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 51.05, 'lon': 3.71667}}, {'facility': 'Chc Montlegia', 'status': 'RECRUITING', 'city': 'Liège', 'zip': '4000', 'country': 'Belgium', 'contacts': [{'name': 'Pieter-Jan Palmers', 'role': 'CONTACT', 'phone': '+3243554180'}, {'name': 'Pieter-Jan Palmers', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 50.63373, 'lon': 5.56749}}, {'facility': 'Hôpital Saint André -Centre Hospitalier Universitaire de Bordeaux', 'status': 'RECRUITING', 'city': 'Bordeaux', 'zip': '33 000', 'country': 'France', 'contacts': [{'name': 'Antoine Cremer, MD', 'role': 'CONTACT', 'email': 'antoine.cremer@chu-bordeaux.fr'}, {'name': 'Antoine Cremer', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'Julien Doublet', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Philippe Gosse', 'role': 'SUB_INVESTIGATOR'}], 'geoPoint': {'lat': 44.84044, 'lon': -0.5805}}, {'facility': 'Hôpital Pitié Salpêtrière', 'status': 'RECRUITING', 'city': 'Paris', 'zip': '75013', 'country': 'France', 'contacts': [{'name': 'Gilles Montalescot, MD, PhD', 'role': 'CONTACT'}, {'name': 'Gilles Montalescot, MD, PhD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 48.85341, 'lon': 2.3488}}, {'facility': 'Uniklinik Erlangen', 'status': 'RECRUITING', 'city': 'Erlangen', 'zip': '91054', 'country': 'Germany', 'contacts': [{'role': 'CONTACT', 'phone': '091318536207'}, {'name': 'Roland Schmieder, Prof.', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 49.59099, 'lon': 11.00783}}, {'facility': 'Justus-Liebig-Universität Gießen', 'status': 'RECRUITING', 'city': 'Gießen', 'zip': '35390', 'country': 'Germany', 'contacts': [{'name': 'Bernhard Unsöld, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 50.58727, 'lon': 8.67554}}, {'facility': 'Universitatsklinikum des Saarlandes', 'status': 'RECRUITING', 'city': 'Homburg', 'country': 'Germany', 'contacts': [{'name': 'Bakuradze Tamara', 'role': 'CONTACT', 'email': 'tamara.bakuradze@uks.eu'}, {'name': 'Michael Böhm, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 49.32637, 'lon': 7.33867}}, {'facility': 'Herzzentrum Leipzig', 'status': 'RECRUITING', 'city': 'Leipzig', 'zip': '04289', 'country': 'Germany', 'contacts': [{'role': 'CONTACT', 'phone': '+49341865-0', 'email': 'info.herzzentrum@helios-gesundheit.de'}], 'geoPoint': {'lat': 51.33962, 'lon': 12.37129}}, {'facility': 'Sana Kliniken Lübeck GmbH', 'status': 'RECRUITING', 'city': 'Lübeck', 'zip': '23560', 'country': 'Germany', 'contacts': [{'name': 'Prof. J. Weil', 'role': 'CONTACT', 'email': 'joachim.weil@sana.de'}, {'name': 'Tolga Agdirlioglu', 'role': 'CONTACT'}, {'name': 'Prof. J. Weil', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 53.86893, 'lon': 10.68729}}, {'facility': 'Hippokration General Hospital of Athens', 'status': 'RECRUITING', 'city': 'Athens', 'zip': '11527', 'country': 'Greece', 'contacts': [{'name': 'Fotis Tatakis', 'role': 'CONTACT', 'email': 'fotistatakis@yahoo.gr'}, {'name': 'Tsioufis Konstantinos', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 37.97945, 'lon': 23.71622}}, {'facility': 'Centre Hospitalier Princesse Grace', 'status': 'RECRUITING', 'city': 'Monaco', 'zip': '98000', 'country': 'Monaco', 'contacts': [{'name': 'Atul Pathak, MD', 'role': 'CONTACT', 'phone': '00 377 97 98 97 71', 'email': 'atul.pathak@chpg.mc'}, {'name': 'Atul Pathak, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 43.73333, 'lon': 7.41667}}, {'facility': 'Zuyderland Medisch Centrum Heerlen', 'status': 'RECRUITING', 'city': 'Heerlen', 'zip': '6419 PC', 'country': 'Netherlands', 'contacts': [{'name': 'Pamela Kleikers, Dr', 'role': 'CONTACT', 'phone': '0031(0)884597522', 'email': 'rd-cardiology@zuyderland.nl'}, {'name': 'Koos Heijnen, RN', 'role': 'CONTACT', 'phone': '0031(0)884597522', 'email': 'k.heijnen@zuyderland.nl'}, {'name': 'Saman Rasoul, Dr', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 50.88365, 'lon': 5.98154}}, {'facility': 'Erasmus Universtiy Medical Center', 'status': 'RECRUITING', 'city': 'Rotterdam', 'country': 'Netherlands', 'contacts': [{'name': 'Joost Daemen, MD, PhD', 'role': 'CONTACT', 'phone': '+31 10 70 393 07', 'email': 'j.daemen@erasmusmc.nl'}, {'name': 'Joost Daemen, MD, PhD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 51.9225, 'lon': 4.47917}}, {'facility': 'Danderyd Sjukhus', 'status': 'RECRUITING', 'city': 'Stockholm', 'zip': '18288', 'country': 'Sweden', 'contacts': [{'name': 'Thomas Kahan', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 59.33258, 'lon': 18.0649}}, {'facility': 'John Radcliffe Hospital', 'status': 'RECRUITING', 'city': 'Oxford', 'state': 'Oxfordshire', 'zip': 'OX3 9DU', 'country': 'United Kingdom', 'contacts': [{'name': 'Dr. Giovanni Luigi De Maria, MD', 'role': 'CONTACT', 'email': 'GiovanniLuigi.DeMaria@ouh.nhs.uk'}, {'name': 'Katharine New', 'role': 'CONTACT'}, {'name': 'Prof. Adrian Banning', 'role': 'SUB_INVESTIGATOR'}], 'geoPoint': {'lat': 51.75222, 'lon': -1.25596}}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2024-11-22'}, 'conditionBrowseModule': {'meshes': [{'id': 'D007674', 'term': 'Kidney Diseases'}, {'id': 'D051436', 'term': 'Renal Insufficiency, Chronic'}, {'id': 'D006973', 'term': 'Hypertension'}, {'id': 'D002318', 'term': 'Cardiovascular Diseases'}, {'id': 'D014652', 'term': 'Vascular Diseases'}], 'ancestors': [{'id': 'D014570', 'term': 'Urologic Diseases'}, {'id': 'D052776', 'term': 'Female Urogenital Diseases'}, {'id': 'D005261', 'term': 'Female Urogenital Diseases and Pregnancy Complications'}, {'id': 'D000091642', 'term': 'Urogenital Diseases'}, {'id': 'D052801', 'term': 'Male Urogenital Diseases'}, {'id': 'D051437', 'term': 'Renal Insufficiency'}, {'id': 'D002908', 'term': 'Chronic Disease'}, {'id': 'D020969', 'term': 'Disease Attributes'}, {'id': 'D010335', 'term': 'Pathologic Processes'}], 'browseLeaves': [{'id': 'M10698', 'name': 'Kidney Diseases', 'asFound': 'Kidney Disease', 'relevance': 'HIGH'}, {'id': 'M17400', 'name': 'Vascular Diseases', 'asFound': 'Vascular Disease', 'relevance': 'HIGH'}, {'id': 'M7115', 'name': 'Diabetes Mellitus', 'relevance': 'LOW'}, {'id': 'M10024', 'name': 'Hypertension', 'asFound': 'Hypertension', 'relevance': 'HIGH'}, {'id': 'M26717', 'name': 'Renal Insufficiency, Chronic', 'asFound': 'Chronic Kidney Disease', 'relevance': 'HIGH'}, {'id': 'M26718', 'name': 'Renal Insufficiency', 'relevance': 'LOW'}, {'id': 'M17319', 'name': 'Urologic Diseases', 'relevance': 'LOW'}, {'id': 'M2875', 'name': 'Urogenital Diseases', 'relevance': 'LOW'}, {'id': 'M27093', 'name': 'Female Urogenital Diseases', 'relevance': 'LOW'}, {'id': 'M14127', 'name': 'Pregnancy Complications', 'relevance': 'LOW'}, {'id': 'M8399', 'name': 'Female Urogenital Diseases and Pregnancy Complications', 'relevance': 'LOW'}, {'id': 'M27095', 'name': 'Male Urogenital Diseases', 'relevance': 'LOW'}, {'id': 'M6147', 'name': 'Chronic Disease', 'relevance': 'LOW'}, {'id': 'M22700', 'name': 'Disease Attributes', 'relevance': 'LOW'}, {'id': 'T1303', 'name': 'Chronic Graft Versus Host Disease', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BXS', 'name': 'Urinary Tract, Sexual Organs, and Pregnancy Conditions'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC14', 'name': 'Heart and Blood Diseases'}, {'abbrev': 'BC18', 'name': 'Nutritional and Metabolic Diseases'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}, {'abbrev': 'Rare', 'name': 'Rare Diseases'}]}}, 'hasResults': False}], 'nextPageToken': 'NF0g5JKFkvghxA'}\n",
      "Fetched Trials:\n",
      "        nct_id                                              title\n",
      "0  NCT03532620  A Multi-center, Open-label, Randomized, 12-mon...\n",
      "1  NCT00328965  An Open Label, Multi-centre, Single Arm Phase ...\n",
      "2  NCT00004266  Randomized Study of Antihypertensives and Anti...\n",
      "3  NCT02517866  A Prospective Study of Azilsartan Medoxomil in...\n",
      "4  NCT06220773  A Randomized, Double-blind, Multi-center, Phas...\n",
      "5  NCT06258473  Addressing Gaps in the Hypertension and Diabet...\n",
      "6  NCT00123227  A Randomised, Double-Blind, Placebo-Controlled...\n",
      "7  NCT03539627  One-center, Observational, Non-interventional,...\n",
      "8  NCT01416766  CONtrolling Disease Using Inexpensive IT - Hyp...\n",
      "9  NCT05198674  The SPYRAL AFFIRM Global Clinical Study of Ren...\n"
     ]
    }
   ],
   "source": [
    "# Example usage\n",
    "query_parameters = {\n",
    "    \"query.cond\": \"diabetes\",\n",
    "    \"query.titles\": \"high blood pressure\"\n",
    "    # ,\n",
    "    # \"query.id\": \"BP28248\"\n",
    "}\n",
    "result_df = fetch_trials(**query_parameters)\n",
    "print(\"Fetched Trials:\")\n",
    "print(result_df)"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "venv",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.11.4"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
